0000912061-18-000015.txt : 20180327 0000912061-18-000015.hdr.sgml : 20180327 20180327171831 ACCESSION NUMBER: 0000912061-18-000015 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20171231 FILED AS OF DATE: 20180327 DATE AS OF CHANGE: 20180327 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NATURAL HEALTH TRENDS CORP CENTRAL INDEX KEY: 0000912061 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-MISCELLANEOUS NONDURABLE GOODS [5190] IRS NUMBER: 592705336 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36849 FILM NUMBER: 18716270 BUSINESS ADDRESS: STREET 1: 609 DEEP VALLEY DRIVE STREET 2: SUITE 395 (EAST BUILDING) CITY: ROLLING HILLS ESTATES STATE: CA ZIP: 90274 BUSINESS PHONE: 310-541-0888 MAIL ADDRESS: STREET 1: 609 DEEP VALLEY DRIVE STREET 2: SUITE 395 (EAST BUILDING) CITY: ROLLING HILLS ESTATES STATE: CA ZIP: 90274 10-K 1 nhtc20171231_10k.htm 10-K Document
false--12-31FY20170000912061YesAccelerated FilerNoNo35350.50.52P3YP3Y0.0015000000012979414129794140.00150000000.0000.000P5YP7YP5YP3Y16922181637524 0000912061 2017-01-01 2017-12-31 0000912061 2017-06-30 0000912061 2018-03-02 0000912061 2016-12-31 0000912061 2017-12-31 0000912061 2016-01-01 2016-12-31 0000912061 2015-01-01 2015-12-31 0000912061 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0000912061 us-gaap:PreferredStockMember 2015-12-31 0000912061 us-gaap:TreasuryStockMember 2017-12-31 0000912061 us-gaap:TreasuryStockMember 2016-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-01-01 2015-12-31 0000912061 us-gaap:TreasuryStockMember 2015-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0000912061 us-gaap:RetainedEarningsMember 2014-12-31 0000912061 us-gaap:PreferredStockMember 2014-12-31 0000912061 us-gaap:PreferredStockMember 2017-12-31 0000912061 us-gaap:TreasuryStockMember 2015-01-01 2015-12-31 0000912061 us-gaap:TreasuryStockMember 2016-01-01 2016-12-31 0000912061 us-gaap:CommonStockMember 2016-12-31 0000912061 us-gaap:RetainedEarningsMember 2015-12-31 0000912061 us-gaap:RetainedEarningsMember 2017-12-31 0000912061 us-gaap:CommonStockMember 2015-01-01 2015-12-31 0000912061 us-gaap:TreasuryStockMember 2017-01-01 2017-12-31 0000912061 2015-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000912061 us-gaap:RetainedEarningsMember 2016-01-01 2016-12-31 0000912061 us-gaap:RetainedEarningsMember 2015-01-01 2015-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-12-31 0000912061 us-gaap:CommonStockMember 2014-12-31 0000912061 2014-12-31 0000912061 us-gaap:PreferredStockMember 2016-12-31 0000912061 us-gaap:CommonStockMember 2015-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0000912061 us-gaap:CommonStockMember 2017-12-31 0000912061 us-gaap:TreasuryStockMember 2014-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000912061 us-gaap:RetainedEarningsMember 2016-12-31 0000912061 2017-01-01 2017-03-31 0000912061 country:CN 2015-06-30 0000912061 us-gaap:FurnitureAndFixturesMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000912061 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember us-gaap:MaximumMember 2017-01-01 2017-03-31 0000912061 us-gaap:FurnitureAndFixturesMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000912061 nhtc:LongTermIncentivePlanPaymentCommencingInFebruary2021AndEndingInDecember2023Member 2016-12-31 0000912061 nhtc:LongTermIncentivePlanPaymentCommencingInFebruaryOfTheCalendarYearImmediatelyFollowingTheConclusionOfThePerformancePeriodMember 2017-12-31 0000912061 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000912061 2015-04-30 0000912061 country:CN 2017-12-31 0000912061 nhtc:EnrollmentPackageRevenueMember 2016-12-31 0000912061 nhtc:AutoShipAdvancesMember 2016-12-31 0000912061 nhtc:UnshippedProductMember 2017-12-31 0000912061 nhtc:UnshippedProductMember 2016-12-31 0000912061 nhtc:AutoShipAdvancesMember 2017-12-31 0000912061 nhtc:EnrollmentPackageRevenueMember 2017-12-31 0000912061 nhtc:FinancialInstitutionInstrumentsMember 2016-12-31 0000912061 us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000912061 nhtc:MunicipalBondsAndNotesMember 2016-12-31 0000912061 nhtc:FinancialInstitutionInstrumentsMember 2017-12-31 0000912061 us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000912061 nhtc:MunicipalBondsAndNotesMember 2017-12-31 0000912061 nhtc:SecuritiesClassActionMember 2017-01-01 2017-12-31 0000912061 nhtc:ShareholderderivativeclaimMember 2017-01-01 2017-12-31 0000912061 nhtc:GeorgeKBroadyMember 2015-01-22 2015-01-22 0000912061 2016-04-08 2016-04-08 0000912061 2015-08-04 2015-08-04 0000912061 2015-05-04 2015-05-04 0000912061 2015-05-13 2015-05-13 0000912061 us-gaap:RestrictedStockMember 2016-04-08 2016-04-08 0000912061 2017-01-24 2017-01-24 0000912061 2015-10-30 2015-10-30 0000912061 us-gaap:RestrictedStockMember 2017-01-24 2017-01-24 0000912061 2015-07-28 0000912061 2016-01-12 0000912061 2015-08-01 2015-08-03 0000912061 2016-01-01 2016-03-31 0000912061 nhtc:EquityIncentive2016PlanMember us-gaap:CommonStockMember 2016-04-07 0000912061 us-gaap:RestrictedStockMember 2015-02-11 2015-02-11 0000912061 2012-08-13 0000912061 2015-05-04 0000912061 us-gaap:RestrictedStockMember 2015-01-20 2015-01-20 0000912061 2017-11-24 2017-11-24 0000912061 2017-03-03 2017-03-03 0000912061 2017-05-19 2017-05-19 0000912061 2017-08-31 2017-08-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2016-01-01 2016-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2017-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2017-01-01 2017-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2016-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2015-12-31 0000912061 2015-11-20 2015-11-20 0000912061 2015-03-27 2015-03-27 0000912061 2015-05-29 2015-05-29 0000912061 2015-08-28 2015-08-28 0000912061 us-gaap:RestrictedStockMember 2016-12-31 0000912061 us-gaap:RestrictedStockMember 2017-01-01 2017-12-31 0000912061 us-gaap:RestrictedStockMember 2017-12-31 0000912061 us-gaap:RestrictedStockMember 2015-12-31 0000912061 us-gaap:RestrictedStockMember 2015-01-01 2015-12-31 0000912061 us-gaap:RestrictedStockMember 2014-12-31 0000912061 us-gaap:RestrictedStockMember 2016-01-01 2016-12-31 0000912061 us-gaap:RestrictedStockMember 2017-01-01 2017-09-30 0000912061 2016-03-24 2016-03-24 0000912061 2016-05-20 2016-05-20 0000912061 2016-11-25 2016-11-25 0000912061 2016-08-26 2016-08-26 0000912061 2017-10-01 2017-12-31 0000912061 country:CN 2016-01-01 2016-12-31 0000912061 country:HK 2015-01-01 2015-12-31 0000912061 country:CN 2017-01-01 2017-12-31 0000912061 country:HK 2017-01-01 2017-12-31 0000912061 country:KY 2017-01-01 2017-12-31 0000912061 country:HK 2016-01-01 2016-12-31 0000912061 country:CN 2015-01-01 2015-12-31 0000912061 country:KY 2016-01-01 2016-12-31 0000912061 country:KY 2015-01-01 2015-12-31 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2015-04-29 2015-04-29 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2017-01-01 2017-12-31 0000912061 nhtc:GeorgeKBroadyMember us-gaap:DirectorMember 2015-10-28 2015-10-28 0000912061 nhtc:GeorgeBroadyMember us-gaap:DirectorMember 2015-07-31 2015-07-31 0000912061 nhtc:GeorgeKBroadyMember us-gaap:DirectorMember 2015-07-31 2015-07-31 0000912061 nhtc:GeorgeBroadyMember us-gaap:DirectorMember 2015-10-28 2015-10-28 0000912061 nhtc:GeorgeBroadyMember us-gaap:DirectorMember 2015-01-22 2015-01-22 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2016-01-01 2016-12-31 0000912061 nhtc:GeorgeKBroadyMember us-gaap:DirectorMember 2015-05-07 2015-05-07 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2015-01-01 2015-12-31 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2017-01-01 2017-12-31 0000912061 2013-02-01 2013-02-28 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2016-01-01 2016-12-31 0000912061 nhtc:GeorgeBroadyMember us-gaap:DirectorMember 2015-05-07 2015-05-07 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2014-10-01 2014-12-31 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2015-01-01 2015-12-31 0000912061 nhtc:GeorgeBroadyMember us-gaap:DirectorMember 2015-02-19 2015-02-19 0000912061 country:US 2015-01-01 2015-12-31 0000912061 country:KR 2017-01-01 2017-12-31 0000912061 us-gaap:EuropeMember 2015-01-01 2015-12-31 0000912061 nhtc:OtherForeignCountriesMember 2017-01-01 2017-12-31 0000912061 nhtc:RussiaAndKazakhstanAndUkraineMember 2017-01-01 2017-12-31 0000912061 us-gaap:EuropeMember 2016-01-01 2016-12-31 0000912061 nhtc:RussiaAndKazakhstanAndUkraineMember 2015-01-01 2015-12-31 0000912061 country:TW 2015-01-01 2015-12-31 0000912061 country:KR 2016-01-01 2016-12-31 0000912061 country:CA 2017-01-01 2017-12-31 0000912061 nhtc:RussiaAndKazakhstanAndUkraineMember 2016-01-01 2016-12-31 0000912061 country:KR 2015-01-01 2015-12-31 0000912061 country:US 2017-01-01 2017-12-31 0000912061 country:TW 2017-01-01 2017-12-31 0000912061 nhtc:OtherForeignCountriesMember 2015-01-01 2015-12-31 0000912061 country:TW 2016-01-01 2016-12-31 0000912061 country:CA 2016-01-01 2016-12-31 0000912061 country:PE 2017-01-01 2017-12-31 0000912061 country:PE 2015-01-01 2015-12-31 0000912061 country:CA 2015-01-01 2015-12-31 0000912061 country:US 2016-01-01 2016-12-31 0000912061 us-gaap:EuropeMember 2017-01-01 2017-12-31 0000912061 country:PE 2016-01-01 2016-12-31 0000912061 nhtc:OtherForeignCountriesMember 2016-01-01 2016-12-31 0000912061 nhtc:OtherForeignCountriesMember 2017-12-31 0000912061 country:US 2016-12-31 0000912061 nhtc:OtherForeignCountriesMember 2016-12-31 0000912061 country:CN 2016-12-31 0000912061 country:HK 2017-12-31 0000912061 country:US 2017-12-31 0000912061 country:HK 2016-12-31 0000912061 us-gaap:MaximumMember us-gaap:SubsequentEventMember 2018-01-26 2018-01-26 0000912061 us-gaap:MinimumMember us-gaap:SubsequentEventMember 2018-01-26 2018-01-26 0000912061 nhtc:EquityIncentive2016PlanMember us-gaap:SubsequentEventMember 2018-02-01 2018-02-01 0000912061 us-gaap:SubsequentEventMember 2018-02-06 2018-02-06 xbrli:pure utreg:Rate nhtc:class xbrli:shares iso4217:USD iso4217:USD xbrli:shares iso4217:CNY nhtc:installment

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 
 
FORM 10-K
 
(Mark One) 
þ
 
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the fiscal year ended December 31, 2017
 
or
 
¨
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from       to      
 
Commission file number: 001-36849
 
NATURAL HEALTH TRENDS CORP.
(Exact name of registrant as specified in its charter) 
 
Delaware
59-2705336
(State or other jurisdiction of
(I.R.S. Employer
incorporation or organization)
Identification No.)
 
609 Deep Valley Drive
Suite 395
Rolling Hills Estates, California 90274
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: (310) 541-0888
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Name of each exchange on which registered
Common Stock, par value $0.001 per share
 
The NASDAQ Stock Market LLC
 
Securities registered pursuant to Section 12(g) of the Act:
None
 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨ No þ
 
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨ No þ
 
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No ¨
 
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. þ
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer ¨
Accelerated filer þ
Non-accelerated filer ¨ (Do not check if a smaller reporting company)
Smaller reporting company ¨
 
Emerging growth company ¨
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨ No þ
 
The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the closing price of such common equity on June 30, 2017: $202,498,798
 
At March 21, 2018, the number of shares outstanding of the registrant’s common stock was 11,376,092 shares.
 
DOCUMENTS INCORPORATED BY REFERENCE
 
Portions of the registrant’s definitive proxy statement to be filed with the United States Securities and Exchange Commission no later than 120 days after the end of the registrant’s fiscal year end to which this report relates are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.
 




NATURAL HEALTH TRENDS CORP.
Annual Report on Form 10-K
December 31, 2017
 
TABLE OF CONTENTS
 
 
 
Page
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 




FORWARD-LOOKING STATEMENTS
 
This Annual Report on Form 10-K, in particular “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and “Item 1. Business,” include “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). When used in this report, the words or phrases “will likely result,” “expect,” “intend,” “will continue,” “anticipate,” “estimate,” “project,” “believe” and similar expressions are intended to identify “forward-looking statements” within the meaning of the Exchange Act. These statements represent our expectations or beliefs concerning, among other things, future revenue, earnings, growth strategies, new products and initiatives, future operations and operating results, and future business and market opportunities.
 
Forward-looking statements in this report speak only as of the date hereof, and forward-looking statements in documents incorporated by reference speak only as of the date of those documents. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. We caution and advise readers that these statements are based on certain assumptions that may not be realized and involve risks and uncertainties that could cause actual results to differ materially from the expectations and beliefs contained herein.
 
For a summary of certain risks related to our business, see “Item 1A. Risk Factors” in this report. Additional factors that could cause actual results to differ materially from our forward-looking statements are set forth in this report, including under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in our financial statements and the related notes.
 
Unless otherwise noted, the terms “we,” “our,” “us,” and “Company,” refer to Natural Health Trends Corp. and its subsidiaries. References to “dollars” and “$” are to United States dollars.




Part I
 
Item 1. BUSINESS

Overview of Business
 
Natural Health Trends Corp. is an international direct-selling and e-commerce company headquartered in Rolling Hills Estates, California. Subsidiaries controlled by us sell personal care, wellness, and “quality of life” products under the “NHT Global” brand. Our wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia and Vietnam; South Korea; Japan; and Europe. We also operate in Russia and Kazakhstan through our engagement with a local service provider. See Note 10 of the Notes to Consolidated Financial Statements in “Item 8. Financial Statements and Supplementary Data” of this report for further information about our net sales by geographic area.
 
Most of our order volume, particularly in our Hong Kong subsidiary, is for personal consumption through existing members’ referrals. The exception is our Chinese entity, where we sell directly to consumers through an e-commerce retail platform. Our objectives are to enrich the lives of the users of our products and enable our members to benefit financially from the sale of our products.
 
We were originally incorporated as a Florida corporation in 1988. We re-incorporated in Delaware effective June 29, 2005.
 
Our common stock is currently traded on the NASDAQ Capital Market under the symbol “NHTC.”
 
Available Information
 
We maintain executive offices at 609 Deep Valley Drive, Suite 395, Rolling Hills Estates, California 90274 and our telephone number is (310) 541-0888. Our website is located at www.naturalhealthtrendscorp.com. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to such reports are available, free of charge, on our website as soon as reasonably practicable after we file electronically such material with, or furnish it to, the United States Securities and Exchange Commission, or SEC. The information provided on our website should not be considered part of this report. The public may read and copy any materials we file with the SEC at the SEC’s Public Reference Room at 100 F Street, N.E., Room 1580, Washington, DC 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1–800–SEC–0330. The SEC maintains an internet website at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.
 
Our Principal Products
 
We offer a line of “NHT Global” branded products in six distinct categories: wellness, herbal, beauty, lifestyle, home, and baby. These product categories, along with the business opportunity we offer in most of our markets, provide our members a platform to further their goal of achieving and maintaining healthy, quality lifestyles complete with product supplementation and the opportunity for financial rewards.


1


The following table summarizes our product offering by category:
Product Category
 
Description
 
Products
 
 
 
 
 
Wellness
Products formulated and designed to meet specific wellness goals of our customers. Includes targeted nutrition for joint health, antioxidant support, digestive health, heart health, vision health, immune support and cellular health
 
Liquid, encapsulated, tableted and powder dietary and nutritional supplements, vitamins, minerals
 
Premium Noni Juice, Triotein®, Cluster X2®, Children’s Chewable MultiVitamin, ReStor Silver®, ReStor Vital®, HerBalance®, Trifusion Max, Glucosamine 2200, FibeRich®, Energin, Enhanced Essential Probiotics®, Omega 3 Essential Fatty Acids, Memory Burst®, StemRenu®, OcuFocus, FE Enzyme Toothpaste, RespFactor®, CogniMax®
 
 
 
 
 
Herbal
Products formulated incorporating ingredients commonly found in traditional Chinese medicine
 
Herbal supplements
 
LivaPro®, Cordyceps Mycelia CS-4, Purus
 
 
 
 
 
Beauty
Products to help improve skin health and bring an appearance of youthful vibrancy. This product line includes anti-aging and hydrating cleansers, creams, lotions, serums and toners to moisturize, protect and improve the appearance of skin
 
Facial skin care and hand and body care
 
Skindulgence® 30-Minute Non-Surgical Facelift System, Time Restore Eye Cream and Essence, BioCell Mask, 24K Renaissance Rejuvenation Serum, Valesce®, Soothe, Floraeda Hydrating Series, NHT Homme®, Complete Renewal 8 Shampoo, Conditioner and Hair Mask, Botanical Hand Protector
 
 
 
 
 
Lifestyle
Products uniquely formulated to improve overall quality of life and to support active, physical and healthy lifestyles including weight management, intimacy support and energy enhancing supplements
 
Supplements and topical gels for improved vitality
 
Alura® Lux by NHT Global, Valura Lux, LaVie Vibrant Energy drink, Twin Slim Diet Jelly®, NaturalGlo 
 
 
 
 
 
Home
Products designed to create a clean and natural living environment for the home
 
Home and car appliances
 
PurAir Air Purifier, AquaPur Water Purifier
 
 
 
 
 
Baby
Products uniquely formulated with gentle ingredients from nature for infants and babies
 
Infant and toddler bath and body care
 
Moisturizing Lotion and Foaming Cleanser

We continuously source unique, proprietary and immediate impact products to offer to our members and customers. Our product development is an ongoing process that is fueled by marketplace trends, new technologies and scientific findings, members’ input, research and vendor proposals.
 
Working closely with raw material manufacturers and contract manufacturers, our mission is to co-develop and bring to market the highest quality products. Our manufacturers are primarily located in the United States, as well as a few in South Korea, Hong Kong and China. Our raw materials are sourced from reputable suppliers around the world. All current and new products introduced into the market are tested to ensure country and state regulatory compliance requirements are met where the products are sold. This includes proper handling, shipping, and shelf-life recommendations for our products. In addition, raw material Certificates of Analysis are reviewed to ensure that appropriate testing has been performed and are within required ingredient specifications.
 

2


Operations of the Business
 
Operating Strategy
 
Our objective is to help our members succeed in achieving their life objectives; be it personal health, beauty, happiness or financial rewards. Our employees focus on assisting our members in attaining their goals.

We believe we have a competitive business model applicable to the markets in which we operate based on six key competencies:
 
Our field leaders are experienced and culturally coherent. They work effectively with our management, implementing our strategies and providing continuous feedback to improve our services.

A discipline and capability has been established to continue launching high-quality consumer products that are designed to facilitate the accomplishment of our corporate objectives.

We have developed and rolled out a comprehensive training system that provides a complete career path appropriate for our members. Our training material covers the needs of our members, be they prospects, new recruits, product evangelists, sales leaders or dream builders.

We have developed a year-round, multi-faceted promotional plan that targets different segments of our membership and has proven most effective in the last few years.

We have implemented a commission structure that makes it as easy as possible to join our business, while giving existing members a chance to start earning money as quickly as possible in multiple ways.

The continuously improving mentality and methodology in our customer services have not only distinguished us as an organization, but have also given us a constant flow of information as to how we can do better to service our members.

Sourcing of Products
 
Our corporate staff works with research and development personnel of our manufacturers and other prospective vendors to create product concepts and develop the product ideas into actual products. We then may enter into supply agreements with the vendors pursuant to which we obtain rights to sell the products under private labels (or trademarks) that are owned by us. In addition, some of our local markets introduce their own products from time to time and these products are sometimes adopted by our other markets.
 
We generally purchase finished goods from manufacturers and sell them to our members for retail and personal consumption. We believe that in the event we are unable to source products from our current or alternate suppliers, our revenue, income and cash flow could be adversely and materially impacted. We have some contracts with our suppliers with automatic renewal rights.
 
Marketing and Distribution
 
We distribute our products internationally primarily through a network marketing system, which is a form of person-to-person direct selling.  Under this system, members primarily refer our products to prospective consumers or they may buy at wholesale prices for personal consumption or for resale to consumers.  The concept of network marketing is based on the strength of personal recommendations that frequently come from friends, neighbors, relatives, and close acquaintances.  We believe that network marketing is an effective way to distribute our products because it allows person-to-person product education and testimonials as well as higher levels of customer service, all of which are not as readily available through other distribution channels. In this document, we generically use the term “member” to refer to members who purchase for their own consumption or for resale, or both, as well as to members who only sign up to consume our products.
 
Each of our products is designated a specified number of bonus volume points. Commissions are paid to members based on total personal and group bonus volume points per weekly sales period. Bonus volume points are essentially a percentage of a product’s wholesale price.


3


Our members are independent full-time or part-time contractors who purchase products directly from our subsidiaries via the internet for their own personal consumption or for resale to retail consumers. Purchasers of our products in China and certain other markets may purchase only for their own personal consumption and not for resale.
 
The following table sets forth the number of active members by market as of the dates indicated. We consider a member “active” if they have placed at least one product order with us during the preceding year. Members may not necessarily reside in the market for which they sign up as a member.
 
December 31,
 
2017
 
2016
Americas1
5,540

 
3,720

Hong Kong (including those members residing in China)2
82,150

 
108,570

Taiwan
4,460

 
4,030

South Korea
200

 
290

Japan
130

 
100

Singapore
80

 
80

Russia and Kazakhstan
790

 
940

Europe
2,320

 
1,230

Total
95,670

 
118,960

_____________________________ 
1 United States, Canada, Mexico and Peru
2 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors”.

Members must agree to the terms and conditions of our member agreement posted on our website. The member agreement sets forth our policies and procedures, and we may elect to terminate a member for non-compliance.
 
We pay commissions to eligible members based on product purchases by such members’ down-line customers and members during a given commission period. To be eligible to receive commissions, members in some countries may be required to make nominal monthly or other periodic purchases of products. See “Working with Members.
 
Members generally place orders through the internet and pay by credit card prior to shipment. Accordingly, we carry minimal accounts receivable and credit losses are historically negligible.
 
We sponsor promotional meetings, product education, motivational and personal development training events for current and potential members. These events are designed to inform prospective and existing members about both existing and new product lines, our latest marketing and promotional plans, and new services improvements. These events also serve as a venue for recognition of member accomplishments. Members typically share their experiences in using our products and developing their business at these events. We are continually developing and updating our marketing strategies and programs to motivate our members.
 
Management Information Systems
 
Our business uses a proprietary web-based system to process orders and to communicate bonus volume activity and commissions to members. We have automated a substantial amount of our financial reporting processes through implementation of Oracle’s E-Business Suite, and have integrated other critical business processes such as inventory management, purchasing and costing in our most significant markets.
 
Employees
 
At December 31, 2017, we employed 149 total full-time employees worldwide, of which 34 were located in the Americas (United States, Canada, Cayman Islands, and Peru), 100 in Greater China (Hong Kong, China, and Taiwan), three in Russia, two in Singapore, two in Malaysia, three in South Korea, three in Europe, and two in Japan.
 

4


Seasonality
 
From quarter to quarter, we are somewhat impacted by seasonal factors and trends such as major cultural events and vacation patterns. For example, most Asian markets celebrate their respective local New Year in the first quarter. This generally has a significant impact on the services of our third-party providers, and can negatively impact our net sales. We believe that net sales can also be negatively impacted during the third quarter, when many of our members traditionally take time off for vacations. In addition, the national holidays in Hong Kong, China and Taiwan in early October tend to have an adverse effect on sales in those markets.
     
Our spending, as well as to some extent revenue, is affected by the major events planned at different times of the year. A major promotional event could significantly increase the reported expenses during the quarter in which the event actually takes place, while the revenue that might be generated by the event may not occur in the same reporting period.

Intellectual Property
 
Most of our products are packaged under a “private label” arrangement. We have obtained or applied for trademark registration for certain names, logos and various product names in several countries in which we are doing business or considering expanding. We also rely on common law trademark rights to protect our unregistered trademarks. These common law trademark rights do not provide us with the same level of protection as afforded by a United States federal trademark. Common law trademark rights are limited to the geographic area in which the trademark is actually utilized, while a United States federal registration of a trademark enables the registrant to discontinue the unauthorized use of the trademark by a third party anywhere in the United States even if the registrant has never used the trademark in the geographic area where the trademark is being used; provided, however, that the unauthorized third party user has not, prior to the registration date, perfected its common law rights in the trademark within that geographic area.
 
We have U.S. and foreign holding and operating company structures for our businesses, which involve the division of our United States and non-United States operations. Under this structure, the foreign holding company retains the economic ownership of the intangible property outside of the United States, including trademarks, trade secrets and other proprietary information.

Working with Members
 
Sponsorship
 
Enrolling new members creates multiple levels in our direct selling structure. The persons that a member enrolls within the network are referred to as “sponsored” members, who may purchase product solely for their own personal consumption, for resale, or both. Persons newly enrolled are assigned into network positions that can be “under” other members, and thus they can be called “down-line” members. If down-line members also enroll new members, they create additional levels within the structure, but their down-line members remain in the same down-line network as the original member that introduced them to our business.
 
While we provide informational brochures and other sales materials, members are primarily responsible for enrolling and educating their new members with respect to products, the compensation plan and how to build a successful membership network.
 
Members are not required to enroll other members as their down-line, and we do not pay any commissions for enrolling new members. However, because of the financial incentives provided to those who succeed in building a member network that consumes and resells products, we believe that many of our members attempt, with varying degrees of effort and success, to enroll additional members. Because they are seeking new opportunities for income, people are often attracted to become members after using our products or after attending introductory seminars. Once a person becomes a member, he or she is able to purchase products directly from us at wholesale prices via the internet. The member is also entitled to enroll other members in order to build a network of members and product users.
 

5


Compensation Plans
 
We employ what is commonly referred to as a binary compensation plan, enhanced with certain unilevel features. Under our compensation plan, members are paid weekly commissions by our subsidiary in which they are enrolled for product purchases by their down-line member network across all geographic markets. Our China subsidiary maintains an e-commerce retail platform and does not pay commissions. This “seamless” compensation plan enables a member located in one country to sponsor other members located in other countries. Currently, there are basically two ways in which members can earn income:

Through commissions paid on the accumulated bonus volume from product purchases made by their down-line members and customers; and

Through retail profits on sales of products purchased by members at discount and wholesale prices and resold at retail prices (in some markets, sales are for personal consumption only and income may not be earned through retail profits).
 
Each of our products is designated a specified number of bonus volume points. Commissions are based on total personal and group bonus volume points per sales period. Bonus volume points are essentially a percentage of a product’s wholesale price. As the member’s business expands, the member receives higher commissions from purchases made by an expanding down-line network. To be eligible to receive commissions, a member may be required to make nominal monthly or other periodic purchases of our products. Certain of our subsidiaries do not require these nominal purchases for a member to be eligible to receive commissions. In determining commissions, the number of levels of down-line members included within the member’s commissionable group increases as the number of memberships directly below the member increases. Under our current compensation plan, some of our commission payout may be limited to a hard cap dollar amount per week or a specific percentage of the total product sales. In some markets, commissions may be further limited.
 
In some markets, we also pay certain bonuses on purchases by up to three generations of personally sponsored members, as well as bonuses on commissions earned by up to three generations of personally sponsored members. From time to time, we may implement promotions in some markets where bonuses on commissions can be earned by up to seven generations of personally sponsored members. Members can also earn income, trips and other prizes in specific time-limited promotions and contests we hold from time to time.
 
Occasionally, we make modifications and enhancements to our compensation plan to help motivate members, which can have an impact on member commissions. We may also enter into agreements for business or market development, which could result in additional compensation to specific members.
 
Member Support
 
We are committed to providing a high level of support services tailored to the needs of our members in each market we are serving. We attempt to meet the needs and build the loyalty of members by providing personalized member services and by maintaining a generous product return policy (see “Product Warranties and Returns”). We believe that maximizing a member’s efforts by providing effective member support has been, and could continue to be, important to our success.

Through product training meetings, regular conventions, web-based messages, member focus groups, regular telephone conference calls and other personal contacts with members, we seek to understand and satisfy the needs of our members. Via our websites, we may provide product fulfillment and tracking services that result in user-friendly and timely product distribution.
 
To help maintain communication with our members, we offer the following support programs:

Teleconferences – we hold teleconferences with associate field leadership on various subjects such as technical product discussions, member organization building and management techniques.

Internet – we maintain a website at www.nhtglobal.com. On this website, the user can read company news, learn more about various products, sign up to be a member, place orders, and track the fulfillment and delivery of their orders.
 
Product Tools – we offer a variety of marketing tools to members, including product catalogs, videos, informational brochures, pamphlets and posters for individual products, which are both printed and available online.
 
Broadcast E-mail and Text Messages – we send announcements via e-mail and/or text messages to members who opt in to receive this form of communication.

6



Social Media Tools – in some countries we maintain country-specific social media sites to foster a community environment around our product offering and business opportunity.

Technology and Internet Initiatives
 
We believe that the internet is important to our business as more consumers communicate online and purchase products over the internet as opposed to traditional retail and direct sales channels. As a result, we have committed significant resources to our e-commerce capabilities and the abilities of our members to take advantage of the internet. Substantially all of our sales take place via the internet. We offer a global web page that allows a member to have a personalized replicating website through which he or she can sell products in all of the countries in which we do business. Links to these websites can be found at our main website for members at www.nhtglobal.com. The information provided on these websites should not be considered part of this report.
 
Rules Affecting Members
 
Our member policies and procedures establish the rules that members must follow in each market. We also monitor member activity in an attempt to provide our members with a “level playing field” so that one member may not be disadvantaged by the activities of another. We require our members to present products and business opportunities in an ethical and professional manner. Members further agree that their presentations to customers must be consistent with, and limited to, the product claims and representations made in our literature.
 
Our policies and procedures require that we produce or pre-approve all sales aids used by members such as presentations, videos, audio recordings, brochures and promotional clothing. Further, members may not use any form of media advertising to promote products unless it is pre-approved by us. Members are not entitled to use our trademarks or other intellectual property without our prior consent. If we are made aware of unapproved materials being used, we notify and direct the relevant members to cease using such materials. In addition to regularly communicating to our members what is and is not appropriate to say about product or income claims, we have engaged a third-party service provider to assist us in monitoring the internet and various social media to identify potential misconduct or violations of our policies and procedures.
 
Our compliance and member services department reviews reports of alleged member misbehavior. If we determine that a member has violated our member policies or procedures, we may terminate the member’s rights completely. Alternatively, we may impose sanctions, such as warnings, probation, withdrawal or denial of an award, suspension of privileges of the membership, fines, withholding commissions, until specified conditions are satisfied or other appropriate injunctive relief. Our members are independent contractors, not employees, and may act independently of us. Further, our members may resign or terminate their membership at any time without notice. See “Item 1A. Risk Factors.”

Government Regulations
 
Direct Selling Activities
 
Direct selling, or multi-level marketing, activities are regulated by various federal, state and local governmental agencies in the United States and other countries. These laws and regulations are generally intended to prevent fraudulent or deceptive schemes. The laws and regulations in our current markets often:
 
impose cancellation/product return, inventory buy-backs and cooling-off rights for consumers and members;

require us or our members to obtain a license from, or register with, governmental agencies;

impose reporting requirements; and

impose upon us requirements, such as requiring members to maintain levels of retail sales to qualify to receive commissions, to ensure that members are being compensated for sales of products and not for recruiting new members.
 

7


The laws and regulations governing direct selling are modified from time to time, and, like other direct selling companies, we may be subject from time to time to government reviews, examinations or investigations in our various markets related to our direct selling activities. This can require us to make changes to our business model and aspects of our global compensation plan in the markets impacted by such changes and examinations.
 
We believe our method of distribution complies in all material respects with the laws and regulations related to direct selling in the countries in which we currently operate, based on advice of our engaged outside professionals in existing markets, the length of time we have been operating under our Hong Kong business model, guidance provided by governmental regulatory authorities and our history of operations to date.
 
At the end of 2005, China adopted new direct selling and anti-pyramiding regulations that are restrictive and contain various limitations, including a restriction on the ability to pay multi-level compensation to independent members. We are not conducting direct selling in China. Rather, consumers and members purchase our products via our Hong Kong-based website or our e-commerce retail platform in China. The regulatory environment in China is complex, and our operations in China can receive regulatory and media attention.
 
The Chinese government scrutinizes activities of direct selling companies. Our business continues to be subject to regulations and examinations by municipal and provincial level regulators. At times, actions by government regulators have impacted our members’ activities in certain locations, and have resulted in a few cases of enforcement actions. In each of these cases, we helped our members with their defense in the legality of their conduct. So far, no material changes to our business model have been required. We expect to receive continued guidance and direction as we work with regulators to address our business model and any changes that need to be made to comply with the direct selling regulations.
       
We believe that neither our Hong Kong-based website nor our e-commerce platform in China require a direct selling license in China, which we currently do not hold. We have previously sought to obtain a direct selling license, and in August 2015 initiated the process for submitting a new preliminary application for a direct selling license in China. If we are able to obtain a direct selling license in China, we believe that the incentives inherent in the direct selling model in China would incrementally benefit our existing business. Increased sales in China that could be derived from obtaining a direct selling license may be partially offset by the higher fixed costs associated with the establishment and maintenance of required service centers and branch offices. We are unable to predict whether and when we will be successful in obtaining a direct selling license to operate in China, and if we are successful, when we will be permitted to conduct direct selling operations and whether such operations would be profitable.
 
Regulation of Our Products
 
Our products and related promotional and marketing activities are subject to extensive governmental regulation by numerous governmental agencies and authorities in the United States, including the U.S. Food and Drug Administration (the “FDA”), the Federal Trade Commission (the “FTC”), the Consumer Product Safety Commission, the United States Department of Agriculture, State Attorneys General and other state regulatory agencies.  In our foreign markets, the products are generally regulated by similar government agencies.

Our personal care products are subject to various laws and regulations that regulate cosmetic products and set forth regulations for determining whether a product can be marketed as a “cosmetic” or requires further approval as an over-the-counter (OTC) drug. In the United States, regulation of cosmetics is under the jurisdiction of the FDA.  The Food, Drug and Cosmetic Act defines cosmetics by their intended use, as “articles intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body . . . for cleansing, beautifying, promoting attractiveness, or altering the appearance.”  Among the products included in this definition are skin moisturizers, eye and facial makeup preparations, perfumes, lipsticks, fingernail polishes, shampoos, permanent waves, hair colors, toothpastes and deodorants, as well as any material intended for use as a component of a cosmetic product.  Conversely, a product will not be considered a cosmetic, but may be considered a drug if it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, or is intended to affect the structure or any function of the body. A product’s intended use can be surmised from marketing or product claims.  The other markets in which we operate have similar regulations.  


8


In Japan, the Ministry of Health, Labour and Welfare regulates the sale and distribution of cosmetics and requires us to have an import business license and to register each personal care product imported into Japan.  In Taiwan, all “medicated” cosmetic products require registration.  In China, personal care products are placed into one of two categories, “general” and “drug.”  Products in both categories require submission of formulas and other information with the health authorities, and drug products require human clinical studies.  The product registration process in China for these products can take from nine to more than 18 months or longer.  Such regulations in any given market can limit our ability to import products and can delay product launches as we go through the registration and approval process for those products.  The sale of cosmetic products is regulated in the European Union under the European Union Cosmetics Directive, which requires a uniform application for foreign companies making personal care product sales, and in Peru by the governing arm DIGEMID (Dirección General de Medicamentos, Insumos y Drogas) and can take up to three months to fully register as saleable.
 
The markets in which we operate all have varied regulations that distinguish foods and nutritional health supplements from “drugs” or “pharmaceutical products.”  Because of the varied regulations, some products or ingredients that are recognized as a “food” in certain markets may be treated as a “pharmaceutical” in other markets.  These regulations may require us to either modify a product or refrain from selling the product in a given market. As a result, we must regularly modify the ingredients and/or the levels of ingredients in our products to ensure all applicable regulatory restrictions are addressed.  In some circumstances, the regulations in foreign markets may require us to obtain regulatory approval prior to introduction of a new product or limit our uses of certain ingredients altogether. There has been an increased movement in the United States and other markets to expand the regulation of dietary supplements. This could impose additional restrictions or requirements in the future.  Because of this increased regulatory focus, our internal review efforts have been enhanced in order to comply with our understanding of current regulations.
 
FDA regulations require current good manufacturing practices (cGMP) for dietary supplements.  The regulations ensure that dietary supplements are produced in a quality manner, do not contain contaminants or impurities, and are accurately labeled. The regulations include requirements for establishing quality control procedures for us and our vendors and suppliers, designing and constructing manufacturing plants, and testing ingredients and finished products.  The regulations also include requirements for record keeping and handling consumer product complaints.  If dietary supplements contain contaminants or do not contain the type or quantity of dietary ingredient they are represented to contain, the FDA would consider those products to be adulterated or misbranded. We seek to ensure compliance with all regulatory requirements through our periodic manufacturer and warehouse audits, as well as our corrective action request (CAR) program, if needed. cGMP also extends to logistics where we seek to minimize any safety risks associated with product distribution.
 
Our business is subject to additional FDA regulations, such as those implementing an adverse event reporting system (“AER’s”), which requires us to document and track adverse events and report serious adverse events, which are events involving hospitalization or death, associated with consumers’ use of our products.  
 
Most of our major markets also regulate advertising and product claims regarding the efficacy of products. This is particularly true with respect to our dietary supplements because we typically market them as foods or health functional foods. For example, in the United States, we are unable to claim that any of our nutritional supplements will diagnose, cure, mitigate, treat or prevent disease. In the United States, the Dietary Supplement Health and Education Act, however, permits substantiated, truthful and non-misleading statements of nutritional support to be made in labeling, such as statements describing general well-being resulting from consumption of a dietary ingredient or the role of a nutrient or dietary ingredient in affecting or maintaining a structure or a function of the body. Most of the other markets in which we operate have not adopted similar legislation, so we may be subject to more restrictive limitations on the claims we can make about our products in these markets.
 
Other Regulatory Issues
 
As a United States entity operating through subsidiaries in foreign jurisdictions, we are subject to foreign exchange control, transfer pricing and custom laws that regulate the flow of funds between our subsidiaries and us for product purchases, management services and contractual obligations, such as the payment of member commissions. As is the case with most companies that operate in direct sales, we might receive inquiries from time to time from government regulatory authorities regarding the nature of our business and other issues, such as compliance with local direct selling, transfer pricing, customs, taxation, foreign exchange control, securities and other laws.


9


Product Warranties and Returns
 
Our refund policies and procedures closely follow industry and country-specific standards, which vary greatly by country. For example, in the United States, the Direct Selling Association recommends that direct sellers permit returns during the twelve-month period following the sale, while in Hong Kong the standard return policy is 14 days following the sale. Our return policies typically conform to local laws or the recommendation of the local direct selling association. In most cases, members who timely return unopened product that is in resalable condition may receive a refund. The amount of the refund may be dependent on the country in which the sale occurred, the timeliness of the return, and any applicable re-stocking fee. NHT Global must be notified of the return in writing and such written requests would be considered a termination notice of the membership. We may alter our return policy in response to special circumstances.
 
Significant Customers

Sales are made to our members and no single customer accounted for 10% or more of our net sales. However, our business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on our net sales and financial results.

Our Industry
 
We are engaged in the direct selling industry, selling wellness, herbal, beauty, lifestyle, home and baby products. More specifically, we are engaged in what is called network marketing or multi-level marketing. This type of organizational structure and approach to marketing and sales include companies selling lifestyle enhancement products, cosmetics and dietary supplements, or selling other types of consumer products. Generally, direct selling is based upon an organizational structure in which independent members purchasing a company’s products are compensated for sales made directly to consumers.
 
Our members are compensated based on sales generated by members they have enrolled and all subsequent members enrolled by their “down-line” network of members. The experience of the direct selling industry has been that once a sizeable network of members is established, new and alternative products and services can be offered to those members for sale to consumers and additional members.
 
Competition
 
The network marketing industry is very diverse, with giant multinational corporations as well as smaller, local operators. Big network marketing companies include Nu Skin Enterprises, Inc., USANA Health Sciences, Inc., and Herbalife, Ltd, which have much greater name recognition and financial resources than we do and also have many more members. They are publicly traded and therefore serve as informational benchmarks, but we don’t overlap with them in terms of marketplace or product range. On the other hand, many medium- and small-sized privately held Chinese, Taiwanese and Hong Kong companies are fierce competitors and are much closer to directly competing with us. Also, a number of our former employees and members now work for competitors, and sometimes try to use relationships and knowledge obtained to compete with us.
 
Our ability to compete with other network marketing companies depends, in significant part, on our success in attracting and retaining members.  There can be no assurance that our programs for attracting and retaining members will be successful.  The pool of individuals interested in network marketing is limited in each market and is reduced to the extent other network marketing companies successfully attract these individuals into their businesses.  Although we believe that we offer an attractive opportunity for our members, there can be no assurance that other network marketing companies will not be able to recruit our existing members or deplete the pool of potential members in a given market.
 
The direct selling channel tends to sell products at a higher price compared to traditional retailers, which poses a degree of competitive risk. There is no assurance that we would continue to compete effectively against retail stores, internet-based retailers or other direct sellers.
 

10


Item 1A. RISK FACTORS

We are exposed to a variety of risks that are present in our business and industry. The following are some of the more significant factors that could affect our business, results of operations and financial condition.
 
We could be adversely affected by management changes or an inability to attract and retain key management, directors and consultants.
 
We incur a low level of overhead and are run by a small number of executives, who rely on a small group of employees. Our future success depends to a significant degree on the skills, experience and efforts of our top management and directors.  We also depend on the ability of our executive officers and other members of senior management to work effectively as a team.  The loss of one or more of our executive officers, members of our senior management or directors could have a material adverse effect on our business, results of operations and financial condition.  Moreover, as our business evolves, we may require additional or different management members, directors or consultants, and there can be no assurance that we will be able to locate, attract and retain them if and when they are needed.

Because our Hong Kong operations account for a substantial portion of our overall business, and substantially all of our Hong Kong business is derived from the sale of products to members in China, any material adverse change in our business relating to either Hong Kong or China would likely have a material adverse impact on our overall business.
 
In 2017, 2016 and 2015, approximately 89%, 92% and 93% of our revenue, respectively, was generated in Hong Kong. Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. This geographic concentration in our business means that events or conditions that could negatively impact this geographic region or our operations in this region would have a greater adverse impact upon our overall business and financial results than would be the case with a company having greater geographic diversification.  

Our operations in China are subject to compliance with a myriad of applicable laws and regulations, and any actual or alleged violations of those laws or government actions otherwise directed at us could have a material adverse impact on our business and the value of our company.

In contrast to our operations in other parts of the world, we have not implemented a direct sales model in China. The Chinese government permits direct selling only by organizations that have a license, which we are in the process of applying for, and has also adopted anti-multilevel marketing legislation. We operate an e-commerce direct selling model in Hong Kong and recognize the revenue derived from sales to both Hong Kong and Chinese members as being generated in Hong Kong. Products purchased by members in China are delivered to third parties that act as the importers of record under agreements to pay applicable duties.  In addition, through a Chinese entity, we sell products in China using an e-commerce retail model. The Chinese entity operates separately from the Hong Kong entity, and a Chinese member may elect to participate in either or both.
 
After consulting with outside professionals and certain Chinese authorities, and given the length of time we have been operating under our Hong Kong business model, we believe that our e-commerce direct selling model in Hong Kong does not violate any applicable laws in China, even though it is used for the internet purchase of our products by members in China. We also believe that our Chinese entity, including its e-commerce retail platform, is operating in compliance with applicable Chinese laws. However, there can be no assurance that the Chinese authorities will agree with our interpretations of applicable laws and regulations or that China will not adopt new laws or regulations. Should the Chinese government determine that our activities violate China’s direct selling or anti-multilevel marketing legislation, or should new laws or regulations be adopted, there could be a material adverse effect on our business, financial condition and results of operations.
 
The Chinese government scrutinizes the activities of direct selling companies. Our business continues to be subject to regulations and examinations by municipal and provincial level regulators. At times, actions by government regulators have impacted our members’ activities in certain locations and have resulted in a few cases of enforcement actions. In each of these cases, we helped our members with their defense of the legality of their conduct, and no material changes to our business model were required.
 

11


However, our business operations and the value of our company can be adversely affected by Chinese government scrutiny of our operations, even if that scrutiny does not result in investigations of our operations. For example, one or more parties encouraged the Beijing City governmental authorities to conduct an investigation of our business, which resulted in a meeting in January 2016 involving members of our Beijing office staff, Beijing City governmental officials, and two complainants. Even though the Beijing City governmental officials advised our staff and the complainants at that meeting that there was insufficient evidence to warrant an investigation of us, mischaracterizations of the meeting immediately appeared in several “news reports.” Similarly, a subsequent meeting between several Guangzhou City government officials and members of our Guangzhou office staff that resulted in our providing routine information about our operations to the government officials was mischaracterized in an online posting made immediately following the meeting. Although we remain in regular contact with Chinese government officials and take other steps to address the risks posed by these events, our business and the value of our company remain vulnerable to Chinese government scrutiny of our operations, whether or not initiated by third parties.

Various other factors could harm our business in Hong Kong and China, such as worsening economic conditions in Hong Kong or China, adverse local publicity, geopolitical or trade tensions between the U.S. and China or other events that may be out of our control.  For example, we were advised to voluntarily suspend marketing activities in China during the third quarter of 2007 when the Chinese government was expected to impose a more intense enforcement program against illegal pyramid scheme activities or “chain sales” activities in transliterated Chinese terms.  We do not conduct such activities, but we did not want to run the risk of being inadvertently entangled in the government enforcement actions and voluntarily withdrew all marketing activities from China during that period.  It may be necessary or advisable to repeat this or similar actions from time to time in the future, and such periods of reduced activity could have a material adverse effect on our business.

Although we attempt to work closely with both national and local Chinese governmental agencies in conducting our business, our efforts to comply with national and local laws may be harmed by a rapidly evolving regulatory climate, concerns about activities resembling violations of direct selling or anti-multi-level marketing legislation, subjective interpretations of laws and regulations, and activities by individual members that may violate laws notwithstanding our strict policies prohibiting such activities.

Any determination that our operations or activities, or the activities of our individual members, employee sales representatives, or importers of record are not in compliance with applicable laws and regulations could result in the imposition of substantial fines, extended interruptions of business, restrictions on our future ability to obtain business licenses or expand into new locations, changes to our business model, the termination of required licenses to conduct business, or other actions, any of which could materially harm our business, financial condition and results of operations. 

Our failure to maintain and expand our member relationships could adversely affect our business.
 
We distribute our products through independent members, and we depend upon them directly for all of our sales in most of our markets. Accordingly, our success depends in significant part upon our ability to attract, retain and motivate a large base of members. Our direct selling organization is headed by a relatively small number of key members. The loss of a significant number of members, or the loss of one or more key members, could materially and adversely affect sales of our products and could impair our ability to attract new members. Moreover, the replacement of members could be difficult because, in our efforts to attract and retain members, we compete with other direct selling organizations, including but not limited to those in the personal care, cosmetic product and nutritional supplement industries. Our members may terminate their services with us at any time and, in fact, like most direct selling organizations, we have a high rate of attrition.

Our number of active members has recently declined and could in the future further decline.  We cannot accurately predict any fluctuation in the number or the productivity of members because we primarily rely upon existing members to enroll and train new members and to motivate new and existing members. Operating results could be adversely affected if our existing and new business opportunities and products do not generate sufficient economic incentive or interest to retain existing members and to attract new members.
 
The number and productivity of our members could be harmed by several factors, including:

adverse publicity or negative perceptions regarding us, our products, our method of distribution or our competitors;

lack of interest in, or the technical failure of, existing or new products;

lack of interest in our existing compensation plan for members or in enhancements or other changes to that compensation plan;

12



our actions to enforce our policies and procedures;

regulatory actions or charges or private actions against us or others in our industry;

general economic and business conditions;

changes in management or the loss of one or more key member leaders;

entry of new competitors, or new products or compensation plan enhancements by existing competitors, in our markets; and

potential saturation or maturity levels in a given country or market which could negatively impact our ability to attract and retain members in such market.

We are currently being sued in three lawsuits alleging, among other things, that we made materially false and misleading statements regarding the legality of our business operations in China.

We, together with our executive officers, have been named as defendants in three complaints (one of which also names our directors as defendants) relating to running an alleged illegal multilevel marketing business in China and making alleged materially false and misleading statements regarding the legality of our business operations in China, among other things. These complaints seek an indeterminate amount of damages, and one of the complaints also seeks various equitable remedies. Notwithstanding potentially applicable insurance coverage, these complaints, or others filed alleging similar facts, could result in monetary or other penalties that may adversely affect our operating results and financial condition. Moreover, the negative publicity stemming from these complaints and the allegations they make could harm our business and operations. Accordingly, any adverse determination against us in these suits, or even the allegations contained in the suits regardless of whether they are ultimately found to be without merit, could harm our business, operations and financial condition.

We are currently involved in, and may in the future face, litigation claims and governmental proceedings and inquiries that could harm our business.
 
We are currently, and have in the past, been a party to lawsuits, claims and governmental proceedings and inquiries.  Prosecuting and defending these matters may require significant expense and attention of our management.  There can be no assurance that we will be able to successfully defend or resolve any such litigation, claims or governmental proceedings or inquiries, or that the significant money, time and effort spent in defending these matters will not adversely affect our business, financial condition and results of operations.

Although our members are independent contractors, improper member actions that violate laws or regulations could harm our business.
 
Our members are independent contractors and, accordingly, we are not in a position to directly provide the same direction, motivation and oversight as we would if members were our own employees.  As a result, there can be no assurance that our members will participate in our marketing strategies or plans, accept our introduction of new products, or comply with our member policies and procedures.  Extensive federal, state, local and foreign laws regulate our business, our products and our network marketing program.  Because we have expanded into foreign countries, our policies and procedures for our members differ due to the different legal requirements of each country in which we do business.  While we have implemented member policies and procedures designed to govern member conduct and to protect the goodwill associated with our trademarks and trade names, it can be difficult to enforce these policies and procedures because of the large number of members and their independent status.  
 

13


Given the size and diversity of our member force, we experience problems with members from time to time, especially with respect to our members in foreign markets. For example, if our members engage in illegal activities in China, those actions could be attributed to us. Chinese laws regarding how and when members may assemble and the activities that they may conduct, or the conditions under which the activities may be conducted, are subject to interpretations and enforcement that sometimes vary from province to province, among different levels of government, and from time to time. Members can be accused of violating one or more of the laws regulating these activities, notwithstanding training that we attempt to provide. Enforcement measures regarding these violations, which can include arrests, raise the uncertainty and perceived risk associated with conducting this business, especially among those who are aware of the enforcement actions but not the specific activities leading to the enforcement action. We believe that this has led some existing members in China - who are signed up as members in Hong Kong - to leave the business or curtail their selling activities and has led some potential members to choose not to participate. Among other things, we are managing this risk with more training and public relations efforts that are designed, among other things, to distinguish our company from businesses that make no attempt to comply with the law. This environment creates uncertainty about the future of doing this type of business in China generally and under our business model, specifically.

In addition, members often desire to enter a market before we have received approval to do business in order to gain an advantage in the marketplace.  Improper member activity in new geographic markets could result in adverse publicity and can be particularly harmful to our ability to ultimately enter these markets.  Violations by our members of applicable law or of our policies and procedures in dealing with customers could reflect negatively on our products and operations, and harm our business reputation.  In addition, it is possible that a judicial or administrative body could hold us civilly or criminally accountable based on vicarious liability because of the actions of our members.  If any of the above or related events involving our members occur, our business, financial condition, or results of operations could be materially adversely affected.

Direct-selling laws and regulations may prohibit or severely restrict our direct sales efforts and cause our revenue and profitability to decline, and regulators could adopt new regulations that harm our business.
 
Our direct selling system is subject to extensive laws, governmental regulations, administrative determinations, court decisions and similar constraints.  These laws and regulations are generally intended to prevent fraudulent or deceptive schemes, often referred to as “pyramid” schemes, which compensate participants for recruiting additional participants irrespective of product sales, use high pressure recruiting methods and/or do not involve legitimate products. They also seek to ensure that claims regarding the ability of participants to earn money are truthful and substantiated.
 
Complying with these widely varying and sometimes inconsistent rules and regulations can be difficult and may require the devotion of significant resources on our part.  There can be no assurance that we or our members are in compliance with all of these regulations.  Our failure or our members’ failure to comply with these regulations or new regulations could lead to the imposition of significant penalties or claims and could negatively impact our business.  If we are unable to continue business in existing markets or commence operations in new markets because of these laws, our revenue and profitability may decline.
 
We are also subject to the risk that new laws or regulations might be implemented or that current laws or regulations might change, which could require us to change or modify the way we conduct our business in certain markets.  This could be particularly detrimental to us if we have to change or modify the way we conduct business in markets that represent a significant percentage of our revenue.

The high level of competition in our industry could adversely affect our business.
 
The business of marketing personal care, cosmetic, nutritional supplements, and lifestyle enhancement products is highly competitive.  This market segment includes numerous manufacturers, members, marketers, and retailers that actively compete for the business of consumers both in the United States and abroad.  The market is highly sensitive to the introduction of new products, which may rapidly capture a significant share of the market.  Sales of similar products by competitors may materially and adversely affect our business, financial condition and results of operations.
 
We are subject to significant competition for the recruitment of members from other direct selling organizations, including those that market similar products.  Many of our competitors are substantially larger than we are, offer a wider array of products, have far greater financial resources and many more active members than we have.  Even more numerous are those medium- and small-sized, all privately held Chinese, Taiwanese and Hong Kong companies that are fierce competitors and are much closer to directly competing with us. Our ability to remain competitive depends, in significant part, on our success in recruiting and retaining members with our products, attractive compensation plan and other incentives.  We believe that we have an attractive product line and that our compensation and incentive programs provide our members with significant earning potential.  However, we cannot be sure that our programs for recruitment and retention of members will be successful.

14


 
Some of our competitors have employed or otherwise contracted for the services of our former officers, employees, consultants, and members, who may try to use information and contacts obtained while under contract with us for competitive advantage.  While we seek to protect our information through contractual and other means, there can be no assurance that we will timely learn of such activity, have the resources to attempt to stop it, or have adequate remedies available to us.
 
Challenges by third parties to the legality of our business operations could harm our business.

We are also subject to the risk of private party challenges to the legality of our operations, including our direct selling system.  The regulatory requirements concerning direct selling systems generally do not include “bright line” rules and are inherently fact-based and subject to judicial or administrative interpretation. An adverse judicial or administrative determination against us with respect to our direct selling system, or in proceedings not involving us directly but which challenge the legality of other direct selling marketing systems, could have a material adverse effect on our business.  There is also risk that challenges and settlements involving other parties could provide incentives for similar actions by members against us and other direct selling companies.  Moreover, challenges to our business system and operations in important markets may come from short sellers, hedge funds, other investors, bloggers and reporters.  Other companies in our industry have recently faced such challenges.  Any challenges regarding us or others in our industry could harm our business if such challenges result in the imposition of any fines or damages on our business, create adverse publicity, increase scrutiny or investigations of us or our industry, detrimentally affect our efforts to recruit or motivate members and attract customers, or interpret laws in a manner inconsistent with our current business practices.

An increase in the amount of compensation paid to members would reduce profitability.
 
We incur significant expense in the payment of compensation to our members, which represented approximately 42%, 44% and 48% of net sales during 2017, 2016 and 2015, respectively.  We compensate our members by paying commissions, bonuses, and certain awards and prizes.  Factors impacting the overall commission payout include the growth and depth of the member network, the member retention rate, the level of promotions, local promotional programs and business development agreements.  Any increase in compensation payments to members as a percentage of net sales will reduce our profitability.  

Our compensation plan includes a cap that may be enforced on member compensation paid out on a weekly dollar limit or as a percentage of product sales. There can be no assurance that enforcement of this cap will ensure profitability (which depends on many other factors).  Moreover, enforcement of this cap could cause key members affected by the cap to leave and join other companies.
 
Currency exchange rate fluctuations could lower our revenue and net income.
 
In 2017, 97% of our revenue was recorded by subsidiaries located outside of North America.  Revenue transactions and related commission payments, as well as other incurred expenses, are typically denominated in the local currency.  Accordingly, our international subsidiaries generally use the local currency as their functional currency.  The results of operations of our international subsidiaries are exposed to foreign currency exchange rate fluctuations during consolidation since we translate into U.S. dollars using the average exchanges rates for the period.  As exchange rates vary, revenue and other operating results may differ materially from our expectations.  Additionally, we may record significant gains or losses related to foreign-denominated cash and cash equivalents and the re-measurement of inter-company balances.  
 
Our most significant foreign exchange exposure, the Hong Kong dollar, is for now pegged to the U.S. dollar.  We also purchase a significant majority of inventories in U.S. dollars.  Our foreign currency exchange rate exposure to the South Korean won, Taiwan dollar, Japanese yen, Chinese yuan, Russian ruble, Kazakhstani tenge, Singaporean dollar, Malaysian ringgit, Vietnamese dong, Canadian dollar, Mexican peso, Peruvian sol and European euro collectively represented approximately 10%, 7% and 6% of our revenue in 2017, 2016 and 2015, respectively.  Our foreign currency exchange rate exposure may increase in the near future as we develop opportunities in Southeast Asia, Canada, Central America, South America and Europe.  Additionally, our foreign currency exchange rate exposure would significantly increase if the Hong Kong dollar were no longer pegged to the U.S. dollar.  Finally, we also experience indirect exchange rate exposure due to the concentration of our sales to members residing in China and the impact of fluctuations in the value of the Chinese yuan on our members’ purchasing power.

Given our inability to predict the degree of exchange rate fluctuations, we cannot estimate the effect these fluctuations may have upon future reported results, product pricing or our overall financial condition.  Further, to date we have not attempted to reduce our exposure to short-term exchange rate fluctuations by using foreign currency exchange contracts.
 

15


Changes in tax or duty laws, and unanticipated tax or duty liabilities, could adversely affect our net income.
 
In the course of doing business we may be subject to various taxes, such as sales and use, value-added, and franchise. We are also subject to income taxes in the United States and numerous foreign jurisdictions. We earn a substantial portion of our income in foreign jurisdictions. Economic and political conditions make tax rules in any jurisdiction, including the United States, subject to significant change. There have been recent changes in U.S. tax law that impact how U.S. multinational corporations are taxed on foreign earnings. There have also been proposals to reform foreign tax laws that could significantly affect the Company’s tax position. Although we cannot predict whether or in what form these proposals will pass, several of the proposals considered, if enacted into law, could have an adverse impact on our income tax expense and cash flows.
 
Our principal domicile is the United States. Under tax treaties, we are eligible to receive foreign tax credits in the United States for taxes paid abroad. Taxes paid to foreign taxing authorities may exceed the credits available to us, resulting in the payment of a higher overall effective tax rate on our worldwide operations.
 
Our effective income tax rate in the future could be adversely affected by a number of factors, including changes in the mix of earnings in countries with differing statutory tax rates, changes in the valuation of deferred tax assets and liabilities, changes in tax laws, and the outcome of income tax audits in various jurisdictions around the world.
 
We may also be subject to examinations of our tax returns and other tax matters by the Internal Revenue Service and other tax authorities and governmental bodies. We regularly assess the likelihood of an adverse outcome resulting from these examinations to determine the adequacy of our provision for taxes, which is subject to significant discretion. There can be no assurance as to the outcome of these examinations. If our effective tax rates were to increase, particularly in the U.S., or if the ultimate determination of taxes owed is for an amount in excess of amounts previously accrued, our financial results or operations could be adversely affected.
 
In addition, our operations are subject to regulations designed to ensure that appropriate levels of customs duties are assessed on the importation of our products. The failure to properly calculate, report and pay such duties when we are subject to them could have a material adverse effect on our financial condition and results of operations. Any change in the laws or regulations regarding such duties, or any interpretation thereof, could result in an increase in the cost of doing business.

Transfer pricing regulations affect our business and results of operations.
 
In many countries, including the United States, we are subject to transfer pricing and other tax regulations designed to ensure that appropriate levels of income are reported as earned by our United States or local entities and are taxed accordingly. We have adopted transfer pricing agreements with our subsidiaries to regulate inter-company transfers, which agreements are subject to transfer pricing laws that regulate the flow of funds between the subsidiaries and the parent corporation for product purchases, management services, and contractual obligations, such as the payment of member compensation. We believe that we operate in compliance with all applicable transfer pricing laws, and we intend to continue to operate in compliance with such laws. However, there can be no assurance that we will continue to be found to be operating in compliance with transfer pricing laws, or that those laws would not be modified, which, as a result, may require changes in our operating procedures or otherwise may have a material adverse effect on our financial results or operations.

Our products and related activities are subject to extensive government regulation, which could delay, limit or prevent the sale of some of our products in some markets. 
 
The formulation, manufacturing, packaging, labeling, importation, advertising, distribution, sale and storage of certain of our products are subject to extensive regulation by various federal agencies, including the Food and Drug Administration (the “FDA”), the FTC, the Consumer Product Safety Commission and the United States Department of Agriculture and by various agencies of the states, localities and foreign countries in which our products are manufactured, distributed and sold.  For example, the FDA requires us and our suppliers to meet relevant current good manufacturing practice (cGMP) regulations for the preparation, packing and storage of foods and over-the-counter (OTC) drugs.  We are also now required to report serious adverse events associated with consumer use of certain of our products.  Other laws and regulations govern or restrict the claims that may be made about our products and the information that must be included and excluded on labels.
 
In markets outside the United States, prior to commencing operations or marketing new products, we may be required to obtain approvals, licenses, or certifications from a ministry of health or a comparable agency. Moreover, a foreign jurisdiction may pass laws that would prohibit the use of certain ingredients in their particular market.  Compliance with these regulations can create delays and added expense in introducing new products to certain markets.
 

16


Failure by our members or us to comply with those regulations could lead to the imposition of significant penalties or claims and could materially and adversely affect our business.  If we are not able to satisfy the various regulations, then we would have to cease sales of that product in that market.  In addition, the adoption of new regulations or changes in the interpretation of existing regulations may result in significant compliance costs or discontinuation of product sales and may adversely affect the marketing of our products, resulting in significant loss of revenues.
 
We cannot predict the nature of any future laws, regulations, interpretations, or applications, nor can we determine what effect additional governmental regulations or administrative orders, when and if promulgated, could have on our business.  These potential effects could include, however, requirements for the reformulation of certain products to meet new standards, the recall or discontinuance of certain products, additional recordkeeping and reporting requirements, expanded documentation of the properties of certain products, expanded or different labeling, or additional scientific substantiation.  Any or all of these requirements could have a material adverse effect on our business, financial condition, or results of operations.

Failure of new products to gain member and market acceptance could harm our business.
 
An important component of our business is our ability to develop new products that create enthusiasm among our member force.  If we fail to introduce new products on a timely basis, our member productivity could be harmed.  In addition, if any new products fail to gain market acceptance, are restricted by regulatory requirements, or have quality problems, this would harm our results of operations.  Factors that could affect our ability to continue to introduce new products include, among others, limited capital and human resources, government regulations, proprietary protections of competitors that may limit our ability to offer comparable products and any failure to anticipate changes in consumer tastes and buying preferences.
 
New regulations governing the marketing and sale of nutritional supplements could harm our business.
 
There has been an increasing movement in the United States and other markets to increase the regulation of dietary supplements, which could impose additional restrictions or requirements in the future.  In the United States, for example, some legislators and industry critics continue to push for increased regulatory authority by the FDA over nutritional supplements.  Our business could be harmed if more restrictive legislation is successfully introduced and adopted in the future.  In particular, the adoption of legislation requiring FDA approval of supplements or ingredients could delay or inhibit our ability to introduce new supplements.  We face similar pressures in our other markets.  In the United States the FTC Guides Concerning the Use of Endorsements and Testimonials in Advertising (“Guides”) require disclosure of material connections between an endorser and the company they are endorsing and require the disclosure of typical results when these are different from those reported by the endorser.  The requirements and restrictions of the Guides may diminish the impact of our marketing efforts and negatively impact our sales results.  If we or our members fail to comply with these Guides, the FTC could bring an enforcement action against us and we could be fined and/or forced to alter our operations.  Our operations also could be harmed if new laws or regulations are enacted that restrict our ability to market or distribute nutritional supplements or impose additional burdens or requirements on nutritional supplement companies or require us to reformulate our products.
 
Regulations governing the production and marketing of our personal care products could harm our business.
 
Our personal care products are subject to various domestic and foreign laws and regulations that regulate cosmetic products and set forth regulations for determining whether a product can be marketed as a “cosmetic” or requires further approval as an over-the-counter drug.  A determination that our cosmetic products impact the structure or function of the human body, or improper marketing claims by our members, may lead to a determination that such products require pre-market approval as a drug.  Such regulations in any given market can limit our ability to import products and can delay product launches as we go through the registration and approval process for those products.  Furthermore, if we fail to comply with these regulations, we could face enforcement action against us and we could be fined, forced to alter or stop selling our products and/or required to adjust our operations.  Our operations also could be harmed if new laws or regulations are enacted that restrict our ability to market or distribute our personal care products or impose additional burdens or requirements on the contents of our personal care products or require us to reformulate our products.


17


If we are found not to be in compliance with good manufacturing practices our operations could be harmed.
 
Regulations on good manufacturing practices and adverse event reporting requirements for the nutritional supplement industry are in effect and require good manufacturing processes for us and our vendors, including stringent vendor qualifications, ingredient identification, manufacturing controls and record keeping.   We are also required to report serious adverse events associated with consumer use of our products.  Our operations could be harmed if regulatory authorities make determinations that we or our vendors are not in compliance with the regulations.  A finding of noncompliance may result in administrative warnings, penalties or actions impacting our ability to continue selling certain of our products.  In addition, compliance with these regulations has increased and may further increase the cost of manufacturing certain of our products as we work with our vendors to assure they are qualified and in compliance.
 
Failure to comply with domestic and foreign laws and regulations governing product claims and advertising could harm our business.
 
Our failure to comply with FTC or state regulations, or with regulations in foreign markets that cover our product claims and advertising, including direct claims and advertising by us, as well as claims and advertising by members for which we may be held responsible, may result in enforcement actions and imposition of penalties or otherwise materially and adversely affect the distribution and sale of our products.  Member activities in our existing markets that violate applicable governmental laws or regulations could result in governmental or private actions against us in markets where we operate.  Given the size of our member force, we cannot ensure that our members will comply with applicable legal requirements.
 
Adverse publicity associated with our products, ingredients or network marketing program, or those of similar companies, could harm our financial condition and operating results.
 
Adverse publicity concerning any actual or claimed failure by us or our members to comply with applicable laws and regulations regarding product claims and advertising, good manufacturing practices, the regulation of our network marketing program, the licensing of our products for sale in our target markets or other aspects of our business, whether or not resulting in enforcement actions or the imposition of penalties, could have an adverse effect on our goodwill and could negatively affect our ability to attract, motivate and retain members, which would negatively impact our ability to generate revenue.  We cannot ensure that all members will comply with applicable legal requirements relating to the advertising, labeling, licensing or distribution of our products.
 
In addition, our members’ and consumers’ perception of the safety and quality of our products and ingredients, as well as similar products and ingredients distributed by other companies, can be significantly influenced by media attention, publicized scientific research or findings, widespread product liability claims and other publicity concerning our products or ingredients or similar products and ingredients distributed by other companies.  Adverse publicity, whether or not accurate or resulting from consumers’ use or misuse of our products, that associates consumption of our products or ingredients or any similar products or ingredients with illness or other adverse effects, questions the benefits of our or similar products or claims that any such products are ineffective, inappropriately labeled or have inaccurate instructions as to their use, could negatively impact our reputation or the market demand for our products.

We are subject to risks relating to product concentration and lack of revenue diversification.
 
Although we have in recent years expanded our line of products, we derive more than 10% of our total revenue from each of our Premium Noni Juice and Enhanced Essential Probiotics® products. Further, we currently source each such product from a single supplier. If demand decreases significantly, government regulation restricts their sale, we are unable to adequately source or deliver the products, or we are unable to offer the products for any reason without suitable replacements, our business, financial condition and results of operations could be materially and adversely affected. Our future success will also depend on our ability to reduce our dependence on these few products by developing and introducing new products and product or feature enhancements in a timely manner. Even if we are able to develop and commercially introduce new products and enhancements, they may not achieve market acceptance and the revenue generated from these new products and enhancements may not offset the costs, which could substantially impair our business, financial condition and results of operations.
 

18


We rely on a limited number of independent third parties to manufacture and supply our products.
 
All of our products are manufactured by a limited number of independent third parties.  There is no assurance that our current manufacturers will continue to reliably supply products to us at the level of quality we require.  If a key manufacturer suffers liquidity problems or experiences operational or other problems assisting with our products, our results could suffer.  In the event any of our third-party manufacturers become unable or unwilling to continue to provide the products in required volumes and quality levels at acceptable prices, we will be required to identify and obtain acceptable replacement manufacturing sources or replacement products.  There is no assurance that we will be able to obtain alternative manufacturing sources or products or be able to do so on a timely basis.  An extended interruption in the supply of certain of our products may result in a substantial loss of revenue.  In addition, any actual or perceived degradation of product quality as a result of our reliance on third party manufacturers may have an adverse effect on revenue or result in increased product returns.  
 
Growth may be impeded by the political and economic risks of entering and operating in foreign markets.
 
Our ability to achieve future growth is dependent, in part, on our ability to continue our international expansion efforts.  However, there can be no assurance that we would be able to grow in our existing international markets, enter new international markets on a timely basis, or that new markets would be profitable.  We must overcome significant regulatory and legal barriers before we can begin marketing in any foreign market.
 
Also, it is difficult to assess the extent to which our products and sales techniques would be accepted or successful in any given country.  In addition to significant regulatory barriers, we may also encounter problems conducting operations in new markets with different cultures and legal systems from those elsewhere.  We may be required to reformulate certain of our products before commencing sales in a given country.  Once we have entered a market, we must adhere to the regulatory and legal requirements of that market.  No assurance can be given that we would be able to successfully reformulate our products in any of our current or potential international markets to meet local regulatory requirements or attract local customers.  The failure to do so could have a material adverse effect on our business, financial condition, and results of operations.  There can be no assurance that we would be able to obtain and retain necessary permits and approvals.
 
In many markets, other direct selling companies already have significant market penetration, the effect of which could be to desensitize the local member population to a new opportunity or to make it more difficult for us to recruit qualified members. There can be no assurance that, even if we are able to commence operations in foreign countries, there would be a sufficiently large population of potential members inclined to participate in a direct selling system offered by us.  We believe our future success could depend in part on our ability to seamlessly integrate our business methods, including member compensation plan, across all markets in which our products are sold.  There can be no assurance that we would be able to further develop and maintain a seamless compensation program.
 
We may be held responsible for certain taxes or assessments relating to the activities of our members and service providers, which could harm our financial condition and operating results.
 
Our members and service providers are subject to taxation, and in some instances, legislation or governmental agencies impose an obligation on us to collect the taxes, such as value added taxes, and to maintain appropriate records.  In addition, we are subject to the risk in some jurisdictions of being responsible for social security and similar taxes with respect to our members.
 
We may be unable to protect or use our intellectual property rights.
 
We rely on trade secret, copyright and trademark laws and confidentiality agreements with employees and third parties, all of which offer only limited protection of our confidential information and trademarks.  Moreover, the laws of some countries in which we market our products may afford little or no effective protection of our intellectual property rights.  The unauthorized copying, use or other misappropriation of our confidential information, trademarks and other intellectual property could enable third parties to benefit from such property without paying us for it.  This could have a material adverse effect on our business, operating results and financial condition.  If we resort to legal proceedings to enforce our intellectual property rights, the proceedings could be burdensome, expensive and result in inadequate remedies.  It is also possible that our use of our intellectual property rights could be found to infringe on prior rights of others and, in that event, we could be compelled to stop or modify the infringing use, which could be burdensome and expensive.
 

19


We do not have a comprehensive product liability insurance program and product liability claims could hurt our business.
 
Currently, we do not have a comprehensive product liability insurance program, although the insurance carried by our suppliers may cover certain product liability claims against us.  As a marketer of dietary supplements, cosmetics and other products that are ingested by consumers or applied to their bodies, we may become subjected to various product liability claims, including that:
 
our products contain contaminants or unsafe ingredients;

our products include inadequate instructions as to their uses; or

our products include inadequate warnings concerning side effects and interactions with other substances.
 
If our suppliers’ product liability insurance fails to cover product liability claims or other product liability claims, or any product liability claims exceeds the amount of coverage provided by such policies or if we are unsuccessful in any third party claim against the manufacturer or if we are unsuccessful in collecting any judgment that may be recovered by us against the manufacturer, we could be required to pay substantial monetary damages which could materially harm our business, financial condition and results of operations. As a result, we may become required to pay high premiums and accept high deductibles in order to secure adequate insurance coverage in the future.  Especially since we do not have direct product liability insurance, it is possible that product liability claims and the resulting adverse publicity could negatively affect our business.
 
Our internal controls and accounting methods may require modification.
 
We continue to review and develop controls and procedures sufficient to accurately report our financial performance on a timely basis.  If we do not develop and implement effective controls and procedures, we may not be able to report our financial performance on a timely basis and our business and stock price would be adversely affected.

We identified a material weakness in our internal control over financial reporting. If we do not adequately address this material weakness or if other material weaknesses or significant deficiencies in our internal control over financial reporting are discovered, our financial statements could contain material misstatements and our business, operations and stock price may be adversely affected.

As disclosed under “Item 9A. Controls and Procedures” of this report, our management has identified a material weakness in our internal control over financial reporting at December 31, 2017. Under standards established by the Public Company Accounting Oversight Board, a material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis. Although no material misstatement of our historical financial statements was identified, the existence of this or one or more material weaknesses or significant deficiencies could result in material misstatements in our financial statements and we could be required to restate our financial statements. Further, significant costs and resources may be needed to remediate the identified material weakness or any other material weaknesses or internal control deficiencies. If we are unable to remediate, evaluate, and test our internal controls on a timely basis in the future, management will be unable to conclude that our internal controls are effective and our independent registered public accounting firm will be unable to express an unqualified opinion on the effectiveness of our internal controls. If we cannot produce reliable financial reports, investors may lose confidence in our financial reporting, the price of our common stock could be adversely impacted and we could be subject to sanctions or investigations by the SEC, NASDAQ or other regulatory authorities, which could negatively impact our business, financial condition and results of operations.

We rely on and are subject to risks associated with our reliance upon information technology systems.
 
Our success is dependent on the accuracy, reliability, and proper use of information processing systems and management information technology.  Our information technology systems are designed and selected to facilitate order entry and customer billing, maintain member records, accurately track purchases and member compensation payments, manage accounting operations, generate reports, and provide customer service and technical support.  Any interruption in these systems could have a material adverse effect on our business, financial condition, and results of operations.
 
There can be no assurance that there will not be delays or interruptions in our information technology services.  An interruption or delay in availability of these services could, if it lasted long enough, prevent us from accepting orders, cause members to leave our business, or otherwise materially adversely affect our business.

20


 
System disruptions or failures, cybersecurity risks, and compromises of data could harm our business.

Because of our diverse geographic operations and our internationally applicable member compensation plans, our business is highly dependent on the secure and efficient functioning of our information technology systems, and the security of personal and sensitive business data. We collect certain personal information, including payment data, from members and consumers, as well as our employees. We also develop and maintain sensitive and proprietary business information. Any systems failure or interruption, breach in security, or loss of data, whatever the cause, could adversely affect our operations and financial results.

Systems disruptions and data breaches can derive from natural disasters, accidental technological events or human error, but can also result from fraud or malice on the part of external or internal parties.  Our systems, networks and software, like those of other companies, have been and are likely to continue to be, the target of cybersecurity threats and attacks, which may range from isolated or random attempts to sophisticated and targeted measures directed specifically at us. The risk of a systems disruption or data breach, particularly through cyber-attack or cyber intrusion, has increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. A material systems disruption or data breach affecting us could damage our reputation, deter members from purchasing our products, and result in cost and liability to us.

Although we have implemented technical and administrative safeguards to maintain the security and integrity of our information technology systems and data, there can be no assurance that our security efforts and measures will be effective in a continually evolving threat environment. In addition to the risks presented by malicious actors and natural disasters, many systems disruptions and data breaches are reportedly caused by human error. Therefore, despite our security policies and mandatory training, our systems and data are exposed to the risk that human error could either create a vulnerability that could be exploited by an attacker, or expose our systems and data to unintended risk of compromise. In addition, as described below, most of our information technology systems and data are hosted by third-party vendors over which we have limited control. We anticipate that we will be required to expend additional resources in order to continue to enhance our technical and administrative safeguards, and to investigate and remediate any vulnerabilities in our systems, networks and software.

In any case, a data breach or other significant disruption of our information systems or those related to our third party vendors, including as a result of cyber-attacks, could (1) disrupt the proper functioning of our systems and networks and therefore operations, (2) result in the unauthorized access to, and destruction, loss, theft, misappropriation or release of personal, confidential, sensitive or otherwise valuable data or other information, (3) result in a violation of applicable privacy, cybersecurity, data breach notification requirements under applicable laws, regulations and contractual provisions, subjecting us to additional regulatory scrutiny, and exposing us to possible fines, lawsuits and related financial liability, (4) require significant management attention and financial resources to investigate and remedy the breach or disruption, and (5) harm our reputation, cause a decrease in the number of our members and revenue, and otherwise damage our business.  The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition or results of operations.

Our systems, software and data reside on third-party servers, exposing us to risks that disruption or intrusion of those servers could temporarily or permanently interrupt our access and damage our business.

Beginning in 2012, most of our systems, software and data reside in the “cloud” on servers operated by third-party vendors to which we have limited access.  We assess the risks presented by these third-party vendors, and our contracts with them contain representations, warranties and other provisions related to the security of our data, and of the systems and software on which we rely. We are, however, limited in our ability to mitigate the risks of a systems disruption or data breach affecting our third-party vendors.  Moreover, any delay or failure in payment of the third-party vendors, disputes with such vendors, or business interruption or failure of the third-party vendors could result in loss of or interruption in access to our systems, software or data.  It is possible that our systems, software and data could in the future be moved to servers of different third parties or to our own servers.  Any such move could result in temporary or permanent loss of access to our systems, software or data.  Any protracted loss of such access would materially and adversely affect our business, financial condition and results of operations.


21


Terrorist attacks, acts of war, epidemics or natural disasters may seriously harm our business.

Terrorist attacks, acts of war, epidemics or natural disasters may cause damage or disruption to us, our employees, our facilities and our members and customers, which could impact our revenues, expenses and financial condition.  The potential for future terrorist attacks, the national and international responses to terrorist attacks, and other acts of war or hostility, such as challenges to Chinese sovereignty claims in the South China Sea or Chinese objection to the Taiwan independence movement and the resultant tension in the Taiwan Strait, could materially and adversely affect our business, results of operations, and financial condition in ways that we currently cannot predict.  Additionally, epidemics such as outbreaks of avian influenza, or natural disasters, whether or not as severe as the Indian Ocean tsunami that occurred in December 2004, may adversely affect our business, financial condition and results of operations.

We may experience substantial negative cash flows, which may have a significant adverse effect on our business and could threaten our solvency.
 
We experienced substantial negative cash flows during the years ended December 31, 2009 and 2008, primarily due to declines in our revenues greater than the decreases in expenditures we could manage.  If we again experience negative cash flows, any resulting decreasing cash balance could impair our ability to support our operations and, eventually, threaten our solvency, which would have a material adverse effect on our business, results of operations and financial condition, as well as our stock price.  Negative cash flows and the related adverse market perception associated therewith may have negatively affected, and may in the future negatively affect, our ability to attract new members and/or sell our products.  There can be no assurance that we will be successful in maintaining an adequate level of cash resources and we could be forced to act more aggressively in the area of expense reduction in order to conserve cash resources as we look for alternative solutions.
 
If we experience negative cash flows, we may need to seek additional debt or equity financing, which may not be available on acceptable terms or at all.  If available, it could have a highly dilutive effect on the holdings of existing stockholders.
 
Unless we are able to maintain revenues, control expenses and achieve positive cash flows, our ability to support our obligations could be impaired and our liquidity could be adversely affected and our solvency and our ability to repay our debts when they come due could be threatened.  We may need to seek additional debt or equity financing on acceptable terms in order to improve our liquidity.  However, we may not be able to obtain additional debt or equity financing on satisfactory terms, or at all, and any new financing could have a dilutive effect to our existing stockholders.
 
Disappointing quarterly revenue or operating results could cause the price of our common stock to fall.
     
Our quarterly revenue and operating results are difficult to predict and may fluctuate significantly from quarter to quarter.  If our quarterly revenue or operating results fall below the expectations of investors or securities analysts, the price of our common stock could fall substantially.
 
Our common stock is particularly subject to volatility because of the industry in which we operate.
 
The market prices of securities of direct selling companies have been extremely volatile, and have experienced fluctuations that have often been unrelated or disproportionate to the operating performance of such companies.  These broad market fluctuations could adversely affect the market price of our common stock.
 
Our common stock continues to experience wide fluctuations in trading volumes and prices. This may make it more difficult for holders of our common stock to sell shares when they want and at prices they find attractive.
 
The public market for our common stock has historically been very volatile experiencing wide fluctuations in trading volumes and prices. There are a number of factors that may contribute to this volatility, including the following:

active participation of speculative traders in our stock (including short sellers);

market rumors regarding our business operations;

22



government scrutiny of our business;

adverse publicity related to our business or industry; and

fluctuations in our operating results.

This market volatility for our stock may make it more difficult for holders of our stock to sell shares when they want and at prices they find attractive. There can be no assurance that a larger or more liquid market will be developed or maintained for our common stock.
 
Future sales by us or our existing stockholders could depress the market price of our common stock.
 
If we or our existing stockholders sell a large number of shares of our common stock, the market price of our common stock could decline significantly.  Further, even the perception in the public market that we or our existing stockholders might sell shares of common stock could depress the market price of our common stock.
 
Item 1B. UNRESOLVED STAFF COMMENTS

None.

Item 2. PROPERTIES
 
We lease 4,900 square feet of office space in Rolling Hills Estates, California for our corporate headquarters with a term expiring in September 2025. In August 2017, we entered into a lease for 2,000 square feet of retail space in Metuchen, New Jersey with a term expiring in November 2022, to help further develop the market for our products in North America. Similarly, we lease 2,400 and 1,600 square feet of retail space in Monterey Park, California and Richmond, British Columbia, respectively. The Monterey Park and Richmond locations have terms expiring in August 2020 and February 2021, respectively. We also maintain an office in Dallas, Texas.

Outside of North America, in February 2017, we entered into a lease for 9,000 square feet of office and retail space in Peru with a term expiring in July 2018. In November 2017, we renewed our lease for 7,300 square feet of office space in Hong Kong with a term expiring in February 2021, nine branch offices throughout China, and additional office space in Japan, Taiwan, South Korea, Singapore, Malaysia, Vietnam and the Cayman Islands. We also lease a multi-purpose facility and factory in Zhongshan, China and 11 service stations throughout the city of Guangzhou, China that serve or will in the future serve the needs of our Chinese consumers. We contract with third parties for fulfillment and distribution operations in all of our international markets. We believe that our existing office space is in good condition, and is suitable and adequate for the conduct of our business.
 

23


Item 3. LEGAL PROCEEDINGS

Securities Class Action

In January 2016, two putative securities class action complaints were filed against us and our top executives in the United States District Court for the Central District of California. On March 29, 2016, the Court consolidated these actions under the caption Ford v. Natural Health Trends Corp., Case No. 2:16-cv-00255-TJH-AFMx, appointed two Lead Plaintiffs, Mahn Dao and Juan Wang, and appointed the Rosen Law Firm and Levi & Korsinsky LLP as co-Lead Counsel for the purported class. Plaintiffs filed a consolidated complaint on April 29, 2016. The consolidated complaint purports to assert claims on behalf of all persons who purchased or otherwise acquired our common stock between March 6, 2015 and March 15, 2016 under (i) Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against Natural Health Trends Corp., and Chris T. Sharng, Timothy S. Davidson and George K. Broady (together, the “Individual Defendants”), and (ii) Section 20(a) of the Securities Exchange Act of 1934 against the Individual Defendants. The consolidated complaint alleges, among other things, that we have been running an allegedly illegal multilevel marketing business in China and that we have made materially false and misleading statements regarding the legality of our business operations in China. The consolidated complaint seeks an indeterminate amount of damages, plus interest and costs. On June 15, 2016, we filed a motion to dismiss the consolidated complaint, which was denied on December 5, 2016. On February 17, 2017, we filed an answer to the consolidated complaint. On July 10, 2017, the Court entered a stipulation between the parties, postponing all deadlines and staying the case to allow the parties to engage in settlement discussions. On July 17, 2017, the parties reached an agreement in principle to settle the action. The proposed class-wide settlement of $1.75 million was submitted to the Court on October 3, 2017.  The Court entered an order preliminarily approving the settlement on November 17, 2017, which was amended on January 4, 2018.  Plaintiffs have provided notice to the settlement class in accordance with the amended order, and a final approval hearing is currently set for April 2, 2018.  If approved, the proposed settlement will be fully funded by our insurers. Defendants continue to believe that these claims are without merit and intend to vigorously defend against them if a settlement is not finalized and approved by the Court.

Shareholder Derivative Claims

In February 2016, a purported shareholder derivative complaint was filed in the Superior Court of the State of California, County of Los Angeles: Zhou v. Sharng. In March 2016, a purported shareholder derivative complaint was filed in the United States District Court for the Central District of California: Kleinfeldt v. Sharng (collectively the “Derivative Complaints”). The Derivative Complaints purport to assert claims for breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement and corporate waste against certain of our officers and directors. The Derivative Complaints also purport to assert fiduciary duty claims based on alleged insider selling and conspiring to enter into several stock repurchase agreements, which allegedly harmed us and our assets. The Derivative Complaints allege, among other things, that we have been running an allegedly illegal multilevel marketing business in China, that we have made materially false and misleading statements regarding the legality of our business operations in China, and that certain officers and directors sold common stock on the basis of this allegedly material, adverse non-public information. The Derivative Complaints seek an indeterminate amount of damages, plus interest and costs, as well as various equitable remedies. On February 1, 2017, pursuant to a stipulation among the parties, the Los Angeles Superior Court entered a stay of the Zhou action pending conclusion of the related federal class action in the United States District Court for the Central District of California: Ford v. Natural Health Trends Corp. A nearly identical stipulated stay was entered in the Kleinfeldt case on February 28, 2017. On November 10, 2017, the parties to both the Zhou and Kleinfeldt actions entered into a Memorandum of Understanding (“MOU”) to resolve both actions, subject to the negotiation of a written settlement agreement and approval by the federal court in the Kleinfeldt matter.  On November 15, 2017, the parties filed a joint status report and stipulation in the Zhou matter, alerting the court to the MOU and seeking to maintain the stay pending finalization and court approval of the parties’ tentative settlement.  The Zhou court entered an order continuing the stay on November 17, 2017. On March 9, 2018, the parties filed a Stipulation of Settlement and supporting papers in the Kleinfeldt action.  On March 22, 2018, plaintiffs filed a motion for preliminary approval of the tentative settlement. The settlement is subject to both preliminary and final approval by the court. If approved, the proposed settlement will require certain corporate governance reforms and permit an award of up to $250,000 in attorneys’ fees to plaintiffs’ counsel, all of which will be fully funded by our insurers. Defendants continue to believe that these claims are without merit and intend to vigorously defend against them if the derivative settlement is not finalized and approved.

The consolidated class action (if the settlement is not approved by the Court) and the Derivative Complaints (if the tentative settlement is not finalized or approved), or other actions alleging similar facts, could result in monetary or other penalties that may materially affect our operating results and financial condition.


24


Item 4. MINE SAFETY DISCLOSURES
Not applicable.

Part II
Item 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Market Information
Our common stock is currently traded on the NASDAQ Capital Market (“Nasdaq”) under the symbol “NHTC.” The following table sets forth the range of the high and low bid quotations of our common stock as reported by Nasdaq. The bid quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions.
 
2017
 
2016
 
High
 
Low
 
High
 
Low
First quarter
$
29.66

 
$
24.45

 
$
36.19

 
$
17.75

Second quarter
29.76

 
27.78

 
38.25

 
26.24

Third quarter
28.98

 
18.55

 
34.30

 
25.89

Fourth quarter
24.93

 
15.19

 
29.95

 
21.44

 
On March 21, 2018, the closing price of our common stock as reported by Nasdaq was $19.15 per share.
 
Holders of Record
At March 21, 2018, there were approximately 110 record holders of our common stock (although we believe that the number of beneficial owners of our common stock is substantially greater).

Dividends
The following tables summarize all cash dividend activity during 2017 and 2016 (in thousands, except per share data), all of which dividend payments were made to holders of our common stock:
Declaration Date
 
Per Share
 
Amount
 
Payment Date
October 30, 2017 (special)
 
$
0.15

 
$
1,701

 
November 24, 2017
October 30, 2017
 
0.12

 
1,360

 
November 24, 2017
July 31, 2017 (special)
 
0.25

 
2,833

 
August 31, 2017
July 31, 2017
 
0.11

 
1,246

 
August 31, 2017
April 24, 2017 (special)
 
0.35

 
3,964

 
May 19, 2017
April 24, 2017
 
0.10

 
1,133

 
May 19, 2017
January 24, 2017 (special)
 
0.35

 
3,962

 
March 3, 2017
January 24, 2017
 
0.09

 
1,019

 
March 3, 2017
 
 
$
1.52

 
$
17,218

 
 
Declaration Date
 
Per Share
 
Amount
 
Payment Date
October 23, 2016 (special)
 
$
0.35

 
$
3,941

 
November 25, 2016
October 23, 2016
 
0.08

 
901

 
November 25, 2016
July 19, 2016
 
0.07

 
787

 
August 26, 2016
April 21, 2016
 
0.06

 
686

 
May 20, 2016
March 1, 2016
 
0.05

 
576

 
March 24, 2016
Total
 
$
0.61

 
$
6,891

 
 
Additionally, on February 6, 2018, the Board of Directors declared a cash dividend of $0.13 on each share of common stock outstanding. Such dividends were paid on March 9, 2018 to stockholders of record on February 27, 2018. Declaration and payment of any future dividends on shares of common stock will be at the discretion of our Board of Directors.

25



Stock Performance Graph

Set forth below is a line graph and table comparing the performance of our common stock to the S&P 500 Index and to a market-weighted index of publicly traded peers from the period from December 31, 2012 through December 31, 2017. The graph assumes $100 was invested in our common stock, the S&P 500 Index and the index of publicly traded peers on December 31, 2012 and that all dividends were reinvested. The publicly traded companies in the peer group consist of Nature’s Sunshine Products, Nu Skin Enterprises Inc., USANA Health Sciences Inc., and Herbalife Ltd. The graph represents past performance and should not be considered to be an indication of future performance.

chart-582c681860f25365be1.jpg
 Period
 
NHTC
 
S&P 500
 
Peer Group
December 31, 2012
 
$
100

 
$
100

 
$
100

December 31, 2013
 
317

 
132

 
302

December 31, 2014
 
1,137

 
151

 
182

December 31, 2015
 
3,342

 
153

 
226

December 31, 2016
 
2,538

 
171

 
219

December 31, 2017
 
1,707

 
208

 
302



26


Item 6. SELECTED FINANCIAL DATA

The following selected consolidated financial data, which have been derived from our audited consolidated financial statements, are not necessarily indicative of the results of future operations and should be read in conjunction with “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations”, and the consolidated financial statements and accompanying notes included elsewhere in this Annual Report on Form 10-K (in thousands, except per share data).
 
Year Ended December 31
 
2017
 
2016
 
2015
 
2014
 
2013
Consolidated Statements of Operations Data:
 
 
 
 
 
 
 
 
 
Net sales
$
197,563

 
$
287,728

 
$
264,860

 
$
124,590

 
$
52,527

Cost of sales
38,645

 
54,903

 
54,098

 
26,981

 
12,551

Gross profit
158,918

 
232,825

 
210,762

 
97,609

 
39,976

Operating expenses:
 
 
 
 
 
 
 
 
 
Commissions expense
83,638

 
125,050

 
126,598

 
56,997

 
24,053

Selling, general and administrative expenses
31,685

 
43,245

 
36,024

 
19,687

 
11,634

Depreciation and amortization
536

 
394

 
263

 
105

 
66

Total operating expenses
115,859

 
168,689

 
162,885

 
76,789

 
35,753

Income from operations
43,059

 
64,136

 
47,877

 
20,820

 
4,223

Other income (expense), net
367

 
(59
)
 
(84
)
 
(184
)
 
(32
)
Income before income taxes
43,426

 
64,077

 
47,793

 
20,636

 
4,191

Income tax provision
19,848

 
8,991

 
552

 
266

 
102

Net income
23,578

 
55,086

 
47,241

 
20,370

 
4,089

Preferred stock dividends

 

 

 
(10
)
 
(15
)
Net income available to common stockholders
$
23,578

 
$
55,086

 
$
47,241

 
$
20,360

 
$
4,074

Net income per common share:
 
 
 
 
 
 
 
 
 
Basic
$
2.10

 
$
4.84

 
$
3.84

 
$
1.67

 
$
0.36

Diluted
$
2.09

 
$
4.83

 
$
3.82

 
$
1.61

 
$
0.36

Weighted-average number of common shares outstanding:
 
 
 
 
 
 
 
 
 
Basic
11,251

 
11,382

 
12,302

 
12,131

 
11,154

Diluted
11,267

 
11,407

 
12,372

 
12,600

 
11,331

Cash dividends declared per common share
$
1.52

 
$
0.61

 
$
0.14

 
$
0.03

 
$

 
 
 
 
 
 
 
 
 
 
Consolidated Balance Sheets Data:
 
 
 
 
 
 
 
 
 
Cash and cash equivalents
$
135,311

 
$
125,921

 
$
104,914

 
$
44,816

 
$
14,550

Inventories
8,398

 
11,257

 
10,455

 
3,760

 
1,828

Working capital
109,322

 
84,090

 
56,199

 
25,253

 
3,598

Long-term incentive
7,904

 
8,190

 
5,770

 
1,665

 

Non-current income taxes payable
19,052

 

 

 

 

Total assets
159,554

 
148,051

 
124,152

 
52,540

 
19,827

Total stockholders’ equity
90,621

 
82,439

 
56,809

 
26,450

 
6,077

 
 
 
 
 
 
 
 
 
 
Consolidated Statements of Cash Flows Data:
 
 
 
 
 
 
 
 
 
Net cash provided by (used in):
 
 
 
 
 
 
 
 
 
Operating activities
$
26,605

 
$
53,174

 
$
81,326

 
$
30,613

 
$
10,686

Investing activities
(278
)
 
(905
)
 
(3,738
)
 
(339
)
 
(292
)
Financing activities
(17,218
)
 
(30,595
)
 
(17,471
)
 
(189
)
 
(52
)
Income taxes paid, net of refunds
6,772

 
8,791

 
707

 
60

 
71


27


Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Business Overview
 
We are an international direct-selling and e-commerce company. Subsidiaries controlled by us sell personal care, wellness, and “quality of life” products under the “NHT Global” brand. Our wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia and Vietnam; South Korea; Japan; and Europe. We also operate in Russia and Kazakhstan through our engagement with a local service provider. See Note 10 of the Notes to Consolidated Financial Statements in “Item 8. Financial Statements and Supplementary Data” of this report for further information about our net sales by geographic area.
 
As of December 31, 2017, we were conducting business through 95,670 active members, compared to 118,960 in 2016 and 109,360 in 2015. We consider a member “active” if they have placed at least one product order with us during the preceding year. Our priority is to focus our resources in our most promising markets, which we consider to be Greater China and countries where our existing members have the connections to recruit prospects and sell our products, such as Southeast Asia and Europe. We also invested some resources in Mexico and Peru during 2017.
 
We generate approximately 97% of our net sales from subsidiaries located outside the Americas, with sales of our Hong Kong subsidiary representing 89% of net sales in the latest fiscal year. Because of the size of our foreign operations, operating results can be impacted negatively or positively by factors such as foreign currency fluctuations, and economic, political and business conditions around the world. In addition, our business is subject to various laws and regulations, in particular, regulations related to direct selling activities that create uncertain risks for our business, including improper claims or activities by our members and potential inability to obtain necessary product registrations. For further information regarding some of the risks associated with the conduct of our business in China, see “Item 1A. Risk Factors,” and more specifically under the captions “Risk Factors - Because our Hong Kong operations account for a substantial portion of our overall business...” and “Risk Factors - Our operations in China are subject to compliance with a myriad of applicable laws and regulations...”.
 
China has been and continues to be our most important business development project. We operate an e-commerce direct selling model in Hong Kong that generates revenue derived from the sale of products to members in Hong Kong and elsewhere, including China. Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. Through a separate Chinese entity, we operate an e-commerce retail platform in China. We believe that neither of these activities require a direct selling license in China, which we do not currently hold. We have previously sought to obtain a direct selling license, and in August 2015 initiated the process for submitting a new preliminary application for a direct selling license in China. If we are able to obtain a direct selling license in China, we believe that the incentives inherent in the direct selling model in China would incrementally benefit our existing business. We do not expect that any increased sales in China derived from obtaining a direct selling license would initially be material and, in any event may be partially offset by the higher fixed costs associated with the establishment and maintenance of required service centers, branch offices, manufacturing facilities, certification programs and other legal requirements. We are unable to predict whether and when we will be successful in obtaining a direct selling license to operate in China, and if we are successful, when we will be permitted to conduct direct selling operations and whether such operations would be profitable.

Income Statement Presentation
 
We mainly derive revenue from sales of products. Substantially all of our product sales are to independent members at published wholesale prices. Product sales are recorded when the products are shipped and title passes to independent members, which generally is upon our delivery to the carrier that completes delivery to the members. We estimate and accrue a reserve for product returns based on our return policies and historical experience. Enrollment package revenue, including any nonrefundable set-up fees, is deferred and recognized over the term of the arrangement, generally twelve months. We bill members for shipping charges and recognize the freight revenue in net sales. Event and training revenue is deferred and recognized as the event or training occurs.
 
Cost of sales consists primarily of products purchased from third-party manufacturers, freight cost for transporting products to our foreign subsidiaries and shipping products to members, import duties, packing materials, product royalties, costs of promotional materials sold to our members at or near cost, and provisions for slow moving or obsolete inventories. Cost of sales also includes purchasing costs, receiving costs, inspection costs and warehousing costs.
 

28


Member commissions are our most significant expense and are classified as an operating expense. Under our compensation plan, members are paid weekly commissions by our subsidiary in which they are enrolled, generally in their home country currency, for product purchases by their down-line member network across all geographic markets. Our China subsidiary maintains an e-commerce retail platform and does not pay commissions. This “seamless” compensation plan enables a member located in one country to enroll other members located in other countries where we are authorized to conduct our business. Currently, there are basically two ways in which our members can earn income:

through commissions paid on the accumulated bonus volume from product purchases made by their down-line members and customers; and

through retail profits on sales of products purchased by members at wholesale prices and resold at retail prices (in some markets, sales are for personal consumption only and income may not be earned through retail profits).
 
Each of our products is designated a specified number of bonus volume points. Commissions are based on total personal and group bonus volume points per weekly sales period. Bonus volume points are essentially a percentage of a product’s wholesale price. As the member’s business expands from successfully enrolling other members who in turn expand their own businesses by selling product to other members, the member receives higher commissions from purchases made by an expanding down-line network. In some of our markets, to be eligible to receive commissions, a member may be required to make nominal monthly or other periodic purchases of our products. Certain of our subsidiaries do not require these nominal purchases for a member to be eligible to receive commissions. In determining commissions, the number of levels of down-line members included within the member’s commissionable group increases as the number of memberships directly below the member increases.

Under our current compensation plan, certain of our commission payouts may be limited to a hard cap dollar amount per week or a specific percentage of total product sales. In some markets, commissions may be further limited. In some markets, we also pay certain bonuses on purchases by up to three generations of personally enrolled members, as well as bonuses on commissions earned by up to three generations of personally enrolled members. Members can also earn additional income, trips and other prizes in specific time-limited promotions and contests we hold from time to time. Member commissions are dependent on the sales mix and, for each of fiscal 2017, 2016 and 2015 represented 42%, 44% and 48%, respectively, of net sales. Occasionally, we make modifications and enhancements to our compensation plan to help motivate members, which can have an impact on member commissions. We may also enter into performance-based agreements for business or market development, which can result in additional compensation to specific members.
 
Selling, general and administrative expenses consist of administrative compensation and benefits, travel, credit card fees and assessments, professional fees, certain occupancy costs, and other corporate administrative expenses (including stock-based compensation). In addition, this category includes selling, marketing, and promotion expenses (including the costs of member training events and conventions that are designed to increase both product awareness and member recruitment). Because our various member conventions are not always held at the same time each year, interim period comparisons will be impacted accordingly. 

The functional currency of our international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.  The resulting translation adjustments are recorded directly into accumulated other comprehensive income.
 
Sales by our foreign subsidiaries are generally transacted in the respective local currencies and are translated into U.S. dollars using average rates of exchange for each monthly accounting period to which they relate.  Most of our product purchases from third-party manufacturers are transacted in U.S. dollars.  Consequently, our sales and net earnings are affected by changes in currency exchange rates, with sales and earnings generally increasing with a weakening U.S. dollar and decreasing with a strengthening U.S. dollar, see “Item 7A. Quantitative and Qualitative Disclosures About Market Risk” and more specifically under the caption “Foreign Currency Exchange Risk” for further information. 


29


Results of Operations
 
The following table sets forth our operating results as a percentage of net sales for the periods indicated:
 
Year Ended December 31,
 
2017
 
2016
 
2015
Net sales
100.0
%
 
100.0
%
 
100.0
%
Cost of sales
19.6

 
19.1

 
20.4

Gross profit
80.4

 
80.9

 
79.6

Operating expenses:
 
 
 
 
 
Commissions expense
42.3

 
43.5

 
47.8

Selling, general and administrative expenses
16.0

 
15.0

 
13.6

Depreciation and amortization
0.3

 
0.1

 
0.1

Total operating expenses
58.6

 
58.6

 
61.5

Income from operations
21.8

 
22.3

 
18.1

Other income (expense), net
0.2

 

 

Income before income taxes
22.0

 
22.3

 
18.1

Income tax provision
10.0

 
3.1

 
0.2

Net income
12.0
%
 
19.2
%
 
17.9
%
 
The following table sets forth revenue by market for the periods indicated (in thousands):
 
Year Ended December 31,
 
2017
 
2016
 
2015
Americas1
$
5,794

 
2.9
%
 
$
5,909

 
2.0
%
 
$
5,992

 
2.3
%
Hong Kong2
174,926

 
88.5

 
263,482

 
91.6

 
245,737

 
92.8

China
7,282

 
3.7

 
9,086

 
3.2

 
4,425

 
1.7

Taiwan
5,591

 
2.8

 
6,213

 
2.2

 
5,965

 
2.3

South Korea
466

 
0.2

 
691

 
0.2

 
1,128

 
0.4

Japan
129

 
0.1

 
86

 

 
92

 

Singapore
184

 
0.1

 
169

 
0.1

 

 

Russia, Kazakhstan and Ukraine3
913

 
0.5

 
858

 
0.3

 
1,139

 
0.4

Europe
2,278

 
1.2

 
1,234

 
0.4

 
382

 
0.1

Total
$
197,563

 
100.0
%
 
$
287,728

 
100.0
%
 
$
264,860

 
100.0
%
_____________________________ 
1 United States, Canada, Mexico and Peru.
2 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors”.
3 We discontinued our Ukraine operations during the second quarter of 2015.

Financial Results of 2017 Compared to 2016

Net Sales
 
Net sales were $197.6 million for the year ended December 31, 2017 compared with $287.7 million a year ago, a decrease of $90.1 million, or 31%.  Hong Kong net sales, substantially all of which were shipped to members residing in China, decreased $88.6 million, or 34%, over the prior year. The sales decrease was primarily attributable to the slowdown we have been experiencing in our Asian markets since the third quarter of 2016. We believe much of this decrease could be traced to factors beyond our control, including the G20 Summit, the 20th Anniversary of Hong Kong’s handover and the 19th National Congress of the Communist Party of China, which impaired our members’ ability to conduct business and impacted the operations of our logistics partners. In addition, Hong Kong experienced a decrease of 26,400 active members, or 24%, during 2017, which contributed to the decrease in product sales volume.

30


 
Outside of our Hong Kong business, net sales decreased $1.6 million, or 7%, compared with the prior year, driven by a 20% decrease in our China e-commerce business and offset by an 85% increase in Europe. The $1.8 million net sales decrease in our China e-commerce business was primarily driven by decreased sales in our Home product line. The $1.0 million net sales increase in Europe was primarily driven by our Wellness product line.
 
As of December 31, 2017, deferred revenue was $4.5 million, which primarily consisted of $2.4 million in unshipped product orders, and $1.7 million and $379,000 pertaining to auto ship advances and unamortized enrollment package revenue, respectively.
 
Gross Profit
 
Gross profit was 80.4% of net sales for the year ended December 31, 2017 compared with 80.9% of net sales for the year ended December 31, 2016. The gross profit margin percentage decrease is primarily due to lower event revenue, offset by lower logistics costs.
 
Commissions
 
Commissions were 42.3% of net sales for the year ended December 31, 2017 compared with 43.5% of net sales for the year ended December 31, 2016.  The decrease as a percentage of net sales was primarily due to less cost incurred for our third quarter incentive trip than expected and recognized during the qualification period in 2016. Excluding this benefit, commissions as a percentage of net sales for 2017 would have been relatively consistent with 2016.
 
Selling, General and Administrative Expenses
 
Selling, general and administrative expenses were $31.7 million for the year ended December 31, 2017 compared with $43.2 million for the year ended December 31, 2016. Selling, general and administrative expenses decreased by $11.6 million, or 27%, mainly due to a decrease in employee-related expenses, event costs, member training costs, and a decrease in credit card fees and assessments due to lower net sales, offset by an increase in professional fees, as compared to the year ended December 31, 2016.
 
Income Taxes
 
An income tax provision of $19.8 million was recognized for the year ended December 31, 2017 compared with $9.0 million for the year ended December 31, 2016. The increase is due to the enactment of the Tax Cuts and Jobs Act (the “Tax Act”) on December 22, 2017 by the U.S. government which is effective for taxable years beginning on or after January 1, 2018. Two major provisions of the Tax Act, however, increased our effective tax rate for the year ended December 31, 2017. The first of such provisions reduces the maximum U.S. federal corporate income tax rate from 35% to 21% effective January 1, 2018 (reducing the value of our net deferred tax asset by $1.0 million), and the second of which requires a one-time repatriation tax on certain un-repatriated earnings of foreign subsidiaries at a rate of 15.5% tax on post-1986 foreign earnings held in cash and an 8% rate on all other post-1986 earnings (resulting in a 2017 tax liability of $20.7 million). As a result of the repatriation tax, we reversed our deferred tax liability previously established for undistributed foreign earnings resulting in a tax benefit of $3.7 million, which partially offset the effect on tax expense of the repatriation tax.

Financial Results of 2016 Compared to 2015

Net Sales
 
Net sales were $287.7 million for the year ended December 31, 2016 compared with $264.9 million a year ago, an increase of $22.8 million, or 9%.  Hong Kong net sales, substantially all of which were shipped to members residing in China, increased $17.7 million, or 7%, over the prior year. Hong Kong experienced an increase of 7,800 active members, or 8%, during 2016, which contributed to the increase in product sales volume. We also launched new Wellness products during 2016, which contributed approximately $11.2 million to our top-line growth. However, we believe our net sales increase was adversely impacted by the following:

A primary factor was the special measures the Chinese government implemented in preparation of the G20 Summit in Hangzhou, one of our top markets, in which they relocated city residents, emptied entire districts, blocked urban traffic and shut down businesses in July, August and early September 2016.


31


Also, we did not offer a comparable incentive trip promotion in 2016 as the 2015 supplemental incentive trip promotion to the U.S., which proved to be appealing and contributed to increased sales in 2015.

Finally, the devaluation of the Chinese yuan, which depreciated 7% against the Hong Kong dollar during 2016, indirectly affected our financial results by increasing the product pricing in the currency of our Chinese members.
 
Outside of our Hong Kong business, net sales increased $5.1 million, or 27%, compared with the prior year, driven by a 105% increase in our China e-commerce business and a 223% increase in Europe, offset by the performance of South Korea, which decreased 39% and our Commonwealth of Independent States (“CIS”) market, which decreased 25%. The $4.7 million net sales increase in our China e-commerce business was primarily driven by increased sales in our Home product line, which was introduced during the fourth quarter of 2015. The $852,000 net sales increase in Europe was primarily driven by our Wellness product line.
 
As of December 31, 2016, deferred revenue was $4.9 million, which primarily consisted of $2.2 million in unshipped product orders, and $2.3 million and $430,000 pertaining to auto ship advances and unamortized enrollment package revenue, respectively.
 
Gross Profit
 
Gross profit was 80.9% of net sales for the year ended December 31, 2016 compared with 79.6% of net sales for the year ended December 31, 2015. The gross profit margin percentage increase is due to higher event and training revenue, higher product margins and lower logistics costs.
 
Commissions
 
Commissions were 43.5% of net sales for the year ended December 31, 2016 compared with 47.8% of net sales for the year ended December 31, 2015.  The decrease as a percentage of net sales resulted primarily from the reduction in our on-going cash and other incentive programs which cost 3.0% of net sales for the year ended December 31, 2016 compared with 6.4% of net sales for the year ended December 31, 2015.
 
Selling, General and Administrative Expenses
 
Selling, general and administrative expenses were $43.2 million for the year ended December 31, 2016 compared with $36.0 million for the year ended December 31, 2015. Selling, general and administrative expenses increased by $7.2 million, or 20%, mainly due to an increase in event costs, member training costs, professional fees, and an increase in credit card fees and assessments due to higher net sales, offset by a decrease in our employee-related expenses, as compared to the year ended December 31, 2015.
 
Income Taxes
 
An income tax provision of $9.0 million was recognized for the year ended December 31, 2016 compared with $552,000 for the year ended December 31, 2015. The increase is due to greater profitability of our international operations, as well as the repatriation of foreign earnings back to the U.S. during the year. As a result of capital return activities approved by the Board of Directors during the first quarter of 2016 and anticipated future capital return activities, we then determined that a portion of our undistributed foreign earnings were no longer deemed reinvested indefinitely by our non-U.S. subsidiaries. We repatriated $19.8 million to the U.S. during the three months ended March 31, 2016, part of which was offset by U.S. net operating losses. Accordingly, the deferred tax liability previously established for undistributed foreign earnings up to existing U.S. net operating losses was reduced. The excess amount repatriated during the year ended December 31, 2016 was generated from current foreign earnings. In addition, during the three months ended December 31, 2016, we released our remaining valuation allowance against U.S. deferred tax assets as it was determined that it is more likely than not that we will realize the tax benefits of our deferred assets in future periods.


32


Liquidity and Capital Resources
 
At December 31, 2017, our cash and cash equivalents totaled $135.3 million, of which $134.2 million is held in bank accounts overseas. Total cash and cash equivalents increased by $9.4 million and $21.0 million during 2017 and 2016, respectively. We consider all highly liquid investments with original maturities of three months or less, when purchased, to be cash equivalents. As of December 31, 2017, we had $73.6 million in available-for-sale investments classified as cash equivalents. In addition, cash and cash equivalents included $8.7 million held in banks located in China subject to foreign currency controls.
 
At December 31, 2017, the ratio of current assets to current liabilities was 3.61 to 1.00 and we had $109.3 million of working capital. Working capital as of December 31, 2017 increased $25.2 million compared to our working capital as of December 31, 2016, primarily due to our proactive expense management efforts designed to better align our cost structure with the challenging environment that we encountered during 2017.

Cash provided by operations during 2017 was $26.6 million compared to $53.2 million during 2016. The decrease in operating cash flows resulted primarily from the decrease in product orders and the impact of our members’ increasing utilization of our eWallet functionality, offset by a reduction in inventories and inventory-related deposits during 2017.

Cash flows used in investing activities totaled $278,000 during 2017 and consisted primarily of capitalizable software development costs and buildout costs for our expansion into Peru and Vietnam. Cash flows used in investing activities totaled $905,000 during the year ended December 31, 2016 and consisted primarily of capitalized software development costs of $666,800 for our Oracle ERP upgrade and enhancement of our back office software platform.

Cash flows used in financing activities during 2017 consisted solely of the following cash dividend payments (in thousands, except per share amounts) to holders of our common stock:
Declaration Date
 
Per Share
 
Amount
 
Record Date
 
Payment Date
October 30, 2017 (special)
 
$
0.15

 
$
1,701

 
November 14, 2017
 
November 24, 2017
October 30, 2017
 
0.12

 
1,360

 
November 14, 2017
 
November 24, 2017
July 31, 2017 (special)
 
0.25

 
2,833

 
August 21, 2017
 
August 31, 2017
July 31, 2017
 
0.11

 
1,246

 
August 21, 2017
 
August 31, 2017
April 24, 2017 (special)
 
0.35

 
3,964

 
May 9, 2017
 
May 19, 2017
April 24, 2017
 
0.10

 
1,133

 
May 9, 2017
 
May 19, 2017
January 24, 2017 (special)
 
0.35

 
3,962

 
February 21, 2017
 
March 3, 2017
January 24, 2017
 
0.09

 
1,019

 
February 21, 2017
 
March 3, 2017
Total
 
$
1.52

 
$
17,218

 
 
 
 

Subsequent to December 31, 2017, on February 6, 2018, the Board of Directors declared a cash dividend of $0.13 on each share of common stock outstanding. Such dividends were paid on March 9, 2018 to stockholders of record on February 27, 2018. Declaration and payment of any future dividends on shares of common stock will be at the discretion of our Board of Directors.

Cash flows used in financing activities during 2016 totaled $30.6 million. We used $23.7 million to repurchase shares of our common stock. On January 12, 2016, the Board of Directors authorized an increase to our stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that our earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, we may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require us to acquire a specific number of shares, and may be suspended from time to time or discontinued. During February 2016, pursuant to the stock repurchase program, we authorized our broker to proceed with the purchase of shares of our common stock in the open market. During the year ended December 31, 2016, the stock repurchase program resulted in our purchasing a total of 903,031 shares of our common stock for an aggregate purchase price of $23.7 million, plus transaction costs. As of December 31, 2017, $32.0 million of the $70.0 million stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax. No shares were purchased under our stock repurchase program during 2017.


33


We believe that our existing internal liquidity, supported by cash on hand and cash flows from operations should be adequate to fund normal business operations and address our financial commitments for the foreseeable future.
 
We do not have any significant unused sources of liquid assets. If necessary, we may attempt to generate more funding from the capital markets, but currently do not believe that will be necessary.

Our priority is to focus our resources on investing in our most important markets, which we consider to be Greater China and countries where our existing members may have the connections to recruit prospects and sell our products, such as Southeast Asia and Europe. We will continue to invest in our Mainland China entity for such purposes as establishing China-based manufacturing capabilities, increasing public awareness of our brand and our products, sourcing more Chinese-made products, building a chain of service stations, opening additional Healthy Lifestyle Centers or branch offices, adding local staffing and other requirements for a China direct selling license application. We also have invested some resources in Mexico and Peru.

Quarterly Results of Operations (Unaudited)

The following table sets forth unaudited quarterly operating results for each of the last eight fiscal quarters. The information for each of these quarters has been prepared on the same basis as the audited annual financial statements included elsewhere in this annual report and, in the opinion of management, includes all adjustments, which includes only normal recurring adjustments, necessary for the fair statement of the results of operations for these periods. This data should be read in conjunction with our audited consolidated financial statements and related notes included in “Item 8. Financial Statements and Supplementary Data” of this annual report. These quarterly operating results are not necessarily indicative of our operating results for any future period.
 
2017
 
2016
 
4th
Quarter1
 
3rd
Quarter
 
2nd
Quarter
 
1st
Quarter
 
4th
Quarter
 
3rd
Quarter
 
2nd
Quarter
 
1st
Quarter
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(In Thousands, Except Per Share Data)
Net sales
$
46,092

 
$
40,132

 
$
51,465

 
$
59,874

 
$
62,312

 
$
70,679

 
$
80,391

 
$
74,346

Gross profit
36,668

 
31,949

 
41,672

 
48,629

 
50,375

 
57,052

 
65,332

 
60,066

Income from operations
8,686

 
8,514

 
12,867

 
12,992

 
20,014

 
15,208

 
14,927

 
13,987

Net income
(4,488
)
 
7,338

 
10,303

 
10,425

 
19,048

 
12,557

 
12,201

 
11,280

Net income per common share:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic
(0.40
)
 
0.65

 
0.92

 
0.93

 
1.70

 
1.12

 
1.08

 
0.96

Diluted
(0.40
)
 
0.65

 
0.91

 
0.93

 
1.70

 
1.12

 
1.07

 
0.95

_____________________________ 
1 Reflects the impact of the Tax Cuts and Jobs Act of 2017 enacted in December 2017.

Contractual Obligations

The following table summarizes our contractual obligations as of December 31, 2017 and the expected effect on our cash flow and liquidity in future periods (in thousands):
 
 
Total
 
2018
 
2019-2020
 
2021-2022
 
Thereafter
Operating leases
 
$
4,690

 
$
1,586

 
$
2,009

 
$
582

 
$
513

Purchase obligations
 
6,895

 
6,895

 

 

 

Long-term incentive compensation
 
9,742

 
1,838

 
1,397

 
4,338

 
2,169

Tax Cut & Jobs Act repatriation tax liability
 
20,708

 
1,657

 
3,313

 
3,313

 
12,425

Other commitments
 
250

 
93

 
140

 
17

 

Total
 
$
42,285

 
$
12,069

 
$
6,859

 
$
8,250

 
$
15,107


We have entered into non-cancelable operating lease agreements for locations within the United States and for our international subsidiaries, with expirations through September 2025 totaling $4.7 million.
 

34


In May 2013, we entered into an exclusive distribution agreement with one of our suppliers to purchase their product through July 2016 which automatically renews annually unless terminated 90 days prior to the termination date. To maintain exclusivity, we are required to purchase a minimum of $40,000 of product per month until the termination date. As of December 31, 2017, we were in compliance with the exclusivity provision.
 
We have a supply agreement with one of our suppliers to maintain worldwide exclusivity in return for purchasing a minimum of $6.6 million of product in 2018, plus certain raw material guarantees. If we do not purchase the minimum product as required, then a Cure Payment, as defined, will be due to the supplier. The term of the agreement is one year commencing January 2018 and shall automatically renew for a successive one year term unless notice of termination is provided by either party.

Subsequent to December 31, 2017, we entered into an exclusive distribution, license and royalty agreement with a new supplier to purchase products through January 2021 and shall renew for successive one year terms unless notice of termination is provided by either party. To maintain exclusivity, we are required to purchase between $453,000 and $3.6 million of product, depending on the product mix and inclusive of royalties, per year until the termination date.

In recognition of the achievement of specified performance goals, financial rewards are awarded under our 2014 Long-Term Incentive Plan with cash payments through December 2023. See Note 1 of the Notes to Consolidated Financial Statements in “Item 8. Financial Statements and Supplementary Data” of this report for additional information.

On December 22, 2017, the U.S. Tax Cuts and Jobs Act (the “Tax Act”) was signed into law. The Tax Act significantly revised the U.S. corporate income tax regime by, among other things, lowering the U.S. corporate tax rate from 35% to 21% effective January 1, 2018, implementing a territorial tax system and imposing a one-time repatriation tax on deemed repatriated earnings of foreign subsidiaries. We are subject to this repatriation tax, resulting in a federal income tax liability as of December 31, 2017 in the amount of $20.7 million. An election is available to allow U.S. shareholders to spread the payment of the one-time repatriation tax liability over eight years. Under the election, 8% of the installment payments are due in each of the first five years, 15% in the sixth year, 20% in the seventh year, and the remaining 25% due in the eight year. As a result of the Tax Act adoption of a territorial tax regime, any foreign source portion of a qualified dividend received by a 10% U.S. corporate shareholder is exempt from U.S. tax, therefore resulting in any future repatriation having a minimal effect on our tax liability.

We have evaluated our tax positions and have determined that there are no uncertain tax positions for the current year or years prior.
 
We have employment agreements with certain members of our management team that can be terminated by either the employee or us upon four weeks’ notice.  The employment agreements entered into with the management team contain provisions that guarantee the payments of specified amounts in the event of a change in control, as defined, or if the employee is terminated without cause, as defined, or terminates employment for good reason, as defined.

Critical Accounting Policies and Estimates 
 
A summary of our significant accounting policies is provided in Note 1 of the Notes to Consolidated Financial Statements in “Item 8. Financial Statements and Supplementary Data” of this report. The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.
 
Critical accounting policies and estimates are defined as both those that are material to the portrayal of our financial condition and results of operations and as those that require management’s most subjective judgments.  Management believes our critical accounting policies and estimates are those related to revenue recognition, as well as those used in the determination of liabilities related to sales returns, member commissions and income taxes.


35


Revenue Recognition.  Product sales are recorded when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon our delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” We primarily receive payment by credit card at the time members place orders. Our sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. Amounts received for unshipped product are recorded as deferred revenue. Such amounts totaled $2.4 million and $2.2 million at December 31, 2017 and 2016, respectively. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs.
 
Enrollment package revenue, including any nonrefundable set-up fees, is deferred and recognized over the term of the arrangement, generally twelve months. Enrollment packages provide members access to both a personalized marketing website and a business management system. No upfront costs are deferred as the amount is nominal. At December 31, 2017 and 2016, enrollment package revenue totaling $379,000 and $430,000 was deferred, respectively. Although we have no immediate plans to significantly change the terms or conditions of enrollment packages, any changes in the future could result in additional revenue deferrals or could cause us to recognize the deferred revenue over a longer period of time. Additionally, deferred revenue includes advances for auto ship orders. In certain markets, when a member’s cumulative commission income reaches a certain threshold, a percentage of the member’s weekly commission is held back as an advance and applied to an auto ship order once the accumulated amount of the advances is sufficient to pay for the pre-selected auto ship package of the member.  Such advances were $1.7 million and $2.3 million at December 31, 2017 and 2016, respectively.
 
Allowance for Sales Returns. An allowance for sales returns is provided during the period the product is shipped.  The allowance is based upon the return policy of each country, which varies from 14 days to one year, and their historical return rates, which range from 1% to 7% of sales.  Sales returns were 2% and 3% of sales for the years ended December 31, 2017 and 2016, respectively.  The allowance for sales returns was $614,000 and $1.6 million at December 31, 2017 and 2016, respectively.  No material changes in estimates have been recognized during the periods presented.
 
Commissions. Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of our products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  We accrue commissions when earned and as the related revenue is recognized and pay commissions on product sales generally two weeks following the end of the weekly sales period.
 
Independent members may also earn incentives based on meeting certain qualifications during a designated incentive period, which may range from several weeks to up to a year.  For each individual incentive, we estimate the total number of qualifiers as well as the expected per qualifier cost and accrue all costs associated with incentives throughout the qualification period. We regularly review and update, if necessary, the estimates of both qualifiers and cost as more information is obtained during the qualification period. Any resulting change in total cost is recognized over the remaining qualification period. Accrued commissions, including the estimated cost of our international recognition incentive program and other supplemental programs, totaled $11.2 million and $13.6 million at December 31, 2017 and 2016, respectively.
 
Income Taxes.  Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory rates for the years in which the temporary differences are expected to be recovered or settled. We evaluate the probability of realizing the future benefits of any of our deferred tax assets and record a valuation allowance when we believe a portion or all of our deferred tax assets may not be realized. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Based on the technical merits of our tax position, tax benefits may be recognized if we determine it is more likely than not that our position will be sustained on examination by tax authorities. The complex nature of these estimates requires us to anticipate the likely application of tax law and make judgments on the largest benefit that has a greater than fifty percent likelihood of being realized prior to the completion and filing of tax returns for such periods. As of December 31, 2017, we no longer have a valuation allowance against our U.S. deferred tax assets. We maintain a valuation allowance in certain foreign jurisdictions with an overall tax loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision.


36


Provision for income taxes depends on the statutory tax rates in each of the jurisdictions in which we operate. As a result of capital return activities, we determined that a portion of our current undistributed foreign earnings are no longer deemed reinvested indefinitely by our non-U.S. subsidiaries. For state income tax purposes, we will continue to periodically reassess the needs of our foreign subsidiaries and update our indefinite reinvestment assertion as necessary. The Tax Cuts and Jobs Act (the “Tax Act”), enacted on December 22, 2017 by the U.S. government requires a one-time repatriation tax on certain un-repatriated earnings of foreign subsidiaries at a rate of 15.5% tax on post-1986 foreign earnings held in cash and an 8% rate on all other post-1986 earnings. Due to the adoption of a territorial tax regime, any foreign source portion of a qualified dividend received by a 10% U.S. corporate shareholder is exempt from U.S. tax, therefore resulting in any future repatriation having a minimal effect on our effective tax rate. To the extent that additional foreign earnings are not deemed permanently reinvested, we expect to recognize additional income tax provision at the applicable U.S. state corporate tax rate(s). As of December 31, 2017, we have accrued tax liabilities for earnings that we plan to repatriate out of accumulated earnings in future periods for state purposes only. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of December 31, 2017.

We estimate what our effective tax rate will be for the full fiscal year at each interim reporting period and record a quarterly tax provision based on that estimated effective tax rate. Throughout the year that estimated rate may change based on variations in our business, changes in our corporate structure, changes in the geographic mix and amount of income, applicable tax laws and regulations, communications with tax authorities, as well as our estimated and actual level of annual pre-tax income. We adjust our income tax provision in the reporting period in which the change in our estimated rate occurs so that the year-to-date provision is consistent with the anticipated annual tax rate. 

Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We have operations both internationally and within the United States, and we are exposed to market risks in the ordinary course of our business. These risks include primarily interest rate, foreign exchange and inflation risks.

Interest Rate Fluctuation Risk

Our cash and cash equivalents consist of cash, available-for-sale securities, comprising municipal notes, bonds and corporate debt, money market funds and time deposits. The primary objective of our investment in available-for-sale securities is to preserve principal while maximizing income without significantly increasing risk. Because our cash and cash equivalents have a relatively short maturity, our portfolio’s fair value is relatively insensitive to interest rate changes. In future periods, we will continue to evaluate our investment policy relative to our overall objectives.

Foreign Currency Exchange Risk

We have foreign currency risks related to our revenue and expenses denominated in currencies other than the U.S. dollar. Our most significant foreign exchange exposure, the Hong Kong dollar, is for now pegged to the U.S. dollar. Our foreign currency exchange rate exposure to the South Korean won, Taiwan dollar, Japanese yen, Chinese yuan, Russian ruble, Kazakhstani tenge, Singaporean dollar, Malaysian ringgit, Vietnamese dong, Canadian dollar, Mexican peso, Peruvian sol and European euro collectively represented approximately 10%, 7% and 6% of our revenue during the years ended December 31, 2017, 2016 and 2015, respectively. We have experienced and will continue to experience fluctuations in our net income as a result of transaction gains and losses related to translating certain balances denominated in currencies other than the U.S. dollar.

Our foreign currency exchange rate exposure may increase in the near future as we further develop opportunities in Southeast Asia, Canada, Central America, South America and Europe. Additionally, our foreign currency exchange rate exposure would significantly increase if the Hong Kong dollar were no longer pegged to the U.S. dollar. We also experience indirect exchange rate exposure to the Chinese yuan, due to the concentration of our sales to members residing in China and the impact of fluctuations in the value of the Chinese yuan on their purchasing power. Given our inability to predict the degree of exchange rate fluctuations, we cannot estimate the effect these fluctuations may have upon future reported results, product pricing or our overall financial condition. Further, to date we have not attempted to reduce our exposure to short-term exchange rate fluctuations by using foreign currency exchange contracts.

Inflation Risk

We do not believe that inflation has had a material effect on our business, financial condition or results of operations. If our costs were to become subject to significant inflationary pressures, we might not be able to fully offset such higher costs through price increases. Our inability or failure to do so could harm our business, financial condition and results of operations.


37


Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

NATURAL HEALTH TRENDS CORP.
 
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
 

38


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  
To the Board of Directors and Shareholders of
Natural Health Trends Corp.


Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheet of Natural Health Trends Corp. (the “Company”) as of December 31, 2017, the related consolidated statements of operations, comprehensive income, stockholders’ equity and cash flows for the year then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) ("PCAOB"), the Company's internal control over financial reporting as of December 31, 2017, based on the criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in 2013 and our report dated March 27, 2018, expressed an adverse opinion on the effectiveness of the Company’s internal control over financial reporting because of the existence of a material weakness.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.


/s/ Marcum LLP

Marcum LLP

We have served as the Company’s auditor since 2017.

Chicago, IL
March 27, 2018

39


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  
Board of Directors and Stockholders
Natural Health Trends Corp.
Rolling Hills Estates, California
 
We have audited the accompanying consolidated balance sheet of Natural Health Trends Corp. (the “Company”) as of December 31, 2016, and the related consolidated statements of operations, comprehensive income, stockholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2016. The Company’s management is responsible for these financial statements. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Natural Health Trends Corp. as of December 31, 2016, and the consolidated results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2016, in conformity with accounting principles generally accepted in the United States of America.
 
 
/s/ Lane Gorman Trubitt, LLC
 
Dallas, Texas
March 10, 2017


40


NATURAL HEALTH TRENDS CORP.
 
CONSOLIDATED BALANCE SHEETS
(In Thousands, Except Share Data)
 
December 31,
 
2017
 
2016
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
135,311

 
$
125,921

Inventories
8,398

 
11,257

Other current assets
7,534

 
4,066

Total current assets
151,243

 
141,244

Property and equipment, net
1,149

 
1,388

Goodwill
1,764

 
1,764

Restricted cash
3,167

 
2,963

Deferred tax asset
1,435

 

Other assets
796

 
692

Total assets
$
159,554

 
$
148,051

LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
1,751

 
$
2,145

Income taxes payable
309

 
663

Accrued commissions
11,170

 
13,611

Other accrued expenses
7,605

 
14,989

Deferred revenue
4,455

 
4,948

Amounts held in eWallets
15,152

 
19,165

Other current liabilities
1,479

 
1,633

Total current liabilities
41,921

 
57,154

Income taxes payable
19,052

 

Deferred tax liability
56

 
268

Long-term incentive
7,904

 
8,190

Total liabilities
68,933

 
65,612

Commitments and contingencies (Note 5)

 

Stockholders’ equity:
 
 
 
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2017 and 2016

 

Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at December 31, 2017 and 2016
13

 
13

Additional paid-in capital
86,683

 
86,574

Retained earnings
44,908

 
38,548

Accumulated other comprehensive loss
(413
)
 
(807
)
Treasury stock, at cost; 1,637,524 and 1,692,218 shares at December 31, 2017 and 2016, respectively
(40,570
)
 
(41,889
)
Total stockholders’ equity
90,621

 
82,439

Total liabilities and stockholders’ equity
$
159,554


$
148,051

 
See accompanying notes to consolidated financial statements.

41


NATURAL HEALTH TRENDS CORP.
 
CONSOLIDATED STATEMENTS OF OPERATIONS
(In Thousands, Except Per Share Data)
 
Year Ended December 31,
 
2017
 
2016
 
2015
Net sales
$
197,563

 
$
287,728

 
$
264,860

Cost of sales
38,645

 
54,903

 
54,098

Gross profit
158,918


232,825

 
210,762

Operating expenses:
 
 
 
 
 
Commissions expense
83,638

 
125,050

 
126,598

Selling, general and administrative expenses
31,685

 
43,245

 
36,024

Depreciation and amortization
536

 
394

 
263

Total operating expenses
115,859

 
168,689

 
162,885

Income from operations
43,059

 
64,136

 
47,877

Other income (expense), net
367

 
(59
)
 
(84
)
Income before income taxes
43,426

 
64,077

 
47,793

Income tax provision
19,848

 
8,991

 
552

Net income
$
23,578


$
55,086

 
$
47,241

Net income per common share:
 
 
 
 
 
Basic
$
2.10

 
$
4.84

 
$
3.84

Diluted
$
2.09

 
$
4.83

 
$
3.82

Weighted-average number of common shares outstanding:
 
 
 
 
 
Basic
11,251

 
11,382

 
12,302

Diluted
11,267

 
11,407

 
12,372

Cash dividends declared per common share
$
1.52

 
$
0.61

 
$
0.14

 
See accompanying notes to consolidated financial statements.


42


NATURAL HEALTH TRENDS CORP.
 
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In Thousands)
 
Year Ended December 31,
 
2017
 
2016
 
2015
Net income
$
23,578

 
$
55,086

 
$
47,241

Other comprehensive income (loss), net of tax:
 
 
 
 
 
Foreign currency translation adjustments
677

 
(838
)
 
(79
)
Release of cumulative translation adjustment
(258
)
 
132

 
(82
)
Net change in foreign currency translation adjustment
419

 
(706
)
 
(161
)
Unrealized loss on available-for-sale securities
(25
)
 

 
(2
)
Comprehensive income
$
23,972

 
$
54,380

 
$
47,078

 
See accompanying notes to consolidated financial statements.


43


NATURAL HEALTH TRENDS CORP.
 
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In Thousands, Except Share Data)
 
Preferred Stock
 
Common Stock
 
Additional
Paid-In
Capital
 
Retained Earnings
(Accumulated Deficit)
 
Accumulated
Other
Comprehensive
(Loss) Income
 
Treasury Stock
 
 
 
Shares
 
Amount
 
Shares
 
Amount
 
 
 
 
Shares
 
Amount
 
Total
BALANCE, December 31, 2014

 
$

 
12,891,317

 
$
13

 
$
85,750

 
$
(54,799
)
 
$
62

 
(384,220
)
 
$
(4,576
)
 
$
26,450

Net income

 

 

 

 

 
47,241

 

 

 

 
47,241

Exercise of warrants

 

 
88,097

 

 
309

 

 

 

 

 
309

Repurchase of common stock

 

 

 

 

 

 

 
(547,042
)
 
(16,071
)
 
(16,071
)
Common stock issued

 

 

 

 
(182
)
 
(380
)
 

 
91,060

 
1,228

 
666

Dividends declared

 

 

 

 

 
(1,709
)
 

 

 

 
(1,709
)
Elimination of CTA upon dissolution

 

 

 

 

 

 
(82
)
 

 

 
(82
)
Foreign currency translation adjustments

 

 

 

 

 

 
(79
)
 

 

 
(79
)
Unrealized loss on available-for-sale securities

 

 

 

 

 

 
(2
)
 

 

 
(2
)
Stock-based compensation

 

 

 

 
86

 

 

 

 

 
86

BALANCE, December 31, 2015

 

 
12,979,414

 
13

 
85,963

 
(9,647
)
 
(101
)
 
(840,202
)
 
(19,419
)
 
56,809

Net income

 

 

 

 

 
55,086

 

 

 

 
55,086

Repurchase of common stock

 

 

 

 

 

 

 
(903,031
)
 
(23,704
)
 
(23,704
)
Common stock issued

 

 

 

 
507

 

 

 
51,015

 
1,234

 
1,741

Dividends declared

 

 

 

 

 
(6,891
)
 

 

 

 
(6,891
)
Elimination of CTA upon dissolution

 

 

 

 

 

 
132

 

 

 
132

Foreign currency translation adjustments

 

 

 

 

 

 
(838
)
 

 

 
(838
)
Stock-based compensation

 

 

 

 
104

 

 

 

 

 
104

BALANCE, December 31, 2016

 

 
12,979,414

 
13

 
86,574

 
38,548

 
(807
)
 
(1,692,218
)
 
(41,889
)
 
82,439

Net income

 

 

 

 

 
23,578

 

 

 

 
23,578

Restricted stock forfeiture

 

 

 

 
(5
)
 

 

 
(1,566
)
 
(33
)
 
(38
)
Common stock issued

 

 

 

 
79

 

 

 
56,260

 
1,352

 
1,431

Dividends declared

 

 

 

 

 
(17,218
)
 

 

 

 
(17,218
)
Elimination of CTA upon dissolution

 

 

 

 

 

 
(258
)
 

 

 
(258
)
Foreign currency translation adjustments

 

 

 

 

 

 
677

 

 

 
677

Unrealized loss on available-for-sale securities

 

 

 

 

 

 
(25
)
 

 

 
(25
)
Stock-based compensation

 

 

 

 
35

 

 

 

 

 
35

BALANCE, December 31, 2017

 
$

 
12,979,414

 
$
13

 
$
86,683

 
$
44,908

 
$
(413
)
 
(1,637,524
)
 
$
(40,570
)
 
$
90,621

 
See accompanying notes to consolidated financial statements. 

44


NATURAL HEALTH TRENDS CORP.
 
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In Thousands)
 
Year Ended December 31,
 
2017
 
2016
 
2015
CASH FLOWS FROM OPERATING ACTIVITIES:
 
 
 
 
 
Net income
$
23,578

 
$
55,086

 
$
47,241

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
 
 
Depreciation and amortization
536

 
394

 
263

Stock-based compensation
35

 
104

 
86

Cumulative translation adjustment realized in net income
(258
)
 
132

 
(82
)
Deferred income taxes
(1,644
)
 
217

 
(15
)
Changes in assets and liabilities:
 
 
 
 
 
Inventories
2,843

 
(851
)
 
(6,762
)
Other current assets
(3,399
)
 
(1,681
)
 
(1,025
)
Other assets
(61
)
 
(90
)
 
(267
)
Accounts payable
(392
)
 
(714
)
 
637

Income taxes payable
18,676

 
303

 
(115
)
Accrued commissions
(2,417
)
 
(6,031
)
 
10,840

Other accrued expenses
(6,033
)
 
51

 
10,714

Deferred revenue
(481
)
 
947

 
1,331

Amounts held in eWallets
(3,875
)
 
2,752

 
14,350

Other current liabilities
(179
)
 
135

 
25

Long-term incentive
(324
)
 
2,420

 
4,105

Net cash provided by operating activities
26,605

 
53,174

 
81,326

CASH FLOWS FROM INVESTING ACTIVITIES:
 
 
 
 
 
Purchases of property and equipment
(278
)
 
(905
)
 
(710
)
Increase in restricted cash

 

 
(3,028
)
Net cash used in investing activities
(278
)
 
(905
)
 
(3,738
)
CASH FLOWS FROM FINANCING ACTIVITIES:
 
 
 
 
 
Proceeds from exercise of warrants

 

 
309

Repurchase of common stock

 
(23,704
)
 
(16,071
)
Dividends paid
(17,218
)
 
(6,891
)
 
(1,709
)
Net cash used in financing activities
(17,218
)
 
(30,595
)
 
(17,471
)
Effect of exchange rates on cash and cash equivalents
281

 
(667
)
 
(19
)
Net increase in cash and cash equivalents
9,390


21,007

 
60,098

CASH AND CASH EQUIVALENTS, beginning of period
125,921

 
104,914

 
44,816

CASH AND CASH EQUIVALENTS, end of period
$
135,311

 
$
125,921

 
$
104,914

 
 
 
 
 
 
SUPPLEMENTAL CASH FLOW DISCLOSURE:
 
 
 
 
 
Cash paid for income taxes, net
$
6,772

 
$
8,791

 
$
707

Issuance of treasury stock for employee awards, net
$
1,393

 
$
1,741

 
$
666


See accompanying notes to consolidated financial statements.

45


NATURAL HEALTH TRENDS CORP.
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 
1.     NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Nature of Operations
 
Natural Health Trends Corp., a Delaware corporation (whether or not including its subsidiaries, the “Company”), is an international direct-selling and e-commerce company headquartered in Rolling Hills Estates, California. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand.
 
The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia and Vietnam; South Korea; Japan; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.

Principles of Consolidation
 
The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.
 
Use of Estimates
 
The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period.

The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates associated with revenue recognition, as well as those used in the determination of liabilities related to sales returns, commissions and income taxes. Various assumptions and other factors prompt the determination of these significant estimates. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. The actual results may differ materially and adversely from the Company’s estimates. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.

Cash and Cash Equivalents
 
Cash and cash equivalents include the Company’s investments in debt securities, comprising municipal notes, bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less, when purchased, to be cash equivalents. Debt securities classified as cash equivalents are required to be accounted for in accordance with ASC 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at December 31, 2017 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive loss in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices.

The Company includes credit card receivables due from certain of its credit card processors in its cash and cash equivalents as the cash proceeds are received within two to five days.

The Company maintains certain cash balances at several institutions located in the United States, Hong Kong and Malaysia which at times may exceed insured limits.  The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.


46


Restricted Cash
 
In June 2015, the Company funded a bank deposit account in the amount of CNY 20 million (USD 3.1 million at December 31, 2017) in anticipation of submitting a direct selling license application in China. Such deposit is required by Chinese laws to establish a consumer protection fund.

The Company periodically maintains a cash reserve with certain credit card processing companies to provide for potential uncollectible amounts and chargebacks. Those cash reserves held by credit card processing companies located in South Korea are reflected in noncurrent assets since they require the Company to provide 100% collateral before processing transactions, which must be maintained indefinitely.
 
Inventories
 
Inventories are stated at the lower of cost or net realizable value, using the first-in, first-out method. The Company reviews its inventory for obsolescence and any inventory identified as obsolete is reserved or written off. The Company’s determination of obsolescence is based on assumptions about the demand for its products, product expiration dates, estimated future sales, and management’s future plans.
 
Property and Equipment
 
Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years for office equipment, office software and capitalized internal-use software development costs and five to seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the assets. Expenditures for maintenance and repairs are charged to expense as incurred.
 
The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of these assets is measured by comparison of its carrying amounts to future undiscounted cash flows the assets are expected to generate. If property and equipment are considered to be impaired, the impairment to be recognized equals the amount by which the carrying value of the asset exceeds its fair value.
 
Goodwill
 
The Company assesses qualitative factors in order to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, through this qualitative assessment, the conclusion is made that it is more likely than not that a reporting unit’s fair value is less than its carrying amount, a two-step impairment test is performed. The Company’s policy is to test for impairment annually during the fourth quarter. Considerable management judgment is necessary to measure fair value. The Company did not recognize any impairment charges for goodwill during the periods presented.
 
Income Taxes
 
The Company recognizes income taxes under the liability method of accounting for income taxes. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be ultimately realized based on the more likely than not recognition criteria. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has evaluated its tax positions and determined that there are no uncertain tax positions for the current year or years prior. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution.  The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense.  Deferred taxes are not provided for state income tax purposes on the portion of undistributed earnings of subsidiaries outside of the United States when these earnings are considered permanently reinvested.


47


Amounts Held in eWallets
 
Commencing in October 2014, the Company requires commission payments of certain members in Hong Kong to be first recorded into an electronic wallet (eWallet) account in lieu of being paid out directly to members. The eWallet functionality allows members to place new product orders utilizing eWallet available balance and/or request commission payout via multiple payment methods. Amounts held in eWallets are reflected on the balance sheet as a current liability.

Long-Term Incentive
 
Financial rewards earned under the 2014 Long-Term Incentive Plan (the “LTI Plan”) are recognized over the performance period as specified performance or other goals are achieved or exceeded. In accordance with the LTI Plan, fifty percent of any cash payment earned is payable in thirty-five equal consecutive monthly installments commencing in February of the calendar year immediately following the conclusion of the performance period and the remaining fifty percent of the payment earned is payable in thirty-five equal consecutive monthly installments commencing in February 2021 and ending in December 2023. As such, certain installments to be paid are reflected on the balance sheet as a non-current liability, and the current portion of the installments is reflected in other accrued expenses.

At the sole discretion of the Compensation Committee of the Company’s Board of Directors, distributions under the LTI Plan are made in cash, or alternatively awarded in the form of common stock or other common stock rights having an equivalent cash value under the terms of the Natural Health Trends Corp. 2016 Equity Incentive Plan. A determination of the form of distribution, if any, is made by the Compensation Committee subsequent to the end of each calendar year. As such, amounts earned are considered non-equity awards. See Note 6 for grant information of distributions settled in common stock.
 
Foreign Currency
 
The functional currency of the Company’s international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.  The resulting translation adjustments are recorded directly into accumulated other comprehensive income.
 
Aggregate transaction gains or losses, including gains or losses related to foreign-denominated cash and cash equivalents and the re-measurement of certain inter-company balances, are included in the statement of operations as other income and expense. Loss on foreign exchange totaling $451,000, $333,000 and $204,000 was recognized during 2017, 2016 and 2015, respectively.
 
Revenue Recognition
 
Product sales are recorded when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product are recorded as deferred revenue. The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return.
 
Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience.
 
Enrollment package revenue, including any nonrefundable set-up fees, is deferred and recognized over the term of the arrangement, generally twelve months. Enrollment packages provide members access to both a personalized marketing website and a business management system. No upfront costs are deferred as the amount is nominal.
 
Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.
 
Various taxes on the sale of products and enrollment packages to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.
 

48


Commissions
 
Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of the Company’s products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  The Company accrues commissions when earned and pays commissions on product sales generally two weeks following the end of the weekly sales period.
 
In some markets, the Company also pays certain bonuses on purchases by up to three generations of personally enrolled members, as well as bonuses on commissions earned by up to three generations of personally enrolled members. Independent members may also earn incentives based on meeting certain qualifications during a designated incentive period, which may range from several weeks to up to a year.  The Company estimates and accrues all costs associated with the incentives as the members meet the qualification requirements.
 
From time to time the Company makes modifications and enhancements to the Company’s compensation plan to help motivate members, which can have an impact on member commissions. The Company also enters into performance-based agreements for business or market development, which may result in additional compensation to specific members.

Operating Leases

The Company leases its physical properties under operating leases. Certain lease agreements include rent holidays and incentives. The Company recognizes rent holiday periods on a straight-line basis over the lease term beginning when the Company has the right to the leased space.

Stock-Based Compensation
 
Stock-based compensation expense is determined based on the grant date fair value of each award, net of estimated forfeitures which are derived from historical experience, and is recognized on a straight-line basis over the requisite service period for the award.
 
Net Income Per Common Share
 
Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock and warrants is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares.

Certain Risks and Concentrations
 
A substantial portion of the Company’s sales are generated in Hong Kong (see Note 10). Substantially all of the Company’s Hong Kong revenues are derived from the sale of products that are delivered to members in China. In contrast to the Company’s operations in other parts of the world, the Company has not implemented a direct sales model in China. The Chinese government permits direct selling only by organizations that have a license, which the Company has applied for, and has also adopted anti-multilevel marketing legislation. The Company operates an e-commerce direct selling model in Hong Kong and recognizes the revenue derived from sales to both Hong Kong and Chinese members as being generated in Hong Kong. Products purchased by members in China are delivered to third parties that act as the importers of record under agreements to pay applicable duties. In addition, through a Chinese entity, the Company sells products in China using an e-commerce retail model. The Chinese entity operates separately from the Hong Kong entity, and a Chinese member may elect to participate separately or in both.

The Company believes that its e-commerce direct selling model in Hong Kong does not violate any applicable laws in China, even though it is used for the internet purchase of the Company’s products by members in China. The Company also believes that its Chinese entity, including its e-commerce retail platform, is operating in compliance with applicable Chinese laws. However, there can be no assurance that the Chinese authorities will agree with the Company’s interpretations of applicable laws and regulations or that China will not adopt new laws or regulations. Should the Chinese government determine that the Company’s activities violate China’s direct selling or anti-multilevel marketing legislation, or should new laws or regulations be adopted, there could be a material adverse effect on the Company’s business, financial condition and results of operations.
 

49


Although the Company attempts to work closely with both national and local Chinese governmental agencies in conducting its business, the Company’s efforts to comply with national and local laws may be harmed by a rapidly evolving regulatory climate, concerns about activities resembling violations of direct selling or anti-multi-level marketing legislation, subjective interpretations of laws and regulations, Chinese nationals collaborating with short traders to damage the Company’s business and activities by individual members that may violate laws notwithstanding the Company’s strict policies prohibiting such activities. Any determination that the Company’s operations or activities, or the activities of its individual members or employee sales representatives, or importers of record are not in compliance with applicable laws and regulations could result in the imposition of substantial fines, extended interruptions of business, restrictions on the Company’s future ability to obtain business licenses or expand into new locations, changes to its business model, the termination of required licenses to conduct business, or other actions, any of which could materially harm the Company’s business, financial condition and results of operations.
 
The Company’s Premium Noni Juice and Enhanced Essential Probiotics® products each account for more than 10% of the Company’s total revenue. The Company currently sources each such product from a single supplier. If demand decreases significantly, government regulation restricts their sale, the Company is unable to adequately source or deliver the products, or the Company ceases offering the products for any reason without suitable replacements, the Company’s business, financial condition and results of operations could be materially and adversely affected.

Sales are made to the Company’s members and no single customer accounted for 10% or more of its net sales. However, the Company’s business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.
 
Fair Value of Financial Instruments
 
The carrying amounts of the Company’s financial instruments, including cash and cash equivalents and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. The Company’s cash equivalents are valued based on level 1 inputs which consist of quoted prices in active markets.
 
Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.

Recently Issued and Adopted Accounting Pronouncements

In November 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-18, Statement of Cash Flows - Restricted Cash, that requires amounts generally described as restricted cash or restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new standard will be effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, and early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting, that simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The new standard was effective for fiscal years beginning after December 15, 2016, including interim periods within those annual years, and early adoption was permitted. The Company adopted this guidance as of the quarter ended March 31, 2017. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases, that requires organizations that lease assets, referred to as “lessees”, to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases with lease terms of more than 12 months. ASU 2016-02 will also require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will include qualitative and quantitative requirements. The new standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those annual years, and early application is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.
 

50


In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. Under this guidance, entities are required to present deferred tax assets and deferred tax liabilities as noncurrent in a classified balance sheet. This guidance was effective for annual and interim periods beginning after December 15, 2016, with early adoption permitted. Entities were permitted to adopt this guidance either prospectively or retrospectively. The Company elected to early adopt this guidance prospectively as of the quarter ended December 31, 2016.

In July 2015, the FASB issued ASU No. 2015-11, Inventory: Simplifying the Measurement of Inventory. Under this guidance, inventory not measured using either the last in, first out (LIFO) or the retail inventory method are to be measured at the lower of cost and net realizable value.  Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable cost of completion, disposal, and transportation.  The new standard was effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, with early adoption permitted. The Company adopted this guidance as of the quarter ended March 31, 2017. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements.

In May 2014, the FASB issued ASU No. 2014-09, Revenue From Contracts With Customers, that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract.  Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard.  In July 2015, the FASB approved the deferral of the effective date for annual reporting periods that begin after December 15, 2017, including interim reporting periods. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements.

Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements.
 
2.     NET INCOME PER COMMON SHARE

The following table illustrates the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data):
 
Year Ended December 31,
 
2017
 
2016
 
2015
 
Income
 
Shares
 
Per Share
 
Income
 
Shares
 
Per Share
 
Income
 
Shares
 
Per Share
Basic net income per common share:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders
$
23,578

 
11,251

 
$
2.10

 
$
55,086

 
11,382

 
$
4.84

 
$
47,241

 
12,302

 
$
3.84

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Warrants to purchase common stock

 

 
 
 

 

 
 
 

 
21

 
 
Non-vested restricted stock

 
16

 
 

 

 
25

 
 

 

 
49

 
 

Diluted net income per common share:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders plus assumed conversions
$
23,578

 
11,267

 
$
2.09

 
$
55,086

 
11,407

 
$
4.83

 
$
47,241

 
12,372

 
$
3.82


Warrants to purchase 88,097 shares of common stock were exercised during April 2015.


51


Certain non-vested restricted stock is anti-dilutive upon applying the treasury stock method since the amount of compensation cost for future service results in the hypothetical repurchase of shares exceeding the actual number of shares to be vested. Non-vested restricted stock totaling 2,232 and 345 shares were not included for the years ended December 31, 2017 and 2016, respectively, as their effect would have been anti-dilutive.

3.     BALANCE SHEET COMPONENTS

The components of certain balance sheet amounts are as follows (in thousands):
 
December 31,
 
2017
 
2016
Cash and cash equivalents:
 
 
 
Cash
$
61,703

 
$
52,453

Cash equivalents
73,608

 
73,468

 
$
135,311

 
$
125,921

Inventories:
 
 
 
Finished goods
$
7,779

 
$
10,722

Raw materials
799

 
617

Inventory reserve for obsolescence
(180
)
 
(82
)
 
$
8,398

 
$
11,257

Property and equipment:
 
 
 
Office equipment
$
530

 
$
517

Office software
916

 
672

Machinery
30

 
28

Furniture and fixtures
276

 
241

Leasehold improvements
957

 
840

Construction in progress (including internal-use software development costs)
10

 
157

Property and equipment, at cost
2,719

 
2,455

Accumulated depreciation and amortization
(1,570
)
 
(1,067
)
 
$
1,149

 
$
1,388

Other accrued expenses:
 
 
 
Sales returns
$
614

 
$
1,632

Employee-related expense
5,568

 
10,541

Warehousing, inventory-related and other
1,423

 
2,816

 
$
7,605

 
$
14,989

Deferred revenue:
 

 
 

Unshipped product
$
2,411

 
$
2,191

Auto ship advances
1,665

 
2,327

Enrollment package revenue
379

 
430

 
$
4,455

 
$
4,948


As of December 31, 2017, cash and cash equivalents include $8.7 million held in banks located within China subject to foreign currency controls.


52


4.     FAIR VALUE MEASUREMENTS

Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):
 
December 31, 2017
 
December 31, 2016
 
Adjusted Cost
 
Gross Unrealized Gains/Losses
 
Fair Value
 
Adjusted Cost
 
Gross Unrealized Gains/Losses
 
Fair Value
Municipal bonds and notes
$
13,320

 
$
(1
)
 
$
13,319

 
$
43,490

 
$

 
$
43,490

Corporate debt securities
49,432

 
(24
)
 
49,408

 
1,673

 
(2
)
 
1,671

Financial institution instruments
10,881

 

 
10,881

 
28,307

 

 
28,307

Total available-for-sale investments
$
73,633

 
$
(25
)
 
$
73,608

 
$
73,470

 
$
(2
)
 
$
73,468


 
Financial institution instruments include instruments issued or managed by financial institutions such as money market fund deposits and time deposits.

5.     COMMITMENTS AND CONTINGENCIES
 
Operating Leases
 
The Company has entered into non-cancelable operating lease agreements for locations within the United States and for its international subsidiaries, with expirations through September 2025. Rent expense in connection with operating leases was $2.0 million, $1.8 million and $1.5 million during 2017, 2016 and 2015, respectively.
 
Future minimum lease obligations as of December 31, 2017 are as follows (in thousands):
2018
$
1,586

2019
1,114

2020
895

2021
337

2022
245

Thereafter
513

Total minimum lease obligations
$
4,690



Purchase Commitments

In May 2013, the Company entered into an exclusive distribution agreement with one of its suppliers to purchase its product through July 2016 which automatically renews annually unless terminated 90 days prior to the termination date. To maintain exclusivity, the Company is required to purchase a minimum of $40,000 of product per month until the termination date. As of December 31, 2017, the Company was in compliance with the exclusivity provision.
 
The Company has a supply agreement with one of its suppliers to maintain worldwide exclusivity in return for purchasing a minimum of $6.6 million of product in 2018, plus certain raw material guarantees. If the Company does not purchase the minimum product as required, then a Cure Payment, as defined, will be due to the supplier. The term of the agreement is one year commencing January 2018 and shall automatically renew for a successive one year term unless notice of termination is provided by either party.

Employment Agreements
 
The Company has employment agreements with certain members of its management team that can be terminated by either the employee or the Company upon four weeks’ notice.  The employment agreements entered into with the management team contain provisions that guarantee the payments of specified amounts in the event of a change in control, as defined, or if the employee is terminated without cause, as defined, or terminates employment for good reason, as defined.



53


Securities Class Action

In January 2016, two putative securities class action complaints were filed against the Company and its top executives in the United States District Court for the Central District of California. On March 29, 2016, the Court consolidated these actions under the caption Ford v. Natural Health Trends Corp., Case No. 2:16-cv-00255-TJH-AFMx, appointed two Lead Plaintiffs, Mahn Dao and Juan Wang, and appointed the Rosen Law Firm and Levi & Korsinsky LLP as co-Lead Counsel for the purported class. Plaintiffs filed a consolidated complaint on April 29, 2016. The consolidated complaint purports to assert claims on behalf of all persons who purchased or otherwise acquired our common stock between March 6, 2015 and March 15, 2016 under (i) Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against the Company and Chris T. Sharng, Timothy S. Davidson and George K. Broady (together, the “Individual Defendants”), and (ii) Section 20(a) of the Securities Exchange Act of 1934 against the Individual Defendants. The consolidated complaint alleges, among other things, that the Company has been running an allegedly illegal multilevel marketing business in China and that it has made materially false and misleading statements regarding the legality of its business operations in China. The consolidated complaint seeks an indeterminate amount of damages, plus interest and costs. On June 15, 2016, the Company filed a motion to dismiss the consolidated complaint, which was denied on December 5, 2016. On February 17, 2017, the Company filed an answer to the consolidated complaint. On July 10, 2017, the Court entered a stipulation between the parties, postponing all deadlines and staying the case to allow the parties to engage in settlement discussions. On July 17, 2017, the parties reached an agreement in principle to settle the action. The proposed class-wide settlement of $1.75 million was submitted to the Court on October 3, 2017. The Court entered an order preliminarily approving the settlement on November 17, 2017, which was amended on January 4, 2018. Plaintiffs have provided notice to the settlement class in accordance with the amended order, and a final approval hearing is currently set for April 2, 2018. If approved, the proposed settlement will be fully funded by the Company’s insurers. Defendants continue to believe that these claims are without merit and intend to vigorously defend against them if a settlement is not finalized and approved by the Court.

Shareholder Derivative Claims

In February 2016, a purported shareholder derivative complaint was filed in the Superior Court of the State of California, County of Los Angeles: Zhou v. Sharng. In March 2016, a purported shareholder derivative complaint was filed in the United States District Court for the Central District of California: Kleinfeldt v. Sharng (collectively the “Derivative Complaints”). The Derivative Complaints purport to assert claims for breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement and corporate waste against certain of the Company’s officers and directors. The Derivative Complaints also purport to assert fiduciary duty claims based on alleged insider selling and conspiring to enter into several stock repurchase agreements, which allegedly harmed the Company and its assets. The Derivative Complaints allege, among other things, that the Company has been running an allegedly illegal multilevel marketing business in China, and it has made materially false and misleading statements regarding the legality of its business operations in China, and that certain officers and directors sold common stock on the basis of this allegedly material, adverse non-public information. The Derivative Complaints seek an indeterminate amount of damages, plus interest and costs, as well as various equitable remedies. On February 1, 2017, pursuant to a stipulation among the parties, the Los Angeles Superior Court entered a stay of the Zhou action pending conclusion of the related federal class action in the United States District Court for the Central District of California: Ford v. Natural Health Trends Corp. A nearly identical stipulated stay was entered in the Kleinfeldt case on February 28, 2017. On November 10, 2017, the parties to both the Zhou and Kleinfeldt actions entered into a Memorandum of Understanding (“MOU”) to resolve both actions, subject to the negotiation of a written settlement agreement and approval by the federal court in the Kleinfeldt matter.  On November 15, 2017, the parties filed a joint status report and stipulation in the Zhou matter, alerting the court to the MOU and seeking to maintain the stay pending finalization and court approval of the parties’ tentative settlement.  The Zhou court entered an order continuing the stay on November 17, 2017.  On March 9, 2018, the parties filed a Stipulation of Settlement and supporting papers in the Kleinfeldt action. On March 22, 2018, plaintiffs filed a motion for preliminary approval of the tentative settlement. The settlement is subject to both preliminary and final approval by the court.  If approved, the proposed settlement will require certain corporate governance reforms and permit an award of up to $250,000 in attorneys’ fees to plaintiffs’ counsel, all of which will be fully funded by the Company’s insurers. Defendants continue to believe that these claims are without merit and intend to vigorously defend against them if the derivative settlement is not finalized and approved.

The consolidated class action (if the settlement is not approved by the Court) and the Derivative Complaints (if the tentative settlement is not finalized or approved), or other actions alleging similar facts, could result in monetary or other penalties that may materially affect the Company’s operating results and financial condition.

54



Other Claims

The Company is currently involved in a legal matter with one of its vendors and an outside party. Per the royalty agreement with the vendor, the Company believes that it is fully indemnified in the event of an unfavorable outcome and any potential settlement costs related to the matter would be fully covered by the Company’s vendor.

6.     STOCKHOLDERS’ EQUITY
 
Authorized Shares
 
The Company is authorized to issue two classes of capital stock consisting of up to 5,000,000 shares of preferred stock, $0.001 par value, and 50,000,000 shares of common stock, $0.001 par value.
 
Dividends
 
The following tables summarize the Company’s cash dividend activity during 2017, 2016 and 2015 (in thousands, except per share data):
Declaration Date
 
Per Common Share
 
Amount
 
Payment Date
October 30, 2017 (special)
 
$
0.15

 
$
1,701

 
November 24, 2017
October 30, 2017
 
0.12

 
1,360

 
November 24, 2017
July 31, 2017 (special)
 
0.25

 
2,833

 
August 31, 2017
July 31, 2017
 
0.11

 
1,246

 
August 31, 2017
April 24, 2017 (special)
 
0.35

 
3,964

 
May 19, 2017
April 24, 2017
 
0.10

 
1,133

 
May 19, 2017
January 24, 2017 (special)
 
0.35

 
3,962

 
March 3, 2017
January 24, 2017
 
0.09

 
1,019

 
March 3, 2017
 
 
$
1.52

 
$
17,218

 
 
Declaration Date
 
Per Common Share
 
Amount
 
Payment Date
October 23, 2016 (special)
 
$
0.35

 
$
3,941

 
November 25, 2016
October 23, 2016
 
0.08

 
901

 
November 25, 2016
July 19, 2016
 
0.07

 
787

 
August 26, 2016
April 21, 2016
 
0.06

 
686

 
May 20, 2016
March 1, 2016
 
0.05

 
576

 
March 24, 2016
Total
 
$
0.61

 
$
6,891

 
 
Declaration Date
 
Per Common Share
 
Amount
 
Payment Date
October 21, 2015
 
$
0.05

 
$
598

 
November 20, 2015
July 28, 2015
 
0.04

 
489

 
August 28, 2015
May 4, 2015
 
0.03

 
372

 
May 29, 2015
February 27, 2015
 
0.02

 
250

 
March 27, 2015
Total
 
$
0.14

 
$
1,709

 
 

Declaration and payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.


55


Stock Repurchases

On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued.

During February 2016, pursuant to the stock repurchase program, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market. During the year ended December 31, 2016, the Company purchased a total of 903,031 shares of its common stock for an aggregate purchase price of $23.7 million, plus transaction costs. No shares of the Company’s common stock were repurchased by the Company during the year ended December 31, 2017. As of December 31, 2017, $32.0 million of the $70.0 million stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.

On July 28, 2015, the Board of Directors approved a stock repurchase program of up to $15.0 million of the Company’s outstanding shares of common stock. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, are anticipated to be conducted through December 2016, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act.  For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases.  The repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. In connection therewith, the Company was advised that George K. Broady, a director of the Company and owner of more than 5% of its outstanding shares of common stock, would participate in the stock repurchase program on a basis roughly proportional to his family’s ownership interest.

During August 2015, pursuant to the foregoing stock repurchase program, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of $3.5 million. The open market repurchases were completed on August 4, 2015. The stock repurchase program, which included both open market purchases and the purchase of shares from Mr. Broady, resulted in the Company purchasing a total of 162,442 shares of its common stock for an aggregate purchase price of $5.0 million, plus transaction costs. During October 2015, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of $3.6 million. The open market repurchases were completed on October 30, 2015. The stock repurchase program, which included both open market purchases and the purchase of shares from Mr. Broady, resulted in the Company purchasing a total of 106,264 shares of its common stock for an aggregate purchase price of $5.0 million, plus transaction costs.

On May 4, 2015, the Board of Directors approved a separate, prior stock repurchase program of up to $5.0 million of the Company’s outstanding shares of common stock.  In connection therewith, the Company was advised by Mr. Broady that he would participate in the stock repurchase program on a basis roughly proportional to his family’s ownership interest (see Note 8). As such, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of $3.5 million in accordance with Rules 10b5-1 and 10b-18 under the Exchange Act. The stock repurchase program, which included both open market purchases and the purchase of shares from Mr. Broady, was completed on May 13, 2015, and resulted in the Company purchasing a total of 186,519 shares of its common stock for an aggregate purchase price of $5.0 million, plus transaction costs. 

On January 22, 2015, the Company entered into a stock repurchase agreement with Mr. Broady that provided for the Company’s purchase from Mr. Broady in off-the-market, private transactions of a total of 91,817 shares of the Company’s common stock, which would be purchased at the rate of 5,000 shares each trading day following the date of the agreement until all of such shares were purchased (see Note 8). The shares were purchased at a per share price equal to the closing price per share of the Company’s common stock on the preceding trading day, as reported on the primary market in which the Company’s common stock is publicly traded. The Company’s purchases concluded on February 19, 2015, and resulted in an aggregate purchase price of $1.1 million.


56


Restricted Stock

Stock-based compensation expense totaled approximately $35,000, $104,000 and $86,000 for 2017, 2016 and 2015, respectively. During March 2016, the Company modified the vesting feature of an award granted to a director who decided to not stand for re-election at the Company’s 2016 annual meeting of stockholders. The modification of the award resulted in an additional $64,000 in stock-based compensation expense for the three months ended March 31, 2016.

At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. As of December 31, 2017, 2,393,873 shares remained available for issuance under the 2016 Plan.

On January 24, 2017, the Company granted 56,260 shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2016 performance incentives totaling $1.4 million. The shares vest on a quarterly basis over three years and are subject to forfeiture in the event of the employee’s termination of service to the Company under specified circumstances.

On April 8, 2016, the Company granted 51,015 shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2015 performance incentives totaling $1.7 million. The shares vest on a quarterly basis over three years and are subject to forfeiture in the event of the employee’s termination of service to the Company under specified circumstances.

The following table summarizes the Company’s restricted stock activity under the 2016 Plan:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2015

 
$

Granted
51,015

 
34.13

Vested
(12,759
)
 
34.13

Nonvested at December 31, 2016
38,256

 
34.13

Granted
56,260

 
25.44

Vested
(35,336
)
 
29.58

Forfeited
(1,148
)
 
28.55

Nonvested at December 31, 2017
58,032

 
28.72


On January 20, 2015, the Company’s Board of Directors granted 60,960 shares of restricted common stock to certain employees and its then-existing outside directors for the purpose of further aligning their interest with those of its stockholders and as to the employee shares, settling fiscal 2014 performance incentives. The shares vested on a quarterly basis over the next three years and were subject to forfeiture in the event of their termination of service to the Company under specified circumstances. On February 11, 2015, the Board of Directors granted an additional 6,116 shares of restricted common stock to its newly-elected outside directors subject to the same conditions.


57


The following table summarizes the Company’s other restricted stock activity:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2014

 
$

Granted
67,076

 
12.15

Vested
(22,364
)
 
12.15

Nonvested at December 31, 2015
44,712

 
12.15

Vested
(22,364
)
 
12.15

Nonvested at December 31, 2016
22,348

 
12.15

Vested
(21,930
)
 
12.15

Forfeited
(418
)
 
12.28

Nonvested at December 31, 2017

 
12.15


On August 13, 2012, the Board of Directors authorized the Company, acting as trustee for certain of its non-officer, overseas employees, to execute a Rule 10b5-1 plan to purchase 100,000 shares of its common stock in accordance with guidelines specified under Rule 10b5-1 of the Exchange Act and the Company’s policies regarding stock transactions.  Pursuant to this authority, the Company, as Trustee, entered into a 10b5-1 plan and began purchasing in December 2012. The latest 10b5-1 plan terminated in November 2014, and the Company, as Trustee, did not enter into a new 10b5-1 plan. The employees received the stock as incentive compensation in quarterly increments over three years beginning March 15, 2013, provided that they were employees of the Company on the date of the distribution. Any common stock that was forfeited by an employee whose employment terminated was delivered to the Company and held as treasury stock.
 
Shares
 
Wtd. Avg. Grant-Date Fair Value
Nonvested at December 31, 2014
23,984

 
1.37

Vested
(23,984
)
 
1.37

Nonvested at December 31, 2015

 



7.     INCOME TAXES
 
The components of income before income taxes consist of the following (in thousands):
 
Year Ended December 31,
 
2017
 
2016
 
2015
Domestic
$
(2,965
)
 
$
(3,106
)
 
$
(7,820
)
Foreign
46,391

 
67,183

 
55,613

Income before income taxes
$
43,426

 
$
64,077

 
$
47,793


 
The components of the income tax provision consist of the following (in thousands):
 
Year Ended December 31,
 
2017
 
2016
 
2015
Current:
 
 
 
 
 
Federal
$
20,277

 
$
7,151

 
$
12

State
2

 
(81
)
 
100

Foreign
1,216

 
1,648

 
456

Total current taxes
21,495

 
8,718

 
568

Deferred taxes
(1,647
)
 
273

 
(16
)
Income tax provision
$
19,848

 
$
8,991

 
$
552




58


A reconciliation of the reported income tax provision to the provision that would result from applying the domestic federal statutory tax rate to pretax income is as follows (in thousands):
 
Year Ended December 31,
 
2017
 
2016
 
2015
Income tax at federal statutory rate
$
15,200

 
$
22,427

 
$
16,250

Effect of permanent differences
459

 
12,496

 
370

Tax Cut & Jobs Act repatriation tax
20,792

 

 

Tax Cut & Jobs Act federal rate change
954

 

 

Change in valuation allowance
(43
)
 
(3,877
)
 
2,017

Foreign rate differential
(15,002
)
 
(21,713
)
 
(18,099
)
Foreign tax credits
(2,105
)
 
(261
)
 

Other reconciling items
(407
)
 
(81
)
 
14

Income tax provision
$
19,848

 
$
8,991

 
$
552


 
Income before income taxes and the statutory tax rate for each country that materially contributed to the foreign rate differential presented above is as follows (in thousands):
 
 
 
Year Ended December 31,
 
Statutory Tax Rate
 
2017
 
2016
 
2015
Cayman Islands
%
 
$
39,954

 
$
58,169

 
$
50,993

Hong Kong
16.5
%
 
3,315

 
3,992

 
2,645

China
25.0
%
 
2,584

 
3,855

 
1,493


Deferred income taxes consist of the following (in thousands):
 
December 31,
 
2017
 
2016
Deferred tax assets:
 
 
 
Net operating losses
$
192

 
$
235

Stock-based compensation
270

 
623

Accrued expenses
1,374

 
3,174

Tax credits

 

Other
6

 

Total deferred tax assets
1,842

 
4,032

Valuation allowance
(192
)
 
(235
)
Net deferred tax assets
1,650

 
3,797

Deferred tax liabilities:
 
 
 
Foreign earnings
(4
)
 
(3,650
)
Other
(267
)
 
(415
)
Total deferred tax liabilities
(271
)
 
(4,065
)
Net deferred tax asset (liability)
$
1,379

 
$
(268
)

The effective income tax rate for the year ended December 31, 2017 was significantly impacted by recording the effect of the Tax Cuts and Jobs Act (the “Tax Act”), enacted on December 22, 2017 by the U.S. government. The Tax Act makes broad and complex changes to the Internal Revenue Code of 1986, as amended, which has affected the Company’s year ended December 31, 2017, including, but not limited to, reducing the maximum U.S. federal corporate tax rate from 35% to 21% effective January 1, 2018, and requiring a one-time repatriation tax on certain un-repatriated earnings of foreign subsidiaries at a rate of 15.5% tax on post-1986 foreign earnings held in cash and an 8% rate on all other post-1986 earnings that is payable over eight years beginning with 8% of the liability due with the filing of the year ended December 31, 2017 federal tax return that will be due in 2018.


59


On December 22, 2017, the Securities and Exchange Commission staff issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740, Income Taxes. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Tax Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in the corporate income tax rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in the Company’s interpretations and assumptions, additional guidance that may be issued by the Internal Revenue Service, and actions it may take. The Company is continuing to gather additional information to determine the final impact. Any adjustments recorded to the provisional amounts through the fourth quarter of 2018 will be included as an adjustment to income tax expense.

As a result of the Tax Act, the Company recorded additional income tax expense of $20.7 million due to the repatriation tax on deemed repatriation of deferred foreign income and of $1.0 million due to a re-measurement of deferred tax assets and liabilities, in the three months ended December 31, 2017. The Deemed Repatriation Transition Tax (the “Repatriation Tax”) is a tax on previously untaxed accumulated earnings and profits (“E&P”) of certain of its foreign subsidiaries. To determine the amount of the Repatriation Tax, the Company must determine, in addition to other factors, the amount of post-1986 E&P of the relevant subsidiaries, as well as the amount of non-U.S. income taxes paid on such earnings. The Company is able to make a reasonable estimate and recorded a provisional Repatriation Tax obligation of $20.7 million.

Because of the complexity of the new Global Intangible Low-Taxed Income (“GILTI”) tax rules, the Company continues to evaluate this provision of the Tax Act and the application of ASC 740. Under U.S. GAAP, the Company is allowed to make an accounting policy choice of either treating taxes due on future U.S. inclusions in taxable income related to GILTI as a current period expense when incurred (the “period cost method”) or factoring such amounts into the Company’s measurement of its deferred taxes (the “deferred method”). The Company is currently in the process of analyzing its structure and, as a result, is not yet able to reasonably estimate the effect of this provision of the Tax Act. Therefore, the Company has not made any adjustments related to potential GILTI tax in its financial statements and has not made a policy decision regarding whether to record deferred tax on GILTI.

As of December 31, 2017, the Company does not have a valuation allowance against its U.S. deferred tax assets. The Company analyzed all sources of available income and determined that they are more likely than not to realize the tax benefits of their deferred assets in future periods or carryback years.

As of December 31, 2017, the Company has a valuation allowance against certain foreign deferred tax assets. The Company is recording a valuation allowance in foreign jurisdictions with an overall deferred tax loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision.

As of December 31, 2017, the Company has no U.S. federal net operating loss or credit carryforwards as any attributes are expected to be fully utilized to offset tax in the current year. At December 31, 2017, the Company has foreign net operating loss carryforwards of approximately $1.25 million in various jurisdictions with various expirations.

As a result of capital return activities approved by the Board of Directors during the first quarter of 2016 and anticipated future capital return activities, the Company determined that a portion of its current undistributed foreign earnings are no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. The Company repatriated $19.8 million to the U.S. during the three months ended March 31, 2016, part of which was offset by U.S. net operating losses. Accordingly, the deferred tax liability previously established for undistributed foreign earnings up to its existing U.S. net operating losses was reduced. The excess amount repatriated during the year ended December 31, 2017 was generated from current foreign earnings. The Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable U.S. corporate income tax rate. As of December 31, 2017, the Company has recorded a state deferred tax liability for earnings that the Company plans to repatriate out of accumulated earnings in future periods. Due to the Tax Act, repatriation from foreign subsidiaries will be offset with a dividends received deduction, resulting in little to no impact on federal tax expense. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of December 31, 2017.


60


The Company and its subsidiaries file tax returns in the United States, California and Texas and various foreign jurisdictions. For federal income tax purposes, fiscal years 2007 through 2016 remain open for examination by tax authorities as a result of net operating loss carryovers from older years being used to offset income in recent tax years. The Company is no longer subject to state income tax examinations for years prior to 2011. No jurisdictions are currently examining any income tax returns of the Company or its subsidiaries except that the Taiwan Taxation Administration is currently examining the Taiwan subsidiary’s 2016 tax return. No adjustments have been proposed at this time.

8.     RELATED PARTY TRANSACTIONS
 
Product Royalties
 
On April 29, 2015, the Company entered into a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called Soothe™. The Company began selling this product in the fourth quarter of 2012 with the permission of BHS. Mr. Broady is owner of BHS. Under the agreement, the Company agreed to pay BHS a royalty of 2.5% of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide. Further, the Company agreed to pay BHS $11,700 as royalties for the period it began selling the product in the fourth quarter of 2012 through 2014. The Company recognized royalties of $1,400, $3,400 and $7,000 during 2017, 2016 and 2015, respectively. The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on 120 days’ notice. Otherwise, the agreement terminates March 31, 2020.

In February 2013, the Company entered into a Royalty Agreement and License with BHS regarding the manufacture and sale of a product called ReStor™.  Under this agreement, the Company agreed to pay BHS a royalty of 2.5% of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide, with certain rights being exclusive outside the United States. On April 29, 2015, the Company and BHS amended the Royalty and Agreement and License to change the royalty to a price per unit instead of 2.5% of sales revenue. This provision was effective retroactive to January 1, 2015.  The Company recognized royalties of $306,000, $475,000 and $555,000 during 2017, 2016 and 2015, respectively.  The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on 120 days’ notice or, under certain circumstances, with no notice. Otherwise, the agreement terminates March 31, 2020.
 
Stock Repurchase Agreements
 
On October 28, 2015, the Company entered into a Stock Repurchase Agreement with Mr. Broady that provided for the Company’s purchase of common stock from Mr. Broady in off-the-market, private transactions at a rate equal to 0.4066 times the number of shares purchased by the Company’s broker in conjunction with the stock repurchase program authorized by the Company’s Board of Directors on July 28, 2015. The Company’s purchases from Mr. Broady concluded on November 2, 2015, were completed at a per share purchase price equal to the weighted average price per share paid by the Company’s broker in its open-market purchases, and resulted in an aggregate purchase price of $1.4 million. See Note 6.

On July 31, 2015, the Company entered into a Stock Repurchase Agreement with Mr. Broady that provided for the Company’s purchase of common stock from Mr. Broady in off-the-market, private transactions at a rate equal to 0.4085 times the number of shares purchased by the Company’s broker in conjunction with the stock repurchase program authorized by the Company’s Board of Directors on July 28, 2015. The Company’s purchases from Mr. Broady concluded on August 6, 2015, were completed at a per share purchase price equal to the weighted average price per share paid by the Company’s broker in its open-market purchases, and resulted in an aggregate purchase price of $1.5 million. See Note 6.

On May 7, 2015, the Company entered into a Stock Repurchase Agreement with Mr. Broady that provided for the Company’s purchase of common stock from Mr. Broady in off-the-market, private transactions at a rate equal to 0.4286 times the number of shares purchased by the Company’s broker in conjunction with the stock repurchase program authorized by the Company’s Board of Directors on May 4, 2015. The Company’s purchases from Mr. Broady concluded on May 13, 2015, were completed at a per share purchase price equal to the weighted average price per share paid by the Company’s broker in its open-market purchases, and resulted in an aggregate purchase price of $1.5 million. See Note 6.


61


On January 22, 2015, the Company entered into a Stock Repurchase Agreement with Mr. Broady that provided for the Company’s purchase from Mr. Broady in off-the-market, private transactions of a total of 91,817 shares of the Company’s common stock, which would be purchased at the rate of 5,000 shares each trading day following the date of the agreement until all of such shares were purchased. The shares were purchased at a per share price equal to the closing price per share of the Company’s common stock on the preceding trading day, as reported on the primary market in which the Company’s common stock was publicly traded. The Company’s purchases concluded on February 19, 2015, and resulted in an aggregate purchase price of $1.1 million. See Note 6.

9.     EMPLOYEE BENEFIT PLANS
 
     The Company has a 401(k) defined contribution plan which permits participating employees in the United States to defer up to a maximum of 90% of their compensation, subject to limitations established by the Internal Revenue Service. Employees age 21 and older are eligible to contribute to the plan starting the first day of the following month of employment.  Participating employees are eligible to receive discretionary matching contributions and profit sharing, subject to certain conditions, from the Company.  In 2017, 2016 and 2015, the Company matched employee deferral contributions up to 4.5% of salary, which vested 100% immediately. No profit sharing has been paid under the plan. The Company recorded compensation expense of $171,000, $134,000 and $115,000 for 2017, 2016 and 2015, respectively, related to its matching contributions to the plan. Certain of the Company’s employees located outside the United States participate in employee benefit plans that are statutory in nature.

10.    SEGMENT INFORMATION
 
The Company sells products to a member network that operates in a seamless manner from market to market, except for the China market where it sells to consumers through an e-commerce platform, and the Russia and Kazakhstan market where the Company’s engagement of a third-party service provider results in a different economic structure than its other markets. Otherwise, the Company believes that all of its other operating segments have similar economic characteristics and are similar in the nature of the products sold, the product acquisition process, the types of customers products are sold to, the methods used to distribute the products, and the nature of the regulatory environment.

There is no separate segment manager who is held accountable by the Company’s chief operating decision-makers, or anyone else, for operations, operating results and planning for the China market or the Russia and Kazakhstan market on a stand-alone basis, and neither market is material for the periods presented. As such, the Company believes that all operating segments should be aggregated into a single reportable segment for disclosure purposes.
 
The Company’s net sales by geographic area are as follows (in thousands):
 
Year Ended December 31,
 
2017
 
2016
 
2015
Net sales from external customers:
 
 
 
 
 
United States
$
3,348

 
$
4,100

 
$
3,246

Canada
1,938

 
1,809

 
2,746

Peru
508

 

 

Hong Kong1
174,926

 
263,482

 
245,737

China
7,282

 
9,086

 
4,425

Taiwan
5,591

 
6,213

 
5,965

South Korea
466

 
691

 
1,129

Russia, Kazakhstan and Ukraine2
913

 
858

 
1,139

Europe
2,278

 
1,234

 
382

Other foreign countries
313

 
255

 
91

Total net sales
$
197,563

 
$
287,728

 
$
264,860


_____________________________ 
1 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors”.
2 The Company discontinued its Ukraine operations during the second quarter of 2015.
 

62


The Company’s net sales by product and service are as follows (in thousands):
 
Year Ended December 31,
 
2017
 
2016
 
2015
Net sales by product and service:
 
 
 
 
 
Product sales
$
187,591

 
$
269,731

 
$
253,041

Enrollment package revenue, freight and other
13,676

 
25,616

 
17,623

Less: sales returns
(3,704
)
 
(7,619
)
 
(5,804
)
Total net sales
$
197,563

 
$
287,728

 
$
264,860


 
Due to system constraints, it is impracticable for the Company to separately disclose sales by product category for the years presented.

The Company’s long-lived assets by geographic area are as follows (in thousands):
 
December 31,
 
2017
 
2016
Long-lived assets:
 
 
 
United States
$
648

 
$
763

Hong Kong
78

 
140

China
112

 
199

Other foreign countries
311

 
286

Total long-lived assets
$
1,149

 
$
1,388


 
11.     SUBSEQUENT EVENTS

On February 6, 2018, the Board of Directors declared a cash dividend of $0.13 on each share of common stock outstanding. Such dividends were paid on March 9, 2018 to stockholders of record on February 27, 2018. Declaration and payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.

On February 1, 2018, the Company granted 34,202 shares of restricted common stock under the 2016 Plan to certain employees for the purpose of settling fiscal 2017 performance incentives. The shares vest on a quarterly basis over the next three years and are subject to forfeiture in the event of their termination of service to the Company under specified circumstances.

On January 26, 2018, the Company entered into an exclusive distribution, license and royalty agreement with a new supplier to purchase products through January 2021 and shall renew for successive one year terms unless notice of termination is provided by either party. To maintain exclusivity, the Company is required to purchase between $453,000 and $3.6 million of product, depending on the product mix and inclusive of royalties, per year until the termination date.


63


Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

Not applicable.
 
Item 9A. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures
 
Management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) as of December 31, 2017. Our disclosure controls and procedures are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation and as disclosed in “Management’s Annual Report on Internal Control over Financial Reporting” below, the principal executive officer and principal financial officer concluded that due to a material weakness in internal control over financial reporting, our disclosure controls and procedures were not effective as of December 31, 2017.

The material weakness identified is related to information technology general controls (“ITGC”) related to our proprietary web-based system. No material financial statement misstatement was identified in relation to this material weakness in our internal control over financial reporting. Management, including our principal executive officer and principal financial officer, believes the consolidated financial statements included in this Annual Report on Form 10-K, fairly represent in all material respects our financial condition, results of operations and cash flows for the periods at and for the periods presented in accordance with U.S. GAAP.

Management’s Annual Report on Internal Control over Financial Reporting
 
Management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by our Board of Directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:
 
pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;

provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and

provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.
 
 Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
 
Management evaluates the effectiveness of our internal control over financial reporting by using the criteria established in Internal Control – Integrated Framework (2013), issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).  Based on this criteria, management concluded that our internal control over financial reporting as of December 31, 2017 was not effective due to the material weakness described below. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.


64


Management identified ITGC deficiencies related to user access controls for our proprietary web-based system, which is used to process orders, record bonus volume activity and calculate member commissions. The Company’s ITGC user access controls specific to our proprietary web-based system did not operate effectively to provide an adequate audit trail for system change management and for the periodic review and testing of user access rights and permissions. Although the control deficiencies identified resulted in no material misstatements to the consolidated financial statements, these ITGC deficiencies, combined with inadequate compensating review controls, create a reasonable possibility that a material misstatement to the consolidated financial statements will not be prevented or detected on a timely basis and represent a material weakness in the Company’s internal control over financial reporting. As a result, management concluded that our internal control over financial reporting was not effective at December 31, 2017.

Remediation Efforts to Address Material Weakness

Management, with oversight from the Audit Committee, has implemented a plan intended to remediate the material weakness related to our proprietary web-based system and strengthen our internal control environment. The remediation plan includes the following:

Enhancement of controls to ensure that the system change management log is adequately backed up, secured and sufficiently maintained; and

Initiation of periodic review and testing of user access rights and permissions.

During the first quarter of 2018, we began the process of revising our controls related to the backup of our proprietary web-based system change management logs and believe those controls are now providing the necessary audit trail. In addition, management has initiated the periodic reviews of user access rights and permissions; however, the required programming changes necessary to improve user access rights and permissions is on-going. We also continue to review and develop additional controls and procedures to improve our control environment, including compensating review controls for our proprietary web-based system. We expect that the remediation of this material weakness will be fully complete during 2018.

Changes in Internal Control over Financial Reporting
 
Other than with respect to the material weakness identified during the fourth quarter and described above, there were no changes in internal control over financial reporting that occurred during the quarter ended December 31, 2017 that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.
 
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
ON INTERNAL CONTROL OVER FINANCIAL REPORTING

Board of Directors and Stockholders
Natural Health Trends Corp.

Adverse Opinion on Internal Control over Financial Reporting

We have audited Natural Health Trends Corp.’s (the "Company") internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, because of the effect of the material weakness described in the following paragraph on the achievement of the objectives of the control criteria, the Company has not maintained effective internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

A material weakness is a control deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis. The following material weakness has been identified and included in “Management's Annual Report on Internal Control Over Financial Reporting:”

65


Management identified Information Technology General Control (“ITGC”) deficiencies related to user access controls of its proprietary web-based system, which is used to process orders, record bonus volume activity and calculate member commissions. The Company’s ITGC user access controls specific to the proprietary web-based system did not operate effectively to provide an adequate audit trail for system change management and for the periodic review and testing of user access rights and permissions. These ITGC deficiencies, combined with inadequate compensating review controls, create a reasonable possibility that a material misstatement to the consolidated financial statements will not be prevented or detected on a timely basis and represent a material weakness in the Company’s internal control over financial reporting.

This material weakness was considered in determining the nature, timing and extent of audit tests applied in our audit of the fiscal December 31, 2017 consolidated financial statements, and this report does not affect our report dated March 27, 2018 on those consolidated financial statements.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the consolidated balance sheet as of December 31, 2017 and the related consolidated statements of operations, comprehensive income, stockholders’ equity, and cash flows for the year then ended of the Company and our report dated March 27, 2018 expressed an unqualified opinion on those consolidated financial statements.

Basis for Opinion

The Company's management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying "Management Annual Report on Internal Control Over Financial Reporting." Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control over Financial Reporting

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of the inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that degree of compliance with the policies or procedures may deteriorate.


/s/ Marcum LLP
Marcum LLP

Chicago, IL
March 27, 2018


66


Item 9B. OTHER INFORMATION

None.
 
Part III 
 
Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The information required by this Item is incorporated by reference from the definitive proxy statement to be filed with the SEC within 120 days after December 31, 2017.
 
Item 11. EXECUTIVE COMPENSATION

The information required by this Item is incorporated by reference from the definitive proxy statement to be filed with the SEC within 120 days after December 31, 2017.
 
Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
 
The information required by this Item is incorporated by reference from the definitive proxy statement to be filed with the SEC within 120 days after December 31, 2017.
 
Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
 
The information required by this Item is incorporated by reference from the definitive proxy statement to be filed with the SEC within 120 days after December 31, 2017.
 
Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

The information required by this Item is incorporated by reference from the definitive proxy statement to be filed with the SEC within 120 days after December 31, 2017.
 
Part IV
 
Item 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

Documents filed as part of this Form 10-K:
 
1.
Financial Statements. See Index to Consolidated Financial Statements under “Item 8. Financial Statements and Supplementary Data” of this report.
2.
Financial Statement Schedules. Financial statement schedules have been omitted because they are not required, not applicable, or because the required information is shown in the financial statements or notes thereto.
3.
Exhibits. The exhibits listed on the accompanying Exhibit Index are filed as a part of, and are incorporated by reference into, this report. We will furnish any of the exhibits referenced in the accompanying Exhibit Index to a requesting shareholder upon payment of a fee equal to our reasonable expenses in furnishing such exhibit(s).

Item 16. FORM 10-K SUMMARY

None.


67


SIGNATURES
 
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.
  
 
NATURAL HEALTH TRENDS CORP.
 
 
 
Date: March 27, 2018
/s/ Chris T. Sharng
 
Chris T. Sharng
 
President
 
(Principal Executive Officer)
 
POWER OF ATTORNEY
 
KNOW ALL MEN BY THESE PRESENTS that each of Natural Health Trends Corp., a Delaware corporation, and the undersigned directors and officers of Natural Health Trends Corp., hereby constitutes and appoints Chris T. Sharng and Timothy S. Davidson, or any one of them, its, his or her true and lawful attorney-in-fact and agent, for it, him or her and in its, his or her name, place and stead, in any and all capacities, with full power to act alone, to sign any and all amendments to this report, and to file each such amendment to the report, with all exhibits thereto, and any and all other documents in connection therewith, with the Securities and Exchange Commission, hereby granting unto said attorney-in-fact and agent full power and authority to do and perform any and all acts and things requisite and necessary to be done in and about the premises as fully to all intents and purposes as it, he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent may lawfully do or cause to be done by virtue hereof.
 
Pursuant to the requirements of the Securities Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
 
Signature
 
Title
 
Date
 
 
 
 
 
/s/ Chris T. Sharng
 
President and Director
 
March 27, 2018
Chris T. Sharng
 
(Principal Executive Officer)
 
 
 
 
 
 
 
/s/ Timothy S. Davidson
 
Senior Vice President and Chief Financial Officer
 
March 27, 2018
Timothy S. Davidson
 
(Principal Financial and Accounting Officer)
 
 
 
 
 
 
 
/s/ Randall A. Mason
 
Chairman of the Board and Director
 
March 27, 2018
Randall A. Mason
 
 
 
 
 
 
 
 
 
/s/ George K. Broady
 
Director
 
March 27, 2018
George K. Broady
 
 
 
 
 
 
 
 
 
/s/ Kin Y. Chung
 
Director
 
March 27, 2018
Kin Y. Chung
 
 
 
 
 
 
 
 
 
/s/ Yiu T. Chan
 
Director
 
March 27, 2018
Yiu T. Chan
 
 
 
 

68


EXHIBIT INDEX
(Pursuant to Item 601 of Regulation S-K)
Exhibit
Number
 
 
Exhibit Description
3.1
 
3.3
 
4.1
 
+10.1
 
+10.2
 
+10.3
 
+10.4
 
+10.5
 
+10.6
 
+10.7
 
+10.8
 
+10.9
 
21.1
 
23.1
 
23.2
 
24.1
 
31.1
 
31.2
 
32.1
 
 
 
 
 
 
 
101.INS
 
Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH
 
XBRL Taxonomy Extension Schema
101.CAL
 
XBRL Taxonomy Extension Calculation
101.DEF
 
XBRL Taxonomy Extension Definition
101.LAB
 
XBRL Taxonomy Extension Labels
101.PRE
 
XBRL Taxonomy Extension Presentation
 
 
+ Management contract or compensatory plan

EX-21.1 2 q42017ex21-1.htm EXHIBIT 21.1 Exhibit


Exhibit 21.1
  
SUBSIDIARIES OF THE REGISTRANT
AS OF DECEMBER 31, 2017
 
NATURAL HEALTH TRENDS CORP.
A DELAWARE CORPORATION
 
Name
 
Jurisdiction
 
 
 
NHT Global, Inc.
 
United States (Delaware)
NHTC International, LLC
 
United States (Delaware)
NHT Global (Canada) Company 
 
Canada
NHTC Holding Company
 
Cayman Islands
NHTC Trading Company
 
Cayman Islands
NHT Global Taiwan Company
 
Cayman Islands
NHT Global CIS Company
 
Cayman Islands
NHT Global (China) Commodities Co., Ltd.
 
China
NHT Global (Zhongshan) Cosmetics Co., Ltd.
 
China
NHT Global Hong Kong Limited
 
Hong Kong
Natural Health Trends Japan, Inc.
 
Japan
NHTC Global Singapore Pte. Ltd.
 
Singapore
NHTC Wellness Products Malaysia Sdn. Bhd.
 
Malaysia
NHTK Ltd.
 
South Korea
NHT Global Europe S.R.L.
 
Italy
NHT Global Peru S.A.C.
 
Peru
 
The names of omitted subsidiaries when considered in the aggregate as a single subsidiary do not constitute a significant subsidiary as of the end of the year covered by this report.



EX-23.1 3 q42017ex23-1.htm EXHIBIT 23.1 Exhibit



Exhibit 23.1
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM'S CONSENT

We consent to the incorporation by reference in the Registration Statement of Natural Health Trends Corp. on Form S-8 (333-210658) of our report dated March 27, 2018, with respect to our audit of the consolidated financial statements of Natural Health Trends Corp. as of December 31, 2017, and for the year then ended, and our report dated March 27, 2018 which included an adverse opinion with respect to our audit of the effectiveness of internal control over financial reporting of Natural Health Trends Corp. as of December 31, 2017, appearing in this Annual Report on Form 10-K of Natural Health Trends Corp. for the year ended December 31, 2017.


/s/ Marcum LLP

Marcum LLP
Chicago, IL
March 27, 2018



EX-23.2 4 q42017ex23-2.htm EXHIBIT 23.2 Exhibit



Exhibit 23.2

Consent of Independent Registered Public Accounting Firm

Natural Health Trends Corp.
Rolling Hills Estates, California

We consent to the incorporation by reference in Registration Statement on Form S-8 (333-210658) of our report dated March 10, 2017, with respect to the consolidated balance sheet of Natural Health Trends Corp. as of December 31, 2016, and the related consolidated statements of operations, comprehensive income, stockholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2016, which appear in this Annual Report on Form 10-K for the year ended December 31, 2017.

/s/ Lane Gorman Trubitt, LLC

Dallas, Texas
March 27, 2018



EX-31.1 5 q42017ex31-1.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
 
CERTIFICATION
 
I, Chris T. Sharng, certify that:
 
1.     I have reviewed this report on Form 10-K of Natural Health Trends Corp.;
 
2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.      The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
 
5.     The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 
a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 
b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
Date: March 27, 2018
 
/s/ Chris T. Sharng
 
 
 
Chris T. Sharng
 
 
 
President
 
 
 
(Principal Executive Officer)
 


EX-31.2 6 q42017ex31-2.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
 
CERTIFICATION
 
I, Timothy S. Davidson, certify that:
 
1.     I have reviewed this report on Form 10-K of Natural Health Trends Corp.;
 
2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.      The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
 
5.     The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 
a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 
b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
Date: March 27, 2018
 
/s/ Timothy S. Davidson
 
 
 
Timothy S. Davidson
 
 
 
Senior Vice President and Chief Financial Officer
 
 
 
(Principal Financial Officer)
 


EX-32.1 7 q42017ex32-1.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
 
CERTIFICATIONS PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Annual Report of Natural Health Trends Corp. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Chris T. Sharng, the Principal Executive Officer, and Timothy S. Davidson, the Principal Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:
 
1.        The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
2.        The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
  
Date: March 27, 2018
 
/s/ Chris T. Sharng
 
 
 
Chris T. Sharng
 
 
 
President
 
 
 
(Principal Executive Officer)
 
 
 
Date: March 27, 2018
 
/s/ Timothy S. Davidson
 
 
 
Timothy S. Davidson
 
 
 
Senior Vice President and Chief Financial Officer
 
 
 
(Principal Financial Officer)
 
  
The foregoing certifications are not deemed filed with the United States Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), and are not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. 



EX-101.SCH 8 nhtc-20171231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2103100 - Disclosure - Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Balance Sheet Components - Components of Balance Sheet Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Commitments and Contingencies - Future Minimum Lease Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Consolidated Balance Sheets (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Employee Benefit Plans link:presentationLink link:calculationLink link:definitionLink 2411401 - Disclosure - Employee Benefit Plans (Details Textual) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Fair Value Measurements (Notes) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Income Taxes - Components of Benefit From Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Income Taxes - Components of Income Before Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2409406 - Disclosure - Income Taxes - Deferred Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2409405 - Disclosure - Income Taxes - Income Tax Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2409407 - Disclosure - Income Taxes Income Taxes - Foreign Rate Differentials (Details) link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Net Income Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Net Income Per Common Share (Notes) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Net Income Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 2410401 - Disclosure - Related Party Transactions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - Segment Information - The Company's Net Sales by Product and Service (Details) link:presentationLink link:calculationLink link:definitionLink 2412404 - Disclosure - Segment Information - Long Lived Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Segment Information - Net Sales by Market (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Stockholders' Equity - Dividend Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Stockholders' Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2413401 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 nhtc-20171231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 nhtc-20171231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 nhtc-20171231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Income Tax Disclosure [Abstract] Schedule of Income before Income Tax, Domestic and Foreign Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Schedule of Components of Income Tax Expense (Benefit) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Income Tax Foreign Rate Differential [Table Text Block] Income Tax Foreign Rate Differential [Table Text Block] [Table Text Block] for Income Tax Foreign Rate Differential components Schedule of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Stockholders' Equity Note [Abstract] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Municipal Bonds and Notes [Member] Municipal Bonds and Notes [Member] Long-term and short-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments. Corporate Debt Securities [Member] Corporate Debt Securities [Member] Financial Institution Instruments [Member] Financial Institution Instruments [Member] Information pertaining to financial institution instruments. Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Available-for-sale Securities, Amortized Cost Basis Available-for-sale Securities, Amortized Cost Basis Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax Available-for-sale Securities Available-for-sale Securities Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] China CHINA Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount Foreign Earnings Repatriated Foreign Earnings Repatriated Net operating loss carryforwards Operating Loss Carryforwards Foreign net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration Accounting Policies [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Restricted Cash and Cash Equivalents [Axis] Restricted Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Software and Software Development Costs [Member] Software and Software Development Costs [Member] Furniture and Fixtures Furniture and Fixtures [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis] Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis] Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain] Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain] Long-Term Incentive Plan, Payment Commencing in February of the Calendar Year Immediately Following the Conclusion of the Performance Period Long-Term Incentive Plan, Payment Commencing in February of the Calendar Year Immediately Following the Conclusion of the Performance Period [Member] Represents the Long-Term Incentive Plan (the “LTI Plan”), payments commencing in February of the calendar year immediately following the conclusion of the performance period. Long-Term Incentive Plan, Payment Commencing in February 2021 and Ending in December 2023 Long-Term Incentive Plan, Payment Commencing in February 2021 and Ending in December 2023 [Member] Represents the Long-Term Incentive Plan (the “LTI Plan”), payments commencing in February 2021 and ending in December 2023. Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Restricted cash Restricted Cash and Cash Equivalents Property, and equipment useful life Property, Plant and Equipment, Useful Life Long-term incentive plan, percentage of award payable in cash nhtc_DeferredCompensationRewardPaymentPercentage Represents the percentage of deferred compensation award payable. Long-term incentive plan, number of installments nhtc_DeferredCompensationRewardPayableEqualConsecutiveMonthlyInstallments Represents the number of equal consecutive monthly installments of deferred compensation award payable. Loss on foreign exchange Foreign Currency Transaction Gain (Loss), Unrealized Segment Reporting [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] United States UNITED STATES Hong Kong HONG KONG China Other foreign countries Other Foreign Countries [Member] Represents other foreign countries. Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Long-lived assets Long-Lived Assets Segment Information Segment Reporting Disclosure [Text Block] Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Net income Net Income (Loss) Attributable to Parent Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation Stock-based compensation Share-based Compensation Cumulative translation adjustment realized in net income Cumulative Translation Adjustment Realized In Net Income Represents cumulative translation adjustment realized in net income. Deferred Income Tax Expense (Benefit) Deferred Income Tax Expense (Benefit) Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Inventories, net Increase (Decrease) in Inventories Other current assets Increase (Decrease) in Other Current Assets Other assets Increase (Decrease) in Other Noncurrent Assets Accounts payable Increase (Decrease) in Accounts Payable Income taxes payable Increase (Decrease) in Income Taxes Payable Accrued commissions Increase (Decrease) in Accrued Liabilities Other accrued expenses Increase (Decrease) in Other Accrued Liabilities Deferred revenue Increase (Decrease) in Deferred Revenue Amounts held in eWallets Increase (Decrease) in Customer Advances and Deposits Other current liabilities Increase (Decrease) in Other Current Liabilities Long-term incentive Increase (Decrease) in Deferred Compensation Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Increase in restricted cash Increase (Decrease) in Restricted Cash Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from exercise of warrants Proceeds from Warrant Exercises Repurchase of common stock Payments for Repurchase of Common Stock Dividends paid Payments of Dividends Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations Effect of exchange rates on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Net increase in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) CASH AND CASH EQUIVALENTS, beginning of period Cash and Cash Equivalents, at Carrying Value CASH AND CASH EQUIVALENTS, end of period Income taxes, net of refunds Income Taxes Paid, Net Stock Issued Stock Issued Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Related Party Transactions [Abstract] Related Party Transactions Related Party Transactions Disclosure [Text Block] Net sales by product and service: Sales Revenue, Goods, Net [Abstract] Product sales Sales Revenue, Goods, Gross Enrollment package revenue, freight and other Shipping and Handling Revenue Less: sales returns Sales Returns, Goods Total net sales Sales Revenue, Goods, Net Commitments and Contingencies Disclosure [Abstract] Loss Contingencies [Table] Loss Contingencies [Table] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] shareholder derivative claim [Member] shareholder derivative claim [Member] shareholder derivative claim [Member] Securities Class Action [Member] Securities Class Action [Member] Securities Class Action [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Litigation Settlement, Amount Litigation Settlement, Amount Rent expense for operating leases Operating Leases, Rent Expense Minimum monthly purchase amount nhtc_PurchaseCommitmentMonthlyAmountMinimum Represents the monthly purchase minimum the Company is required to purchase until the termination date. Minimum annual purchase amount Purchase Commitment, Remaining Minimum Amount Committed Purchase commitment term nhtc_PurchaseCommitmentTerm Period of time that a purchase commitment agreement is in effect. Purchase commitment renewal term nhtc_PurchaseCommitmentRenewalTerm Period of time that a purchase commitment agreement is automatically renewed for after the original term ends unless notice of termination is given by either party to the agreement. Income Tax Foreign Rate Differential [Table] Income Tax Foreign Rate Differential [Table] Income Tax Foreign Rate Differential components CAYMAN ISLANDS CAYMAN ISLANDS Income Tax Foreign Rate Differential [Line Items] Income Tax Foreign Rate Differential [Line Items] [Line Items] for Income Tax Foreign Rate Differential components Income (Loss) from Continuing Operations before Income Taxes, Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign statutorytaxrate statutorytaxrate Statutory tax rate of foreign subsidiary. Balance Sheet Components [Abstract] Balance Sheet Components [Abstract] Supplemental Balance Sheet Disclosures [Text Block] Supplemental Balance Sheet Disclosures [Text Block] Domestic Income (Loss) from Continuing Operations before Income Taxes, Domestic Foreign Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Condensed Balance Sheet Statement [Table] Condensed Balance Sheet Statement [Table] Deferred Revenue Arrangement Type [Axis] Deferred Revenue Arrangement Type [Axis] Deferred Revenue [Domain] Deferred Revenue [Domain] Unshipped Product [Member] Unshipped Product [Member] Represents unshipped product. Auto Ship Advances [Member] Auto Ship Advances [Member] Represents Auto Ship advances. Enrollment Package Revenue [Member] Enrollment Package Revenue [Member] Represents enrollment package revenue. Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Condensed Balance Sheet Statements, Captions [Line Items] Condensed Balance Sheet Statements, Captions [Line Items] Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Cash Cash Cash Equivalents, at Carrying Value Cash Equivalents, at Carrying Value Cash and Cash Equivalents, at Carrying Value Inventory, Finished Goods, Gross Inventory, Finished Goods, Gross Inventory, Raw Materials and Supplies, Gross Inventory, Raw Materials and Supplies, Gross Inventory Valuation Reserves Inventory Valuation Reserves Inventories, net Inventory, Net Property and Equipment [Abstract] Property, Plant and Equipment [Abstract] Office equipment Office equipment Represents other equipment. Capitalized Computer Software, Gross Capitalized Computer Software, Gross Machinery and Equipment, Gross Machinery and Equipment, Gross Furniture and Fixtures, Gross Furniture and Fixtures, Gross Leasehold Improvements, Gross Leasehold Improvements, Gross Construction in Progress, Gross Construction in Progress, Gross Property, Plant and Equipment, Gross Property, Plant and Equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, Plant and Equipment, Net Property, Plant and Equipment, Net Other accrued expenses: Other accrued expenses: Represents other accrued expenses abstract. Accrued Sales Returns Accrued Sales Returns Accrued Sales Returns Accrued Employee Benefits, Current Accrued Employee Benefits, Current Accrued Warehousing And Inventory Related Expense Accrued Warehousing And Inventory Related Expense Accrued Warehousing And Inventory Related Expense Other Accrued Liabilities, Current Other Accrued Liabilities, Current Deferred Revenue [Abstract] Deferred Revenue [Abstract] Deferred Revenue Deferred Revenue Deferred Revenue, Current Deferred Revenue, Current Schedule of Dividends Payable Schedule of Dividends Payable [Table Text Block] Nonvested Restricted Stock Shares Activity [Table Text Block] Nonvested Restricted Stock Shares Activity [Table Text Block] Schedule of Future Minimum Rental Payments for Operating Leases Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Products and Services [Axis] Products and Services [Axis] Products and Services [Domain] Products and Services [Domain] Soothe Soothe [Member] Represents Soothe. ReStore [Member] ReStore [Member] Represents a product called ReStore™. Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Director Director [Member] Broady Health Sciences Broady Health Sciences [Member] Represents Broady Health Sciences. Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] George Broady George Broady Member Represents George Broady. George K. Broady George K. Broady [Member] George K. Broady, a director of the Company. Related Party Transaction [Line Items] Related Party Transaction [Line Items] Royalty rate Royalty Rate Represents the royalty rate. Royalty expense Royalty Expense Termination notice, number of days Number Of Days Termination Notice Represents number of days termination notice. Treasury stock acquired rate Treasury Stock Acquired Rate Represents the treasury stock acquired rate times the number of shares purchased. Repurchase of common stock Treasury Stock, Value, Acquired, Cost Method Repurchase of common stock (in shares) Treasury Stock, Shares, Acquired Shares repurchased per trading day Stock Repurchase Program Number Of Shares Repurchased Per Day The number of shares acquired per day under a share repurchase program. Statement of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Inventories, net Other current assets Other Assets, Current Total current assets Assets, Current Property and equipment, net Goodwill Goodwill Restricted cash Restricted Cash and Cash Equivalents, Noncurrent Deferred Tax Assets, Net, Noncurrent Deferred Tax Assets, Net, Noncurrent Other assets Other Assets, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Liabilities Liabilities [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Income taxes payable Accrued Income Taxes, Current Accrued commissions Accrued Liabilities, Current Other accrued expenses Deferred revenue Amounts held in eWallets Other Deferred Credits, Current Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current Accrued Income Taxes, Noncurrent Accrued Income Taxes, Noncurrent Deferred Tax Liabilities, Net, Noncurrent Deferred Tax Liabilities, Net, Noncurrent Long-term incentive Deferred Compensation Cash-based Arrangements, Liability, Classified, Noncurrent Total liabilities Liabilities Commitments and Contingencies Commitments and Contingencies Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2017 and 2016 Preferred Stock, Value, Issued Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at December 31, 2017 and 2016 Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Retained earnings (accumulated deficit) Retained Earnings (Accumulated Deficit) Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income (Loss), Net of Tax Treasury stock, at cost; 1,637,524 and 1,692,218 shares at December 31, 2017 and 2016, respectively Treasury Stock, Value Total stockholders’ equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders’ equity Liabilities and Equity Canada CANADA PERU PERU Taiwan TAIWAN, PROVINCE OF CHINA South Korea KOREA, REPUBLIC OF Commonwealth of Independent States (Russia, Kazakhstan and Ukraine) Russia and Kazakhstan and Ukraine [Member] Geographic locations of Russia and Kazakhstan and Ukraine. Europe [Member] Europe [Member] Net sales Available-for-sale Securities [Table Text Block] Available-for-sale Securities [Table Text Block] Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Preferred Stock Preferred Stock [Member] Common Stock Common Stock [Member] Additional Paid-In Capital Additional Paid-in Capital [Member] Retained Earnings (Accumulated Deficit) Retained Earnings [Member] Accumulated Other Comprehensive (Loss) Income AOCI Attributable to Parent [Member] Treasury Stock Treasury Stock [Member] Statement [Line Items] Statement [Line Items] Treasury stock, shares Treasury Stock, Shares Common stock, shares issued Common Stock, Shares, Issued Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] BALANCE Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Adjustments to Additional Paid in Capital, Other Adjustments to Additional Paid in Capital, Other Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Stock Issued During Period, Value, Restricted Stock Award, Forfeitures Stock Issued During Period, Value, Restricted Stock Award, Forfeitures Restricted Stock Award, Forfeitures Restricted Stock Award, Forfeitures Exercise of warrants (in shares) Stock Issued During Period, Shares, Other Exercise of warrants Stock Issued During Period, Value, Other Repurchase of common stock (in shares) Repurchase of common stock Shares issued for stock-based compensation awards (in shares) Stock Issued During Period, Shares, Share-based Compensation, Gross Shares issued for stock-based compensation awards Stock Issued During Period, Value, Share-based Compensation, Gross Dividends declared Dividends Elimination of CTA upon dissolution Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Unrealized loss on available-for-sale securities Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Stock-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition BALANCE Compensation and Retirement Disclosure [Abstract] Employee Benefit Plans Pension and Other Postretirement Benefits Disclosure [Text Block] Schedule of Additional Balance Sheet Components [Table Text Block] Schedule of Additional Balance Sheet Components [Table Text Block] Schedule of Additional Balance Sheet Components [Table Text Block] Earnings Per Share [Abstract] Net Income (Loss) Available to Common Stockholders, Basic Net Income (Loss) Available to Common Stockholders, Basic Net income allocated to common stockholders (in dollars per share) Earnings Per Share, Basic Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Basic Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Class of Warrant or Right, Number of Securities Called by Warrants or Rights Class of Warrant or Right, Number of Securities Called by Warrants or Rights Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Net Income (Loss) Available to Common Stockholders, Diluted Net Income (Loss) Available to Common Stockholders, Diluted Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted Net income allocated to common stockholders plus assumed conversions (in dollars per share) Earnings Per Share, Diluted Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block] Deferred tax assets: Deferred Tax Assets, Gross [Abstract] Net operating losses Deferred Tax Assets, Operating Loss Carryforwards Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Accrued expenses Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities Tax credits Deferred Tax Assets, Tax Credit Carryforwards Other Deferred Tax Assets, Other Total deferred tax assets Deferred Tax Assets, Gross Valuation allowance Deferred Tax Assets, Valuation Allowance Deferred tax assets, net Deferred Tax Assets, Net of Valuation Allowance Deferred tax liabilities: Deferred Tax Liabilities, Gross [Abstract] Foreign earnings Deferred Tax Liabilities, Undistributed Foreign Earnings Other Deferred Tax Liabilities, Other Total deferred tax liabilities Deferred Tax Liabilities, Gross Deferred Tax Assets, Net Deferred Tax Assets, Net Total deferred tax liabilities Deferred Tax Liabilities, Net Dividends Per Share, Common (in dollars per share) Common Stock, Dividends, Per Share, Cash Paid CommonStockSpecialDividendsPerShareDeclared CommonStockSpecialDividendsPerShareDeclared Special dividends declared during the period for each share of common stock outstanding. Dividends, cash Dividends, Cash Payment Date Dividends Payable, Date to be Paid Dividends, Common Stock, Cash Dividends, Common Stock, Cash 2016 Operating Leases, Future Minimum Payments Due, Next Twelve Months 2017 Operating Leases, Future Minimum Payments, Due in Two Years 2018 Operating Leases, Future Minimum Payments, Due in Three Years 2019 Operating Leases, Future Minimum Payments, Due in Four Years 2020 Operating Leases, Future Minimum Payments, Due in Five Years Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Total minimum lease obligations Operating Leases, Future Minimum Payments Due Principles of Consolidation Consolidation, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Inventories Inventory, Policy [Policy Text Block] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Amounts Held in Distributor eWallets Amounts Held in Distributor eWallets [Policy Text Block] Represents the policy of amounts held in customer eWallets. Long-Term Incentive Compensation Related Costs, Policy [Policy Text Block] Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Revenue Recognition Revenue Recognition, Policy [Policy Text Block] Commissions Commissions, Policy [Policy Text Block] Operating Leases Lease, Policy [Policy Text Block] Stock-Based Compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Income Per Share Earnings Per Share, Policy [Policy Text Block] Certain Risks and Concentrations Concentration Risk, Credit Risk, Policy [Policy Text Block] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Recently Issued and Adopted Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Income Statement [Abstract] Cost of sales Cost of Goods Sold Gross profit Gross Profit Operating expenses: Operating Expenses [Abstract] Commissions expense Sales Commissions and Fees Selling, general and administrative expenses Selling, General and Administrative Expense Depreciation and amortization Depreciation, Depletion and Amortization Total operating expenses Operating Expenses Income from operations Operating Income (Loss) Other income (expense), net Other Nonoperating Income (Expense) Income tax provision Income Tax Expense (Benefit) Net income Income per common share: Weighted-average number of common shares outstanding: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Common Stock, Dividends, Per Share, Cash Paid Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, shares issued Preferred Stock, Shares Issued Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Treasury stock, shares Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Equity Incentive 2016 Plan [Member] Equity Incentive 2016 Plan [Member] Equity Incentive 2016 Plan Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Restricted Stock [Member] Restricted Stock [Member] Title of Individual [Axis] Title of Individual [Axis] Relationship to Entity [Domain] Relationship to Entity [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Number of classes of stock Number Of Classes Of Stock Number Of Classes Of Stock Authorized amount of shares to be repurchased Stock Repurchase Program, Authorized Amount Treasury stock, purchase price Treasury Stock Value Acquired Cost Method Excluding Related Party Equity impact of the cost of shares that were repurchased during the period, excluding those repurchased from a related party. Recorded using the cost method. Remaining authorized repurchase amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Number of shares authorized to be repurchased Stock Repurchase Program, Number of Shares Authorized to be Repurchased Allocated Share-based Compensation Expense Allocated Share-based Compensation Expense Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Stock Issued During Period, Value, Restricted Stock Award, Gross Stock Issued During Period, Value, Restricted Stock Award, Gross Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value Earnings Per Share [Text Block] Earnings Per Share [Text Block] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Maximum compensation percentage Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage Age requirement for 401 K contributions Age Requirement For 401K Contributions Represents age requirement for 401K contributions. Employer matching contribution, percent of employees' gross pay Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Employers matching contribution, immediate vesting percentage Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage Defined contribution plan, cost recognized Defined Contribution Plan, Cost Recognized Income tax at federal statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Effect of permanent differences Effect of permanent differences Effect of permanent differences. TaxcutsandjobsactTransitionTax TaxcutsandjobsactTransitionTax One-time transition tax related to Tax Cuts and Jobs Act Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Foreign rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount Other reconciling items Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount Income tax provision Subsequent Event [Table] Subsequent Event [Table] Minimum [Member] Maximum [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event [Member] Restricted Stock [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Common Stock, Dividends, Per Share, Declared Common Stock, Dividends, Per Share, Declared Long-term Purchase Commitment, Amount Long-term Purchase Commitment, Amount Document And Entity Information Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Current Reporting Status Entity Current Reporting Status Entity Voluntary Filers Entity Voluntary Filers Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Entity Public Float Entity Public Float Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Statement of Comprehensive Income [Abstract] Other comprehensive income (loss), net of tax: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Release of cumulative translation adjustment Net change in foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Unrealized losses on available-for-sale securities Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Current: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Federal Current Federal Tax Expense (Benefit) State Current State and Local Tax Expense (Benefit) Foreign Current Foreign Tax Expense (Benefit) Total current taxes Current Income Tax Expense (Benefit) Deferred foreign taxes Deferred Foreign Income Tax Expense (Benefit) Income Taxes Income Tax Disclosure [Text Block] Fair Value Disclosures [Text Block] Fair Value Disclosures [Text Block] EX-101.PRE 12 nhtc-20171231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 chart-582c681860f25365be1.jpg begin 644 chart-582c681860f25365be1.jpg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ݫ.+GX?Z[>:5+YF%OI]>L?#SQ[X=^*.F7.H^$/'5[=RZ9;HOBKPWJ6E6VL^'M5B9''V34[2 SHOGVCW-L\<[]N4<68?&8V.29OA* MW#W$O)4FLGQ]2$X8^G05Z^+X?S*"CA,^P,(N-6I/".&88&C5P_\ ;6691B:T M<*ML+F=.M66#Q5*> S"TFL)7::KQ@KSJX'$12HXZC%6E)TFJ]"$H?7,-A:DU M3/8**P?[*U3_ *&.^_\ #1?_E?1_96J?]#'??\ @!HO_P KZ^L/3-T]/Q7^ M8KDO G_(IZ+_ ->K_P#I5<5?.E:I_P!#'?=1_P N&B^H_P"H?_\ JK/\! CP MCH89B["S(9R%4NPN)PSE4 12YRQ5 %4G"@* * .OHHHH **** "BBB@ H/\ MA_/^E%!SV]1^6>?TH _)3]I7X3?#G]K/Q5X&U+XY>"O#WPWD\&7/Q)\(^&_# M7[5OP<7XB>!-2UBV\7P7?@3Q]X"\2:=X[L/AWI \8ZQX'\/W'B3PYXID_P"$ MV\>?"#7)/!D>G^ =:FN-1'VY^R5\%+_]GCX!^"?A)J1^&B7?ARX\87[6'P<^ M'J?"WX7Z'%XN\<^)O&=MX:\$^"QJNMW-CH7AFW\0Q:#;:IJVKZCK_B=].D\4 M>(+J36M9OMOS#J'[&W[0OQ^U'Q1;_M@_M7^*]4^$%]XJ\91Z!^SK^S+977[/ MGA;7?AK>>)O$2>$M ^.OQ,].\#>*_@W\/=7ODU* MRO?".NV4C7=W]Z?#3X:> O@YX!\)_"[X7>%-%\#?#WP+HMGX=\(^$?#MH+'1 M/#^B6"&.TTW3;16?R;:!2=JEW8LS.[,[,Q .Y(R,<_@2#^8P:9Y:!50 JJ@! M0C,@ P A7"@@& !3Z* ,E]"TF76+3Q!+91S:Q8:?>:78W\S2RS65A MJ,]I<:A!:"21H[;[?+I]@;Z2&-)KM;&RCN))(K2!(]7:,8Y^NYL_]]9W#J<8 M/':EHH 0J" .>.A!(/Y@@G/?)Y[YI>G2BB@ K\/O^"D'_*37_@A'_P!G-_M; M_P#K&GCJOW!K\/O^"D'_ "DU_P""$?\ V.J /V_3[B_[J_P A M3J:GW%_W5_D*=0 4444 %%%% !1110 4444 %%%% !7)>"/^1>A_["/B#_U( MM6KK:Y+P1_R+T/\ V$?$'_J1:M0!UM%%% !1110 4444 %%%% !1110 4444 M TC4]>UN^MM+T?1M/O-5U74KR00VFGZ=I]O)=WU[=2L0L=O:VT,L\SD@+' M&QZX%?._P"T?4_%U]XA_:'\7V-Q9>(/BA:V=IX(T:_C*7?@KX-Z;-+=>#M#> M&3<]IJ_BB2>;QYXL17#?VEK&GZ7,"F@VVW.^*S'XS_$C2?@!8GS_ 5X?CT; MQ[\>;B,Y@N=&^U&Z\"?"R:1-V)O'6J6#Z]XEM"8Y!X(T*2TG @\36_F?52*$ M554 !0 !V ' 'H!P!P.!7YYA_P#C+>+I8YWGP[P-BL3@\!O['->,Y49X M3-,=%KW:V&X6P=>ODN'DI3I2S['Y]2Q%"EC>'L%6/"A_PJ9HZV^ R>I4I4/Y M<3F[A*EB:R:TE3RVC.>#@U*47C:^.A4A&M@:,QU%%%?H9[H4444 %%%% !2' MI^*_S%+2'I^*_P Q0!R7@7_D6=/_ .NFI?\ IWU"NNKD? O_ "+.G_\ 734O M_3OJ%==0 4444 %%%% !1110 4444 %%%% !7'ZS_P C7X0_W?$?_IMMZ["N M/UG_ )&OPA_N^(__ $VV] '84444 %%%% !1110 4444 '7K7C7Q"^"GAOQQ MJEMXOTR^U;P#\3=+MS;Z-\2_!LMO8>)8($PT6EZW#<07&D^,?#9E4>?X:\5V M.J::4:1K-;"[9+N/V6BO,S?)LKS[!2R_-\%1QV%E.G6C"JI1J4,31?-A\9@\ M13E#$8+'86I:KA,=@ZM#&82M&-;#5Z56,9KGQ6$PV-HNABJ,*U)RC-*5U*%2 M#O3JTIQ:J4:U*5ITJU*4*M*:4ZXBCG@GAD26&:"9 \4T4L;-'+%*A#QR(S)(A#(S*0:CO+ M.TU"UN;&^MK>]LKRWFM;NTNX8KFUNK6XC:*XMKFWF5X9[>>)FCFAF1XI48JZ M,I(KYFN/A'XU^$:Y_X5SK_E7^H? M"[4IG>5XM*AM]2\!7$SK&^A:,7?4$^23XGX1^/Z[QGPS36DXQC6XSR>C&WQT MXJG2XMP5"%_>I1P_%$*5&*]CQ9F6*G4CY=\QRO?VV;Y='[22GF^$@OYHQ48Y MK1@NL%3S*,()B_]>K_^E5Q7'?#KXS^%OB#> M7OAMX-5\'?$3188I_$?PT\96T>D^,M'B=P@OXK-9I[/Q!X?E?;]D\4>&;S5_ M#]V'0)?1S%K=.Q\"<^$]%Q_SZM_Z4W%?793G&69[@J>8Y1C:&/P=252G[6A* M[I5Z,G3Q&%Q%*2C5PN,PM52HXO!XFG2Q6$KPG0Q-&E6A.$?4PN+PV-HQKX6M M"O2DY1YX._+.#Y9TZD7:5.K3DG"K2J1C5I33A4A&::774445Z1T!1110 444 M4 %%%!('7U _$G _4T ?#W[4OQ'_ &K_ KX]^'7A']E;X:6_P 0]?\ &/A' MQY)KFI?$==+\/?L]_#B/2=2\(IIWC+Q]XXL]7L_B)?\ C<'4+NR^'?P<\$:7 M=6_Q3A/BD^*/%WPKTGPU_P )[IWLW[,MOXSM/@MX5M_B'X_\:_%#QO#?>,4\ M4>-_B#\-[7X1^)-7U@>.?$INX?\ A7EC&MCX;\/Z,Q&@^#8;&?4K*_\ !NEZ M!JUIKGB$U_4_R3_;%_:U_95\<_%SX+>//AO\ &7X-^)OC=^S]X\\5OX2\ M(_%VS_:-T+0=)U#P_>W7A?XG:CX/U/X>?"+Q[&GB11,/ 7C#6'\&>)5M?#]Y M+H5EK'AY=8U!=;_1C_@GQ+]K_9%^$^IGXMV_QOEUQO'WB*Z^(.F^$/%_@'PW M/?>(OB?XUUR_\)^!?!OC[/C+P[\-OAM>ZA;5(O 'A+PX\]Q.L MDWMXI)IYYI$BAAAB0R2S32R%8XHHHU9Y)'94C16 M=V55)&?I6NZ)KVCV7B'0]8TO6= U&S34=.UO2M0M-1TB_P!/E3S8KZRU.SFF MLKJSDC_>)=03R0,GSB0J": -6BBN:T[QGX1UBWUB[TGQ1X=U.U\/27$.O7.G MZYI5];Z++:1R2W4>KSVMW+%IDEO'%+).E\]NT*1R-*$5&( .EHJA-JFFVUK# M?7%_9065R]I';WSSPQ6:1NS74DL26XD:10;X M.>?\_P"?:@ K\/O^"D'_ "DU_P""$?\ V.J_<&OP^_P""D'_* M37_@A'_VA_["/B#_P!2+5JZVN2\$?\ (O0_]A'Q!_ZD M6K4 =;1110 4444 %%%% !1110 4444 %%%% '(ZW_R,?@[_ *_-;_\ 3#=5 MUU:?%SXD6/PK\"ZOXMN;*;6-0C:TTGPS MX:LV U+Q;XOURZBTKPMX5TQ,,S7NNZU]?*?AL'XY?&B[\%_A\AR]EXJ^+/DRZ3XZ\=1JVV.Z ML? MI-<^ ?#%T$EC.NW/C2^MI,VUG-7Q_&&;X[!87!Y/D=2$.)N)<1++,EJ2 MIQKPRZ*INKF?$.)H3O&I@\@P"J8WV=;V=#'9B\LR65>CB,VPTGY>:8JM2ITL M+@Y)9AF%1X?"-Q4UAUR\V(Q]2#3C*E@:'-6Y9\M.MB/J^# M^^'7@]U\27L.L_$/Q?JMWXU^)GB&%2(]9\;ZXL+ZDMEN.Z/0M"MHK/PQX8M< M*MIX=T;3HM@D:8O['1TZ45[N2Y1@<@RK 9-EM.5/!9=AJ>&H^TG*K7J8 MC%5YMU<3C,35<\1C,76E.OBL55JXBO.=6K.3[,)A:."PU#"4(N-*A3C3AS2< MYRLO>J5)RO*I5J2O4K59MSJU93J3GXK_,4 MM(>GXK_,4 ;?$;X4>"OBA M9Z?%XGTV5=5T.Y-]X6\5Z-=SZ)XP\'ZH5"IJGA7Q-I[1:GHUV"L9FCAE>POX MXQ;:G97UHSV[Z'PTMI;+P)X6LY[ZZU.>STBWM)]3OQ +_4IK9I(9=0OOLL5O M:_;;YT:ZN_LT$%N;B60P0Q1;8U[@]/Q7^8KDO G_ "*>B_\ 7J__ *57%>=1 MRG+,/F.,S;#X+#T,RS"E0HX_&48*E5QT,*FL-]<=/ECBJF&@Y4\/6KQJ5J%& M4J-*<*4I0>$,+AZ=>KBJ=&G#$8B,(UZL(J,ZZI)JE[9QLJDJ<6XTYS4I0@W" M,E%M'74445Z)N%%%% !1110 444'^H_GS0!^;'[/\ 1_C1XP^'?@:PN8?$ MFI:*_A&30_'.F>,)[@ZN9M*USPU#J$-O[Y^Q1H.J>'/V;O FGZ_;?'.#Q+-J M7Q"UGQ9/^TDGA&W^-&L^+_$7Q,\8Z_XL\4>,M-^']W>^ M#_ .$M\0ZEJ/B; MP[X<\#SCPAX<\):MH.B>'(+72K"VMHO@3X\:-^U)\?\ QCI^H?$'_@G'XA\4 M6/PTUWXF^'?AYXA\(_\ !2K7_P!GZ'Q'X2U;Q1;6>F^,=9\&_#EO#=_'>^)_ M#OA;P_KEIHGB[4->O?":ZMJ6E6\Z2W%X\OZ"_L:>%M>\%_LZ^!_#?B7X4:K\ M$-:L-2^(+W?PPUKXN:W\>-3\,)?_ !+\8ZE9BZ^+WB.]U'6O'3:S8WEMXBCU M:^O)WAAU>/2XF6WT^%$ ,_\ ;8^'VF?%3]GKQ+X!OOB_9? S4->\3_#.7PC\ M0]8T[2=>\-6GC_P]\2O"GBSP#X=\9>%-?O\ 2=#\<^!O&_B[0=(\&>-OA]JF ML:/;>/O#&NZIX1CU?3+O6+6]A_*'Q-XRTCX@_P#!(K]OG1?'7PA^'GPK\:?# M/P+XF\.?%9? 'B"/7?@EXW^(>A_ OX3>,-#^*_PO\07=GH-S:Z?JF@ZAX(GU MK0]D:WINGZQI-_$; M>^TS5;*VU'3[V LK&&[LKR*>UN8BRJ3'-$Z$J#MR 1R[?#'X;OX(@^&C^ /! M3_#NUL8M,MO DGA709?!MOIT#^;!8P^&);!]$2SAD DCMA8^4LG[P+ORU %# MXF:AX??P'XYTK5?B3'\+DNO!/B%[KQY9:YX;T;6/ FF:A9W>EIXZT^]\3Q7N MA:?-H%S.M_IFJ:[I][H4.IVEN;^WNH5DMI/P&TOP'KWP;F^#GP0M=)^#NO\ M[.&@?\%.?@A;_%3X^?"3X4> ?@]H7QR^&_BG]GCXK>(O!FG_ +0NC?"?3].^ M&WB7XB^ _P!JFS^!W@_QAXMTRST[PAXV;5OAK'J6@:%KK^)=$?\ >_4_@K\+ MM:\46WB_5?!'AB_U>T^'FJ_"F)KGP_HWTMSUT'@[PE:^&5\%VWACP];^#TT]]*7PK!HFE MQ>&UTN0,'TU=!CM%TD6#AV#60LQ;,&;=$=QR ?SO_!*XBU+X]>#M)_:#?26_ M8?M=5_X+12?!U?&%TL?P_G/A_P#:/^">G^ /[)\YQX=FT71?@U=?M/#X)R+* M6L_AA'XMF\%!/#6G6L\/Z\?\$[+OXI7_ .PA^Q]??&MM>?XJ7G[-WP=N?'#^ M*Q./%LFN3>!M&DEE\6B[/VT>*I;9K67Q)]OQJ']MO?F_5;WSP/JR_P#"?A?5 M-+L-#U+P[H6H:-I4FGS:9I-]H^FW>F:?-I&S^RI;'3[FUEL[233/+C_LZ2W@ MC>QV*+5H@HQT &./\_Y]Z ,;Q%'X@ET/5(_"MUH]EXC>RG71KOQ!8WVIZ+;Z MB5_T:74]/TS4M(O[RS1^9K>TU.QGD7B.YB/S5^ /[<]C\;[;_@IQ_P $./\ MA9'B/X4:O$_[2?[5PT8>"?!GC;P]/;W2_L>>/C=OJ;^(/'_BB*[@DM=B6\=F MEC)%)?^?S0_\ P7ZC_P#+:MQ/N+_NK_(4Z@#! M\KQ+_P _FA_^"_4?_EM1Y7B7_G\T/_P7ZC_\MJWJ* ,'RO$O_/YH?_@OU'_Y M;4>5XE_Y_-#_ /!?J/\ \MJWJ* ,'RO$O_/YH?\ X+]1_P#EM1Y7B7_G\T/_ M ,%^H_\ RVK>HH P?*\2_P#/YH?_ (+]1_\ EM1Y7B7_ )_-#_\ !?J/_P M MJWJ* ,'RO$O_ #^:'_X+]1_^6U'E>)?^?S0__!?J/_RVK>HH P?*\2_\_FA_ M^"_4?_EM7+>#8O$)T&(Q7>BJG]H:]@/8:@S9_M_5-_(U1!M+[BHVY"D!BQ&X M^CUR7@C_ )%Z'_L(^(/_ %(M6H O^5XE_P"?S0__ 7ZC_\ +:CRO$O_ #^: M'_X+]1_^6U;U% &#Y7B7_G\T/_P7ZC_\MJ/*\2_\_FA_^"_4?_EM6]10!@^5 MXE_Y_-#_ /!?J/\ \MJ/*\2_\_FA_P#@OU'_ .6U;U% &#Y7B7_G\T/_ ,%^ MH_\ RVH\KQ+_ ,_FA_\ @OU'_P"6U;U% &#Y7B7_ )_-#_\ !?J/_P MJ/*\ M2_\ /YH?_@OU'_Y;5O44 8/E>)?^?S0__!?J/_RVH\KQ+_S^:'_X+]1_^6U; MU% 'G&LQ>(?^$@\)![O12YN]8\HBPU$*I&B76_>#J9+ ID#:R$'!)(RIZGRO M$O\ S^:'_P""_4?_ );5GZW_ ,C'X._Z_-;_ /3#=5O:MJNG:%I>I:WK%[;: M;I.D6%YJFJ:C>2+#9Z?IVGV\EW?7UW,Y"16UI:PRW$\CD*D4;,2,5%6K3HTZ ME:M4A2I4H2J5:M6<:=.G3A%RG4J3DU&$(13E*4FHQBFVTD*4HQC*4I*,8IRE M*32C&*5W*3=DDDFVV[):L^=OCKXN\=V%CX?^&'@K5])M_B3\7KR]\,^&[VSL M+X7/A'0K>U$_C7XDS>;J4D*6O@G1IA-8B4%;[Q3J'AW2E&Z]9D]2\$^")?A[ MX2\/>"?"JZ#IWA[PQI5IH^E6HL-2DD6UM(P@FNIVU0275]=.9+O4+R;,][?3 MW%W<.\\\CMY5\!=*U+QKJOB']HOQ797%EJWQ(L[72_AUHM_$8KSP=\&-/N'O M/#%E- X+V>M>.;IV\?>*8RYE22_T+1[@#_A'XD3Z1N3 M\7*HRQE6KG5:+7UNFJ.6TYIJ5#*HRYZ=1QEK"MF52V-KJT)^Q6 PU>'M<%=X M/E>)?^?S0_\ P7ZC_P#+:CRO$O\ S^:'_P""_4?_ );5O45^@'MF#Y7B7_G\ MT/\ \%^H_P#RVH\KQ+_S^:'_ ."_4?\ Y;5O44 8/E>)?^?S0_\ P7ZC_P#+ M:CRO$O\ S^:'_P""_4?_ );5O44 8/E>)?\ G\T/_P %^H__ "VH\KQ+_P _ MFA_^"_4?_EM6]10!@^5XE_Y_-#_\%^H__+:D,7B7_G\T/J/^8?J/J/\ J+?Y M[UOTAZ?BO\Q0!YSX+C\0GPY8F&ZT58_,U':KV&H,P_XFE\&RPU- 06W$84$ MX.<9/4^5XE_Y_-#_ /!?J/\ \MJS_ O_ "+.G_\ 734O_3OJ%==0!@^5XE_Y M_-#_ /!?J/\ \MJ/*\2_\_FA_P#@OU'_ .6U;U% &#Y7B7_G\T/_ ,%^H_\ MRVH\KQ+_ ,_FA_\ @OU'_P"6U;U% &#Y7B7_ )_-#_\ !?J/_P MJ/*\2_\ M/YH?_@OU'_Y;5O44 8/E>)?^?S0__!?J/_RVH\KQ+_S^:'_X+]1_^6U;U% & M#Y7B7_G\T/\ \%^H_P#RVH\KQ+_S^:'_ ."_4?\ Y;5O44 8/E>)?^?S0_\ MP7ZC_P#+:N4U:/Q"/$_A0-=:*9"OB#RV%AJ(5<:?;[]Z_P!IDMEDUQ^L_\C7X0_W?$?\ Z;;>@#2\KQ+_ ,_FA_\ @OU'_P"6U'E>)?\ G\T/ M_P %^H__ "VK>HH P?*\2_\ /YH?_@OU'_Y;4>5XE_Y_-#_\%^H__+:MZB@# M!\KQ+_S^:'_X+]1_^6U'E>)?^?S0_P#P7ZC_ /+:MZB@#!\KQ+_S^:'_ ."_ M4?\ Y;4>5XE_Y_-#_P#!?J/_ ,MJWJ* ,'RO$O\ S^:'_P""_4?_ );4>5XE M_P"?S0__ 7ZC_\ +:MZB@#!\KQ+_P _FA_^"_4?_EM1Y7B7_G\T/_P7ZC_\ MMJWJ* , Q>)?^?S0^H_YA^H^H_ZBW^>]9_@+=_PB.A[RI?[&=Y0$(7^T3[R@ M8LP0MDJ&9F"X#,QR3UQZ?BO\Q7)>!/\ D4]%_P"O5_\ TJN* .NHHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "OP^_X*0?\ *37_ ((1_P#9S?[6 M_P#ZQIXZK]P:_#[_ (*0?\I-?^"$?_9S?[6__K&GCJ@#]OT^XO\ NK_(4ZFI M]Q?]U?Y"G4 %%%% !1110 4444 %%%% !1110 5R7@C_ )%Z'_L(^(/_ %(M M6KK:Y+P1_P B]#_V$?$'_J1:M0!UM%%% !1110 4444 %%%% !1110 4444 M%KF^G*6UI.Z7?@?\.-1^'OA&:3Q3>0:Q\1_&FK7?C?XG:_ #Y.I^--:2'[9 M;6!'YWNN;B_&X7%83$P<*E.IP[EG$-":5J52E5BXRC+ 8?'TY.G4JX>3]C1%C1415544* MJJ JJ% 55'"J %4<* , "G445^@I))):)*R79(]P****8!1110 4444 % M%%% !2'I^*_S%+2'I^*_S% ')>!?^19T_P#ZZ:E_Z=]0KKJY'P+_ ,BSI_\ MUTU+_P!.^H5UU !1110 4444 %%%% !1110 4444 %K_P#I5<4 M==1110 4444 %%%% !1110 4444 !..M)D=?\_EUKYH_:\\&?%OX@? 3Q=X5 M^!?C7P_X(^*=YJ/@S4?#$_BO5/$&A>&?%Z>&O&WA[Q1X@^%?B+Q%X0W>,_#& M@_%[POHNM_#/6?%?@N&[\6^%=,\4W?B#0-/U*_TZ+3[G\O[KXM1>(O\ @E'^ MV#=> +7X^?L]_%?X,_#C5M-\:?#[6?B+K/\ PFGP-^*.A?!?X9^.=+T_X9?$ M3POXBU2TU7X7^*_#FJ>%OB5X.U;P;KS^'==T+QUJ%O=:3X9O[KQ!X-T4 _=C MIUI,C_(.>_;KV...>U?#/_!2KXM?$SX%_L&_M2_%?X/F[@^(O@OX2^(]0\-Z MO9)#)=^%I+B:TTG4?&UL+J.:S\_P'HFH:GXSA^V136B/H"O=036R2QM^<'Q< M^)?Q)^'/[<.B?L9^"_&WCJ3]F_QK\=_V%-*\<3WGC#7-2UCP?!\3O@Y^W?XU M\>?#R'QYK.HW?BN'2?BYXE_9?^ LGB73;;6UO+N7XB>+HEEMS\391< '] N1 M^?H"3P<'@<\'@^AZTO7I7\_OP-^)WQ.^,O[1F@_LS?$SQO\ $'2_@+X,UK_@ MKFOAOQE8>-=>\-:YXID_9D_:=_9]^$_P>T[5/&5MJ-KXHUV7X&>$_BW\2;'2 MK^YU6Y2_UCP=X?\ $VO-JOB/P:VHQ_J!_P $^OBC\0?C9^PY^R3\7?BK))<_ M$7XD_L[_ E\:>,-2FLETZ36]=U_P9I-_>>(GT](H8K%O$OFIXA:TMX8;: Z MH8[6*.W6)% /L*OP^_X*0?\ *37_ ((1_P#9S?[6_P#ZQIXZK]J/$5UKEEH> MJ7?AK2;/7=>M[*>72='U#6#H%EJ5\BY@M+K6ETS66TR&9OE>\&E:@81\WV67 M[M?@#^W/XA^,&K?\%./^"' \?_##PIX-CM_VD_VKGTF70_BN_C5M2N7_ &// M'R74%U!)\.?"ATR."W5)XIQ)?FX?,!A@WI, #^A5/N+_ +J_R%.K 6[\0[5_ MXDMC]T?\QPGMZC1\'ZC@TOVOQ#_T!;'_ ,'C?_*>@#>HK!^U^(?^@+8_^#QO M_E/1]K\0_P#0%L?_ >-_P#*>@#>HK!^U^(?^@+8_P#@\;_Y3T?:_$/_ $!; M'_P>-_\ *>@#>HK!^U^(?^@+8_\ @\;_ .4]'VOQ#_T!;'_P>-_\IZ -ZBL' M[7XA_P"@+8_^#QO_ )3T?:_$/_0%L?\ P>-_\IZ -ZBL'[7XA_Z MC_X/&_^ M4]'VOQ#_ - 6Q_\ !XW_ ,IZ -ZN2\$?\B]#_P!A'Q!_ZD6K5?\ M?B'_H"V M/_@\;_Y3URW@VZUU=!B$6D63I_:&O89M:*G)U_5"PVC2GX5RRAMWS@!L+DJ M#T>BL'[7XA_Z MC_ .#QO_E/1]K\0_\ 0%L?_!XW_P IZ -ZBL'[7XA_Z MC M_P"#QO\ Y3T?:_$/_0%L?_!XW_RGH WJ*P?M?B'_ * MC_X/&_\ E/1]K\0_ M] 6Q_P#!XW_RGH WJ*P?M?B'_H"V/_@\;_Y3T?:_$/\ T!;'_P 'C?\ RGH MWJ*P?M?B'_H"V/\ X/&_^4]X\/>&M#M7CADO\ 4_$; M1K+HWT[+#:6LTC!:Y\7C,)E^%Q&-Q^* MPV"P6%I3KXK&8RO2PV%PU"E%RJ5L1B*TH4:-&G%.4ZE2<80BG*4DE)>/?CAH?A;6O M^$&\*Z1JGQ,^*D]O'<6WP\\(&WDOM/M[A3]FU7QKKERR:'X!\/NYCSJOB2ZM M[BZC9_[%TS6+E!;-YM)JOQW^.,$?]B:7JGP)^&-T7\W5K^ZAL_C9XNLWM_-PK3[%1%^ M)_MCB#BJT.&*<\BR.?Q\6YK@[X[&TWHY<+9!C()SC)<[H9[G]&EEJ<%XY8/AMX OAX;U.UBU M&WDOX%UKQMXP@L[J>W'B_6_[/MK-;JZ&@>&]'\PSO]5=.E><:SK6QF(^N9EF&.Q%7&YEFF.=&E0EC,PQM>4ZM>K[&A1H4: M:<,-@L)1P^!P%#"X'#8;#4N_!X&A@:HK!^U^(?\ H"V/_@\;_P"4]'VOQ#_T!;'_ ,'C?_*>@#>H MK!^U^(?^@+8_^#QO_E/1]K\0_P#0%L?_ >-_P#*>@#>HK!^U^(?^@+8_P#@ M\;_Y3T?:_$/_ $!;'_P>-_\ *>@#>HK!^U^(?^@+8_\ @\;_ .4]'VOQ#_T! M;'_P>-_\IZ -ZD/3\5_F*POM?B'_ * MC_X/&_\ E/2&[\0_] 6QZC_F.'U' M_4'_ /UT 4/ O_(LZ?\ ]=-2_P#3OJ%==7G'@NYUU?#EB(=(LWC\S4=K-K11 MC_Q-+XME1I3XPQ(!W'( /!R!U/VOQ#_T!;'_ ,'C?_*>@#>HK!^U^(?^@+8_ M^#QO_E/1]K\0_P#0%L?_ >-_P#*>@#>HK!^U^(?^@+8_P#@\;_Y3T?:_$/_ M $!;'_P>-_\ *>@#>HK!^U^(?^@+8_\ @\;_ .4]'VOQ#_T!;'_P>-_\IZ - MZBL'[7XA_P"@+8_^#QO_ )3T?:_$/_0%L?\ P>-_\IZ -ZBL'[7XA_Z MC_X M/&_^4]'VOQ#_ - 6Q_\ !XW_ ,IZ -ZN/UG_ )&OPA_N^(__ $VV]:7VOQ#_ M - 6Q_\ !XW_ ,IZY35KG73XG\*%M'LQ(%\0>6HUK*OG3[NTDT5@_:_$/_0%L?\ P>-_\IZ/M?B'_H"V/_@\;_Y3T ;U%8/VOQ#_ M - 6Q_\ !XW_ ,IZ/M?B'_H"V/\ X/&_^4] &]16#]K\0_\ 0%L?_!XW_P I MZ/M?B'_H"V/_ (/&_P#E/0!O45@_:_$/_0%L?_!XW_RGH^U^(?\ H"V/_@\; M_P"4] &]16#]K\0_] 6Q_P#!XW_RGH^U^(?^@+8_^#QO_E/0!O45@_:_$/\ MT!;'_P 'C?\ RGH^U^(?^@+8_P#@\;_Y3T ;IZ?BO\Q7)>!/^13T7_KU?_TJ MN*OF[\0_] 6QZC_F.'U'_4'_ /UUG^ BQ\(Z&64*QLR70-O",;BDZKI]S:ZAI MNH6L%W97,,\2./*+G]E3X 7GP8\2_L^W7PWTJX^$OC6QGL/&WA>6_P!>,GC> M&[L['3;Z7QIXA35H_%'BR^U'3=,TW3-2U+7M;OK_ %'3;"RTZ\N9;&U@MX_H M6B@#R/4/@UX6U7QG;^*]3EU;4[%?A=K'PDU3P=JVM:]K?@[Q/X6UG4+*]N4\ M6>%]NK'6-9L=7UG4].NXK&WRK#]FOX%Z9X+U M3X?V7PS\,P^%M:UC1?$.IV1M[F6\NO$/A@:0GA/Q VNSW4OB%->\'1>'O#MO MX-UF'5HM3\(6OA[0;7PU=:5;:-IL5K[C10!XAK7[-OP)\0^#_"_@'5OA9X.N M?"/@M]3?PQHBZ4EK;:-_;UM?V?B9+26R>VN_)\76>K:M:>,X)KF6#QE;:MJL M'BJ/6(]2O5G]EL;&RTNRM--TVSM=/T^PM;>RL;&RMX;2SLK.TA2WM;2TM;=( MX+:VMH(XX+>WAC2&&&-(HD2-%46J* "OP^_X*0?\I-?^"$?_ &.J_<&OP^_X*0?\ *37_ ((1_P#9S?[6_P#ZQIXZH _;]/N+_NK_ "%.IJ?< M7_=7^0IU !1110 4444 %%%% !1110 4444 %#M< M/](DAEO(IXF8W7@GP/=XO#.>(RK)!HRS#,(=)PGF&+<9T\'!J2FJ;C5QE6GS3PN#Q"A)+6US MXZ7WB;5K_P &? +0;7XD^)M/NGL-=\7W=U/8_"/P+=1L([B+Q%XMM4E;Q%K= MF[C?X-\$KJFL"1&@U>[\/1DW2:W@KX&6.FZ]:?$'XDZ]=_%;XI6Z/]C\3Z_: M06NA^$1-L$ME\-O!L+S:/X*LBL:QO?PF_P#%>H1[O[8\27^[8OLNAZ%HOAG2 M=/T'P[I.FZ%HFE6R6>F:1I%E;:=IFGVB$E+:RL;.*&VMH5))$<,2*22Q!8DG M5KGP?"5;&XK#YMQCCJ?$&8X:K3Q.!RVG1EA^%\CQ%.49TJV6Y34G5>-S'#RC M"5//,XJ8S,*595JV4PR3#XJK@%%+*Y5JM/%9M6CCL13E&I0P\8.GEN"J1=X3 MP^%E*;K8B#2:QN+E6KQFI3PJP=.I*@@#'3_/^>]%%%?;GL'(ZW_R,?@[_K\U MO_TPW5==7(ZW_P C'X._Z_-;_P#3#=5UU !1110 4444 %%%% !1110 4444 M %(>GXK_ #%+2'I^*_S% ')>!?\ D6=/_P"NFI?^G?4*ZZN1\"_\BSI__734 MO_3OJ%==0 4444 %%%% !1110 4444 %%%% !7'ZS_R-?A#_ '?$?_IMMZ[" MN/UG_D:_"'^[XC_]-MO0!V%%%% !1110 4444 %%%% !1110 4444 (>GXK_ M #%N2_VI>1L1H>B:Q/M@/DYSGF4\/X18W-\;3P=&=6&' MH1<:M;%8W%U5)T<#EV!PT*V-S+,,1RR6&P& P^)QN)DG"A0J2T.7%XW"X&E[ M;%5HTH.2IP5I3JUJLK\E'#T:<9UL17J6:IT*%.I6J/W80D]#V/5-5TS0]/O= M7UK4;'2-*TZWDO-1U/4[NWL-/L+2%2\UW>WMW)#;6EM"BL\L\\L<2*"685\U M-\3_ (A_&5C8_ :QC\.>"9#LNOCOXSTB:33;V$,%E/PH\$WHM+SQI-EB+?Q7 MX@_LGP1&\?VBP'BN)3;M=TOX(:UXYU&R\5?M#ZW8>.=0LKB+4-#^&.C17-O\ M'O!MY ZR6MPNCWN+SXA>(;,ABGBCQK');Q3.9]"\,Z 0,_2RJJ *H"JH"JH& M JCHH X"@< #@#@ "OEO8\4<6ZXJ6,X+X%< M)5ASVH976Q/$4J=2A6_M;AO'4*^!?F\F99IK5=7*,O?_ "YIS2S;%0[5:]*4 MH992FK^YAIU,>XRA/ZUE]:$Z+\J^''P<\'_#634-5T]=2\0>,]>2-?%/Q$\6 MWIUWQSXG:-E:./4];FC0VVF0,B_8?#VC0:9XK_\ I5<5UIZ?BO\ M,5R7@3_D4]%_Z]7_ /2JXH ZZBBB@ HHHH **** "BBB@ HHHH *AN/.,$OV M8QK/Y;^2TRN\2R[3Y;2I&R.\8?:9%1T=DW!'5R&$U5[NU@OK6YL[E#);W<$U MM.BO)$7AGC:&5!)$R2QEHW90\;I(F=R.K , #\?_ -C?XY_'S6=>^,/PB^,7 MBGQ)HO[%_!\ZR M_LZWOB^ZGTW6=#\+-J_BOX8Z;\0O#ND_%OP+HWQ*BM;WQ9XOX%_:*^/'@:3X M./&/[0.D?M$?%W]O7P)\ /C5=_%KQ1\)?BE9_#7X?\ B;]GGXP_M)6O MB;]FSQU\-?A9\,O#&I?#'XJ>&?@UJG@GPEKWBSP1!XZ\#^)=3\6Z=K>C:5XD M\):+Y_Z::)^QG\/M&O/$6MGQS\9M5\8:CX(\0?#GPCX]U?XDZC<^.?A;X0\4 MZ9X!TWQ!9?#_ ,316D%];:QJ[?"[P#>ZGXQ\3#Q/XSU*X\+Z5!J.O7>GP/9S M='??LG?"G6/"<&@:^OB;Q!XCMO''A3XHP?%36?$$MY\58?B;X&ABM/!_CF#Q M=]EC%MJN@:;&^B66F6VFP^%'\.7NL>&;OP[<^']>UW3=2 /S:^#G[5/QX^/? MQ[TC]D=OB'K/@B;P7JG_ 4L77_C3H?A_P ,SZ[XUM_V1/C_ / CX._!:WNI M=2T6Z\+6NH1:9\?+7Q!\5;+3M"M8_$WB/P!:6Z)I/AKQ'K6AR_HM^P]\<]?_ M &F?V/OV9OV@/%>FV.D>*/C!\$?AQ\0/$MAI221Z1#XA\1^&;"]UMM%CF>6: M/1;C5&NKO1HYIIYHM,N+2.6>9U:5Z=W^Q7\#9- \(:/I.G>)_"^I^#;GXM7- MCXV\+^,-;T;X@:G)^T!JS^(?CR?$'C"*:75-9?XP>(WC\3^-)[IOM;^*+#1/ M$NA7&A:YX<\/7^E_1_@SP=X7^'GA#PMX!\$:'I_ACP9X(\.:'X1\)>&](@%K MI/A_PSX:TRUT70=$TNU4E;;3]*TJRM+"R@4D16]O&F3@D@%SQ#JT^A:)JFKV MNB:QXDN-.LI[N'0?#\>GRZUJTD*[EL=,CU74M'TU[V<_+"M[JEC;EO\ 67,0 M^:OP!_;G^)6M>,?^"G'_ 0W34?@_P#%CP"-._:3_:NGAE\;Z?X%MX-6:X_8 M\\?0/;Z8_AKX@^*'DGMEC%Q<"]CL8A;EC#+-*GDM_0O7X??\%( !_P %-?\ M@A)@ ?\ &3?[6W_K&GCJ@#]HEUFY"J/^$?UWA1UBTP'IW']K<'VI?[9N?^A? MUS_OUIG_ ,MJW$^XO^ZO\A3J ,'^V;G_ *%_7/\ OUIG_P MJ/[9N?\ H7]< M_P"_6F?_ "VK>HH P?[9N?\ H7]<_P"_6F?_ "VH_MFY_P"A?US_ +]:9_\ M+:MZB@#!_MFY_P"A?US_ +]:9_\ +:C^V;G_ *%_7/\ OUIG_P MJWJ* ,'^ MV;G_ *%_7/\ OUIG_P MJ/[9N?\ H7]<_P"_6F?_ "VK>HH P?[9N?\ H7]< M_P"_6F?_ "VH_MFY_P"A?US_ +]:9_\ +:MZB@#!_MFY_P"A?US_ +]:9_\ M+:N6\&ZM<1Z#$JZ%K4@&H:\=R1:=M^;7]48CYM44[D+%7&W 93M++ACZ/7(^ M"2%\/0DD ?VCX@Y/_8Q:O^@')/0 $G@&@#0_MFY_Z%_7/^_6F?\ RVKDO&OQ M6\+_ YT*?Q+XX:Z\-Z+ \< N]0_LX27=Y/N%KINEV,&IS:CK&K7KJ8K+2=) MM+W4KR7"6]K(:\WUCXY:IXPU.^\(_L]Z'8_$/6["Y>PUWQ_J5Q<6OP?\$W<3 M*ES;ZEXCLLS^,]?M#(A?PAX(:]N8Y0;?7-9\.@F4;W@?X&:9HFNP^/O'VN7W MQ4^*B0R11>-/$MO;PV?AJ*?9Y^G?#KPI;F31? >E-LV,VF)/X@U"-C_;GB#5 M9"7KX2KQ7C,\JSP7 V&PV:C@:=6AB<%F?$&38V$*53Q99G5QDY4,_@9\*9PA^VPV^E MP?&[QK:.'5Q:PW=^UK\(=)F1QF:[M]2\?RH!Y$/A2?\ ?+[+X%\*^%/AIH:> M'? _P_O] TH3RW=PEM#8S7FI:A<-ON=5UK5+O6KC5-:OJ]Y>ZC=/ M\T]RYQCU+_/Y]:*]')N$\'EN+_M?'XG$Y_Q'4I3HU<_S7V4\31HU'&57!Y3A M:4*>"R/+I.%)3P65T,/];]A1KYI6S''QGC:G1A,LI8>K]:K5*F-Q\H.$L;B> M652$)-.=+"TXJ-'!8=N,4Z.&A#VO)">)GB*Z=:6#_;-S_P!"_KG_ 'ZTS_Y; M4?VS<_\ 0OZY_P!^M,_^6U;U%?5'I&#_ &S<_P#0OZY_WZTS_P"6U']LW/\ MT+^N?]^M,_\ EM6]10!@_P!LW/\ T+^N?]^M,_\ EM1_;-S_ -"_KG_?K3/_ M );5O44 8/\ ;-S_ -"_KG_?K3/_ );4?VS<_P#0OZY_WZTS_P"6U;U% 'G& MLZM<-X@\),="UI2EWK!5#%IVZ3=HETI"8U0J2H^8[F08!P20 >I_MFY_Z%_7 M/^_6F?\ RVK/UO\ Y&/P=_U^:W_Z8;JNNH P?[9N?^A?US_OUIG_ ,MJ/[9N M?^A?US_OUIG_ ,MJWJ* ,'^V;G_H7]<_[]:9_P#+:C^V;G_H7]<_[]:9_P#+ M:MZB@#!_MFY_Z%_7/^_6F?\ RVH_MFY_Z%_7/^_6F?\ RVK>HH P?[9N?^A? MUS_OUIG_ ,MJ/[9N?^A?US_OUIG_ ,MJWJ* ,'^V;G_H7]<_[]:9_P#+:C^V M;G_H7]<_[]:9_P#+:MZB@#!_MFY_Z%_7/^_6F?\ RVI#K-S_ -"_KG4?\LM, M]1_U%JWZ0]/Q7^8H \Y\%ZM<1^'+%%T/6I0)-1PZ1:=M.=4OF.-^J(V5)*G* MCD<9!!/4_P!LW/\ T+^N?]^M,_\ EM6?X%_Y%G3_ /KIJ7_IWU"NNH P?[9N M?^A?US_OUIG_ ,MJ/[9N?^A?US_OUIG_ ,MJWJ* ,'^V;G_H7]<_[]:9_P#+ M:C^V;G_H7]<_[]:9_P#+:MZB@#!_MFY_Z%_7/^_6F?\ RVH_MFY_Z%_7/^_6 MF?\ RVK>HH P?[9N?^A?US_OUIG_ ,MJ/[9N?^A?US_OUIG_ ,MJWJ* ,'^V M;G_H7]<_[]:9_P#+:C^V;G_H7]<_[]:9_P#+:MZB@#!_MFY_Z%_7/^_6F?\ MRVKE-6U:X;Q/X4N%W&O2:X_6?^ M1K\(?[OB/_TVV] &E_;-S_T+^N?]^M,_^6U']LW/_0OZY_WZTS_Y;5O44 8/ M]LW/_0OZY_WZTS_Y;4?VS<_]"_KG_?K3/_EM6]10!@_VS<_]"_KG_?K3/_EM M1_;-S_T+^N?]^M,_^6U;U% &#_;-S_T+^N?]^M,_^6U']LW/_0OZY_WZTS_Y M;5O44 8/]LW/_0OZY_WZTS_Y;4?VS<_]"_KG_?K3/_EM6]10!@_VS<_]"_KG M_?K3/_EM1_;-S_T+^N?]^M,_^6U;U% & =9N?^A?USJ/^66F>H_ZBU9_@([O M".AMM9-UF6*. '0M<3G8X5F4.N=K!690P(#,,$]<>GXK_,5R7@3_ )%/1?\ MKU?_ -*KB@#KJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\/O^ M"D'_ "DU_P""$?\ V.J_<&OP^_P""D'_*37_@A'_V -#\2^.M0\2WGANVEO/$5I MH*^&-'U*VU6X\/VL$\NN16EU(VDB&5=0^SO&ZCYS,>,.$\HK_5(UDT_1-4M;CQ%8^$/AG8WEEKU\]E:M$/&WBBRUB*ZL8XI-2UK2[K M1(-8TG2U2XN=.$]U8VMU-%XA_:QU^]C2V^'7P;^'FF_VSJFG75]XC\>^)/B# MJ<6EV=HTNF^(+#0_#7A[PI8ZC#K%[Y=D=*O/$>BW^EPM+J%SY_EQV,_GKCG* M:UHY=E_%&:SFDZ/U+A/B&&$Q"D[)T;DIQJ2Y*F.AA:,WR2CRJ-5N_&UNGBFU\0V^CZY\5-9LM"73K?P^-'E\'WNC>&(O#^FZQX6OM1>?Q/>0 M:G:SZJ^LR0V\6K1:%:6^CJEGW%6+M' <"XO"2WY^)\_R/+*$DU>+A+AZOQ?B M5?9QJX2C.+:3CI+ETE]=;E&&'PU&<56YHXW&I13I M34U3Y:-5U)PO05?Z \0>,_"'A.$W/BGQ3X<\-6P*!KGQ!KFEZ- IDW% TNI7 M=LH+A6*@G+;6QG!QX1JW[8_[-NE71T^'XI:+XBU(ZQX=\.0Z=X+M-9\;74OB M+QA="Q\'Z#_Q2VFZI;0ZMXMO"+?PS97-S!)KLF?[,^TJK.(_#W[&/[,?AM+8 M6_PA\,:O/;^'_&OA62_\7_VCXWU34/#GQ!U!=0\4:+K6I>+K[6;S7K&\V)IM MHFM2W\FCZ$I\/Z-+8:-)+8R?0.F>%?#.BO-)H_A[1-*>XBTB"X?3M)L+)YX- M M$L-#AGDMK>-YX]&L8X[/2EE9QIUJBV]GY,("4>S\0\7:3Q?!N0I\O/AX8' M.^*Y*\7S^SQTL?P;%.,K[^(6G:;? M)X"_X130FU3X7RWEIXLTG4]4\4W]C)X=OUU.PO-&T*/Q%8:5#XJU:WDLO#4^ MJ.K$>5>#+KQC\;-)TR3XU>&?BYX'^'VI^*M&T"S^"?AOP7XF@74;CQK;77BA M+OXQ^.-(WZGJ/A[PY]NE\/>/-+TU/#/@3POXHLKKP_XFU'Q)L4M^C.T?GG.2 M3G/KDG(] >!VQ7)>" !X>AP /^)CK_0>GB+5@/R''TXKFQ'!6*S;EI\3<49K MG^7N2GB,@GA:YA1DI\V&KYCA*.%G+ZQ4E352E@LHPD\106$=/#UL+BZN M(PV(JJKB)TE&I1P^&\J\&_';X#IX;T^/PQJL/A7PQI]M\5K;3;#4? _BKX?Z M?IFF? K5DT/XD36^E:]X9T)-.T'PS>O&;?4?LUOI6N:?)'JWAJ?6-,<7E=PO MQF^$AM+R_?XF^ [>STVQ\#ZEJ5Q>>+-#L8],L?B;+Y'PZN=2:]O;?^SX_'-Q M_HWA+[9Y#>(;K-KI:W5P/+KTK 'KW_B8]>O4_EZ=L5GWVD:5J<4L&I:;87\, M\EG+-#>V5K=Q2RZ?<)=V$DD=Q%(DDEE=1IC3 MH4I8.%.C2A2I4J6#G1HTXTZ"IPA3IQQ4HTZ4:D4X4XJT**5%7DE5/:<^'U)1 MHY=FN'P\:B4(/-L%7E3PZQ:E&FN7),+"4Z>7_P"SJ2C3A+%Q6*5.G0?U*++3 M7-&OY)(;+5M,O)8=0O=)ECM=0L[B2+5-.7?J&FR)#.[I?V*?->63*+FU7YIX MHQS6GN'OTS]UO\.OMU]J\[3X1?"N+6=.\16_PY\$6NNZ3XF\5>--.UBT\,:/ M::E:>,/'.D3Z!XS\50WEK:0SKXC\5Z+=7&E^(M:+MJ6L6,TEM?W,\;$5RT'[ M.?P ;?X86MEX6\1^+?"HT_P1:ZT_B&WT72KCPYK^F76 MDF+5Y9+I=4TV:UUHAWMFU(VC&W.G-C%?]SAI?%9_6:L;VC!PNOJL[G6Q7MN0.IQSCGC)]!Z_A2Y!Z$'_ZW7\J\J0?$GXPZ M&X^+WA[XO75GHWQ#U*/3+Z;P_P"&K+PQ_P *ZFT^_@U&WM/A)K4-A%K'B#P# MI2Z=I^I^));S73<0WU_>/-:B^'7BNQTW[#I_QF^(CSQ>%O'NBV]_K5A\/-:N M#KWB[5X]6\/^,;T2>";1;S5/AQ&LVB^$M*!MO#=[HD[0^+])\2ZC#;:I"*K7 M3DI8632;Y73JTI(/A-#'J6F6'A>\C7XTW6I:OX=\8:-:ZUKGQ4TSS&\+S6 MVB:)HWPSU?9<+H_BK3LZ:.AC7XTQ:GHXEF^&%]I#>)?'\FO&.V\7Z5J,7A!X MM2?X7VFDAKO6;2?Q)!,=(M_'FHWK6^E74:ZC>^&],LG:UL$(XB;MS87$T[NW MO*A.UZSI)OV->K9.-J_>-&2+?CKI&ER,_P@\+>*-9L_ _ M@#49H_#'Q3BL+'5?B!K'B*XTOXA>&-);Q5X4TJ:V\->#-"CMO%&B^*]7:VO? M%R7$NA?\(YHFH6JSW/40^,_%@UBXTZ\^%/BZ&P_X3]?"5AKMOK7@*]L+GPPW MA637C\3+NV3Q7#JFG>%8]9B?P8^E2V,WC;^W9+:]3PP_AN:36X''%4Y-+DQ" M;Y5[V$Q44G*4XI.3H\BLX2YGS6BG"4FHU*;G,\GQ<(SG[;*YQ@JK_=YUD\YR M5*&&J2<*4<SBJ?/5G'$TZ<95<%C(4/2:*\!N/V@M,TR.S?Q!\,/ MCCH#3?"[QW\5]027X5Z]XCCT+2? %Y:VVH^&-4OO S>*],D^(VMPW::CX.^' M^D7VJ^)?%MA%A165[-J$$\:7DMEC/%4IPHXF.#J3A5PRJTY4XXF=.A[2,W"52K149/VM/FZ36_^1C\'?\ 7YK? M_IANJZZO"M2^+_PMNI/#_BJ/X@>$D\-:1X\\1?#_ %/7KG7+&STFQ\;6UY)X M'E\+7-]>2P6\>NGQA<6_AF+3B_VBXURXM]-MUENIHHVZ)_CC\'(]<\/^&F^* M7@$^(/%7C7Q-\-_#FC)XKT:74M:^('@S2[[6O%O@O3K2.[>:Y\4>&M*TV_O] M]Y3G[D&K\T_=C= MZ&*RC-I.JHY9F+="6(C72P6);HRPE%XG%QJI4KTY87#IU\0IV=&BG5J*,%S' MJ=%>&S?M*? V'1[G7E^)/AZ[TJT^&-G\9I;K3&O]6W_"_4=2NM(L/&EM!I=C M>7-[HMYJ5E=6=O+9P3SRS02!+\3Z@+/Q9XI\*P>-=$L+ZXL=%N+6QM+OPU=6VI2:W=SPZ!8_:(++4=4M- M1E2S,K&825N7%89WY;6KTG?GY^2UI:\WLZG+;XN2=K\LK:3R+/*?-[3)LUAR M*JY*>7XN+BJ#PZKN2E17*J+Q>%55NRIO$X=3LZU/F],HKQ:']H#X975O:7%K M?^*+K[?H_P 4]=LK:W^&WQ*DOKJQ^#6K66A^/$BT\^$DO?[1MM3U"UM_#FD/ M FJ>/4D:Z\!6GB6SAGN(U7XZ^$YM7U[1++0/BC?W_AW2_A=K%Z+3X1_$8VL] MA\6M7DT?P^^EW\WAV"RU:YT.2&6^^(.GZ?<3ZA\-](BDU3QK:Z-9H\@/KF$T MMB:#O:W+5A)N])UU91DWK07M5WIVFKQ:97]@9Y>2>49E#D;4_:8+$4E!QQT< MLES.I3BH\F8SC@9W:Y,6_J\K54XKVBBO,8?B?;7.KZ3I-OX*^)CC4_&WBSP1 M-J<_@36-/TG2+CPEIVH:A/XBU:\U06)B\%:XVGG3_"GBVTBOM(\1ZC>:?!IT MLD5TLZ\PWQPG;29]2M/@W\<+ZYB^&&F?$N#14\%:=IVK7LNI:C=Z>/AU;KKG MB72M.A^*%BMI_:.I>%=0U*RBLM,N;2ZDU0F<1*/%X=7_ 'E[RNTTIADF:3<4L+RN7L_XM;#T5'VU>MAJ;FZU6"IIUJ%6+E4< M5!076KW1[;X7?$6>&P\<:'X1EUQH_!MIHMQI6K^$+/ MQ3=_$#3I;WQC!?:AX+\/7UZ/!FN&WL6\3IXNMKVWTSPWJ>BVYUMN$)RB1R;&RA&IS8"$9+#M>US?*:,DL5AJ^+HN4*V-A."E1P]3F3$8K#4JWN%%>)/\ $/XHG6/$&G1_ O6X=/TRP^%-WHVNZA\0/AW; M6/B2Y\9:P]G\1=*M;6TU?4=3TZ^^$&DHNLZM)JEE!IWC(RQ:=X,OK^X+R)I: M?XP^)]WJFGV]W\+M*TO29/'GC?0=5U*[^).E3W5IX'T2TU%_!?CW3M,T[0;P M:G-XWOK?3;:?PCGXK_ #%>*P^)?CW=>%UU)?A3\.[#Q1-\ M-M(UJ/PSJ/QAU9[*W^*=S=7"ZSX$O?$6F?"N_0>$M+L5MI;3X@V6EWE]JE[+ M-:MX(L;>W2^N-U]1^+;:W>0CPU\/;3P[;^/=$L[/4+KQIK\NJ:E\-I?!MG>: M_K@TV#P:EM8^-++QY+=Z'I/AF;4)]%U'PO9IXCN_$FG:C=#P_"UB:A.U2O3B_.H] ?XL M/?7*Z_HT^I)\/9-1C^'EMIPLY=(\31Z7+XFOKV2Z@O?">GV\,5Q-T)DU8_#9O"D-X/&_G:?IF@"^; MP_=^%5CUF[\26>L.^AHEB(NW[K$*_+O0JJW-SVO>.EN1\U_AYH7MSQNY955C MS7Q>6/D]K?ES+!RO[%4'+EM5][G^L1]ERW]JZ==4^9T*G+Z+17@.E^(?VE)O M#T=SJ_PO^$UGXG/AGXN74NEV/Q;\2WVD)XNT?7X+;X):,FKR_"^UN7T/QWX< M:YU/X@ZZ=,2\^'NJ10Z7HVB^-[>9[^&^VO?M!#5]>A3X;_#)M%MT^$)\-WS? M$_Q$E_J;ZOK(@^.*ZK8CX;O#I2^ ]#S?_#QH+O4?^%BZ@%T_61X'@%2FY0G@(U1:7!XG M\,3ZEIECX1@O+RXT[Q-XM>PBM[W'GUWX[+H,UQ;?#?X9R^)!\/M$U.WTF;XM M>(H='E^)]Q>72>(/!\VN1_":XNX/!NEZ>EIC5G[%17GLFJ?$X:JT, M7@_P<^BCQO8:>FH/XZUB/4#\.Y/"B7FI^*6TL> W@'BNT\:&3P_9^#!J1TZ^ M\/(OBB7QC8WKGPRN+!K?QP;2A-<_#OX;PZU_PCGQ$NVT^'XJ^()].'BK2]6A MA^%VBKJDGPJMKAM$\8Z*TVH>,_$!TM;SP%J$::7I.@>.X)3J4;>(@FTX5_=< MD[8;$->[.$&TU2?,FYIQ<;\\%.<;PA.49CE>(DH-5LM2J*E**EF^5PDE5HUJ MT>>,L8I4W&-&<:JFHNC6E1H5E"MB*$*GKE"M4LH[KX8P::\'Q0OK.]N+?7-9CL_BQ?ZC;WOP]CM+"'X>Z M-(^M>$X+;4-2N?B-) ^E7:>!Y7BN6YJY\2?$?4=2T.XB\$>%+?7K/Q]XJTFS MTF7XBR7=E??#.#Q!9:6OCR75-,\(W<]AK][X-9_$MMX'ETN:WAUQ[;PG>>+; M>.<^((A8FFVURU[J,Y.^%Q*5H2E!VDZ/*Y-Q;A!-SG%QG",H3@Y#RK$J$)NK MEO+4JT:*MG&4RFIUZ5*M!SIQQKJTZ485H1K5YPC1P]6-6A7J4ZU"M3I^^T5X MF=9^-MQXG\-V-EI_P8;0!XN^(D/C=O\ A,_%MSXET_P+:V&IK\+]0\/:5'X4 M@L[WQ;J&L#1H_B%HNK7NG:/X?LIM1_X1[7/$%S!:BX([+]HF\\,K%<>(O@UH M'B^?X:>&89+RU\'^-_%7A[3/B\MU=/XQU&*QN?&GA/4-9^'$MD;*V\-:1+>: M)XHM[I;J]U;6KF&2&PBCZS=R4236O]D\JINKFF448U'3U^N/$.G&IBL1A92J0P5+%5(JE]6EB*D5!U/J MM3#UJ<*BQ%%3]LHKY*\ /'%[X<\?_ +7WP%\ :GI'CS2/$%YX%\2: MY\-?"_B:T\ 7/@6"$>!=C^)O^"O?[-.J:S;>&/BMX/UF#0OB/^R#X:O-2\6> M-/%7VKX?>+[?3[K6_$DVD^*_@]H87PEHVCH;WPUXNNO,UCQGX>U._<6J$L15 MC*RP6)FKR7-&>#4;*=.*?OXN,K3C.52/NWY*-134*CI0JNCEN"J0YZG$.48> M7+2E[*K0SZ52]3#XJM."=#)*U+FH5,/1PE6]50>(QV%E1G6PL,;B<'^II91U M(&, Y(X)Z#\>WK1D?7KTYZ=1QW]NM>4ZA\,+_4VU!KGXJ_%1!?:U\/M:CBT[ M6] T:+3'\"/927FF::=*\+6MPNB>/YK-G\?Z9?3W\>J)>WMII#Z#9R1V\7A7 MQ[\;?LY?LS:5X=^('[0O[0_B/X5>%M3\7?$C2M)O/&_QC\6Z-X;UW7OBGI^H MZK>^&Y(8[PQWD'A?2[#4+CX;Z6=D7P_M;25_#1LFB4BG4KW?+AM+I)SK0C=> MTY6[053:G>JE>[]V#M)OESCA!X?VG[7XBZ7IW@#P1\/[F:T\:?M$?&" MYE\->!]=N]?\+'Q)KNA6_B9W\4-K)N;W4/$^JW<7C'Q-;PPVNMZGJFD65G:P M??\ \$;_ /9C^/GAJ'XW?!_2?"_B_0_$GQ(O_B';^+IO"6LZ7>3_ !.\.Z+- M\-[OQ=!:>,=&TG6M/\16'A^*X\,1ZM%I]F[Z5)<06LLMM=2R3$98M\O-0P\; M\G,EB:DG&[GSI?[*E+E2I\NL5)RFGRJG%U'4HY)%UE2S'-*JBZRH.6486DJJ MBJ'U=U+9W4='VKEB?:I*LZ,:5!Q59XBI'"^ZZAXV\':2'.J>*_#6FB/0]5\3 M2&_U[2;,1^'-":)-:U]S>%=4U9L:?I[31+>7$)D0'*N/BG\,[2Z M-C<_$+P1!?#6O"?AMK*7Q5H2W:>(?'L45QX(T.2V^WF:/5O&%O-%/X7T]T6Z MU^"6.;2HKJ)U<\>_P2^ OA#1(KRW^#/P]AT_P;X!\9>#M-@TGX::1K&HZ;\/ M/$TXU_QKX'T'3=/T2_U:Y\/^++ZRBOM8\':5;W%MXGU.&U6;3+^]^SH?D9?^ M"BO[-NGI(WAWX'_ML:EJ,[:5'%I>@?\ !-+]MVTO[YM.BBLM-59=0_9[T;3E M72;%0MO)>ZE;1:=8V[1V[Q)&L)F/UU_$L+3^'2+JUO\ EW[ZNU0O:JTHNRYJ M:NU&4K1NK_8$-*#SC%?Q5>K'!8&]L2E1ERPEF/+SX-2E5AS2]GB9J,)U*5)S MJ_8)_:#^#!N(+2+XB^'+F[N;SXG:=;6ME<3WUS<:A\&5#?%"P@@L[:>6:^\% M9":W:1JUQ!*1##'/*0E,7X_?#6>P34=/O/%.M6L_@;P-\2+5M ^&_P 2==>^ M\'_$;4QI/A/4K"+2_"5R]]F?4H[BUT*VNFU*ZL;74;V&!K?3[EX_K+ 'KTQU/;\>OOU/92?$ZW_M*TTVW\%?$RZ-Q\1[CX<7% MZG@36+;3=/N;309/$#^+[N]U(6,GCTFW>2X6?R> M@\!G/A/1#R,VC'!ZC_2;CK[U\!?M _\ !0KQ[\#?BSXH^&&B_P#!-7_@HQ^T M!IOAH:*]M\6?@/\ #7X%>(/A9XH.KZ#IFMRCPSJWC+]H7P-XCNFT6;49- UC M^T/"^F^3KFF:E;VIN[..WOKG[=^#&N7/B?X4?#SQ->>&_$7@R\\2>$=$\07G M@[QA;65EXN\(W6M6::G<^%O%=EIM]JFG6?B?P[-=/H_B"UT_4]2L;;5[*\AL M]0O;=([J76$:D>;VE13N[QM!0459+E^*3>NMV]WT5D<.(J8:I[)8?#2P_)#E MJ.==UY59\S?/=TZ<8))J*A&-K*[;;;/3J***T.8**** "BBB@ HHHH **** M"BBB@ HHKX[_ &Y_C7\3OV?O@)JGQ,^&G@[7?$Z:1XA\/VWQ"UKPKX0O_B3X MI^&'PNU":YMO&?Q:\/\ PKTB6+6?B9>> 8#9ZK=^%-)^U7R:.^J>)5T?Q';^ M';CPYJX!]B45^76A_M=^-O'?BO\ 9)^#/PK^*WP5^).H_M0?#_\ :#^-_AS] MHCPEHTWB/P3?_!?X$#X7:59W=CX5TGQ6=)O?&GB+QO\ &3P9H/B7['XJ@TBQ MTW0/&\^FZ9HNM7>E:?H7U;^QS^T'_P -4_LQ_!CX_2Z OA;4/B1X+L]7UWPW M'VNA>*+&[O= \6:5I]\X66_TJQ\3Z/J\&D:A-'%/?:6EG=SPPS321( ?3 M%?A#_P %3?$%MX._X*!_\$4O'&H66KZEI?@O]H']K37M4T[PYIEQX@\3WUG) M^R9XDT18/#?A73O,UWQ7JHN]9M9WT7P[9:EK"Z7!J>KK8OI^E:A/!^XOB'7] M.\+Z)JGB'5VO%TS1[*?4+YM/TO5=;O1;6Z[I3:Z3H=CJ6KZA-C[EIIUA=W3-%ITL3\^+AB:F&KT\'B*>%Q4ZG3Q#_A"-9\,_#J34O".HV.IQW-KXSTK5+NQ^WVM]H<5I>7MEJ$ME M\H#_ (+0VF #_P $K?\ @M*V .6_X)_>(#R._/C\]:4?\%HK0=/^"5O_ 6D M'T_X)_:^/Y>/Z^8EPOC\0DL?QIQ7B:;=ZN&P\\@RG#R=[I4J^49#@LXHQ7PI M1S>3MK*4II3.2.#J--8C'8S$1;@W3YJ.&@N3FNH3P5'#8J,9N2\T2'3&\W1VU+Q)/ MXWU6'4[G5BT\&K6.I6,<=DMOI[6?GM<:F_YJWGQ!UOQ-':V/BO\ 8/\ ^"Q' MQ+NI=,UK09;#Q1X]_9_\+:+K$WB&>"=171_VQ?!OAK0]0\/P!TT;6K%=& MCTJ*6YU"1+G55MKJ'7_X?1VO_2*[_@M+_P"*_M?_ /F_IG_#Y^R'3_@E5_P6 MB_\ %?FO?_-]4/P_X2JIK,,LJY[#5*GQ/FF<<5TH)N[C3I<28_-:=.+=_&(E!G3E# MZ#_9VTOPOK_CB+1-6_X)A?%K]GRTCLM"UT?$_P",5Q^R5XOTH:[\.A:CP87N M?AU^T=\8?'Q\7Q2N]]IGB%= +R:E;W.J:UKD>HR17,_Z-66EZ;IL?DZ?865C M#]IOKSR;.TM[6(7>IW6T,%TL*WEW:>.P?M(?\%'-0E\FP_X)N>#-+9(VEDN/&G[=?PXTRQ:L%XX5/F_P!L?MA_M"^+7O7D M(V?9QH_[%?AE;%+=4;S3<&\-P9H_*$ AD\WZP^!EW^T!>^#;F;]I+P[\'O#/ MC\:]>I9Z=\$?&?CCQUX/?PRMGIQTZZN=9^('@3X>:Y%KLM^VJQWMA%H4NG06 MD.GS0:E<3W%S!:_EW_P^CM?^D5W_ 6E_P#%?VO_ /S?T?\ #Z.U_P"D5W_! M:7_Q7]K_ /\ -_0!^T5U]I^S7'V+R/M?D2_9?M/F?9_M'EMY'G^3^]\GS=GF MF+]X(]VP%L5^+VD^&O\ @O%+;7$GAWXS_P#!)6ST635M>DT^SO?V*]%?6/%=I#K>@_L%ZQJ&FS7F MF>+==TS6+);FV^(R:TO;=8IUE_0ZOQ6_X?1VO_ $BN_P""TO\ XK^U M_P#^;^C_ (?1VO\ TBN_X+2_^*_M?_\ F_H ^]?C'X._;>UOQD]]\!?C]^S3 M\.O )TS3XH_#GQ3_ &6?B/\ %OQ4FKQB;^T[U_%WAC]JSX0Z6^GW9: V6FCP M@D]B(Y1-J5_YRF'Q^3RU=PS!-[[ 0NYL;C\V?M4?"_]HGXL_#S3/#?[,W[4'_#)GCVU\6Z?K&H M_$C_ (4EX$^//]J>%K;2M:M+_P (?\(=\0=0TW1;'^T=3OM(U;_A(()VU&S_ M +$^P0Q-;ZE=,GYV_P##Z.U_Z17?\%I?_%?VO_\ S?T?\/H[7_I%=_P6E_\ M%?VO_P#S?T 7_P#AB;_@KM_TFT_\YK_LP?\ S6U^A?[+OPT_:"^%/PWNO#/[ M2G[3'_#5GQ!E\4:KJMM\3/\ A3'@?X%?9?#5W9:3!IGA3_A"_ &H:EH<_P#9 M-Y9ZI>_V[)<#4+_^U_LUQ&L6GVS-^/BU M\,/%\GB7QK^VS^TG^T!H[Z/?Z8O@3XK>&OV6=(\+QWEW+9R0:\EU\'/V\*"T?4-"TG MQK\!?'>N0:AK$['Q;\/M+U7_@FC_P %C-*US7=0\1P^%]"U#]@S5[;5/%%QI_AF^U#5 MK;0K27XB)/J%QI6E03ZM?16T"/#G[2W[1_[+5[I?BVQ\42^/OV8_$W@7 MPOXZU>VL])UG2V\)ZM?_ !!^'GQ+T:;PK>R:M%JU[:6VAVFHR:KHVCS1ZI%; M0W=K>?G;_P /H[7_ *17?\%I?_%?VO\ _P W]'_#Z.U_Z17?\%I?_%?VO_\ MS?T ;'_#ICXI?])CO^"O/?\ YK)^S+W_ .[3?R].V*_13]FSX'ZU^SW\,;3X M=:]\?/CM^TEJ%KK&L:J_Q._:*U_P?XD^)-Y%JT\I^!O!'P^T!M)T<( M8-(AB\.0W,,$DBW5W=N5=?S3_P"'T=K_ -(KO^"TO_BO[7__ )OZ/^'T=K_T MBN_X+2_^*_M?_P#F_H _9K5+%M3TV_T^.^O=+DO;*\M(]2TQX8M1TZ2[MI;= M;ZPEN(+F".]M&E%Q:R36\\27$<;2PRH&C;\?O^'3/Q3_ .DQW_!7C_P\?[,? M_P!"9_\ K[UC?\/H[7_I%=_P6E_\5_:__P#-_1_P^CM?^D5W_!:7_P 5_:__ M /-_0!]1_LP_L*>-OV'%^''[2GQ ^#/B? MX>VUQJ5YI=W'XGMM.\!? KX'?A=H+:-HUEI,UWH>E>-?V??'OB*"ZUR6T?6=:>\\3WL<^KWMY-:Q6=J M\-I#XM!_P2=^*4,T,Q_X+$_\%)YO'7[,/B;P%X6\;ZW;6VD:QI3>$]9OOB%\.OB7 MI$WA6ZEU:+6+JTM-%L]1?5M'TB:/5([6&ZM+O\\?^'T=K_TBN_X+2_\ BO[7 M_P#YOZ#_ ,%HK4X_XU7?\%I>H_YQ_P"O^HQ_S/\ Q]>W6@#U;P3_ ,$]/&UW MX/T"SUO_ (*4_P#!2OQ%;V<,SX\\=8:?_J-,MOL2?9+?]UOD^]7X[?#;_@MU MX2U[P;I6K>$_^":7_!8SQ;H%U-K"66O^'_V#-7U'2;U[37=4L[Z.WO+7XB30 M226&HV]WIUVBR,8;RTN(7P\; =U_P^CM?^D5W_!:7_Q7]K__ ,W] '[+ZQIL M>LZ3J>D2W6H6,>J:??:=)>Z3?3Z9JEHE]:S6CW.G:C:LMS87]NLQFLKV!EFM M+I(KB)A)&I'X_'_@BY\,O^C[/^"N?;_G)Q^T[V'_ &,O?J?>LG_A]':_](KO M^"TO_BO[7_\ YOZ/^'T=K_TBN_X+2_\ BO[7_P#YOZ /J3]E[_@G?X-_97^( MU[\2= _:9_;P^+][>^%=3\)OX6_:4_;+^,OQ]^'UO;ZIJ&D:A)K-GX)\?ZQ? MZ):^)[1]'BMM-\010C4+"QOM5L[>18=2N0WZ"U^*W_#Z.U_Z17?\%I?_ !7] MK_\ \W]'_#Z.U_Z17?\ !:7_ ,5_:_\ _-_0!]T?%G]B#X._&?QUJWQ#\7>+ M_P!J'2=>UJ+3(;NQ^&O[:/[6_P '_!\2:3IMKI5J=,\ ?"KXT>#_ 1H\DMM M9Q2ZA-I.@6.\ETC]H/4+])ENI=0U; M]MW]M_5+Z]O!()I+S4+B]_:*E-]*+71]7T"#5/[1^'OBK MPEJUSY>DZ[JMI]BO+^XTYOM7GO9MMZQIOAH>(_%WBK[-J/B*_?5-9 MN/[8\;^(/$WB";[9?2//Y-QJLL%OGRK6*"$",?F?_P /H[7_ *17?\%I?_%? MVO\ _P W]'_#Z.U_Z17?\%I?_%?VO_\ S?T ?LKKFBZ5XDT;5O#^N64&I:-K MFF:AH^K:=F>(-:3Q:?#7AV^_8-U>#6/$RZ9I-IZD;>.7[-;S1O)L5@: /U!^"?[$7['G[-WB&3Q?\ _V8/@-\'?&$^@7'A:[\ M8?#GX6^#_"?BV_\ #UY=:??7VD:EXGTG2K?7=2L;^^TK3;Z_AU#4+D7U]8VM MY=F:Y@24?4=?BM_P^CM?^D5W_!:7_P 5_:__ /-_1_P^CM?^D5W_ 6E_P#% M?VO_ /S?T ?IUXR_9G_9T^(GB&^\7>/_ ("?!;QOXJU-;5-1\2^+_A3X!\3^ M(+]+&TAL+)+W6M<\/7^IW:VEC;6]G:K<74@M[2"&VA"0Q1QKK6'P%^"&E6UG M9Z7\'OA9IUII\4%O86MA\.O!EG;64%LJI;0VD%MHD45M%;HBK#' L:1*JK&J MA0!^5_\ P^CM?^D5W_!:7_Q7]K__ ,W]'_#Z.U_Z17?\%I?_ !7]K_\ \W] M'[4TA&>N?P)'\B*_%?\ X?1VO_2*[_@M+_XK^U__ .;^C_A]':_](KO^"TO_ M (K^U_\ ^;^@#]IC&IZE_P ))!_)Q3@ HP,X]V9C^;$G]:_%?_A]':_](KO^ M"TO_ (K^U_\ ^;^C_A]':_\ 2*[_ (+2_P#BO[7_ /YOZ /VII,#W/U)(_$9 MYK\5_P#A]':_](KO^"TO_BO[7_\ YOZ/^'T=K_TBN_X+2_\ BO[7_P#YOZ / MVH"J.B@?0 ?RI:_%;_A]':_](KO^"TO_ (K^U_\ ^;^C_A]':_\ 2*[_ (+2 M_P#BO[7_ /YOZ /VE>.-N6C1B2N254D\@$?B'J7PWU@RW$D>KVFBZ9XBTW4+>ZT;6- M%N=%\2:'J#6LVI:%<1ZO]ODBTC6?#VM0:IIFE7NGZW9M;2)/ZI10!^>_A?\ MX)^>$? =[X3\=^!/'FL>$_C=X9\??'?XAR?$G2?"_AB+1;_5?VFH/#J?&G1X M/AB((_"6D^&-?U+P9X&\5Z5IEH7O+3QOX)T3Q7XBU3Q=J&J>-5\6_67P-^#' M@3]G?X0?#CX'_#.PN-.\"?"[PAHO@SPU!?7/V[4Y=/T:U6#[?K&H&.%M2UO5 MKG[1JNMZF\4;ZCJ]]>WSQHUP47U:B@ KY^^*_P (]<\??%?]F3Q[IFJ:79:7 M\$?B/X\\9^(K&_\ MQOM7L/%?P*^)_PLL;71?L\4ELMY:ZSXXL-1N6OY+>'^ MS+6^$,CW;00R?0-% "8'O^9_QHP/?\S_ (TM% "8'O\ F?\ &C ]_P S_C2T M4 )@>_YG_&C ]_S/^-+10 F![_F?\:,#W_,_XTM% "8'O^9_QHP/?\S_ (TM M% "8'O\ F?\ &C ]_P S_C2T4 -*Y[GJIZGLP/K[5\]_LN?!_7/@7\'M-^'7 MB/5-)UC5;/QI\8/$LE]H?VY=/>T^(GQF^(7Q)TJW07\-O<_:;'2?%]C8:@6B M$1U&UNS;-):F&5_H;(]??\/6B@!,#W_,_P"-&![_ )G_ !I:* $P/?\ ,_XT M8'O^9_QI:* $P/?\S_C1@>_YG_&EHH 3 ]_S/^-&![_F?\:6B@!,#W_,_P"- M&![_ )G_ !I:* $P/?\ ,_XT8'O^9_QI:,CKGCUH ^=?BE\'-=\=?&S]FGXF M:;JND6>D?!3Q'\4]9\0Z??"^.I:M;^._A/KW@#38M%:WADM5FL]3U6"]OOMT ML"&PBE%N9+G9&?HG ]_S/^-+10 F![_F?\:,#W_,_P"-+10 F![_ )G_ !HP M/?\ ,_XTM% "8'O^9_QHP/?\S_C2T4 )@>_YG_&C ]_S/^-+10 F![_F?\:, M#W_,_P"-+10 F![_ )G_ !IKIN )X=&Y)_@=6/?N!CZT^B@#YU_93^#FN_ M7X%^#_A;XEU72=:UGP[>^-KFZU'0A?+IDZ>)_B'XN\86:VZZA#;78:WL?$-K M:W/FPJ#=P7!B+P^6[?1.![_F?\:6B@!,#W_,_P"-&![_ )G_ !I_P"9_P :6B@!,#W_ #/^-&![_F?\:6B@!,#W_,_XT8'O^9_Q MI:* $P/?\S_C1@>_YG_&EHH 3 ]_S/\ C7SG\2/@UKWC/X^_LZ?%G3]5TBTT M3X.0_&:/7M,O!?'5=5/Q)\&:/X;TDZ0T$$EFHL+O3I;C4?MLT!-O)']E$LNY M1]&Y'7/'K10 F![_ )G_ !HP/?\ ,_XTM% "8'O^9_QHP/?\S_C2T4 )@>_Y MG_&C ]_S/^-+10 F![_F?\:,#W_,_P"-+10 F![_ )G_ !HP/?\ ,_XTM% " M8'O^9_QHP/?\S_C2T4 ,=-P !/#HW)/\#JQ[]P,?6OGK]E#X/:[\ OV>_AC\ M(?$VJ:1K6N^!]#NM+U'4]"%ZNDWKYC@_9@TG3=< M_:;\3^'_ (J?%SPOXD_:C?1[CQ-KN@:IX)MM2^'NI>'OAYI/PQT36/A5/=> M[X:#JFG>&-$TXPW'B./Q=$-9A.L^0+MVH ^;_A7XE_:<\(1?M8>$O&WQ>O/C M9X8TOX@_#[X<_LS_ !?\4^$/A]X-^(ESXZ\?>'],T3Q_X9UVT^&GASPC\/O% M?AKX3>/=8TZYT;Q5I/@W1;X&+QMX-\1#5KSP%-K=[?\ 'FI?M*?"+]ICX=Z[ MIGQNUSXK?!K4_#OQJ\1_&GX':C\-O ,6F_#CX4>!?ASJVI?#KQSX"\<:%I%C M\29/B3J?Q+LO"?@K5M.\<^)?%VA_$BV\4>.=:\,^'O!Z^!8K6U]E^"7[)G_" MH&L#K_[1'[1OQZ31-7TS6?#4'QQ\3?#O6;7PQ/I7AKQ+X7MH-%L_ /PN^'%F MD,EEXIOKRZN-0M]1U2XU2STF[.HJM@L,E/PQ^R1J_AWXXZI\9[K]K']J_P 4 M:;K'B?7/$U[\%/$7B[X5'X,/_:NFWNF:=X>&D:%\&M#\@R? M$&2VCNM/M9M9;6C<:JNI 'R?^R/^U=\:OB#X@_80N/B+XEL?$.G_ /!0']AS MQU^UD^BVOAW2=)3X+^,/#+?LY^*['PEX3:TMK?4-0\$/X-_:-C\+77_"6W.N MZZWB#P!IFNMJ22>)];LU]9_9P\6?'#]HO]AKX9^+O$G[0E]\,OB%K'_"8OX^ M^-?A7P'\,8->71_!WC[QYX>DOM T#QEH/B7X7^%;JXL- TN74M0UCPCXFT^P MTRVU-;;3X]1NX-:T[W/X1?L??"'X)ZQHNM>"%\3+<^!_AOJOP;^$D&MZVFM6 M/P8^$FL>(].\57WPY^&]K'/!GBN\\4V7CCP/XB^%MK\2-5CO MO$/B#Q7/X9U_5==^$/B#PSJ/A=_$'B*YU"2PC\(6MU*%U+Q):>%H? TOC#PK:^-_$UG\,/ M'&M>";:XN;3P;XL\<_"VW\&>+_&GA.Q>/3O#?BW6]9T;3K6RLK.&QMOI^O,_ MA!\.;WX4^ ='\$:C\2_B9\7[_2Y=4GN_B%\7M9T+7/'NORZGJEWJ*_VQ>>&/ M#7@[PXD6FPW,>E:7:Z+X8T>TM],LK1)()[W[5?77IE !1110 4444 %%%% ' MR)^W!\1_B!\)O@.GCKX:>)(O#'B2P^-'[,N@W-W/H>D^((=0\+>/OVDOA1\. MO&NA/9ZQ#-!:MK?A'Q=K6GV^KVRC4-&NIH-2L&^TVR*WG_[:4/[4FA6/AOQ[ M^SE\;V\/>+;'QM\+O#O@SX!W?P\\!>(/ OQFOM8\?Z;!XYTGXG>)-;T:_P#B M+H^CCP#+KVHP:]\,_$G@:3X=:;X+?#&C2^+_AUXSEU'P5&OB9X:MA<^(?#_B6P33W\4^ M$M$EU6 :9YU_I\-QIPN8(;R=CY1\8/V3M=^+/Q)TGXC6?[6O[6'PF72_#VG> M&V\"_"/Q7\)M!\"ZA:6NI2:IJ=Y=6?B/X,>+_$=OJWB:9H+?7]4TCQ/IEW+8 MV&FVNFOIB:?:F, O^/+?X@_$R\^+%OX/^.NN_ ?PUX.N_#WA.X\=^&]#^'_B M'5]-?0]$U'QA\0-8T-/B7X>\5>!M,NL^)?".@W^M^)?"_B>TTFQ\)^*+.STR MRU2_76=,^%/A7\?OVOO'GB3]FG]F#XA>-X/A_P#%[Q-^R+^TY^TQXV^+VF_# M/0]*F\96GPS^-/P]^$G[/,VI>"=>BUOP_P""+SQIX2^)&B_%KXV>"=.B2[TK M7K>+P1H%[X=T6YO5K[]^*O[,D?Q(^&VG_#?0/C?\(=4U+6M<\1WNEZ_?>./ASX_T>]\/7&N:V=0FTV/0[>2=M+TBVN+N6 MRM9;6YY>3]B_PCJ7AKP)8^*/BS\>/&/Q!\">&?BEX'A^.FO>-]#@^,/B/P'\ M9;K3[KXA>"/$>M>'?!V@^%V\.ZPV@>#_ +#'H'@_0-0\-7?@GPKKGAG4-(\1 MZ=-K-V ?-WP8_:^^*OQNN_\ @E=\0XKS3/"7A/\ ;#_9K^(WQ0^*?P[LM#T^ M_LSXJMOA!\,_'NAR:'XEU$7&OZ=IGAW6]:\06UC;6\X76]+O[.75F::RC63L M]5^*OQ(^'O\ P4:^%_PB\0?'_P 2WWP\^.GPH^-&LZ/\)/&_P-L=%\ /XP\" MS>#M:\*:-\"?C?X;\&:;-J?C_1O!L/Q!\2_%'P+\1/B!XOU'6_"]LGB?PAHW MA^U\/:G:VGT6W[*7PTL_&7[-OBKPO=>(O ^E_LJ>$/$7@/X4?#[PI-H-KX"M M?"7B/PGH7@>;1-7T[4O#VJ:SE>%_#>C:9H":;K^DG3%M3,6N)9I6;LM,^ M">DQ^,M.\<>*_%OC3XC:KX9\3^,/%/P]M_&UQX8FT[X:7GC6QU#1=3M_"$/A MSPKX:N7AL_#>K:OX7T:^\4W?B;7M+\.:QJ^D0:R;?4;LS 'M%%%% !1110 4 M444 %%%% 'Q/\)_&WQ?\>?$;]OCX#-#F_P"% M>^'?&?[+OP+^),EM-;C1?%_CGQ-K%C=>(+H3WJW-CI%^[Z;8JDGE M?PD\3?M,>&M)_:A\&>._B_=_&70K;XP^$/A7^S!\:?$7A+P)X.^)&J7_ (T\ M+>%M*^(%IXAT[X;^&/"?P\\3Z;\'/B!J?B)M&\5Z)X-T&6^@\-^)?#NO66I7 M?@^;7M8^CX_V8M.L;C]J#4?#_P 6_C#X4U[]JC6;#Q!XG\2^&M4\#6.O?#S6 MM+^&?A+X2:;J7PGO+CP!>Q>'KRS\&>"?#\,$WB"V\6O#J]O/KT)CU.ZDF&9\ M$OV53\(#IIU_]H/]H?X\MH&K6^K^&#\;_$GP^U:/PO):>%M:\(6UGH=G\/OA MC\-]-M[2/2?$.JLSW5E>ZC-=RV\DNH-#8VEO$ ?/WQ/\5?M+? K]H?1_&5E\ M8=7^,OP/3X8?M"?$;XU?!'4?A[X"TVR^%O@'X>^#I];^$^O?#3QKX=T:U^(D M_CSQ'XQLK/P-JVD?$7Q#XXL/B);7_C;Q7X8TSP:O@4:37$?LD_M/_&WQ[XQ_ M8]T;XB^*[#Q+#^VS_P $^]8_;#DBM_#NCZ0?A#X]\.:M^SU-J?A/PG!86EO/ M??#^\T']I33-)TJ/Q;/KVOP:G\.(]3OM:O)_%6JQ0_4/A#]D74_"_P 9-:^+ M.I?M6?M5^.M'U_Q#XH\0ZE\%/&GBOX47/P9G;Q)I][I=MHCZ+H'P9\/>,9O# M/A6SNX(_"^@77CJYL+3^S=/.IIJX6Z%WT'PA_8_^$OP1U/2]8\%-XH?4?"/P MJA^!?PNN/$.M0Z__ ,*A^#-IK4'B"P^&GP^2[TY1:^&K34M-\.,TGB'_ (2+ M7-1L/!W@S1M8UG4='\*Z+96H!X/^S;^U3XCU/]BG]FSXC?%SQUX+U'XT_&'P M[%I5KK/B:;PQ\/-#\1>*K:^UJ/6O$]UI,5YI.F:?H7AW0M*G\4:]I>BRK,]I M:)H>D-+K.KZ5'<^D?\$Y?C-XQ_:#_8>_9C^,7Q$\7Z9X[^(/CWX1>%=>\=>* MM)L] TRSUCQ;=6SC7;I='\,?\230Y6O%;SM"L0(]'DS8-F2!G;L/AO\ L? /7O#5C\9_!'PNM[JV\(2_'#PWX#\?ZS91WEW*6/39-9\)>--7M[77;%1JFCW@M[VP M99HP1]95XS\=O@IHOQ]\$6'@3Q!XF\6^%M,L/B!\+?B.M]X,F\/VVK3ZY\'_ M (C^&/BKX0M9IO$?AWQ-9_V3_P )AX.T&YUBUBL(I]3TZVN-*:[AM;VY#@'S M3^V+!^U)H-_X%\=_L^?'%M%UU/B5\'_"GA[]GF\^'7@37? ?Q'M3\1>/ M=:T5?BCX:\7>!M,GDUKQ-I6@:WJVN^%?$T=GI_P^U?3=+L--U+4SKEC%\5?V M4-<^)_Q6TWXHVG[6?[5_PPAT_2-%T-_AQ\+?%GPHT/X=7VGZ9J1U34UGLM>^ M#/BCQ7:W?BV<11>*=2TCQAIFI7EK::=;V%WIBZ5I9L]SXK?LPCXD_#O0/AWX M?^.WQY^"<6B>-KWQ[=^*O@[KW@'3/%OB;6=0U76]?O+7Q+=^.OAO\0-(OM&G M\0Z[<:[)IMOHED)-2L]+>6:2&PC@8 _/'X?_ +2'[8_C+5_@E^SA\1/%.G?# M+XVI^P-\9_VKOB#\1]*^'VD6-OXN\2^&?BGX:^&'P.@UKP=XAAUW2_!5KK.A M:I)\2?C;X T>:/5M+\0WMAX+T/7M!T6TO3?^X_"#]J_XG_&;Q9_P3-\<07=A MX6\#?M?_ +&GQ&^.GC[X:6^D:??PVOC >!/V<_'/A=]-\57D3^(+6S\-O\1_ M%6DBR@E6UUJTN[&]U &YL(0_NM_^Q3X'U[PUX.TWQ=\3?C=XR\;^%? 7Q/\ MA5J/QHUWQEH<'Q:\<_#'XR7^FZE\0_ GC'7/#_@_0] DT/6+G0?"\FFR>&O" M_AG5_",_A?1K_P &:IX?U-=0OM0[M_V7OA[;?$7X ?$#PY>>(/!EM^S7\/O& M'PP^&GP_\+'P[8_#ZW\&^--,\%:+?Z5J>E7?AS4-7DBTO2/A]X5T_P .KI6O M:1'I%O82(L ?,6D?$WXUZ1^WO#X.^->I_&OX>?#GQ]:^.=%_9J\/>& M+_X#^-?V9/BP/ WA>/7-8M_&VJ6GPLM?VBOAM\>5T%/$OQ"TSPMK?C@_#;Q% MX9\/:E#X?U.^U/PEK&D7_P"EE>'^&_@9IFD>-Y?'OB3QQ\0OB7JUAK7BK6/ MUI\0=4\/ZCI/PP'C&2\75]/\#6>@^%_#DD4":7>S^'=-U/Q/<^*/$NF>&)KK MP_9Z]%IM_J4-[[A0 4444 %%%% !1110 AX!^AKXI^$/C#XP_$7Q#^WCX#G^ M(]M:ZC\./VD(OAS\(O$\G@G0)9/A]X/\1_LR_LZ_$R&R?1K./$WB[PMJW@33?%?P]\11_#GP-\*H[SX4:E-\/;RW\.M'X*^'7A M>P@DUVP\57-KJ%O>:[:7$&L7TMVH!\[_ <\2_M*:)X9_:*\$_$#XOWOQ@T] M_C[H7PA_9A^-VM>$/!?@WXD:_H7B7PCX)MOB!>^(M*^'?A?PK\/-?E^#OCJZ M^)]MH?B_0/!^@6^N:?X&O+36-(OKG0Y-?\08'QA^('[3?[.7QNUOXC1?%K4/ MCE\"]#^ '[3'QG^,OP6U/X?^!= M/A1HGPW\/P>(_@N_PK\9>%="MO']UXF\ M8ZK8:QX)U;0_B5KWCT>-[6T\4^-?#D?@_P#X1 Z'=_3_ ,$OV6_^%0#3#KWQ M]_:!^/$V@:K+JOAF?XV^(O &I_\ ",E_#%UX1@L="L?AW\-/AKI%I8VFCZEK M*0F73+F_>75[G[3?SV]OIUM9<]X*_9 OO"OQ4\1?$?7/VJ/VIOB=H'BC5_&6 MKZQ\%?B/XG^$NI?!J[/C&RO-,;2I] \/?!CPQXHO/#_AS3;J/3_#&@:AXSO- M+L+/3]-AO+;4EM%W 'S?^RM^T?\ &WQE\1_V=?A]\0_&%EXF?]J?_@G?;_MA MMJ4&@Z#I4GPO^(VD>)_@YHGBSPWX5T^PTZV2]^'NH6G[0'AU?">G^*I==U_3 M9_A]?2ZOXCUN7Q'>?9^:\*?ME_'"?]CG_@G=-;10_$']IW]MI?!?@D^*+?P] MX?T^PTF[L/A%XW^,WQB^**^#SJ7AOPJUYIO@7X;>(X_!WA*;7-(\/2^.M?\ M"MMJ]T/"]KK'F?;?P@_9$^%/P1O[;5_!76O#_P )=#^ WP\UCQ'JMGX@ MO_A=\%_"^HW.K>&?AMX(DO-)5$T#2-0EL;B2[\2)XD\1^(%T#PO:^*]=UZS\ M,Z)!9\[X<_8D^%WACX,?L]_!NP\3?$>7_AEG5M"UWX&_$V?7- C^*/@K5]"\ M/:_X+2^75K'PK9^&=:75_ GBWQ5X'\2Z;KGA'4-&\3>&/$.IV6M:;=SO!=P M'IW[-?QD\'?'CX1Z)\0/!6J^,=3LCK?C?P;K\'Q%T6W\-_$#P[X^^&WC;Q!\ M/?B1X-\;>'[.RL+#2/$_@WQWX9\0>&M6M-+MVT4SZ;]IT*[U#1;C3]0NO>*\ MX^%/PK\(?!KP;;^"/!5I=0:6NM>*_%.IWFHWDFI:SXA\8>/?%6L^.?'7B_Q! MJ4RK)J/B'QAXR\0ZYXEUR\*0Q2ZEJ=P+6WM+-+>U@]'H **** "BBB@ HHHH M ^3?VPO'_C_X:^"/A/X@^'GB>+PU?:I^U?\ LC?#_P 2^=H&DZ_'K_@'XK_M M$?#SX8>.?#>W5DD&D3:IX;\77WV77M.4:KI=W!!-9.C,SKYM^UI;_M1>'_%7 MPP\;? ?XZ2:;?77Q;^#'@ZQ_9SN_AOX%UGP%\3_!>J^/-('QRU'QWXOO]#U' MXH:#J7AGX42>,O&?A_Q+X&\5>%-&\)R>$=._MKP]XUDU6?3-1^E/CC\$]&^. M_AKPSX8UWQ/XN\+6GA;XH?"OXM6%YX.F\/6]_<>)O@[X_P##_P 3/!MM?R>( MO#GB6UET0>*_#&CW&L6$%I;3ZI8PS::][#;74X?RCXE_LGZW\1OC%8_%RU_: MR_:N^'-O9VGAS3I/A9\./%GPIT?X7WFF:%?QZCJ%A+8ZU\&O$?C.T3QC.@7Q MA>Z1XWTS5M2@2T@LM0TR/2=%&F@$'Q%B^(GQ'L?BUJ?A7]H?Q'^SMX2\(Z]% MX>'CSPOX3^'GBK5K/3O 'AW4;_QIJ^D0_%/PMXS\&6+W'C'Q!+H7B.^U/PIX M@E?3/ATVDZ+!I%]J4VL0_ OAK]I_]LOQ#+X$^!?Q%UW1OA;\=O!G_!-+Q;^V M%\2O%NC^"M,MM)\6_%,>.9O /PNTC7O#'B2UUZV\)^'19^&=;\8?&+X?Z%?0 MZ]8ZWXATWPQHGB[1M+T26;6/T9^*W[+Q^(_P_P#"'P_\-_'OX_? ^'PGXMN/ M&DWB7X,Z_P##[2_%'BS6KN\U;5KC_A+;OQW\-/B%I>HV$GB'6KOQ,;&TTC3H MVU^.PU!V=M.LDAYC6OV(OA[XJ\-^&=*\:_$#XQ>,_%FC_"WXB?!'Q/\ %G7? M%FAQ?$_XG_"/XKZG8ZOX]\!?$#6]$\(Z/H\^D:Q>Z3I,FFWGA3P]X2UWP;]@ M'_"#:OX::^U9M0 /*OA'^TY\1?C#\2_^"?/BJVOH?#7PW_:O_86^)W[0/BSX M9#2M*OVTWQK:V?[)7B?PI^%_@MI7Q=LV3Q5XE?4?#VH:]\6=)%UVYU-KN8#Z M0E_9P\$Q_%7X+?%+1-3\0>%3\!?ACXZ^$?@+P#X;7PS8?#V'P7\09/ATVL6- M]I,OAJZU@R:?#\*O!%GX=.EZ_I5OHMEIEQ;0VTD>HW@D]&T;X>:'HGCWQK\1 MX9]4N_$WCG2?!V@:G+?WJW%I8Z#X%37WT'1M&M4@B%A8)J/BOQ-K=TC27$MU MJ^N7UPTJQ?9[> [NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ IH8'CD,\ FDE1)8WCD4,DBE'4]&1_E9 M3[,I(/L37\T?[/DGQP\':9+^TGX0D^)'A_X6_LT?MT?\%;?''[5'C?7/C!JG MB'0/B9^R]\'OB9^UAX6\%?L_^&/A'J_BSQ)J/B'Q+X?U_2/A=-\/M9U'1/!V ME_"KPQ\-=0M/#FN7\/B.;0-5 /Z7Z,]O3V/\^A_#IWK\IW_;7_:CM?"MOXNO M_P!F;P_H_A;QG\4/V-/"7PL\9^*/'UEI6C^*=%_:E^)6G_#7Q?"NC>$-0^). MMRZI\&)];\,>*+7Q'*VB^$?BKH'BBW@T9_#.LZ+JFGMG^(/VS=4^#?QF^*7@ M3QI\*OAW!\6]8\6?\$^_@CI/CGPGJ_B6/PYXV^(?[3W_ L'0K&[\8/J^BP: MEH7@[X;:IX<\4S>&=.AO-6UCQ/;:AI?AW^T--\0^(H!9@'ZT4F1C=SC&?NMG MG_9QNSZC&1W%?E;X7_;@^(GQ&^-?B3]C*3X>>!-'_: \.^-?CYX7\3:OJWB/ MQ&?A7KWP_P#@]\.OV:_B%'XR\*I8VL/B^34_'.B?M<_"#1KSPB]W/=?#S4X_ M']_<:UXKT[PWX??Q?X1J^H>((?\ @W7UWQ&VJ^(=+\::!_P2;\1^+]-\0Z;X MH\2Q^*_#_C7PW^S#J6O:-XATGQI;7MAXK?7M U^QM=3TSQ-]MM]8GO;.#5)G M6YDD6@#]R P;H&X]59?_ $(#/X4ZOQ_LO%'B3]E;]F7XT?M,:+^S*GA/QA\- M/V9= \9:!I?B/]HO7_$WA_XQ26=E<>)/%EEJ=OIQ\4CP]JV@0Z/IMS;^)9?# MU[J%X?%,M@;N#3AJ,B^D']MCXG67QMUK]F/7/!/P[L/BQKG[4EI\"_AAXCM= M?\5W?@.]\)7?[*>J_M=WWBGQ+97.E:?KK^*/#/@OPUXA\)-X5T>^AM?%6NC2 M=>LM4T#0F\0P>'P#]-P0<=><]01T]<@8]LXSVS2U^%'[+'Q@\5_#GP7^RWX/ MU;X6^"?$OC+Q!K/_ 5RUFP\3:MXW\:ZI=> ?$'P>_:2^(%S:^$/#>KZSX?U M/7+_ ,$>++6\MM!N=9U61-*/#>F7%QJ'@:'6XF\,QZQH<$VM@'[#45\W_L_P#Q7^)7Q.UC MXZ6'CKX?V/A+0_AA\7;CX*K%_%W@;QA'!K,MK;VI?Z0H **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** & M2(LB-&V[:ZLK;'>-L,"#M>-E=&P>&1E93AE(8 CR+X6_ 3X2?!?PUXF\'?#; MP98>'?#'C'Q9XT\=>*-$-YK&LZ?K?B[XCZUJ/B/Q]K]_#XBU+6/.U#QEK^KZ MIK7B63*IK.J:C?7U_'-/O!'Q+T?PQ8>(O'*:;X?\5?#/7+?Q-\-W\,+)XJDG\,>'_A[X@M;?6/ G@K MP_/IO@CP?J$,=SX>\.Z?(H-=WXL_9/\ V>_'6I_%;6/%WPQT37]3^-EK\.[; MXEWNHW>NRS^(C\(M0FUCX67T;KJZ#0=8^'.M3R:YX(UWPR-%UKPOKI76M'U" MTU2..[7Z(HH ^:-=_8]_9O\ $B>"7U?X7Z7(I?B-I^OVGCS5;WQEH;IH7C9-:\1ZC:>,M"MK'1?$]MJNF: M?86MMLO^RY\!&_9W?]DY?AKHD/[.TG@*X^%TOPHMKG6;3PO-\.KRSGTV]\%S MI:ZK#J,_AR]TRYN-,O=+EU![:\TR>;3[E);*1X#[]10!\GW7[$/[,^H^&/%/ M@S6?AW<^(?#'C/P%<_"_Q!H_B;Q[\3O$]I<_#Z^OM)U#4?"%I_PD'C;4YM&T M+5+G0M&_M6QT2734U2WTRRLM0-S96\=N)_&/[%'[,?C^^\3ZMXO^%MCK.N^+ MO'7PZ^)^K^))?$?C:V\4Q?$?X3Z /"?P^\>:%XHL?$]KXA\)^,/#7A0S^%K3 MQ'X4U+1-6N/#-[J/A_4;J]TC4]0L[KZIHH ^5](_8G_9@T%?"::)\)M'TE/ MK?&J3PDNFZQXMLAH,W[1>I7VL?&V>P\CQ$FRX^(^JZE>:AXDN)/,GGO)1/;2 M6LD4+1^7?%S_ ()__"#Q1\*-8\"?"KPWX-^'^N3_ 9^'?[/&EW_ (FTOQIX MY\+#X"?#CQAI_BG3?@QJ/AZW^(?A?5(/!]U:0:KH&GZMX:\2:#XS\&C7)M>\ M+:]:ZK86JM]\T4 ?'W['?[*6A_LK>#-8T/2+?0='NO%-QINHZYX;\#:K\5KK MX=Z?J>FQW]N=1\/:7\6OB3\2];L-3U.VO(;?7+ZSU/2K75+;2="BDT>.?3&N M[O[!HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHK-UFWU*[TC5;71M0ATG6+G3;ZWTK5;FQ&J6^F:E-:RQV.H3 MZ8UQ:+J,-E=-%I"-Y)2;C&347-I-J$>52DTKJ,7.48IRV7-*, M;O625VM*BOE;^[S/J>BOEC_A6W[5G_ $%W_TR?7^GH?VMC_\ HFL[_P#!_#WE_P!3[S?W>9]3 MT5\RZ;\._P!I^WU'3Y]2_:,\$:AIL%]9S:AI\/P"M+":_L(KF*2]LH;X?$:X M-E+=VJRV\=X+>X-J\JSB"4QB-OIGMSSU_+_ZPX]Z^DR+.,PS>GB)X_A;/N%Y M4)TXTZ6>U^&J]3%J<9.53#OAOB+B"G&%)I1FL54PTVY1=.%2/,X]^#Q5?%*H MZ^78W+G!Q48XR> FZO,FVX/ 8[&Q2@U:7M'3;NN525^7C-$^)'P]\2VOBJ^\ M.^.O!^O67@75K_0/&UWHWB71=4M_!^NZ5IMEK&IZ)XIEL;V=?#VKZ=I.HZ?J ME]IFKFSOK73KZSOIX$M;J"63GM#^.WP2\3ZYH7AGPU\8/A?XA\2>)_"\GCCP MUX?T/Q]X5U;6_$/@J+RQ)XQT/2K#5;B_U?PHAEB4^(]/M[C1@\L2?;=\L:M^ M6WQ5\*^)OA9\>_VC/VZ?V5[%_B-XY\!_$+1? G[9O[/?P^OM/U37?VBO@9X; M^"_PNU'3[O1-#MKQX$_:L_9_M=2USQ%\%_MJ6=_\2?"-YXN^ FN.TGB;P#KO M@/R?P-K&K:__ ,%'OV-7^%7CCX>^$-7O_P#@C/K%W;R?$#P#J_B26;P[>_&S M]F_6+73H/!UIX^^%WB'PWJ$EE%;ZK);:C>N]I8V-W!<:(DEK)=6/OG:?KY=_ MM4?LQ6&BQ^)+[]HOX$V7AV;4/$FD0Z]>?%SX?VNBS:KX-DCB\7:9%JL_B&.Q MDU#PK+-%'XELDG-QH,DB1ZM'9NP4]!H7Q]^!?BGPYKWC'PS\:/A/XC\(^%OL M/_"3^*="^(O@_5_#GAO^TXXI=..OZY8:S<:9HXOX9X)K(ZA=6XO(IX7MO-66 M,M^'OP=N_#EQ_P $JZMX#U[6-+\2_\ !;73[WQ5H=IIECI7F^*/ MVC/VI+V^.CPSZMK]UH.D>+[J/1M4M=)EU_4FU2V;1)WU#6@;&^G[+XH1V6FP M?\$4OC%XA_X1_P#X91\/Z]X1N?C_ .+!:VEWX2T[QD_[(/BOP_\ LB^+_B7J MEG%-8Q?#_P )_&GQ#>Z?H.OZ^Y\.>#OBSXH^&NNW-]I%S9V&HV@!^U?@CXK? M#+XE2ZI;_#_X@>#?&EUH<.FSZY9>&/$FD:U?Z)#K(O&TB76K"PNY[W2$U5=/ MOWTPZE;VO]H)97#T\*ZGXDUW1O#NA>(_% M_AYM.O[[6-&\/7&O7GAC2-6\0::TZZG!H<_B'Q%=:397-W]5_96_P""Q]SJ>HW&E?\ !6/] MGK3-+GOKR;3=-G_X)B:)J,^GV$MQ))9V4VH-^U=;&^EM+=H[>2\-M;FY:,SF M"(N44 _86BOS.^ /[/?_ 4Z\$?%KPGXG_:!_P""B_P6^.?PCTQ]8/B[X6^% M/V"-*^#.O^*$N] U2RT9=/\ B3;?M$^.)O#9TGQ!%]4_M.TTVXT9 MA:KJ!OK7],: "BO@3]JCX)?\% OB3X^T?6_V4_VYOA3^S-\/[3PG9:9K/@?Q MU^QIIO[1&K:MXMAU;6;J]\4V_C*\^.'PTDTNPO-)N]%TN+PVNAW:6MQI%SJ0 MU29M5-K9_,W_ RA_P %GO\ I+C^SJ>O_.+C0O3K_P G:=NM '[*5YMXT^,G MPE^'%_;:7\0/B9X!\$:A>61U*WM/%OB[0/#L\FG>?):C4"FKW]H8K![N*2RC MO9O+M9KU39Q3/= PUUWAJSUS3_#N@V'B;6;;Q%XCLM&TJTU[7[+25T&TUO6K M:PMX-5U>UT1+S45T>VU/4([B^@TI;^]73HITLQ=W(@$\GXD?M\ZAXA^#WQ-_ M:0_:,^ WQ1^$OQ#U;0?V?? VE_M@_P#!/G]H.R@'AO\ :1^$_A6S^)&O^!9O M@?XT@BG\6> OC=KNBZ]\0/!/A?38M#^(/PR^)/B#^R/#WB7PIH&O6T?BE@#] MG?%?Q(^'W@2YT&S\:^-_"?A*Z\47;V'ARV\2>(=)T6?7+V.2S@>VTJ+4;NVD MOI4N-0T^WD%NKK'<:A86\C+-?6D_#I_$]]+IG MAM?'7C3PWX1/B#4H;>:[ET[1/^$@U+3_ .UK^*TMY[J2RL/M%REM!-.T0ABD M=?YS?VT_VH/#/B7]I'5?CY>Z+KA\$_L8^+-3_8^_:W_91LKPP_M,_%S]F'X^ M> _@+^T!X@^.?AWX>R7)U^Z^'OPI^*VE?#1]6LO!>GR)X]^#OA;]H?6=;\<# M3- @\)Q?0/QP^)2>,=(_X(TZUI?[3/P>_:2\=7'[>>H/=?&2UU?P)>_#7Q1X MNG_87_;)CU%=%D^%%OH6@7'A_2=4UZR\*:?>Z# ;A;RYTRRUR:3Q!J%S83 ' M[Q:-K>C^(])T[7_#^JZ;KFAZQ96VI:3K.CW]IJ>E:GI]Y$LUI?:=J-C-<65] M9W4+I+;W5K/-;SQLKQ2.I!KS#P=^T1\ /B)X5\1^.? 'QQ^#_CGP3X/U=] \ M6^,/!_Q-\$^)O"WA;7(Q9M+HWB/Q#HFN7VD:'JL2ZA8M)IVIWEK>(M[:$P?Z M3!YGRG\&?V8O!/[(O[$_Q%^#_P 3OC>GASPIXBU;]HWX@_$;XK>'+BT^!_A? MX:2_M)_$[QS\1_%-M\*H[S5=?M/A!X'\ :A\0[G1?AXD^LZE)X:L;"RU*YO3 M>O*8_@:QT+XA^#O$'[+,6O>/M"^+7['?P:_X*/6^J)\=O^$0\!^'HO''PKUW M]BOXIZ?\+?$/Q6U'X5Z#X3^&7BE/@_\ M9^(/"'@:+XP6'AC1/#VNZM;_#O5 M]7BB\6^#]<\37@!^[.J_$#P)H6CZ/X@UOQIX2T?0?$,MA;Z!K>J>)-%T_2-; MN-5MGO-+@TC4KN^ALM3FU*T1[G3X[*>=[RW1I[<21*SCKJ_FE^#]C?>#OB%I M?CCX_:4;?]D#Q%\$?^"QNG_ S1/$NB7C:6NF_$G]N/3?&7P[\.:'IMU!LMK_ M .*7[,<#W7P6\-06Z:SK/PTBU?0/"<,FGO=:/'^V?[#6B?$WPU^Q;^R1X=^- M*:Q%\8-!_9H^!>C?%*+Q#-)<^(8?B#IGPQ\,67BZ#7[J5Y);K7;?7(+VWUFY MDDDDGU.*ZE>21W9V /J>BBB@ HKSA=!^)O\ PD5Q?-\0?#S>&W\;VFKV^@CX M>NNH0>!(O!MQI5WX-DU__A,F6?6KKQN]OXNB\9_V/"MKH\+^$/\ A&9WG_X2 M2'F9O"7QV;06LX?C)X,B\0GP'=:,FMO\&9);%?B#+K,=W:>-SH?_ LR,MH= MKH@?2)? _P#:ROY''E:YL4M*MVX M3U).6#<(PQ/L ME5C*56F\)+%1565/VVBO-X]!^)P\02WLOQ"\.R>'6\:VFK0Z$OP\>._B\#1> M"IM)O/![:]_PF;B76+KQRT/C"'QC_9$:VFC1/X./ANX>7_A)8N:F\)?'5M!: MRA^,G@R+Q"? =QHR:X_P:DEL4^(,FLI=VWCJN:V#Q$K.I9*6$][D<>5QYL5%6JW;I\SBURR]JJ;<5(AE M^$FZ:EGF5TE..&,W5C4]GD]23E@W",<3[)5(RE5@\)+%1565/V MVBO-X]!^)P\0RWTOQ"\.R>'&\:VNK1:"OP\:._C\#1^"IM)NO![:]_PF<@EU MFY\!Y&:ZM/#S:QKYTJ)HVC06IUG4-K(S_:#OVK<*DY2<94 M*M-)S7/-T7%\CBHM*G6G.U12I1Y/QY\;?@U\+=2T M;1OB;\6OAG\.]7\1PWEQX>TOQUX\\+>$=1U^#3EWZA-HMGXAU73KC58[!"'O MI+&.=+-&5[EHD96/HMC?66IV5GJ6G7=M?Z?J%K;WMA?65Q#=6=[9W<*7%K=V MEU;O)!&_$;>)- \/Z?;P?##PE\)_AY\1]#\9_ W3 M-?\ 6M7%WXBT630)+[4XS^B"@D#D_Y_Q)[#J37\^NJ_MR?M%>+_ Y^UQX] M\-_M#? SX5>(/@!\,/V_=,\;?LY:K%8^,/C;\*O&/P;N_%/_ SY\0=1\&ZK MX*T6'P;8V5EX:T?5-6UCQCX@\<_#+XZ>'_B%HFK^"IM-$OAY;CZR_;!T;]IC MQU_P2?\ VBV_9^^(?B_XL?M!_$K]FKQ'XF\!ZQHD/A32O%&IR>+_ IINJZW MX1^%$GPZT70+6VU>]\+S^)=%^%%]')J7B*VU_5-#>X\2ZM?P6^H$ _0'0_CM M\%?$WB&#PGX>^+7PWUOQ-=WUWIEEH.E>-O#=_JVH:EIUM?W>IZ?IEE;:E)-J ME]I=OI>I2ZK:::MW<:8EA>&_CMQ:S^7ZO7Y,>+_VC_@]-I__ 32T+]E:T^ MOBKX7?$OX]>$O VA^&;_ ,)W5]XE^"7PYT?]G7XT>,HO%O@OPOI?B'0]6^$/ MB_P+:^ D^%>OV?C'PW%'X4;QEJWA_P 46=GJ-O-H6J^%?!#]K#XV^(/AQ^PM MKWQ)_:$U:_\ "/[6OCOXV^ OB9\?Q7:WNM^ '\(>$;'PYK7CNPMD /WX\#_M :3KVM_#']M#]@#P#\//V?M/\'_"R\M/BK\$? MVFO@Y^R%XJ^,.F7=S#HS_$.Y3P]I_P 8?BU\6?!_Q!\.Z[IH\*6_@JX?Q._B M;P9I>HZ=;@'[XT4BDD GWY]1G@_B,'\:6@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** *MO8V5K)<2VMI;6\MV_F7,D M%O##)<2;G;S)WB1&F?=)(V^0LVYW.3(\/W_P#5.\?W&*F[10!G)I&E1V\EI'IM@EM,T32VZ65JL$K0B,0M M)"L0B2R^SP_9)()@RS0/;!/(> M&57=98FC,PLK>/). MR"TM(H;>%"Q%RS7 M//\ LXG9I?+W MDM5>#P]H-K;VMI;:+I,%K9!UL[>'3;**"T66<74BVT,<"Q6ZR7(%PXA1 \X$ MS9E^:MBB@!KHDB/'(JNCJR.C@,KHP(965@596!(96!# D$$$BHS;P- ;5H8V MMFB,#0,BM"T)3RS"8B#&83&2AB*^7L^7;MXJ:B@".2&*50LL:2*KQR*'4.!) M%(LL4@# @212(LD;CYXW4.A5@#4E%% !1110 4444 %%%% !1110!3FT^QN+ MB*ZGL[2:YA\OR;B6V@DGB\J0RQ^7,\;21^7(3(FQEV.2ZX8DT7&G6%UFR2S:?3-$9+J&T:>8VL4[21VQED M,"Q[VS=AABMXHX((HX88D$<44*+%'&BC"I''&%1%4J0:;90ZEJ,*8*17]_' MW>Q*0"([J:5 0"!FGW.@ MZ)>:;-H]WH^EW.DW)!N-,N-/LYM.N")$F'GV,L#VLV)8XY1YD+8DC20?.BL- M:B@"A=:5IE\]K)>Z?8WSGGM)C"4,M MM++;R;H9'0^(_#;]G3P5\,OBI\=?B_I6I:_K'BK]H#QMH'CSQ4GB >&[FP\/ MZMX<^&7@;X16-GX*?3_#FF:OHVC7'@KX<>$+34M/O-6U9;[4=.FU625;J_O# M+[[10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% K!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$! end XML 14 nhtc20171231_10k_htm.xml IDEA: XBRL DOCUMENT 0000912061 2017-01-01 2017-12-31 0000912061 us-gaap:PreferredStockMember 2015-12-31 0000912061 2015-05-29 2015-05-29 0000912061 2015-08-28 2015-08-28 0000912061 us-gaap:RestrictedStockMember 2016-12-31 0000912061 us-gaap:RestrictedStockMember 2017-01-01 2017-12-31 0000912061 us-gaap:RestrictedStockMember 2017-12-31 0000912061 us-gaap:RestrictedStockMember 2015-12-31 0000912061 us-gaap:RestrictedStockMember 2015-01-01 2015-12-31 0000912061 us-gaap:RestrictedStockMember 2014-12-31 0000912061 us-gaap:RestrictedStockMember 2016-01-01 2016-12-31 0000912061 us-gaap:RestrictedStockMember 2017-01-01 2017-09-30 0000912061 us-gaap:TreasuryStockMember 2017-12-31 0000912061 2016-03-24 2016-03-24 0000912061 2016-05-20 2016-05-20 0000912061 2016-11-25 2016-11-25 0000912061 2016-08-26 2016-08-26 0000912061 2017-10-01 2017-12-31 0000912061 country:CN 2016-01-01 2016-12-31 0000912061 country:HK 2015-01-01 2015-12-31 0000912061 country:CN 2017-01-01 2017-12-31 0000912061 country:HK 2017-01-01 2017-12-31 0000912061 country:KY 2017-01-01 2017-12-31 0000912061 us-gaap:TreasuryStockMember 2016-12-31 0000912061 country:HK 2016-01-01 2016-12-31 0000912061 country:CN 2015-01-01 2015-12-31 0000912061 country:KY 2016-01-01 2016-12-31 0000912061 country:KY 2015-01-01 2015-12-31 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2015-04-29 2015-04-29 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2017-01-01 2017-12-31 0000912061 nhtc:GeorgeKBroadyMember us-gaap:DirectorMember 2015-10-28 2015-10-28 0000912061 nhtc:GeorgeBroadyMember us-gaap:DirectorMember 2015-07-31 2015-07-31 0000912061 nhtc:GeorgeKBroadyMember us-gaap:DirectorMember 2015-07-31 2015-07-31 0000912061 nhtc:GeorgeBroadyMember us-gaap:DirectorMember 2015-10-28 2015-10-28 0000912061 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-12-31 0000912061 nhtc:GeorgeBroadyMember us-gaap:DirectorMember 2015-01-22 2015-01-22 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2016-01-01 2016-12-31 0000912061 nhtc:GeorgeKBroadyMember us-gaap:DirectorMember 2015-05-07 2015-05-07 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2015-01-01 2015-12-31 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2017-01-01 2017-12-31 0000912061 2013-02-01 2013-02-28 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2016-01-01 2016-12-31 0000912061 nhtc:GeorgeBroadyMember us-gaap:DirectorMember 2015-05-07 2015-05-07 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2014-10-01 2014-12-31 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2015-01-01 2015-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000912061 nhtc:GeorgeBroadyMember us-gaap:DirectorMember 2015-02-19 2015-02-19 0000912061 country:US 2015-01-01 2015-12-31 0000912061 country:KR 2017-01-01 2017-12-31 0000912061 us-gaap:EuropeMember 2015-01-01 2015-12-31 0000912061 nhtc:OtherForeignCountriesMember 2017-01-01 2017-12-31 0000912061 nhtc:RussiaAndKazakhstanAndUkraineMember 2017-01-01 2017-12-31 0000912061 us-gaap:EuropeMember 2016-01-01 2016-12-31 0000912061 nhtc:RussiaAndKazakhstanAndUkraineMember 2015-01-01 2015-12-31 0000912061 country:TW 2015-01-01 2015-12-31 0000912061 country:KR 2016-01-01 2016-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-01-01 2015-12-31 0000912061 country:CA 2017-01-01 2017-12-31 0000912061 nhtc:RussiaAndKazakhstanAndUkraineMember 2016-01-01 2016-12-31 0000912061 country:KR 2015-01-01 2015-12-31 0000912061 country:US 2017-01-01 2017-12-31 0000912061 country:TW 2017-01-01 2017-12-31 0000912061 nhtc:OtherForeignCountriesMember 2015-01-01 2015-12-31 0000912061 country:TW 2016-01-01 2016-12-31 0000912061 country:CA 2016-01-01 2016-12-31 0000912061 country:PE 2017-01-01 2017-12-31 0000912061 country:PE 2015-01-01 2015-12-31 0000912061 us-gaap:TreasuryStockMember 2015-12-31 0000912061 country:CA 2015-01-01 2015-12-31 0000912061 country:US 2016-01-01 2016-12-31 0000912061 us-gaap:EuropeMember 2017-01-01 2017-12-31 0000912061 country:PE 2016-01-01 2016-12-31 0000912061 nhtc:OtherForeignCountriesMember 2016-01-01 2016-12-31 0000912061 nhtc:OtherForeignCountriesMember 2017-12-31 0000912061 country:US 2016-12-31 0000912061 nhtc:OtherForeignCountriesMember 2016-12-31 0000912061 country:CN 2016-12-31 0000912061 country:HK 2017-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-12-31 0000912061 country:US 2017-12-31 0000912061 country:HK 2016-12-31 0000912061 us-gaap:MaximumMember us-gaap:SubsequentEventMember 2018-01-26 2018-01-26 0000912061 us-gaap:MinimumMember us-gaap:SubsequentEventMember 2018-01-26 2018-01-26 0000912061 nhtc:EquityIncentive2016PlanMember us-gaap:SubsequentEventMember 2018-02-01 2018-02-01 0000912061 us-gaap:SubsequentEventMember 2018-02-06 2018-02-06 0000912061 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0000912061 2017-06-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0000912061 us-gaap:RetainedEarningsMember 2014-12-31 0000912061 us-gaap:PreferredStockMember 2014-12-31 0000912061 us-gaap:PreferredStockMember 2017-12-31 0000912061 us-gaap:TreasuryStockMember 2015-01-01 2015-12-31 0000912061 us-gaap:TreasuryStockMember 2016-01-01 2016-12-31 0000912061 us-gaap:CommonStockMember 2016-12-31 0000912061 us-gaap:RetainedEarningsMember 2015-12-31 0000912061 us-gaap:RetainedEarningsMember 2017-12-31 0000912061 us-gaap:CommonStockMember 2015-01-01 2015-12-31 0000912061 2018-03-02 0000912061 us-gaap:TreasuryStockMember 2017-01-01 2017-12-31 0000912061 2015-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000912061 us-gaap:RetainedEarningsMember 2016-01-01 2016-12-31 0000912061 us-gaap:RetainedEarningsMember 2015-01-01 2015-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-12-31 0000912061 us-gaap:CommonStockMember 2014-12-31 0000912061 2014-12-31 0000912061 2016-12-31 0000912061 us-gaap:PreferredStockMember 2016-12-31 0000912061 us-gaap:CommonStockMember 2015-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0000912061 us-gaap:CommonStockMember 2017-12-31 0000912061 us-gaap:TreasuryStockMember 2014-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000912061 us-gaap:RetainedEarningsMember 2016-12-31 0000912061 2017-01-01 2017-03-31 0000912061 country:CN 2015-06-30 0000912061 us-gaap:FurnitureAndFixturesMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000912061 2017-12-31 0000912061 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember us-gaap:MaximumMember 2017-01-01 2017-03-31 0000912061 us-gaap:FurnitureAndFixturesMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000912061 nhtc:LongTermIncentivePlanPaymentCommencingInFebruary2021AndEndingInDecember2023Member 2016-12-31 0000912061 nhtc:LongTermIncentivePlanPaymentCommencingInFebruaryOfTheCalendarYearImmediatelyFollowingTheConclusionOfThePerformancePeriodMember 2017-12-31 0000912061 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000912061 2015-04-30 0000912061 country:CN 2017-12-31 0000912061 nhtc:EnrollmentPackageRevenueMember 2016-12-31 0000912061 nhtc:AutoShipAdvancesMember 2016-12-31 0000912061 nhtc:UnshippedProductMember 2017-12-31 0000912061 2016-01-01 2016-12-31 0000912061 nhtc:UnshippedProductMember 2016-12-31 0000912061 nhtc:AutoShipAdvancesMember 2017-12-31 0000912061 nhtc:EnrollmentPackageRevenueMember 2017-12-31 0000912061 nhtc:FinancialInstitutionInstrumentsMember 2016-12-31 0000912061 us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000912061 nhtc:MunicipalBondsAndNotesMember 2016-12-31 0000912061 nhtc:FinancialInstitutionInstrumentsMember 2017-12-31 0000912061 us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000912061 nhtc:MunicipalBondsAndNotesMember 2017-12-31 0000912061 nhtc:SecuritiesClassActionMember 2017-01-01 2017-12-31 0000912061 2015-01-01 2015-12-31 0000912061 nhtc:ShareholderderivativeclaimMember 2017-01-01 2017-12-31 0000912061 nhtc:GeorgeKBroadyMember 2015-01-22 2015-01-22 0000912061 2016-04-08 2016-04-08 0000912061 2015-08-04 2015-08-04 0000912061 2015-05-04 2015-05-04 0000912061 2015-05-13 2015-05-13 0000912061 us-gaap:RestrictedStockMember 2016-04-08 2016-04-08 0000912061 2017-01-24 2017-01-24 0000912061 2015-10-30 2015-10-30 0000912061 us-gaap:RestrictedStockMember 2017-01-24 2017-01-24 0000912061 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0000912061 2015-07-28 0000912061 2016-01-12 0000912061 2015-08-01 2015-08-03 0000912061 2016-01-01 2016-03-31 0000912061 nhtc:EquityIncentive2016PlanMember us-gaap:CommonStockMember 2016-04-07 0000912061 us-gaap:RestrictedStockMember 2015-02-11 2015-02-11 0000912061 2012-08-13 0000912061 2015-05-04 0000912061 us-gaap:RestrictedStockMember 2015-01-20 2015-01-20 0000912061 2017-11-24 2017-11-24 0000912061 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0000912061 2017-03-03 2017-03-03 0000912061 2017-05-19 2017-05-19 0000912061 2017-08-31 2017-08-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2016-01-01 2016-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2017-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2017-01-01 2017-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2016-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2015-12-31 0000912061 2015-11-20 2015-11-20 0000912061 2015-03-27 2015-03-27 pure utreg:Rate nhtc:class shares iso4217:USD iso4217:USD shares iso4217:CNY nhtc:installment false --12-31 FY 2017 0000912061 Yes Accelerated Filer No No 35 35 0.5 0.5 2 P3Y P3Y 0.001 50000000 12979414 12979414 0.001 5000000 0.000 0.000 P5Y P7Y P5Y P3Y 1692218 1637524 10-K 2017-12-31 NATURAL HEALTH TRENDS CORP. 202498798 11376092 135311000 125921000 8398000 11257000 7534000 4066000 151243000 141244000 1149000 1388000 1764000 1764000 3167000 2963000 1435000 0 796000 692000 159554000 148051000 1751000 2145000 309000 663000 11170000 13611000 7605000 14989000 4455000 4948000 15152000 19165000 1479000 1633000 41921000 57154000 19052000 0 56000 268000 7904000 8190000 68933000 65612000 0 0 13000 13000 86683000 86574000 44908000 38548000 -413000 -807000 40570000 41889000 90621000 82439000 159554000 148051000 197563000 287728000 264860000 38645000 54903000 54098000 158918000 232825000 210762000 83638000 125050000 126598000 31685000 43245000 36024000 536000 394000 263000 115859000 168689000 162885000 43059000 64136000 47877000 367000 -59000 -84000 43426000 64077000 47793000 19848000 8991000 552000 23578000 55086000 47241000 2.10 4.84 3.84 2.09 4.83 3.82 11251000 11382000 12302000 11267000 11407000 12372000 1.52 0.61 0.14 23578000 55086000 47241000 677000 -838000 -79000 258000 -132000 82000 419000 -706000 -161000 -25000 0 -2000 23972000 54380000 47078000 0 0 12891317 13000 85750000 -54799000 62000 384220 -4576000 26450000 47241000 47241000 88097 309000 309000 547042 16071000 16071000 -182000 -380000 91060 1228000 666000 1709000 1709000 82000 82000 -79000 -79000 -2000 -2000 86000 86000 0 0 12979414 13000 85963000 -9647000 -101000 840202 -19419000 56809000 55086000 55086000 903031 23704000 23704000 507000 51015 1234000 1741000 6891000 6891000 -132000 -132000 -838000 -838000 104000 104000 0 0 12979414 13000 86574000 38548000 -807000 1692218 -41889000 82439000 23578000 23578000 -5000 1566 33000 38000 79000 56260 1352000 1431000 17218000 17218000 258000 258000 677000 677000 -25000 -25000 35000 35000 0 0 12979414 13000 86683000 44908000 -413000 1637524 -40570000 90621000 23578000 55086000 47241000 536000 394000 263000 35000 104000 86000 258000 -132000 82000 -1644000 217000 -15000 -2843000 851000 6762000 3399000 1681000 1025000 61000 90000 267000 -392000 -714000 637000 18676000 303000 -115000 -2417000 -6031000 10840000 -6033000 51000 10714000 -481000 947000 1331000 -3875000 2752000 14350000 -179000 135000 25000 -324000 2420000 4105000 26605000 53174000 81326000 278000 905000 710000 0 0 3028000 -278000 -905000 -3738000 0 0 309000 0 23704000 16071000 17218000 6891000 1709000 -17218000 -30595000 -17471000 281000 -667000 -19000 9390000 21007000 60098000 125921000 104914000 44816000 135311000 125921000 104914000 6772000 8791000 707000 1393000 1741000 666000 Principles of Consolidation<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation. Use of Estimates<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates associated with revenue recognition, as well as those used in the determination of liabilities related to sales returns, commissions and income taxes. Various assumptions and other factors prompt the determination of these significant estimates. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. The actual results may differ materially and adversely from the Company’s estimates. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected. Cash and Cash Equivalents<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents include the Company’s investments in debt securities, comprising municipal notes, bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less, when purchased, to be cash equivalents. Debt securities classified as cash equivalents are required to be accounted for in accordance with ASC 320, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Investments - Debt and Equity Securities</span><span style="font-family:inherit;font-size:10pt;">. As such, the Company determined its investments in debt securities held at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;"> should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive loss in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company includes credit card receivables due from certain of its credit card processors in its cash and cash equivalents as the cash proceeds are received within two to five days. </span></div><br/> Restricted Cash<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2015, the Company funded a bank deposit account in the amount of CNY </span><span style="font-family:inherit;font-size:10pt;"><span>20 million</span></span><span style="font-family:inherit;font-size:10pt;"> (USD </span><span style="font-family:inherit;font-size:10pt;"><span>3.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;">) in anticipation of submitting a direct selling license application in China. Such deposit is required by Chinese laws to establish a consumer protection fund.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The Company periodically maintains a cash reserve with certain credit card processing companies to provide for potential uncollectible amounts and chargebacks. Those cash reserves held by credit card processing companies located in South Korea are reflected in noncurrent assets since they require the Company to provide 100% collateral before processing transactions, which must be maintained indefinitely. 20000000 3100000 Inventories<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>Inventories are stated at the lower of cost or net realizable value, using the first-in, first-out method. The Company reviews its inventory for obsolescence and any inventory identified as obsolete is reserved or written off. The Company’s determination of obsolescence is based on assumptions about the demand for its products, product expiration dates, estimated future sales, and management’s future plans. Property and Equipment<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;"> years for office equipment, office software and capitalized internal-use software development costs and </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">seven</span><span style="font-family:inherit;font-size:10pt;"> years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the assets. Expenditures for maintenance and repairs are charged to expense as incurred.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of these assets is measured by comparison of its carrying amounts to future undiscounted cash flows the assets are expected to generate. If property and equipment are considered to be impaired, the impairment to be recognized equals the amount by which the carrying value of the asset exceeds its fair value. Goodwill<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>The Company assesses qualitative factors in order to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, through this qualitative assessment, the conclusion is made that it is more likely than not that a reporting unit’s fair value is less than its carrying amount, a two-step impairment test is performed. The Company’s policy is to test for impairment annually during the fourth quarter. Considerable management judgment is necessary to measure fair value. The Company did not recognize any impairment charges for goodwill during the periods presented. Income Taxes<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes income taxes under the liability method of accounting for income taxes. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be ultimately realized based on the more likely than not recognition criteria. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has evaluated its tax positions and determined that there are no uncertain tax positions for the current year or years prior. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution.  The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense.  Deferred taxes are not provided for state income tax purposes on the portion of undistributed earnings of subsidiaries outside of the United States when these earnings are considered permanently reinvested.</span></div><br/> Amounts Held in eWallets<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>Commencing in October 2014, the Company requires commission payments of certain members in Hong Kong to be first recorded into an electronic wallet (eWallet) account in lieu of being paid out directly to members. The eWallet functionality allows members to place new product orders utilizing eWallet available balance and/or request commission payout via multiple payment methods. Amounts held in eWallets are reflected on the balance sheet as a current liability. Long-Term Incentive<div style="line-height:120%;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial rewards earned under the 2014 Long-Term Incentive Plan (the “LTI Plan”) are recognized over the performance period as specified performance or other goals are achieved or exceeded. In accordance with the LTI Plan, </span><span style="font-family:inherit;font-size:10pt;">fifty percent</span><span style="font-family:inherit;font-size:10pt;"> of any cash payment earned is payable in </span><span style="font-family:inherit;font-size:10pt;">thirty-five</span><span style="font-family:inherit;font-size:10pt;"> equal consecutive monthly installments commencing in February of the calendar year immediately following the conclusion of the performance period and the remaining </span><span style="font-family:inherit;font-size:10pt;">fifty percent</span><span style="font-family:inherit;font-size:10pt;"> of the payment earned is payable in </span><span style="font-family:inherit;font-size:10pt;">thirty-five</span><span style="font-family:inherit;font-size:10pt;"> equal consecutive monthly installments commencing in February 2021 and ending in December 2023. As such, certain installments to be paid are reflected on the balance sheet as a non-current liability, and the current portion of the installments is reflected in other accrued expenses.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>At the sole discretion of the Compensation Committee of the Company’s Board of Directors, distributions under the LTI Plan are made in cash, or alternatively awarded in the form of common stock or other common stock rights having an equivalent cash value under the terms of the Natural Health Trends Corp. 2016 Equity Incentive Plan. A determination of the form of distribution, if any, is made by the Compensation Committee subsequent to the end of each calendar year. As such, amounts earned are considered non-equity awards. See Note 6 for grant information of distributions settled in common stock. Foreign Currency<div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>The functional currency of the Company’s international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.  The resulting translation adjustments are recorded directly into accumulated other comprehensive income. 451000 333000 204000 Revenue Recognition<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales are recorded when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product are recorded as deferred revenue. The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Enrollment package revenue, including any nonrefundable set-up fees, is deferred and recognized over the term of the arrangement, generally twelve months. Enrollment packages provide members access to both a personalized marketing website and a business management system. No upfront costs are deferred as the amount is nominal.</span></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>Various taxes on the sale of products and enrollment packages to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority. Commissions<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of the Company’s products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  The Company accrues commissions when earned and pays commissions on product sales generally two weeks following the end of the weekly sales period.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In some markets, the Company also pays certain bonuses on purchases by up to three generations of personally enrolled members, as well as bonuses on commissions earned by up to three generations of personally enrolled members. Independent members may also earn incentives based on meeting certain qualifications during a designated incentive period, which may range from several weeks to up to a year.  The Company estimates and accrues all costs associated with the incentives as the members meet the qualification requirements.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>From time to time the Company makes modifications and enhancements to the Company’s compensation plan to help motivate members, which can have an impact on member commissions. The Company also enters into performance-based agreements for business or market development, which may result in additional compensation to specific members. Operating Leases<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The Company leases its physical properties under operating leases. Certain lease agreements include rent holidays and incentives. The Company recognizes rent holiday periods on a straight-line basis over the lease term beginning when the Company has the right to the leased space. Stock-Based Compensation<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>Stock-based compensation expense is determined based on the grant date fair value of each award, net of estimated forfeitures which are derived from historical experience, and is recognized on a straight-line basis over the requisite service period for the award. Net Income Per Common Share<div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock and warrants is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares. Certain Risks and Concentrations<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A substantial portion of the Company’s sales are generated in Hong Kong (see Note 10). Substantially all of the Company’s Hong Kong revenues are derived from the sale of products that are delivered to members in China. In contrast to the Company’s operations in other parts of the world, the Company has not implemented a direct sales model in China. The Chinese government permits direct selling only by organizations that have a license, which the Company has applied for, and has also adopted anti-multilevel marketing legislation. The Company operates an e-commerce direct selling model in Hong Kong and recognizes the revenue derived from sales to both Hong Kong and Chinese members as being generated in Hong Kong. Products purchased by members in China are delivered to third parties that act as the importers of record under agreements to pay applicable duties. In addition, through a Chinese entity, the Company sells products in China using an e-commerce retail model. The Chinese entity operates separately from the Hong Kong entity, and a Chinese member may elect to participate separately or in both.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company believes that its e-commerce direct selling model in Hong Kong does not violate any applicable laws in China, even though it is used for the internet purchase of the Company’s products by members in China. The Company also believes that its Chinese entity, including its e-commerce retail platform, is operating in compliance with applicable Chinese laws. However, there can be no assurance that the Chinese authorities will agree with the Company’s interpretations of applicable laws and regulations or that China will not adopt new laws or regulations. Should the Chinese government determine that the Company’s activities violate China’s direct selling or anti-multilevel marketing legislation, or should new laws or regulations be adopted, there could be a material adverse effect on the Company’s business, financial condition and results of operations.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although the Company attempts to work closely with both national and local Chinese governmental agencies in conducting its business, the Company’s efforts to comply with national and local laws may be harmed by a rapidly evolving regulatory climate, concerns about activities resembling violations of direct selling or anti-multi-level marketing legislation, subjective interpretations of laws and regulations, Chinese nationals collaborating with short traders to damage the Company’s business and activities by individual members that may violate laws notwithstanding the Company’s strict policies prohibiting such activities. Any determination that the Company’s operations or activities, or the activities of its individual members or employee sales representatives, or importers of record are not in compliance with applicable laws and regulations could result in the imposition of substantial fines, extended interruptions of business, restrictions on the Company’s future ability to obtain business licenses or expand into new locations, changes to its business model, the termination of required licenses to conduct business, or other actions, any of which could materially harm the Company’s business, financial condition and results of operations.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><span style="font-family:inherit;font-size:10pt;">The Company’s </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Premium Noni Juice</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Enhanced Essential Probiotics</span><span style="font-family:inherit;font-size:12pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">®</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span>products each account for more than 10% of the Company’s total revenue. The Company currently sources each such product from a single supplier. If demand decreases significantly, government regulation restricts their sale, the Company is unable to adequately source or deliver the products, or the Company ceases offering the products for any reason without suitable replacements, the Company’s business, financial condition and results of operations could be materially and adversely affected. Fair Value of Financial Instruments<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The carrying amounts of the Company’s financial instruments, including cash and cash equivalents and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. The Company’s cash equivalents are valued based on level 1 inputs which consist of quoted prices in active markets.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items. Recently Issued and Adopted Accounting Pronouncements<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-18, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows - Restricted Cash</span><span style="font-family:inherit;font-size:10pt;">, that requires amounts generally described as restricted cash or restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new standard will be effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, and early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting</span><span style="font-family:inherit;font-size:10pt;">, that simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The new standard was effective for fiscal years beginning after December 15, 2016, including interim periods within those annual years, and early adoption was permitted. The Company adopted this guidance as of the quarter ended March 31, 2017. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">, that requires organizations that lease assets, referred to as “lessees”, to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases with lease terms of more than 12 months. ASU 2016-02 will also require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will include qualitative and quantitative requirements. The new standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those annual years, and early application is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued ASU No. 2015-17, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Balance Sheet Classification of Deferred Taxes</span><span style="font-family:inherit;font-size:10pt;">. Under this guidance, entities are required to present deferred tax assets and deferred tax liabilities as noncurrent in a classified balance sheet. This guidance was effective for annual and interim periods beginning after December 15, 2016, with early adoption permitted. Entities were permitted to adopt this guidance either prospectively or retrospectively. The Company elected to early adopt this guidance prospectively as of the quarter ended December 31, 2016. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2015, the FASB issued ASU No. 2015-11,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Inventory: Simplifying the Measurement of Inventory.</span><span style="font-family:inherit;font-size:10pt;"> Under this guidance, inventory not measured using either the last in, first out (LIFO) or the retail inventory method are to be measured at the lower of cost and net realizable value.  Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable cost of completion, disposal, and transportation.  The new standard was effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, with early adoption permitted. The Company adopted this guidance as of the quarter ended March 31, 2017. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue From Contracts With Customers</span><span style="font-family:inherit;font-size:10pt;">, that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract.  Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard.  In July 2015, the FASB approved the deferral of the effective date for annual reporting periods that begin after December 15, 2017, including interim reporting periods. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements NET INCOME PER COMMON SHARE<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table illustrates the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data):</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="33"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="32" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,578</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,251</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.10</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,086</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,382</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.84</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,241</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,302</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.84</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warrants to purchase common stock</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested restricted stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders plus assumed conversions</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,578</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,267</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.09</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,086</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,407</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.83</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,241</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,372</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.82</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warrants to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>88,097</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock were exercised during April 2015.</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">Certain non-vested restricted stock is anti-dilutive upon applying the treasury stock method since the amount of compensation cost for future service results in the hypothetical repurchase of shares exceeding the actual number of shares to be vested. Non-vested restricted stock totaling </span><span style="font-family:inherit;font-size:10pt;"><span>2,232</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>345</span></span><span style="font-family:inherit;font-size:10pt;"> shares were not included for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span>, respectively, as their effect would have been anti-dilutive. <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="33"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="32" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,578</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,251</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.10</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,086</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,382</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.84</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,241</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,302</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.84</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warrants to purchase common stock</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested restricted stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders plus assumed conversions</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,578</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,267</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.09</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,086</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,407</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.83</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,241</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,372</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.82</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 23578000 11251000 2.10 55086000 11382000 4.84 47241000 12302000 3.84 21000 16000 25000 49000 23578000 11267000 2.09 55086000 11407000 4.83 47241000 12372000 3.82 88097 2232 345 BALANCE SHEET COMPONENTS<div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of certain balance sheet amounts are as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,703</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,453</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,608</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,468</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>135,311</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>125,921</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,779</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,722</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>799</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>617</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory reserve for obsolescence</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(180</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(82</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,398</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,257</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Office equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>530</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>517</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Office software</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>916</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>672</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Machinery</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>276</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>241</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>957</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>840</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Construction in progress (including internal-use software development costs)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>157</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,719</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,455</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,570</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,067</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,149</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,388</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued expenses:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>614</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,632</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee-related expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,568</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,541</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warehousing, inventory-related and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,423</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,816</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,605</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,989</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unshipped product</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,411</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,191</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Auto ship advances</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,665</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,327</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Enrollment package revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>379</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>430</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,455</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,948</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;">, cash and cash equivalents include </span><span style="font-family:inherit;font-size:10pt;"><span>$8.7 million</span></span> held in banks located within China subject to foreign currency controls. <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,703</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,453</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,608</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,468</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>135,311</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>125,921</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,779</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,722</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>799</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>617</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory reserve for obsolescence</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(180</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(82</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,398</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,257</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Office equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>530</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>517</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Office software</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>916</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>672</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Machinery</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>276</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>241</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>957</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>840</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Construction in progress (including internal-use software development costs)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>157</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,719</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,455</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,570</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,067</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,149</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,388</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued expenses:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>614</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,632</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee-related expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,568</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,541</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warehousing, inventory-related and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,423</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,816</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,605</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,989</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unshipped product</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,411</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,191</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Auto ship advances</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,665</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,327</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Enrollment package revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>379</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>430</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,455</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,948</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 61703000 52453000 73608000 73468000 135311000 125921000 7779000 10722000 799000 617000 180000 82000 8398000 11257000 530000 517000 916000 672000 30000 28000 276000 241000 957000 840000 10000 157000 2719000 2455000 1570000 1067000 1149000 1388000 614000 1632000 5568000 10541000 1423000 2816000 7605000 14989000 2411000 2191000 1665000 2327000 379000 430000 4455000 4948000 8700000 FAIR VALUE MEASUREMENTS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Gains/Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Gains/Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Municipal bonds and notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,320</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,319</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,490</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,490</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,432</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(24</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,408</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,673</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,671</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial institution instruments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,881</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,881</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,307</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,307</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total available-for-sale investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,633</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,608</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,470</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,468</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>Financial institution instruments include instruments issued or managed by financial institutions such as money market fund deposits and time deposits. <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Gains/Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Gains/Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Municipal bonds and notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,320</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,319</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,490</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,490</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,432</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(24</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,408</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,673</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,671</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial institution instruments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,881</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,881</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,307</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,307</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total available-for-sale investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,633</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,608</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,470</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,468</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 13320000 -1000 13319000 43490000 0 43490000 49432000 -24000 49408000 1673000 -2000 1671000 10881000 0 10881000 28307000 0 28307000 73633000 -25000 73608000 73470000 -2000 73468000 COMMITMENTS AND CONTINGENCIES<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Operating Leases</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has entered into non-cancelable operating lease agreements for locations within the United States and for its international subsidiaries, with expirations through September 2025. Rent expense in connection with operating leases was </span><span style="font-family:inherit;font-size:10pt;"><span>$2.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> during </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2015</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum lease obligations as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,586</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>895</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>337</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>245</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>513</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total minimum lease obligations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,690</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Purchase Commitments</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2013, the Company entered into an exclusive distribution agreement with one of its suppliers to purchase its product through July 2016 which automatically renews annually unless terminated 90 days prior to the termination date. To maintain exclusivity, the Company is required to purchase a minimum of </span><span style="font-family:inherit;font-size:10pt;"><span>$40,000</span></span><span style="font-family:inherit;font-size:10pt;"> of product per month until the termination date. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;">, the Company was in compliance with the exclusivity provision.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has a supply agreement with one of its suppliers to maintain worldwide exclusivity in return for purchasing a minimum of </span><span style="font-family:inherit;font-size:10pt;"><span>$6.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> of product in 2018, plus certain raw material guarantees. If the Company does not purchase the minimum product as required, then a Cure Payment, as defined, will be due to the supplier. The term of the agreement is </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> year commencing January 2018 and shall automatically renew for a successive </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> year term unless notice of termination is provided by either party. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Employment Agreements</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has employment agreements with certain members of its management team that can be terminated by either the employee or the Company upon four weeks’ notice.  The employment agreements entered into with the management team contain provisions that guarantee the payments of specified amounts in the event of a change in control, as defined, or if the employee is terminated without cause, as defined, or terminates employment for good reason, as defined.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Securities Class Action</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2016, two putative securities class action complaints were filed against the Company and its top executives in the United States District Court for the Central District of California. On March 29, 2016, the Court consolidated these actions under the caption </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Ford v. Natural Health Trends Corp.</span><span style="font-family:inherit;font-size:10pt;">, Case No. 2:16-cv-00255-TJH-AFMx, appointed two Lead Plaintiffs, Mahn Dao and Juan Wang, and appointed the Rosen Law Firm and Levi &amp; Korsinsky LLP as co-Lead Counsel for the purported class. Plaintiffs filed a consolidated complaint on April 29, 2016. The consolidated complaint purports to assert claims on behalf of all persons who purchased or otherwise acquired our common stock between March 6, 2015 and March 15, 2016 under (i) Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against the Company and Chris T. Sharng, Timothy S. Davidson and George K. Broady (together, the “Individual Defendants”), and (ii) Section 20(a) of the Securities Exchange Act of 1934 against the Individual Defendants. The consolidated complaint alleges, among other things, that the Company has been running an allegedly illegal multilevel marketing business in China and that it has made materially false and misleading statements regarding the legality of its business operations in China. The consolidated complaint seeks an indeterminate amount of damages, plus interest and costs. On June 15, 2016, the Company filed a motion to dismiss the consolidated complaint, which was denied on December 5, 2016. On February 17, 2017, the Company filed an answer to the consolidated complaint. On July 10, 2017, the Court entered a stipulation between the parties, postponing all deadlines and staying the case to allow the parties to engage in settlement discussions. On July 17, 2017, the parties reached an agreement in principle to settle the action. The proposed class-wide settlement of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.75 million</span></span><span style="font-family:inherit;font-size:10pt;"> was submitted to the Court on October 3, 2017. The Court entered an order preliminarily approving the settlement on November 17, 2017, which was amended on January 4, 2018. Plaintiffs have provided notice to the settlement class in accordance with the amended order, and a final approval hearing is currently set for April 2, 2018. If approved, the proposed settlement will be fully funded by the Company’s insurers. Defendants continue to believe that these claims are without merit and intend to vigorously defend against them if a settlement is not finalized and approved by the Court.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Shareholder Derivative Claims</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, a purported shareholder derivative complaint was filed in the Superior Court of the State of California, County of Los Angeles: </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zhou v. Sharng</span><span style="font-family:inherit;font-size:10pt;">. In March 2016, a purported shareholder derivative complaint was filed in the United States District Court for the Central District of California: </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Kleinfeldt v. Sharng</span><span style="font-family:inherit;font-size:10pt;"> (collectively the “Derivative Complaints”). The Derivative Complaints purport to assert claims for breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement and corporate waste against certain of the Company’s officers and directors. The Derivative Complaints also purport to assert fiduciary duty claims based on alleged insider selling and conspiring to enter into several stock repurchase agreements, which allegedly harmed the Company and its assets. The Derivative Complaints allege, among other things, that the Company has been running an allegedly illegal multilevel marketing business in China, and it has made materially false and misleading statements regarding the legality of its business operations in China, and that certain officers and directors sold common stock on the basis of this allegedly material, adverse non-public information. The Derivative Complaints seek an indeterminate amount of damages, plus interest and costs, as well as various equitable remedies. On February 1, 2017, pursuant to a stipulation among the parties, the Los Angeles Superior Court entered a stay of the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zhou</span><span style="font-family:inherit;font-size:10pt;"> action pending conclusion of the related federal class action in the United States District Court for the Central District of California:</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Ford v. Natural Health Trends Corp.</span><span style="font-family:inherit;font-size:10pt;"> A nearly identical stipulated stay was entered in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Kleinfeldt</span><span style="font-family:inherit;font-size:10pt;"> case on February 28, 2017. On November 10, 2017, the parties to both the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zhou</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Kleinfeldt</span><span style="font-family:inherit;font-size:10pt;"> actions entered into a Memorandum of Understanding (“MOU”) to resolve both actions, subject to the negotiation of a written settlement agreement and approval by the federal court in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Kleinfeldt</span><span style="font-family:inherit;font-size:10pt;"> matter.  On November 15, 2017, the parties filed a joint status report and stipulation in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zhou</span><span style="font-family:inherit;font-size:10pt;"> matter, alerting the court to the MOU and seeking to maintain the stay pending finalization and court approval of the parties’ tentative settlement.  The </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zhou</span><span style="font-family:inherit;font-size:10pt;"> court entered an order continuing the stay on November 17, 2017.  On March 9, 2018, the parties filed a Stipulation of Settlement and supporting papers in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Kleinfeldt</span><span style="font-family:inherit;font-size:10pt;"> action. On March 22, 2018, plaintiffs filed a motion for preliminary approval of the tentative settlement. The settlement is subject to both preliminary and final approval by the court.  If approved, the proposed settlement will require certain corporate governance reforms and permit an award of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$250,000</span></span><span style="font-family:inherit;font-size:10pt;"> in attorneys’ fees to plaintiffs’ counsel, all of which will be fully funded by the Company’s insurers. Defendants continue to believe that these claims are without merit and intend to vigorously defend against them if the derivative settlement is not finalized and approved.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consolidated class action (if the settlement is not approved by the Court) and the Derivative Complaints (if the tentative settlement is not finalized or approved), or other actions alleging similar facts, could result in monetary or other penalties that may materially affect the Company’s operating results and financial condition. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Claims</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The Company is currently involved in a legal matter with one of its vendors and an outside party. Per the royalty agreement with the vendor, the Company believes that it is fully indemnified in the event of an unfavorable outcome and any potential settlement costs related to the matter would be fully covered by the Company’s vendor. 2000000.0 1800000 1500000 <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,586</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>895</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>337</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>245</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>513</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total minimum lease obligations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,690</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 1586000 1114000 895000 337000 245000 513000 4690000 40000 6600000 1750000 250000 STOCKHOLDERS’ EQUITY<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Authorized Shares</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is authorized to issue </span><span style="font-family:inherit;font-size:10pt;">two</span><span style="font-family:inherit;font-size:10pt;"> classes of capital stock consisting of up to </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>5,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of preferred stock, </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>$0.001</span></span><span style="font-family:inherit;font-size:10pt;"> par value, and </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>50,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>$0.001</span></span><span style="font-family:inherit;font-size:10pt;"> par value. </span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Dividends</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables summarize the Company’s cash dividend activity during </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2015</span><span style="font-family:inherit;font-size:10pt;"> (in thousands, except per share data):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declaration Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Common Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 30, 2017 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,701</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">November 24, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,360</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">November 24, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 31, 2017 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,833</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">August 31, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,246</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">August 31, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 24, 2017 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,964</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">May 19, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 24, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">May 19, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 24, 2017 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,962</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">March 3, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 24, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.09</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,019</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">March 3, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.52</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,218</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declaration Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Common Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 23, 2016 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,941</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">November 25, 2016</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 23, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.08</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>901</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">November 25, 2016</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 19, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.07</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>787</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">August 26, 2016</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 21, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.06</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>686</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">May 20, 2016</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 1, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.05</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>576</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">March 24, 2016</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.61</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,891</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declaration Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Common Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 21, 2015</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.05</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>598</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">November 20, 2015</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 28, 2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.04</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>489</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">August 28, 2015</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 4, 2015</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.03</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>372</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">May 29, 2015</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 27, 2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.02</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">March 27, 2015</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.14</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,709</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declaration and payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Repurchases</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from </span><span style="font-family:inherit;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$70.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During February 2016, pursuant to the stock repurchase program, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market. During the year ended December 31, 2016, the Company purchased a total of </span><span style="font-family:inherit;font-size:10pt;"><span>903,031</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock for an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$23.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, plus transaction costs. No shares of the Company’s common stock were repurchased by the Company during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$32.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the </span><span style="font-family:inherit;font-size:10pt;"><span>$70.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On July 28, 2015, the Board of Directors approved a stock repurchase program of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company’s outstanding shares of common stock. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, are anticipated to be conducted through December 2016, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act.  For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases.  The repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. In connection therewith, the Company was advised that George K. Broady, a director of the Company and owner of more than 5% of its outstanding shares of common stock, would participate in the stock repurchase program on a basis roughly proportional to his family’s ownership interest.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During August 2015, pursuant to the foregoing stock repurchase program, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:10pt;">. The open market repurchases were completed on August 4, 2015. The stock repurchase program, which included both open market purchases and the purchase of shares from Mr. Broady, resulted in the Company purchasing a total of </span><span style="font-family:inherit;font-size:10pt;"><span>162,442</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock for an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, plus transaction costs. During October 2015, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.6 million</span></span><span style="font-family:inherit;font-size:10pt;">. The open market repurchases were completed on October 30, 2015. The stock repurchase program, which included both open market purchases and the purchase of shares from Mr. Broady, resulted in the Company purchasing a total of </span><span style="font-family:inherit;font-size:10pt;"><span>106,264</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock for an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, plus transaction costs. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 4, 2015, the Board of Directors approved a separate, prior stock repurchase program of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company’s outstanding shares of common stock.  In connection therewith, the Company was advised by Mr. Broady that he would participate in the stock repurchase program on a basis roughly proportional to his family’s ownership interest (see Note 8). As such, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> in accordance with Rules 10b5-1 and 10b-18 under the Exchange Act. The stock repurchase program, which included both open market purchases and the purchase of shares from Mr. Broady, was completed on May 13, 2015, and resulted in the Company purchasing a total of </span><span style="font-family:inherit;font-size:10pt;"><span>186,519</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock for an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, plus transaction costs. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 22, 2015, the Company entered into a stock repurchase agreement with Mr. Broady that provided for the Company’s purchase from Mr. Broady in off-the-market, private transactions of a total of </span><span style="font-family:inherit;font-size:10pt;"><span>91,817</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company’s common stock, which would be purchased at the rate of </span><span style="font-family:inherit;font-size:10pt;"><span>5,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares each trading day following the date of the agreement until all of such shares were purchased (see Note 8). The shares were purchased at a per share price equal to the closing price per share of the Company’s common stock on the preceding trading day, as reported on the primary market in which the Company’s common stock is publicly traded. The Company’s purchases concluded on February 19, 2015, and resulted in an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense totaled approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$35,000</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$104,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$86,000</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2015</span><span style="font-family:inherit;font-size:10pt;">, respectively. During March 2016, the Company modified the vesting feature of an award granted to a director who decided to not stand for re-election at the Company’s 2016 annual meeting of stockholders. The modification of the award resulted in an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$64,000</span></span><span style="font-family:inherit;font-size:10pt;"> in stock-based compensation expense for the three months ended March 31, 2016.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to </span><span style="font-family:inherit;font-size:10pt;"><span>2,500,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. As of December 31, 2017, </span><span style="font-family:inherit;font-size:10pt;"><span>2,393,873</span></span><span style="font-family:inherit;font-size:10pt;"> shares remained available for issuance under the 2016 Plan. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 24, 2017, the Company granted </span><span style="font-family:inherit;font-size:10pt;"><span>56,260</span></span><span style="font-family:inherit;font-size:10pt;"> shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2016 performance incentives totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;">. The shares vest on a quarterly basis over </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> years and are subject to forfeiture in the event of the employee’s termination of service to the Company under specified circumstances. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 8, 2016, the Company granted </span><span style="font-family:inherit;font-size:10pt;"><span>51,015</span></span><span style="font-family:inherit;font-size:10pt;"> shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2015 performance incentives totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:10pt;">. The shares vest on a quarterly basis over </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> years and are subject to forfeiture in the event of the employee’s termination of service to the Company under specified circumstances. </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company’s restricted stock activity under the 2016 Plan:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Price at Date of Issuance</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2015</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,015</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12,759</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,256</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,260</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.44</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(35,336</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,148</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,032</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 20, 2015, the Company’s Board of Directors granted </span><span style="font-family:inherit;font-size:10pt;"><span>60,960</span></span><span style="font-family:inherit;font-size:10pt;"> shares of restricted common stock to certain employees and its then-existing outside directors for the purpose of further aligning their interest with those of its stockholders and as to the employee shares, settling fiscal 2014 performance incentives. The shares vested on a quarterly basis over the next </span><span style="font-family:inherit;font-size:10pt;">three years</span><span style="font-family:inherit;font-size:10pt;"> and were subject to forfeiture in the event of their termination of service to the Company under specified circumstances. On February 11, 2015, the Board of Directors granted an additional </span><span style="font-family:inherit;font-size:10pt;"><span>6,116</span></span><span style="font-family:inherit;font-size:10pt;"> shares of restricted common stock to its newly-elected outside directors subject to the same conditions.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company’s other restricted stock activity:</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Price at Date of Issuance</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2014</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67,076</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,364</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,712</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,364</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,348</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21,930</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(418</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.28</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 13, 2012, the Board of Directors authorized the Company, acting as trustee for certain of its non-officer, overseas employees, to execute a Rule 10b5-1 plan to purchase </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>100,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock in accordance with guidelines specified under Rule 10b5-1 of the Exchange Act and the Company’s policies regarding stock transactions.  Pursuant to this authority, the Company, as Trustee, entered into a 10b5-1 plan and began purchasing in December 2012. The latest 10b5-1 plan terminated in November 2014, and the Company, as Trustee, did not enter into a new 10b5-1 plan. The employees received the stock as incentive compensation in quarterly increments over </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> years beginning March 15, 2013, provided that they were employees of the Company on the date of the distribution. Any common stock that was forfeited by an employee whose employment terminated was delivered to the Company and held as treasury stock.</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Grant-Date Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2014</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,984</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(23,984</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.37</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2015</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 5000000 0.001 50000000 0.001 <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declaration Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Common Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 30, 2017 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,701</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">November 24, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,360</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">November 24, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 31, 2017 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,833</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">August 31, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,246</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">August 31, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 24, 2017 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,964</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">May 19, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 24, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">May 19, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 24, 2017 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,962</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">March 3, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 24, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.09</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,019</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">March 3, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.52</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,218</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declaration Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Common Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 23, 2016 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,941</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">November 25, 2016</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 23, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.08</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>901</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">November 25, 2016</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 19, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.07</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>787</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">August 26, 2016</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 21, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.06</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>686</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">May 20, 2016</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 1, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.05</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>576</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">March 24, 2016</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.61</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,891</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declaration Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Common Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 21, 2015</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.05</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>598</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">November 20, 2015</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 28, 2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.04</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>489</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">August 28, 2015</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 4, 2015</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.03</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>372</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">May 29, 2015</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 27, 2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.02</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">March 27, 2015</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.14</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,709</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div> 0.15 1701000 2017-11-24 0.12 1360000 2017-11-24 0.25 2833000 2017-08-31 0.11 1246000 2017-08-31 0.35 3964000 2017-05-19 0.10 1133000 2017-05-19 0.35 3962000 2017-03-03 0.09 1019000 2017-03-03 1.52 17218000 0.35 3941000 2016-11-25 0.08 901000 2016-11-25 0.07 787000 2016-08-26 0.06 686000 2016-05-20 0.05 576000 2016-03-24 0.61 6891000 0.05 598000 2015-11-20 0.04 489000 2015-08-28 0.03 372000 2015-05-29 0.02 250000 2015-03-27 0.14 1709000 15000000.0 70000000.0 903031 23700000 32000000.0 70000000.0 15000000.0 3500000 162442 5000000.0 3600000 106264 5000000.0 5000000.0 3500000 186519 5000000.0 91817 5000 1100000 35000 104000 86000 64000 2500000 2393873 56260 1400000 51015 1700000 The following table summarizes the Company’s restricted stock activity under the 2016 Plan:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Price at Date of Issuance</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2015</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,015</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12,759</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,256</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,260</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.44</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(35,336</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,148</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,032</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Price at Date of Issuance</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2014</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67,076</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,364</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,712</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,364</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,348</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21,930</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(418</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.28</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 0 0 51015 34.13 12759 34.13 38256 34.13 56260 25.44 35336 29.58 1148 28.55 58032 28.72 60960 6116 0 0 67076 12.15 22364 12.15 44712 12.15 22364 12.15 22348 12.15 21930 12.15 418 12.28 0 12.15 100000 23984 1.37 23984 1.37 0 0 INCOME TAXES<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of income before income taxes consist of the following (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Domestic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,965</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,106</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,820</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,391</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67,183</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,613</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,426</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64,077</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,793</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of the income tax provision consist of the following (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,277</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,151</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,216</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,648</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>456</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,495</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,718</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>568</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,647</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>273</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax provision</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,848</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,991</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>552</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the reported income tax provision to the provision that would result from applying the domestic federal statutory tax rate to pretax income is as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax at federal statutory rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,200</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,427</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of permanent differences</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>459</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,496</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>370</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax Cut &amp; Jobs Act repatriation tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,792</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax Cut &amp; Jobs Act federal rate change</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>954</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,877</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,017</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign rate differential</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,002</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21,713</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18,099</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign tax credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,105</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(261</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other reconciling items</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(407</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(81</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax provision</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,848</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,991</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>552</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before income taxes and the statutory tax rate for each country that materially contributed to the foreign rate differential presented above is as follows (in thousands): </span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:40%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Statutory Tax Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cayman Islands</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,954</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,169</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,993</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hong Kong</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,315</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,992</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,645</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">China</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,584</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,855</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,493</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income taxes consist of the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>192</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>270</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>623</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,374</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,174</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,842</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,032</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(192</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(235</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,650</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,797</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign earnings</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,650</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(267</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(415</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(271</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,065</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax asset (liability)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,379</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(268</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The effective income tax rate for the year ended December 31, 2017 was significantly impacted by recording the effect of the Tax Cuts and Jobs Act (the “Tax Act”), enacted on December 22, 2017 by the U.S. government. The Tax Act makes broad and complex changes to the Internal Revenue Code of 1986, as amended, which has affected the Company’s year ended December 31, 2017, including, but not limited to, reducing the maximum U.S. federal corporate tax rate from 35% to 21% effective January 1, 2018, and requiring a one-time repatriation tax on certain un-repatriated earnings of foreign subsidiaries at a rate of 15.5% tax on post-1986 foreign earnings held in cash and an 8% rate on all other post-1986 earnings that is payable over eight years beginning with 8% of the liability due with the filing of the year ended December 31, 2017 federal tax return that will be due in 2018. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 22, 2017, the Securities and Exchange Commission staff issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</span><span style="font-family:inherit;font-size:10pt;">. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Tax Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in the corporate income tax rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in the Company’s interpretations and assumptions, additional guidance that may be issued by the Internal Revenue Service, and actions it may take. The Company is continuing to gather additional information to determine the final impact. Any adjustments recorded to the provisional amounts through the fourth quarter of 2018 will be included as an adjustment to income tax expense.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of the Tax Act, the Company recorded additional income tax expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$20.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> due to the repatriation tax on deemed repatriation of deferred foreign income and of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> due to a re-measurement of deferred tax assets and liabilities, in the three months ended December 31, 2017. The Deemed Repatriation Transition Tax (the “Repatriation Tax”) is a tax on previously untaxed accumulated earnings and profits (“E&amp;P”) of certain of its foreign subsidiaries. To determine the amount of the Repatriation Tax, the Company must determine, in addition to other factors, the amount of post-1986 E&amp;P of the relevant subsidiaries, as well as the amount of non-U.S. income taxes paid on such earnings. The Company is able to make a reasonable estimate and recorded a provisional Repatriation Tax obligation of </span><span style="font-family:inherit;font-size:10pt;"><span>$20.7 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Because of the complexity of the new Global Intangible Low-Taxed Income (“GILTI”) tax rules, the Company continues to evaluate this provision of the Tax Act and the application of ASC 740. Under U.S. GAAP, the Company is allowed to make an accounting policy choice of either treating taxes due on future U.S. inclusions in taxable income related to GILTI as a current period expense when incurred (the “period cost method”) or factoring such amounts into the Company’s measurement of its deferred taxes (the “deferred method”). The Company is currently in the process of analyzing its structure and, as a result, is not yet able to reasonably estimate the effect of this provision of the Tax Act. Therefore, the Company has not made any adjustments related to potential GILTI tax in its financial statements and has not made a policy decision regarding whether to record deferred tax on GILTI.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;">, the Company does not have a valuation allowance against its U.S. deferred tax assets. The Company analyzed all sources of available income and determined that they are more likely than not to realize the tax benefits of their deferred assets in future periods or carryback years.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;">, the Company has a valuation allowance against certain foreign deferred tax assets. The Company is recording a valuation allowance in foreign jurisdictions with an overall deferred tax loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;">, the Company has </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> U.S. federal net operating loss or credit carryforwards as any attributes are expected to be fully utilized to offset tax in the current year. At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;">, the Company has foreign net operating loss carryforwards of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.25 million</span></span><span style="font-family:inherit;font-size:10pt;"> in various jurisdictions with various expirations.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of capital return activities approved by the Board of Directors during the first quarter of 2016 and anticipated future capital return activities, the Company determined that a portion of its current undistributed foreign earnings are no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. The Company repatriated </span><span style="font-family:inherit;font-size:10pt;"><span>$19.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the U.S. during the three months ended March 31, 2016, part of which was offset by U.S. net operating losses. Accordingly, the deferred tax liability previously established for undistributed foreign earnings up to its existing U.S. net operating losses was reduced. The excess amount repatriated during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;"> was generated from current foreign earnings. The Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable U.S. corporate income tax rate. As of December 31, 2017, the Company has recorded a state deferred tax liability for earnings that the Company plans to repatriate out of accumulated earnings in future periods. Due to the Tax Act, repatriation from foreign subsidiaries will be offset with a dividends received deduction, resulting in little to no impact on federal tax expense. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The Company and its subsidiaries file tax returns in the United States, California and Texas and various foreign jurisdictions. For federal income tax purposes, fiscal years 2007 through 2016 remain open for examination by tax authorities as a result of net operating loss carryovers from older years being used to offset income in recent tax years. The Company is no longer subject to state income tax examinations for years prior to 2011. No jurisdictions are currently examining any income tax returns of the Company or its subsidiaries except that the Taiwan Taxation Administration is currently examining the Taiwan subsidiary’s 2016 tax return. No adjustments have been proposed at this time. <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Domestic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,965</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,106</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,820</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,391</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67,183</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,613</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,426</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64,077</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,793</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> -2965000 -3106000 -7820000 46391000 67183000 55613000 43426000 64077000 47793000 <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,277</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,151</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,216</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,648</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>456</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,495</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,718</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>568</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,647</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>273</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax provision</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,848</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,991</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>552</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 20277000 7151000 12000 2000 -81000 100000 1216000 1648000 456000 21495000 8718000 568000 -1647000 273000 -16000 19848000 8991000 552000 <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax at federal statutory rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,200</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,427</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of permanent differences</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>459</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,496</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>370</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax Cut &amp; Jobs Act repatriation tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,792</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax Cut &amp; Jobs Act federal rate change</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>954</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,877</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,017</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign rate differential</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,002</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21,713</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18,099</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign tax credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,105</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(261</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other reconciling items</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(407</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(81</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax provision</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,848</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,991</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>552</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 15200000 22427000 16250000 459000 12496000 370000 20792000 0 0 954000 0 0 -43000 -3877000 2017000 -15002000 -21713000 -18099000 2105000 261000 0 -407000 -81000 14000 19848000 8991000 552000 <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:40%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Statutory Tax Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cayman Islands</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,954</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,169</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,993</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hong Kong</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,315</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,992</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,645</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">China</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,584</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,855</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,493</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 0 39954000 58169000 50993000 0.165 3315000 3992000 2645000 0.250 2584000 3855000 1493000 <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>192</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>270</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>623</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,374</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,174</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,842</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,032</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(192</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(235</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,650</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,797</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign earnings</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,650</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(267</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(415</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(271</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,065</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax asset (liability)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,379</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(268</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div> 192000 235000 270000 623000 1374000 3174000 0 0 6000 0 1842000 4032000 192000 235000 1650000 3797000 4000 3650000 267000 415000 271000 4065000 1379000 268000 20700000 1000000.0 20700000 0 1250000 19800000 RELATED PARTY TRANSACTIONS<div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Product Royalties</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 29, 2015, the Company entered into a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Soothe</span><span style="font-family:inherit;font-size:10pt;">™. The Company began selling this product in the fourth quarter of 2012 with the permission of BHS. Mr. Broady is owner of BHS. Under the agreement, the Company agreed to pay BHS a royalty of </span><span style="font-family:inherit;font-size:10pt;"><span>2.5%</span></span><span style="font-family:inherit;font-size:10pt;"> of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide. Further, the Company agreed to pay BHS </span><span style="font-family:inherit;font-size:10pt;"><span>$11,700</span></span><span style="font-family:inherit;font-size:10pt;"> as royalties for the period it began selling the product in the fourth quarter of 2012 through 2014. The Company recognized royalties of </span><span style="font-family:inherit;font-size:10pt;"><span>$1,400</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$3,400</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$7,000</span></span><span style="font-family:inherit;font-size:10pt;"> during </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2015</span><span style="font-family:inherit;font-size:10pt;">, respectively. The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on </span><span style="font-family:inherit;font-size:10pt;"><span>120 days</span></span><span style="font-family:inherit;font-size:10pt;">’ notice. Otherwise, the agreement terminates March 31, 2020.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2013, the Company entered into a Royalty Agreement and License with BHS regarding the manufacture and sale of a product called </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">ReStor™.</span><span style="font-family:inherit;font-size:10pt;">  Under this agreement, the Company agreed to pay BHS a royalty of </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>2.5%</span></span><span style="font-family:inherit;font-size:10pt;"> of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide, with certain rights being exclusive outside the United States. On April 29, 2015, the Company and BHS amended the Royalty and Agreement and License to change the royalty to a price per unit instead of 2.5% of sales revenue. This provision was effective retroactive to January 1, 2015.  The Company recognized royalties of </span><span style="font-family:inherit;font-size:10pt;"><span>$306,000</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>$475,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>$555,000</span></span><span style="font-family:inherit;font-size:10pt;"> during </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2015</span><span style="font-family:inherit;font-size:10pt;">, respectively.  The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>120</span></span><span style="font-family:inherit;font-size:10pt;"> days’ notice or, under certain circumstances, with no notice. Otherwise, the agreement terminates March 31, 2020.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Repurchase</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Agreements</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 28, 2015, the Company entered into a Stock Repurchase Agreement with Mr. Broady that provided for the Company’s purchase of common stock from Mr. Broady in off-the-market, private transactions at a rate equal to </span><span style="font-family:inherit;font-size:10pt;"><span>0.4066</span></span><span style="font-family:inherit;font-size:10pt;"> times the number of shares purchased by the Company’s broker in conjunction with the stock repurchase program authorized by the Company’s Board of Directors on July 28, 2015. The Company’s purchases from Mr. Broady concluded on November 2, 2015, were completed at a per share purchase price equal to the weighted average price per share paid by the Company’s broker in its open-market purchases, and resulted in an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;">. See Note 6.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On July 31, 2015, the Company entered into a Stock Repurchase Agreement with Mr. Broady that provided for the Company’s purchase of common stock from Mr. Broady in off-the-market, private transactions at a rate equal to </span><span style="font-family:inherit;font-size:10pt;"><span>0.4085</span></span><span style="font-family:inherit;font-size:10pt;"> times the number of shares purchased by the Company’s broker in conjunction with the stock repurchase program authorized by the Company’s Board of Directors on July 28, 2015. The Company’s purchases from Mr. Broady concluded on August 6, 2015, were completed at a per share purchase price equal to the weighted average price per share paid by the Company’s broker in its open-market purchases, and resulted in an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;">. See Note 6.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 7, 2015, the Company entered into a Stock Repurchase Agreement with Mr. Broady that provided for the Company’s purchase of common stock from Mr. Broady in off-the-market, private transactions at a rate equal to </span><span style="font-family:inherit;font-size:10pt;"><span>0.4286</span></span><span style="font-family:inherit;font-size:10pt;"> times the number of shares purchased by the Company’s broker in conjunction with the stock repurchase program authorized by the Company’s Board of Directors on May 4, 2015. The Company’s purchases from Mr. Broady concluded on May 13, 2015, were completed at a per share purchase price equal to the weighted average price per share paid by the Company’s broker in its open-market purchases, and resulted in an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;">. See Note 6.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">On January 22, 2015, the Company entered into a Stock Repurchase Agreement with Mr. Broady that provided for the Company’s purchase from Mr. Broady in off-the-market, private transactions of a total of </span><span style="font-family:inherit;font-size:10pt;"><span>91,817</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company’s common stock, which would be purchased at the rate of </span><span style="font-family:inherit;font-size:10pt;"><span>5,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares each trading day following the date of the agreement until all of such shares were purchased. The shares were purchased at a per share price equal to the closing price per share of the Company’s common stock on the preceding trading day, as reported on the primary market in which the Company’s common stock was publicly traded. The Company’s purchases concluded on February 19, 2015, and resulted in an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span>. See Note 6. 0.025 11700 1400 3400 7000 P120D 0.025 306000 475000 555000 P120D 0.4066 1400000 0.4085 1500000 0.4286 1500000 91817 5000 1100000  EMPLOYEE BENEFIT PLANS<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><span style="font-family:inherit;font-size:10pt;">      The Company has a 401(k) defined contribution plan which permits participating employees in the United States to defer up to a maximum of </span><span style="font-family:inherit;font-size:10pt;"><span>90%</span></span><span style="font-family:inherit;font-size:10pt;"> of their compensation, subject to limitations established by the Internal Revenue Service. Employees age </span><span style="font-family:inherit;font-size:10pt;"><span>21</span></span><span style="font-family:inherit;font-size:10pt;"> and older are eligible to contribute to the plan starting the first day of the following month of employment.  Participating employees are eligible to receive discretionary matching contributions and profit sharing, subject to certain conditions, from the Company.  In </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2015</span><span style="font-family:inherit;font-size:10pt;">, the Company matched employee deferral contributions up to </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>4.5%</span></span><span style="font-family:inherit;font-size:10pt;"> of salary, which vested </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> immediately. No profit sharing has been paid under the plan. The Company recorded compensation expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$171,000</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$134,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$115,000</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2015</span>, respectively, related to its matching contributions to the plan. Certain of the Company’s employees located outside the United States participate in employee benefit plans that are statutory in nature. 0.90 P21Y 0.045 1 171000 134000 115000 SEGMENT INFORMATION<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company sells products to a member network that operates in a seamless manner from market to market, except for the China market where it sells to consumers through an e-commerce platform, and the Russia and Kazakhstan market where the Company’s engagement of a third-party service provider results in a different economic structure than its other markets. Otherwise, the Company believes that all of its other operating segments have similar economic characteristics and are similar in the nature of the products sold, the product acquisition process, the types of customers products are sold to, the methods used to distribute the products, and the nature of the regulatory environment.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There is no separate segment manager who is held accountable by the Company’s chief operating decision-makers, or anyone else, for operations, operating results and planning for the China market or the Russia and Kazakhstan market on a stand-alone basis, and neither market is material for the periods presented. As such, the Company believes that all operating segments should be aggregated into a single reportable segment for disclosure purposes.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s net sales by geographic area are as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales from external customers:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,348</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,246</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canada</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,938</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,809</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,746</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Peru</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>508</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hong Kong</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>174,926</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>263,482</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>245,737</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">China</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,282</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,086</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,425</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Taiwan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,591</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,213</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,965</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">South Korea</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>466</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>691</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,129</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Russia, Kazakhstan and Ukraine</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>913</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>858</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,139</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,278</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,234</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>382</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other foreign countries</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>313</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>255</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>197,563</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>287,728</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>264,860</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">_____________________________</sup> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors”.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> The Company</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">discontinued its Ukraine operations during the second quarter of 2015.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s net sales by product and service are as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales by product and service:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>187,591</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>269,731</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>253,041</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Enrollment package revenue, freight and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,676</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,616</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,623</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: sales returns</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,704</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,619</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,804</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>197,563</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>287,728</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>264,860</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Due to system constraints, it is impracticable for the Company to separately disclose sales by product category for the years presented. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s long-lived assets by geographic area are as follows (in thousands):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-lived assets:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>648</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>763</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hong Kong</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">China</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other foreign countries</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>311</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>286</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-lived assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,149</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,388</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales from external customers:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,348</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,246</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canada</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,938</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,809</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,746</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Peru</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>508</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hong Kong</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>174,926</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>263,482</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>245,737</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">China</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,282</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,086</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,425</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Taiwan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,591</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,213</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,965</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">South Korea</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>466</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>691</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,129</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Russia, Kazakhstan and Ukraine</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>913</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>858</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,139</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,278</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,234</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>382</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other foreign countries</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>313</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>255</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>197,563</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>287,728</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>264,860</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 3348000 4100000 3246000 1938000 1809000 2746000 508000 0 0 174926000 263482000 245737000 7282000 9086000 4425000 5591000 6213000 5965000 466000 691000 1129000 913000 858000 1139000 2278000 1234000 382000 313000 255000 91000 197563000 287728000 264860000 <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales by product and service:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>187,591</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>269,731</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>253,041</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Enrollment package revenue, freight and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,676</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,616</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,623</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: sales returns</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,704</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,619</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,804</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>197,563</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>287,728</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>264,860</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 187591000 269731000 253041000 13676000 25616000 17623000 3704000 7619000 5804000 197563000 287728000 264860000 <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-lived assets:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>648</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>763</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hong Kong</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">China</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other foreign countries</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>311</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>286</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-lived assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,149</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,388</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 648000 763000 78000 140000 112000 199000 311000 286000 1149000 1388000  SUBSEQUENT EVENTS<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">February 6, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Board of Directors declared a cash dividend of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.13</span></span><span style="font-family:inherit;font-size:10pt;"> on each share of common stock outstanding. Such dividends were paid on </span><span style="font-family:inherit;font-size:10pt;">March 9, 2018</span><span style="font-family:inherit;font-size:10pt;"> to stockholders of record on </span><span style="font-family:inherit;font-size:10pt;">February 27, 2018</span><span style="font-family:inherit;font-size:10pt;">. Declaration and payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 1, 2018, the Company granted </span><span style="font-family:inherit;font-size:10pt;"><span>34,202</span></span><span style="font-family:inherit;font-size:10pt;"> shares of restricted common stock under the 2016 Plan to certain employees for the purpose of settling fiscal 2017 performance incentives. The shares vest on a quarterly basis over the next three years and are subject to forfeiture in the event of their termination of service to the Company under specified circumstances.</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">On January 26, 2018, the Company entered into an exclusive distribution, license and royalty agreement with a new supplier to purchase products through January 2021 and shall renew for successive one year terms unless notice of termination is provided by either party. To maintain exclusivity, the Company is required to purchase between </span><span style="font-family:inherit;font-size:10pt;"><span>$453,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.6 million</span></span> of product, depending on the product mix and inclusive of royalties, per year until the termination date. 0.13 34202 453000 3600000 XML 15 R1.htm IDEA: XBRL DOCUMENT v3.8.0.1
Document And Entity Information - USD ($)
12 Months Ended
Dec. 31, 2017
Mar. 02, 2018
Jun. 30, 2017
Document And Entity Information      
Entity Registrant Name NATURAL HEALTH TRENDS CORP.    
Entity Central Index Key 0000912061    
Current Fiscal Year End Date --12-31    
Entity Filer Category Accelerated Filer    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Well-known Seasoned Issuer No    
Entity Common Stock, Shares Outstanding (in shares)   11,376,092  
Entity Public Float     $ 202,498,798
Document Type 10-K    
Document Period End Date Dec. 31, 2017    
Document Fiscal Year Focus 2017    
Document Fiscal Period Focus FY    
Amendment Flag false    
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Current assets:    
Cash and cash equivalents $ 135,311 $ 125,921
Inventories, net 8,398 11,257
Other current assets 7,534 4,066
Total current assets 151,243 141,244
Property and equipment, net 1,149 1,388
Goodwill 1,764 1,764
Restricted cash 3,167 2,963
Deferred Tax Assets, Net, Noncurrent 1,435 0
Other assets 796 692
Total assets 159,554 148,051
Current liabilities:    
Accounts payable 1,751 2,145
Income taxes payable 309 663
Accrued commissions 11,170 13,611
Other accrued expenses 7,605 14,989
Deferred revenue 4,455 4,948
Amounts held in eWallets 15,152 19,165
Other current liabilities 1,479 1,633
Total current liabilities 41,921 57,154
Accrued Income Taxes, Noncurrent 19,052 0
Deferred Tax Liabilities, Net, Noncurrent 56 268
Long-term incentive 7,904 8,190
Total liabilities 68,933 65,612
Commitments and Contingencies
Stockholders’ equity:    
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2017 and 2016 0 0
Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at December 31, 2017 and 2016 13 13
Additional paid-in capital 86,683 86,574
Retained earnings (accumulated deficit) 44,908 38,548
Accumulated other comprehensive (loss) income (413) (807)
Treasury stock, at cost; 1,637,524 and 1,692,218 shares at December 31, 2017 and 2016, respectively (40,570) (41,889)
Total stockholders’ equity 90,621 82,439
Total liabilities and stockholders’ equity $ 159,554 $ 148,051
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Balance Sheets (Parentheticals) - $ / shares
Dec. 31, 2017
Dec. 31, 2016
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 0.000 0.000
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized 50,000,000 50,000,000
Common stock, shares issued 12,979,414 12,979,414
Treasury stock, shares 1,637,524 1,692,218
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Income Statement [Abstract]      
Net sales $ 197,563 $ 287,728 $ 264,860
Cost of sales 38,645 54,903 54,098
Gross profit 158,918 232,825 210,762
Operating expenses:      
Commissions expense 83,638 125,050 126,598
Selling, general and administrative expenses 31,685 43,245 36,024
Depreciation and amortization 536 394 263
Total operating expenses 115,859 168,689 162,885
Income from operations 43,059 64,136 47,877
Other income (expense), net 367 (59) (84)
Income before income taxes 43,426 64,077 47,793
Income tax provision 19,848 8,991 552
Net income $ 23,578 $ 55,086 $ 47,241
Income per common share:      
Net income allocated to common stockholders (in dollars per share) $ 2.10 $ 4.84 $ 3.84
Net income allocated to common stockholders plus assumed conversions (in dollars per share) $ 2.09 $ 4.83 $ 3.82
Weighted-average number of common shares outstanding:      
Weighted Average Number of Shares Outstanding, Basic 11,251 11,382 12,302
Weighted Average Number of Shares Outstanding, Diluted 11,267 11,407 12,372
Common Stock, Dividends, Per Share, Cash Paid $ 1.52 $ 0.61 $ 0.14
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Statement of Comprehensive Income [Abstract]      
Net income $ 23,578 $ 55,086 $ 47,241
Other comprehensive income (loss), net of tax:      
Foreign currency translation adjustments 677 (838) (79)
Release of cumulative translation adjustment (258) 132 (82)
Net change in foreign currency translation adjustment 419 (706) (161)
Unrealized losses on available-for-sale securities (25) 0 (2)
Comprehensive income $ 23,972 $ 54,380 $ 47,078
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Preferred Stock
Common Stock
Additional Paid-In Capital
Retained Earnings (Accumulated Deficit)
Accumulated Other Comprehensive (Loss) Income
Treasury Stock
Treasury stock, shares             (384,220)
Common stock, shares issued     12,891,317        
Preferred stock, shares outstanding   0          
BALANCE at Dec. 31, 2014 $ 26,450 $ 0 $ 13 $ 85,750 $ (54,799) $ 62 $ (4,576)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income 47,241       47,241    
Exercise of warrants (in shares)     88,097        
Exercise of warrants 309     309      
Repurchase of common stock (in shares)             (547,042)
Repurchase of common stock (16,071)           $ (16,071)
Shares issued for stock-based compensation awards (in shares)             91,060
Shares issued for stock-based compensation awards 666     (182) (380)   $ 1,228
Dividends declared (1,709)       (1,709)    
Elimination of CTA upon dissolution (82)         (82)  
Foreign currency translation adjustments (79)         (79)  
Unrealized loss on available-for-sale securities (2)         (2)  
Stock-based compensation 86     86      
BALANCE at Dec. 31, 2015 56,809 $ 0 $ 13 85,963 (9,647) (101) $ (19,419)
Treasury stock, shares             (840,202)
Common stock, shares issued     12,979,414        
Preferred stock, shares outstanding   0          
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income $ 55,086       55,086    
Repurchase of common stock (in shares) (903,031)           (903,031)
Repurchase of common stock $ (23,704)           $ (23,704)
Shares issued for stock-based compensation awards (in shares)             51,015
Shares issued for stock-based compensation awards 1,741     507     $ 1,234
Dividends declared (6,891)       (6,891)    
Elimination of CTA upon dissolution 132         132  
Foreign currency translation adjustments (838)         (838)  
Unrealized loss on available-for-sale securities 0            
Stock-based compensation 104     104      
BALANCE at Dec. 31, 2016 $ 82,439 $ 0 $ 13 86,574 38,548 (807) $ (41,889)
Treasury stock, shares (1,692,218)           (1,692,218)
Common stock, shares issued 12,979,414   12,979,414        
Preferred stock, shares outstanding   0          
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income $ 23,578       23,578    
Adjustments to Additional Paid in Capital, Other       (5)      
Stock Issued During Period, Shares, Restricted Stock Award, Forfeited             (1,566)
Stock Issued During Period, Value, Restricted Stock Award, Forfeitures             $ (33)
Restricted Stock Award, Forfeitures (38)            
Shares issued for stock-based compensation awards (in shares)             56,260
Shares issued for stock-based compensation awards 1,431     79     $ 1,352
Dividends declared (17,218)       (17,218)    
Elimination of CTA upon dissolution (258)         (258)  
Foreign currency translation adjustments 677         677  
Unrealized loss on available-for-sale securities (25)         (25)  
Stock-based compensation 35     35      
BALANCE at Dec. 31, 2017 $ 90,621 $ 0 $ 13 $ 86,683 $ 44,908 $ (413) $ (40,570)
Treasury stock, shares (1,637,524)           (1,637,524)
Common stock, shares issued 12,979,414   12,979,414        
Preferred stock, shares outstanding   0          
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net income $ 23,578 $ 55,086 $ 47,241
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 536 394 263
Stock-based compensation 35 104 86
Cumulative translation adjustment realized in net income (258) 132 (82)
Deferred Income Tax Expense (Benefit) (1,644) 217 (15)
Changes in assets and liabilities:      
Inventories, net 2,843 (851) (6,762)
Other current assets (3,399) (1,681) (1,025)
Other assets (61) (90) (267)
Accounts payable (392) (714) 637
Income taxes payable 18,676 303 (115)
Accrued commissions (2,417) (6,031) 10,840
Other accrued expenses (6,033) 51 10,714
Deferred revenue (481) 947 1,331
Amounts held in eWallets (3,875) 2,752 14,350
Other current liabilities (179) 135 25
Long-term incentive (324) 2,420 4,105
Net cash provided by operating activities 26,605 53,174 81,326
CASH FLOWS FROM INVESTING ACTIVITIES:      
Purchases of property and equipment (278) (905) (710)
Increase in restricted cash 0 0 (3,028)
Net cash used in investing activities (278) (905) (3,738)
CASH FLOWS FROM FINANCING ACTIVITIES:      
Proceeds from exercise of warrants 0 0 309
Repurchase of common stock 0 (23,704) (16,071)
Dividends paid (17,218) (6,891) (1,709)
Net cash used in financing activities (17,218) (30,595) (17,471)
Effect of exchange rates on cash and cash equivalents 281 (667) (19)
Net increase in cash and cash equivalents 9,390 21,007 60,098
CASH AND CASH EQUIVALENTS, beginning of period 125,921 104,914 44,816
CASH AND CASH EQUIVALENTS, end of period 135,311 125,921 104,914
Income taxes, net of refunds 6,772 8,791 707
Stock Issued $ 1,393 $ 1,741 $ 666
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
Net Income Per Common Share (Notes)
12 Months Ended
Dec. 31, 2017
Earnings Per Share [Abstract]  
Earnings Per Share [Text Block] NET INCOME PER COMMON SHARE

The following table illustrates the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data):
 
Year Ended December 31,
 
2017
 
2016
 
2015
 
Income
 
Shares
 
Per Share
 
Income
 
Shares
 
Per Share
 
Income
 
Shares
 
Per Share
Basic net income per common share:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders
$
23,578

 
11,251

 
$
2.10

 
$
55,086

 
11,382

 
$
4.84

 
$
47,241

 
12,302

 
$
3.84

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Warrants to purchase common stock

 

 
 
 

 

 
 
 

 
21

 
 
Non-vested restricted stock

 
16

 
 

 

 
25

 
 

 

 
49

 
 

Diluted net income per common share:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders plus assumed conversions
$
23,578

 
11,267

 
$
2.09

 
$
55,086

 
11,407

 
$
4.83

 
$
47,241

 
12,372

 
$
3.82


Warrants to purchase 88,097 shares of common stock were exercised during April 2015.

Certain non-vested restricted stock is anti-dilutive upon applying the treasury stock method since the amount of compensation cost for future service results in the hypothetical repurchase of shares exceeding the actual number of shares to be vested. Non-vested restricted stock totaling 2,232 and 345 shares were not included for the years ended December 31, 2017 and 2016, respectively, as their effect would have been anti-dilutive.
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1
Balance Sheet Components
12 Months Ended
Dec. 31, 2017
Balance Sheet Components [Abstract]  
Supplemental Balance Sheet Disclosures [Text Block] BALANCE SHEET COMPONENTS

The components of certain balance sheet amounts are as follows (in thousands):
 
December 31,
 
2017
 
2016
Cash and cash equivalents:
 
 
 
Cash
$
61,703

 
$
52,453

Cash equivalents
73,608

 
73,468

 
$
135,311

 
$
125,921

Inventories:
 
 
 
Finished goods
$
7,779

 
$
10,722

Raw materials
799

 
617

Inventory reserve for obsolescence
(180
)
 
(82
)
 
$
8,398

 
$
11,257

Property and equipment:
 
 
 
Office equipment
$
530

 
$
517

Office software
916

 
672

Machinery
30

 
28

Furniture and fixtures
276

 
241

Leasehold improvements
957

 
840

Construction in progress (including internal-use software development costs)
10

 
157

Property and equipment, at cost
2,719

 
2,455

Accumulated depreciation and amortization
(1,570
)
 
(1,067
)
 
$
1,149

 
$
1,388

Other accrued expenses:
 
 
 
Sales returns
$
614

 
$
1,632

Employee-related expense
5,568

 
10,541

Warehousing, inventory-related and other
1,423

 
2,816

 
$
7,605

 
$
14,989

Deferred revenue:
 

 
 

Unshipped product
$
2,411

 
$
2,191

Auto ship advances
1,665

 
2,327

Enrollment package revenue
379

 
430

 
$
4,455

 
$
4,948


As of December 31, 2017, cash and cash equivalents include $8.7 million held in banks located within China subject to foreign currency controls.
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements (Notes)
12 Months Ended
Dec. 31, 2017
Fair Value Disclosures [Abstract]  
Fair Value Disclosures [Text Block] FAIR VALUE MEASUREMENTS

Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):
 
December 31, 2017
 
December 31, 2016
 
Adjusted Cost
 
Gross Unrealized Gains/Losses
 
Fair Value
 
Adjusted Cost
 
Gross Unrealized Gains/Losses
 
Fair Value
Municipal bonds and notes
$
13,320

 
$
(1
)
 
$
13,319

 
$
43,490

 
$

 
$
43,490

Corporate debt securities
49,432

 
(24
)
 
49,408

 
1,673

 
(2
)
 
1,671

Financial institution instruments
10,881

 

 
10,881

 
28,307

 

 
28,307

Total available-for-sale investments
$
73,633

 
$
(25
)
 
$
73,608

 
$
73,470

 
$
(2
)
 
$
73,468


 
Financial institution instruments include instruments issued or managed by financial institutions such as money market fund deposits and time deposits.
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies
12 Months Ended
Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies COMMITMENTS AND CONTINGENCIES
 
Operating Leases
 
The Company has entered into non-cancelable operating lease agreements for locations within the United States and for its international subsidiaries, with expirations through September 2025. Rent expense in connection with operating leases was $2.0 million, $1.8 million and $1.5 million during 2017, 2016 and 2015, respectively.
 
Future minimum lease obligations as of December 31, 2017 are as follows (in thousands):
2018
$
1,586

2019
1,114

2020
895

2021
337

2022
245

Thereafter
513

Total minimum lease obligations
$
4,690



Purchase Commitments

In May 2013, the Company entered into an exclusive distribution agreement with one of its suppliers to purchase its product through July 2016 which automatically renews annually unless terminated 90 days prior to the termination date. To maintain exclusivity, the Company is required to purchase a minimum of $40,000 of product per month until the termination date. As of December 31, 2017, the Company was in compliance with the exclusivity provision.
 
The Company has a supply agreement with one of its suppliers to maintain worldwide exclusivity in return for purchasing a minimum of $6.6 million of product in 2018, plus certain raw material guarantees. If the Company does not purchase the minimum product as required, then a Cure Payment, as defined, will be due to the supplier. The term of the agreement is one year commencing January 2018 and shall automatically renew for a successive one year term unless notice of termination is provided by either party.

Employment Agreements
 
The Company has employment agreements with certain members of its management team that can be terminated by either the employee or the Company upon four weeks’ notice.  The employment agreements entered into with the management team contain provisions that guarantee the payments of specified amounts in the event of a change in control, as defined, or if the employee is terminated without cause, as defined, or terminates employment for good reason, as defined.


Securities Class Action

In January 2016, two putative securities class action complaints were filed against the Company and its top executives in the United States District Court for the Central District of California. On March 29, 2016, the Court consolidated these actions under the caption Ford v. Natural Health Trends Corp., Case No. 2:16-cv-00255-TJH-AFMx, appointed two Lead Plaintiffs, Mahn Dao and Juan Wang, and appointed the Rosen Law Firm and Levi & Korsinsky LLP as co-Lead Counsel for the purported class. Plaintiffs filed a consolidated complaint on April 29, 2016. The consolidated complaint purports to assert claims on behalf of all persons who purchased or otherwise acquired our common stock between March 6, 2015 and March 15, 2016 under (i) Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against the Company and Chris T. Sharng, Timothy S. Davidson and George K. Broady (together, the “Individual Defendants”), and (ii) Section 20(a) of the Securities Exchange Act of 1934 against the Individual Defendants. The consolidated complaint alleges, among other things, that the Company has been running an allegedly illegal multilevel marketing business in China and that it has made materially false and misleading statements regarding the legality of its business operations in China. The consolidated complaint seeks an indeterminate amount of damages, plus interest and costs. On June 15, 2016, the Company filed a motion to dismiss the consolidated complaint, which was denied on December 5, 2016. On February 17, 2017, the Company filed an answer to the consolidated complaint. On July 10, 2017, the Court entered a stipulation between the parties, postponing all deadlines and staying the case to allow the parties to engage in settlement discussions. On July 17, 2017, the parties reached an agreement in principle to settle the action. The proposed class-wide settlement of $1.75 million was submitted to the Court on October 3, 2017. The Court entered an order preliminarily approving the settlement on November 17, 2017, which was amended on January 4, 2018. Plaintiffs have provided notice to the settlement class in accordance with the amended order, and a final approval hearing is currently set for April 2, 2018. If approved, the proposed settlement will be fully funded by the Company’s insurers. Defendants continue to believe that these claims are without merit and intend to vigorously defend against them if a settlement is not finalized and approved by the Court.

Shareholder Derivative Claims

In February 2016, a purported shareholder derivative complaint was filed in the Superior Court of the State of California, County of Los Angeles: Zhou v. Sharng. In March 2016, a purported shareholder derivative complaint was filed in the United States District Court for the Central District of California: Kleinfeldt v. Sharng (collectively the “Derivative Complaints”). The Derivative Complaints purport to assert claims for breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement and corporate waste against certain of the Company’s officers and directors. The Derivative Complaints also purport to assert fiduciary duty claims based on alleged insider selling and conspiring to enter into several stock repurchase agreements, which allegedly harmed the Company and its assets. The Derivative Complaints allege, among other things, that the Company has been running an allegedly illegal multilevel marketing business in China, and it has made materially false and misleading statements regarding the legality of its business operations in China, and that certain officers and directors sold common stock on the basis of this allegedly material, adverse non-public information. The Derivative Complaints seek an indeterminate amount of damages, plus interest and costs, as well as various equitable remedies. On February 1, 2017, pursuant to a stipulation among the parties, the Los Angeles Superior Court entered a stay of the Zhou action pending conclusion of the related federal class action in the United States District Court for the Central District of California: Ford v. Natural Health Trends Corp. A nearly identical stipulated stay was entered in the Kleinfeldt case on February 28, 2017. On November 10, 2017, the parties to both the Zhou and Kleinfeldt actions entered into a Memorandum of Understanding (“MOU”) to resolve both actions, subject to the negotiation of a written settlement agreement and approval by the federal court in the Kleinfeldt matter.  On November 15, 2017, the parties filed a joint status report and stipulation in the Zhou matter, alerting the court to the MOU and seeking to maintain the stay pending finalization and court approval of the parties’ tentative settlement.  The Zhou court entered an order continuing the stay on November 17, 2017.  On March 9, 2018, the parties filed a Stipulation of Settlement and supporting papers in the Kleinfeldt action. On March 22, 2018, plaintiffs filed a motion for preliminary approval of the tentative settlement. The settlement is subject to both preliminary and final approval by the court.  If approved, the proposed settlement will require certain corporate governance reforms and permit an award of up to $250,000 in attorneys’ fees to plaintiffs’ counsel, all of which will be fully funded by the Company’s insurers. Defendants continue to believe that these claims are without merit and intend to vigorously defend against them if the derivative settlement is not finalized and approved.

The consolidated class action (if the settlement is not approved by the Court) and the Derivative Complaints (if the tentative settlement is not finalized or approved), or other actions alleging similar facts, could result in monetary or other penalties that may materially affect the Company’s operating results and financial condition.

Other Claims

The Company is currently involved in a legal matter with one of its vendors and an outside party. Per the royalty agreement with the vendor, the Company believes that it is fully indemnified in the event of an unfavorable outcome and any potential settlement costs related to the matter would be fully covered by the Company’s vendor.
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Equity
12 Months Ended
Dec. 31, 2017
Stockholders' Equity Note [Abstract]  
Stockholders' Equity STOCKHOLDERS’ EQUITY
 
Authorized Shares
 
The Company is authorized to issue two classes of capital stock consisting of up to 5,000,000 shares of preferred stock, $0.001 par value, and 50,000,000 shares of common stock, $0.001 par value.
 
Dividends
 
The following tables summarize the Company’s cash dividend activity during 2017, 2016 and 2015 (in thousands, except per share data):
Declaration Date
 
Per Common Share
 
Amount
 
Payment Date
October 30, 2017 (special)
 
$
0.15

 
$
1,701

 
November 24, 2017
October 30, 2017
 
0.12

 
1,360

 
November 24, 2017
July 31, 2017 (special)
 
0.25

 
2,833

 
August 31, 2017
July 31, 2017
 
0.11

 
1,246

 
August 31, 2017
April 24, 2017 (special)
 
0.35

 
3,964

 
May 19, 2017
April 24, 2017
 
0.10

 
1,133

 
May 19, 2017
January 24, 2017 (special)
 
0.35

 
3,962

 
March 3, 2017
January 24, 2017
 
0.09

 
1,019

 
March 3, 2017
 
 
$
1.52

 
$
17,218

 
 
Declaration Date
 
Per Common Share
 
Amount
 
Payment Date
October 23, 2016 (special)
 
$
0.35

 
$
3,941

 
November 25, 2016
October 23, 2016
 
0.08

 
901

 
November 25, 2016
July 19, 2016
 
0.07

 
787

 
August 26, 2016
April 21, 2016
 
0.06

 
686

 
May 20, 2016
March 1, 2016
 
0.05

 
576

 
March 24, 2016
Total
 
$
0.61

 
$
6,891

 
 
Declaration Date
 
Per Common Share
 
Amount
 
Payment Date
October 21, 2015
 
$
0.05

 
$
598

 
November 20, 2015
July 28, 2015
 
0.04

 
489

 
August 28, 2015
May 4, 2015
 
0.03

 
372

 
May 29, 2015
February 27, 2015
 
0.02

 
250

 
March 27, 2015
Total
 
$
0.14

 
$
1,709

 
 

Declaration and payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.

Stock Repurchases

On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued.

During February 2016, pursuant to the stock repurchase program, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market. During the year ended December 31, 2016, the Company purchased a total of 903,031 shares of its common stock for an aggregate purchase price of $23.7 million, plus transaction costs. No shares of the Company’s common stock were repurchased by the Company during the year ended December 31, 2017. As of December 31, 2017, $32.0 million of the $70.0 million stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.

On July 28, 2015, the Board of Directors approved a stock repurchase program of up to $15.0 million of the Company’s outstanding shares of common stock. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, are anticipated to be conducted through December 2016, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act.  For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases.  The repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. In connection therewith, the Company was advised that George K. Broady, a director of the Company and owner of more than 5% of its outstanding shares of common stock, would participate in the stock repurchase program on a basis roughly proportional to his family’s ownership interest.

During August 2015, pursuant to the foregoing stock repurchase program, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of $3.5 million. The open market repurchases were completed on August 4, 2015. The stock repurchase program, which included both open market purchases and the purchase of shares from Mr. Broady, resulted in the Company purchasing a total of 162,442 shares of its common stock for an aggregate purchase price of $5.0 million, plus transaction costs. During October 2015, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of $3.6 million. The open market repurchases were completed on October 30, 2015. The stock repurchase program, which included both open market purchases and the purchase of shares from Mr. Broady, resulted in the Company purchasing a total of 106,264 shares of its common stock for an aggregate purchase price of $5.0 million, plus transaction costs.

On May 4, 2015, the Board of Directors approved a separate, prior stock repurchase program of up to $5.0 million of the Company’s outstanding shares of common stock.  In connection therewith, the Company was advised by Mr. Broady that he would participate in the stock repurchase program on a basis roughly proportional to his family’s ownership interest (see Note 8). As such, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of $3.5 million in accordance with Rules 10b5-1 and 10b-18 under the Exchange Act. The stock repurchase program, which included both open market purchases and the purchase of shares from Mr. Broady, was completed on May 13, 2015, and resulted in the Company purchasing a total of 186,519 shares of its common stock for an aggregate purchase price of $5.0 million, plus transaction costs. 

On January 22, 2015, the Company entered into a stock repurchase agreement with Mr. Broady that provided for the Company’s purchase from Mr. Broady in off-the-market, private transactions of a total of 91,817 shares of the Company’s common stock, which would be purchased at the rate of 5,000 shares each trading day following the date of the agreement until all of such shares were purchased (see Note 8). The shares were purchased at a per share price equal to the closing price per share of the Company’s common stock on the preceding trading day, as reported on the primary market in which the Company’s common stock is publicly traded. The Company’s purchases concluded on February 19, 2015, and resulted in an aggregate purchase price of $1.1 million.

Restricted Stock

Stock-based compensation expense totaled approximately $35,000, $104,000 and $86,000 for 2017, 2016 and 2015, respectively. During March 2016, the Company modified the vesting feature of an award granted to a director who decided to not stand for re-election at the Company’s 2016 annual meeting of stockholders. The modification of the award resulted in an additional $64,000 in stock-based compensation expense for the three months ended March 31, 2016.

At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. As of December 31, 2017, 2,393,873 shares remained available for issuance under the 2016 Plan.

On January 24, 2017, the Company granted 56,260 shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2016 performance incentives totaling $1.4 million. The shares vest on a quarterly basis over three years and are subject to forfeiture in the event of the employee’s termination of service to the Company under specified circumstances.

On April 8, 2016, the Company granted 51,015 shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2015 performance incentives totaling $1.7 million. The shares vest on a quarterly basis over three years and are subject to forfeiture in the event of the employee’s termination of service to the Company under specified circumstances.

The following table summarizes the Company’s restricted stock activity under the 2016 Plan:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2015

 
$

Granted
51,015

 
34.13

Vested
(12,759
)
 
34.13

Nonvested at December 31, 2016
38,256

 
34.13

Granted
56,260

 
25.44

Vested
(35,336
)
 
29.58

Forfeited
(1,148
)
 
28.55

Nonvested at December 31, 2017
58,032

 
28.72


On January 20, 2015, the Company’s Board of Directors granted 60,960 shares of restricted common stock to certain employees and its then-existing outside directors for the purpose of further aligning their interest with those of its stockholders and as to the employee shares, settling fiscal 2014 performance incentives. The shares vested on a quarterly basis over the next three years and were subject to forfeiture in the event of their termination of service to the Company under specified circumstances. On February 11, 2015, the Board of Directors granted an additional 6,116 shares of restricted common stock to its newly-elected outside directors subject to the same conditions.

The following table summarizes the Company’s other restricted stock activity:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2014

 
$

Granted
67,076

 
12.15

Vested
(22,364
)
 
12.15

Nonvested at December 31, 2015
44,712

 
12.15

Vested
(22,364
)
 
12.15

Nonvested at December 31, 2016
22,348

 
12.15

Vested
(21,930
)
 
12.15

Forfeited
(418
)
 
12.28

Nonvested at December 31, 2017

 
12.15


On August 13, 2012, the Board of Directors authorized the Company, acting as trustee for certain of its non-officer, overseas employees, to execute a Rule 10b5-1 plan to purchase 100,000 shares of its common stock in accordance with guidelines specified under Rule 10b5-1 of the Exchange Act and the Company’s policies regarding stock transactions.  Pursuant to this authority, the Company, as Trustee, entered into a 10b5-1 plan and began purchasing in December 2012. The latest 10b5-1 plan terminated in November 2014, and the Company, as Trustee, did not enter into a new 10b5-1 plan. The employees received the stock as incentive compensation in quarterly increments over three years beginning March 15, 2013, provided that they were employees of the Company on the date of the distribution. Any common stock that was forfeited by an employee whose employment terminated was delivered to the Company and held as treasury stock.
 
Shares
 
Wtd. Avg. Grant-Date Fair Value
Nonvested at December 31, 2014
23,984

 
1.37

Vested
(23,984
)
 
1.37

Nonvested at December 31, 2015

 

XML 27 R13.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes
12 Months Ended
Dec. 31, 2017
Income Tax Disclosure [Abstract]  
Income Taxes INCOME TAXES
 
The components of income before income taxes consist of the following (in thousands):
 
Year Ended December 31,
 
2017
 
2016
 
2015
Domestic
$
(2,965
)
 
$
(3,106
)
 
$
(7,820
)
Foreign
46,391

 
67,183

 
55,613

Income before income taxes
$
43,426

 
$
64,077

 
$
47,793


 
The components of the income tax provision consist of the following (in thousands):
 
Year Ended December 31,
 
2017
 
2016
 
2015
Current:
 
 
 
 
 
Federal
$
20,277

 
$
7,151

 
$
12

State
2

 
(81
)
 
100

Foreign
1,216

 
1,648

 
456

Total current taxes
21,495

 
8,718

 
568

Deferred taxes
(1,647
)
 
273

 
(16
)
Income tax provision
$
19,848

 
$
8,991

 
$
552



A reconciliation of the reported income tax provision to the provision that would result from applying the domestic federal statutory tax rate to pretax income is as follows (in thousands):
 
Year Ended December 31,
 
2017
 
2016
 
2015
Income tax at federal statutory rate
$
15,200

 
$
22,427

 
$
16,250

Effect of permanent differences
459

 
12,496

 
370

Tax Cut & Jobs Act repatriation tax
20,792

 

 

Tax Cut & Jobs Act federal rate change
954

 

 

Change in valuation allowance
(43
)
 
(3,877
)
 
2,017

Foreign rate differential
(15,002
)
 
(21,713
)
 
(18,099
)
Foreign tax credits
(2,105
)
 
(261
)
 

Other reconciling items
(407
)
 
(81
)
 
14

Income tax provision
$
19,848

 
$
8,991

 
$
552


 
Income before income taxes and the statutory tax rate for each country that materially contributed to the foreign rate differential presented above is as follows (in thousands):
 
 
 
Year Ended December 31,
 
Statutory Tax Rate
 
2017
 
2016
 
2015
Cayman Islands
%
 
$
39,954

 
$
58,169

 
$
50,993

Hong Kong
16.5
%
 
3,315

 
3,992

 
2,645

China
25.0
%
 
2,584

 
3,855

 
1,493


Deferred income taxes consist of the following (in thousands):
 
December 31,
 
2017
 
2016
Deferred tax assets:
 
 
 
Net operating losses
$
192

 
$
235

Stock-based compensation
270

 
623

Accrued expenses
1,374

 
3,174

Tax credits

 

Other
6

 

Total deferred tax assets
1,842

 
4,032

Valuation allowance
(192
)
 
(235
)
Net deferred tax assets
1,650

 
3,797

Deferred tax liabilities:
 
 
 
Foreign earnings
(4
)
 
(3,650
)
Other
(267
)
 
(415
)
Total deferred tax liabilities
(271
)
 
(4,065
)
Net deferred tax asset (liability)
$
1,379

 
$
(268
)

The effective income tax rate for the year ended December 31, 2017 was significantly impacted by recording the effect of the Tax Cuts and Jobs Act (the “Tax Act”), enacted on December 22, 2017 by the U.S. government. The Tax Act makes broad and complex changes to the Internal Revenue Code of 1986, as amended, which has affected the Company’s year ended December 31, 2017, including, but not limited to, reducing the maximum U.S. federal corporate tax rate from 35% to 21% effective January 1, 2018, and requiring a one-time repatriation tax on certain un-repatriated earnings of foreign subsidiaries at a rate of 15.5% tax on post-1986 foreign earnings held in cash and an 8% rate on all other post-1986 earnings that is payable over eight years beginning with 8% of the liability due with the filing of the year ended December 31, 2017 federal tax return that will be due in 2018.

On December 22, 2017, the Securities and Exchange Commission staff issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740, Income Taxes. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Tax Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in the corporate income tax rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in the Company’s interpretations and assumptions, additional guidance that may be issued by the Internal Revenue Service, and actions it may take. The Company is continuing to gather additional information to determine the final impact. Any adjustments recorded to the provisional amounts through the fourth quarter of 2018 will be included as an adjustment to income tax expense.

As a result of the Tax Act, the Company recorded additional income tax expense of $20.7 million due to the repatriation tax on deemed repatriation of deferred foreign income and of $1.0 million due to a re-measurement of deferred tax assets and liabilities, in the three months ended December 31, 2017. The Deemed Repatriation Transition Tax (the “Repatriation Tax”) is a tax on previously untaxed accumulated earnings and profits (“E&P”) of certain of its foreign subsidiaries. To determine the amount of the Repatriation Tax, the Company must determine, in addition to other factors, the amount of post-1986 E&P of the relevant subsidiaries, as well as the amount of non-U.S. income taxes paid on such earnings. The Company is able to make a reasonable estimate and recorded a provisional Repatriation Tax obligation of $20.7 million.

Because of the complexity of the new Global Intangible Low-Taxed Income (“GILTI”) tax rules, the Company continues to evaluate this provision of the Tax Act and the application of ASC 740. Under U.S. GAAP, the Company is allowed to make an accounting policy choice of either treating taxes due on future U.S. inclusions in taxable income related to GILTI as a current period expense when incurred (the “period cost method”) or factoring such amounts into the Company’s measurement of its deferred taxes (the “deferred method”). The Company is currently in the process of analyzing its structure and, as a result, is not yet able to reasonably estimate the effect of this provision of the Tax Act. Therefore, the Company has not made any adjustments related to potential GILTI tax in its financial statements and has not made a policy decision regarding whether to record deferred tax on GILTI.

As of December 31, 2017, the Company does not have a valuation allowance against its U.S. deferred tax assets. The Company analyzed all sources of available income and determined that they are more likely than not to realize the tax benefits of their deferred assets in future periods or carryback years.

As of December 31, 2017, the Company has a valuation allowance against certain foreign deferred tax assets. The Company is recording a valuation allowance in foreign jurisdictions with an overall deferred tax loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision.

As of December 31, 2017, the Company has no U.S. federal net operating loss or credit carryforwards as any attributes are expected to be fully utilized to offset tax in the current year. At December 31, 2017, the Company has foreign net operating loss carryforwards of approximately $1.25 million in various jurisdictions with various expirations.

As a result of capital return activities approved by the Board of Directors during the first quarter of 2016 and anticipated future capital return activities, the Company determined that a portion of its current undistributed foreign earnings are no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. The Company repatriated $19.8 million to the U.S. during the three months ended March 31, 2016, part of which was offset by U.S. net operating losses. Accordingly, the deferred tax liability previously established for undistributed foreign earnings up to its existing U.S. net operating losses was reduced. The excess amount repatriated during the year ended December 31, 2017 was generated from current foreign earnings. The Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable U.S. corporate income tax rate. As of December 31, 2017, the Company has recorded a state deferred tax liability for earnings that the Company plans to repatriate out of accumulated earnings in future periods. Due to the Tax Act, repatriation from foreign subsidiaries will be offset with a dividends received deduction, resulting in little to no impact on federal tax expense. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of December 31, 2017.

The Company and its subsidiaries file tax returns in the United States, California and Texas and various foreign jurisdictions. For federal income tax purposes, fiscal years 2007 through 2016 remain open for examination by tax authorities as a result of net operating loss carryovers from older years being used to offset income in recent tax years. The Company is no longer subject to state income tax examinations for years prior to 2011. No jurisdictions are currently examining any income tax returns of the Company or its subsidiaries except that the Taiwan Taxation Administration is currently examining the Taiwan subsidiary’s 2016 tax return. No adjustments have been proposed at this time.
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
Related Party Transactions
12 Months Ended
Dec. 31, 2017
Related Party Transactions [Abstract]  
Related Party Transactions RELATED PARTY TRANSACTIONS
 
Product Royalties
 
On April 29, 2015, the Company entered into a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called Soothe™. The Company began selling this product in the fourth quarter of 2012 with the permission of BHS. Mr. Broady is owner of BHS. Under the agreement, the Company agreed to pay BHS a royalty of 2.5% of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide. Further, the Company agreed to pay BHS $11,700 as royalties for the period it began selling the product in the fourth quarter of 2012 through 2014. The Company recognized royalties of $1,400, $3,400 and $7,000 during 2017, 2016 and 2015, respectively. The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on 120 days’ notice. Otherwise, the agreement terminates March 31, 2020.

In February 2013, the Company entered into a Royalty Agreement and License with BHS regarding the manufacture and sale of a product called ReStor™.  Under this agreement, the Company agreed to pay BHS a royalty of 2.5% of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide, with certain rights being exclusive outside the United States. On April 29, 2015, the Company and BHS amended the Royalty and Agreement and License to change the royalty to a price per unit instead of 2.5% of sales revenue. This provision was effective retroactive to January 1, 2015.  The Company recognized royalties of $306,000, $475,000 and $555,000 during 2017, 2016 and 2015, respectively.  The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on 120 days’ notice or, under certain circumstances, with no notice. Otherwise, the agreement terminates March 31, 2020.
 
Stock Repurchase Agreements
 
On October 28, 2015, the Company entered into a Stock Repurchase Agreement with Mr. Broady that provided for the Company’s purchase of common stock from Mr. Broady in off-the-market, private transactions at a rate equal to 0.4066 times the number of shares purchased by the Company’s broker in conjunction with the stock repurchase program authorized by the Company’s Board of Directors on July 28, 2015. The Company’s purchases from Mr. Broady concluded on November 2, 2015, were completed at a per share purchase price equal to the weighted average price per share paid by the Company’s broker in its open-market purchases, and resulted in an aggregate purchase price of $1.4 million. See Note 6.

On July 31, 2015, the Company entered into a Stock Repurchase Agreement with Mr. Broady that provided for the Company’s purchase of common stock from Mr. Broady in off-the-market, private transactions at a rate equal to 0.4085 times the number of shares purchased by the Company’s broker in conjunction with the stock repurchase program authorized by the Company’s Board of Directors on July 28, 2015. The Company’s purchases from Mr. Broady concluded on August 6, 2015, were completed at a per share purchase price equal to the weighted average price per share paid by the Company’s broker in its open-market purchases, and resulted in an aggregate purchase price of $1.5 million. See Note 6.

On May 7, 2015, the Company entered into a Stock Repurchase Agreement with Mr. Broady that provided for the Company’s purchase of common stock from Mr. Broady in off-the-market, private transactions at a rate equal to 0.4286 times the number of shares purchased by the Company’s broker in conjunction with the stock repurchase program authorized by the Company’s Board of Directors on May 4, 2015. The Company’s purchases from Mr. Broady concluded on May 13, 2015, were completed at a per share purchase price equal to the weighted average price per share paid by the Company’s broker in its open-market purchases, and resulted in an aggregate purchase price of $1.5 million. See Note 6.

On January 22, 2015, the Company entered into a Stock Repurchase Agreement with Mr. Broady that provided for the Company’s purchase from Mr. Broady in off-the-market, private transactions of a total of 91,817 shares of the Company’s common stock, which would be purchased at the rate of 5,000 shares each trading day following the date of the agreement until all of such shares were purchased. The shares were purchased at a per share price equal to the closing price per share of the Company’s common stock on the preceding trading day, as reported on the primary market in which the Company’s common stock was publicly traded. The Company’s purchases concluded on February 19, 2015, and resulted in an aggregate purchase price of $1.1 million. See Note 6.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
Employee Benefit Plans
12 Months Ended
Dec. 31, 2017
Compensation and Retirement Disclosure [Abstract]  
Employee Benefit Plans  EMPLOYEE BENEFIT PLANS
 
     The Company has a 401(k) defined contribution plan which permits participating employees in the United States to defer up to a maximum of 90% of their compensation, subject to limitations established by the Internal Revenue Service. Employees age 21 and older are eligible to contribute to the plan starting the first day of the following month of employment.  Participating employees are eligible to receive discretionary matching contributions and profit sharing, subject to certain conditions, from the Company.  In 2017, 2016 and 2015, the Company matched employee deferral contributions up to 4.5% of salary, which vested 100% immediately. No profit sharing has been paid under the plan. The Company recorded compensation expense of $171,000, $134,000 and $115,000 for 2017, 2016 and 2015, respectively, related to its matching contributions to the plan. Certain of the Company’s employees located outside the United States participate in employee benefit plans that are statutory in nature.
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Information
12 Months Ended
Dec. 31, 2017
Segment Reporting [Abstract]  
Segment Information SEGMENT INFORMATION
 
The Company sells products to a member network that operates in a seamless manner from market to market, except for the China market where it sells to consumers through an e-commerce platform, and the Russia and Kazakhstan market where the Company’s engagement of a third-party service provider results in a different economic structure than its other markets. Otherwise, the Company believes that all of its other operating segments have similar economic characteristics and are similar in the nature of the products sold, the product acquisition process, the types of customers products are sold to, the methods used to distribute the products, and the nature of the regulatory environment.

There is no separate segment manager who is held accountable by the Company’s chief operating decision-makers, or anyone else, for operations, operating results and planning for the China market or the Russia and Kazakhstan market on a stand-alone basis, and neither market is material for the periods presented. As such, the Company believes that all operating segments should be aggregated into a single reportable segment for disclosure purposes.
 
The Company’s net sales by geographic area are as follows (in thousands):
 
Year Ended December 31,
 
2017
 
2016
 
2015
Net sales from external customers:
 
 
 
 
 
United States
$
3,348

 
$
4,100

 
$
3,246

Canada
1,938

 
1,809

 
2,746

Peru
508

 

 

Hong Kong1
174,926

 
263,482

 
245,737

China
7,282

 
9,086

 
4,425

Taiwan
5,591

 
6,213

 
5,965

South Korea
466

 
691

 
1,129

Russia, Kazakhstan and Ukraine2
913

 
858

 
1,139

Europe
2,278

 
1,234

 
382

Other foreign countries
313

 
255

 
91

Total net sales
$
197,563

 
$
287,728

 
$
264,860


_____________________________ 
1 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors”.
2 The Company discontinued its Ukraine operations during the second quarter of 2015.
 
The Company’s net sales by product and service are as follows (in thousands):
 
Year Ended December 31,
 
2017
 
2016
 
2015
Net sales by product and service:
 
 
 
 
 
Product sales
$
187,591

 
$
269,731

 
$
253,041

Enrollment package revenue, freight and other
13,676

 
25,616

 
17,623

Less: sales returns
(3,704
)
 
(7,619
)
 
(5,804
)
Total net sales
$
197,563

 
$
287,728

 
$
264,860


 
Due to system constraints, it is impracticable for the Company to separately disclose sales by product category for the years presented.

The Company’s long-lived assets by geographic area are as follows (in thousands):
 
December 31,
 
2017
 
2016
Long-lived assets:
 
 
 
United States
$
648

 
$
763

Hong Kong
78

 
140

China
112

 
199

Other foreign countries
311

 
286

Total long-lived assets
$
1,149

 
$
1,388

XML 31 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
Subsequent Events
12 Months Ended
Dec. 31, 2017
Subsequent Events [Abstract]  
Subsequent Events  SUBSEQUENT EVENTS

On February 6, 2018, the Board of Directors declared a cash dividend of $0.13 on each share of common stock outstanding. Such dividends were paid on March 9, 2018 to stockholders of record on February 27, 2018. Declaration and payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.

On February 1, 2018, the Company granted 34,202 shares of restricted common stock under the 2016 Plan to certain employees for the purpose of settling fiscal 2017 performance incentives. The shares vest on a quarterly basis over the next three years and are subject to forfeiture in the event of their termination of service to the Company under specified circumstances.

On January 26, 2018, the Company entered into an exclusive distribution, license and royalty agreement with a new supplier to purchase products through January 2021 and shall renew for successive one year terms unless notice of termination is provided by either party. To maintain exclusivity, the Company is required to purchase between $453,000 and $3.6 million of product, depending on the product mix and inclusive of royalties, per year until the termination date.
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
Nature of Operations and Summary of Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2017
Accounting Policies [Abstract]  
Principles of Consolidation Principles of Consolidation
 
The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.
Use of Estimates Use of Estimates
 
The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period.

The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates associated with revenue recognition, as well as those used in the determination of liabilities related to sales returns, commissions and income taxes. Various assumptions and other factors prompt the determination of these significant estimates. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. The actual results may differ materially and adversely from the Company’s estimates. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.
Cash and Cash Equivalents Cash and Cash Equivalents
 
Cash and cash equivalents include the Company’s investments in debt securities, comprising municipal notes, bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less, when purchased, to be cash equivalents. Debt securities classified as cash equivalents are required to be accounted for in accordance with ASC 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at December 31, 2017 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive loss in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices.

The Company includes credit card receivables due from certain of its credit card processors in its cash and cash equivalents as the cash proceeds are received within two to five days.

Restricted Cash Restricted Cash
 
In June 2015, the Company funded a bank deposit account in the amount of CNY 20 million (USD 3.1 million at December 31, 2017) in anticipation of submitting a direct selling license application in China. Such deposit is required by Chinese laws to establish a consumer protection fund.

The Company periodically maintains a cash reserve with certain credit card processing companies to provide for potential uncollectible amounts and chargebacks. Those cash reserves held by credit card processing companies located in South Korea are reflected in noncurrent assets since they require the Company to provide 100% collateral before processing transactions, which must be maintained indefinitely.
Inventories Inventories
 
Inventories are stated at the lower of cost or net realizable value, using the first-in, first-out method. The Company reviews its inventory for obsolescence and any inventory identified as obsolete is reserved or written off. The Company’s determination of obsolescence is based on assumptions about the demand for its products, product expiration dates, estimated future sales, and management’s future plans.
Property and Equipment Property and Equipment
 
Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years for office equipment, office software and capitalized internal-use software development costs and five to seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the assets. Expenditures for maintenance and repairs are charged to expense as incurred.
 
The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of these assets is measured by comparison of its carrying amounts to future undiscounted cash flows the assets are expected to generate. If property and equipment are considered to be impaired, the impairment to be recognized equals the amount by which the carrying value of the asset exceeds its fair value.
Goodwill Goodwill
 
The Company assesses qualitative factors in order to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, through this qualitative assessment, the conclusion is made that it is more likely than not that a reporting unit’s fair value is less than its carrying amount, a two-step impairment test is performed. The Company’s policy is to test for impairment annually during the fourth quarter. Considerable management judgment is necessary to measure fair value. The Company did not recognize any impairment charges for goodwill during the periods presented.
Income Taxes Income Taxes
 
The Company recognizes income taxes under the liability method of accounting for income taxes. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be ultimately realized based on the more likely than not recognition criteria. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has evaluated its tax positions and determined that there are no uncertain tax positions for the current year or years prior. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution.  The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense.  Deferred taxes are not provided for state income tax purposes on the portion of undistributed earnings of subsidiaries outside of the United States when these earnings are considered permanently reinvested.

Amounts Held in Distributor eWallets Amounts Held in eWallets
 
Commencing in October 2014, the Company requires commission payments of certain members in Hong Kong to be first recorded into an electronic wallet (eWallet) account in lieu of being paid out directly to members. The eWallet functionality allows members to place new product orders utilizing eWallet available balance and/or request commission payout via multiple payment methods. Amounts held in eWallets are reflected on the balance sheet as a current liability.
Long-Term Incentive Long-Term Incentive
 
Financial rewards earned under the 2014 Long-Term Incentive Plan (the “LTI Plan”) are recognized over the performance period as specified performance or other goals are achieved or exceeded. In accordance with the LTI Plan, fifty percent of any cash payment earned is payable in thirty-five equal consecutive monthly installments commencing in February of the calendar year immediately following the conclusion of the performance period and the remaining fifty percent of the payment earned is payable in thirty-five equal consecutive monthly installments commencing in February 2021 and ending in December 2023. As such, certain installments to be paid are reflected on the balance sheet as a non-current liability, and the current portion of the installments is reflected in other accrued expenses.

At the sole discretion of the Compensation Committee of the Company’s Board of Directors, distributions under the LTI Plan are made in cash, or alternatively awarded in the form of common stock or other common stock rights having an equivalent cash value under the terms of the Natural Health Trends Corp. 2016 Equity Incentive Plan. A determination of the form of distribution, if any, is made by the Compensation Committee subsequent to the end of each calendar year. As such, amounts earned are considered non-equity awards. See Note 6 for grant information of distributions settled in common stock.
Foreign Currency Foreign Currency
 
The functional currency of the Company’s international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.  The resulting translation adjustments are recorded directly into accumulated other comprehensive income.
Revenue Recognition Revenue Recognition
 
Product sales are recorded when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product are recorded as deferred revenue. The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return.
 
Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience.
 
Enrollment package revenue, including any nonrefundable set-up fees, is deferred and recognized over the term of the arrangement, generally twelve months. Enrollment packages provide members access to both a personalized marketing website and a business management system. No upfront costs are deferred as the amount is nominal.
 
Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.
 
Various taxes on the sale of products and enrollment packages to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.
Commissions Commissions
 
Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of the Company’s products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  The Company accrues commissions when earned and pays commissions on product sales generally two weeks following the end of the weekly sales period.
 
In some markets, the Company also pays certain bonuses on purchases by up to three generations of personally enrolled members, as well as bonuses on commissions earned by up to three generations of personally enrolled members. Independent members may also earn incentives based on meeting certain qualifications during a designated incentive period, which may range from several weeks to up to a year.  The Company estimates and accrues all costs associated with the incentives as the members meet the qualification requirements.
 
From time to time the Company makes modifications and enhancements to the Company’s compensation plan to help motivate members, which can have an impact on member commissions. The Company also enters into performance-based agreements for business or market development, which may result in additional compensation to specific members.
Operating Leases Operating Leases

The Company leases its physical properties under operating leases. Certain lease agreements include rent holidays and incentives. The Company recognizes rent holiday periods on a straight-line basis over the lease term beginning when the Company has the right to the leased space.
Stock-Based Compensation Stock-Based Compensation
 
Stock-based compensation expense is determined based on the grant date fair value of each award, net of estimated forfeitures which are derived from historical experience, and is recognized on a straight-line basis over the requisite service period for the award.
Income Per Share Net Income Per Common Share
 
Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock and warrants is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares.
Certain Risks and Concentrations Certain Risks and Concentrations
 
A substantial portion of the Company’s sales are generated in Hong Kong (see Note 10). Substantially all of the Company’s Hong Kong revenues are derived from the sale of products that are delivered to members in China. In contrast to the Company’s operations in other parts of the world, the Company has not implemented a direct sales model in China. The Chinese government permits direct selling only by organizations that have a license, which the Company has applied for, and has also adopted anti-multilevel marketing legislation. The Company operates an e-commerce direct selling model in Hong Kong and recognizes the revenue derived from sales to both Hong Kong and Chinese members as being generated in Hong Kong. Products purchased by members in China are delivered to third parties that act as the importers of record under agreements to pay applicable duties. In addition, through a Chinese entity, the Company sells products in China using an e-commerce retail model. The Chinese entity operates separately from the Hong Kong entity, and a Chinese member may elect to participate separately or in both.

The Company believes that its e-commerce direct selling model in Hong Kong does not violate any applicable laws in China, even though it is used for the internet purchase of the Company’s products by members in China. The Company also believes that its Chinese entity, including its e-commerce retail platform, is operating in compliance with applicable Chinese laws. However, there can be no assurance that the Chinese authorities will agree with the Company’s interpretations of applicable laws and regulations or that China will not adopt new laws or regulations. Should the Chinese government determine that the Company’s activities violate China’s direct selling or anti-multilevel marketing legislation, or should new laws or regulations be adopted, there could be a material adverse effect on the Company’s business, financial condition and results of operations.
 
Although the Company attempts to work closely with both national and local Chinese governmental agencies in conducting its business, the Company’s efforts to comply with national and local laws may be harmed by a rapidly evolving regulatory climate, concerns about activities resembling violations of direct selling or anti-multi-level marketing legislation, subjective interpretations of laws and regulations, Chinese nationals collaborating with short traders to damage the Company’s business and activities by individual members that may violate laws notwithstanding the Company’s strict policies prohibiting such activities. Any determination that the Company’s operations or activities, or the activities of its individual members or employee sales representatives, or importers of record are not in compliance with applicable laws and regulations could result in the imposition of substantial fines, extended interruptions of business, restrictions on the Company’s future ability to obtain business licenses or expand into new locations, changes to its business model, the termination of required licenses to conduct business, or other actions, any of which could materially harm the Company’s business, financial condition and results of operations.
 
The Company’s Premium Noni Juice and Enhanced Essential Probiotics® products each account for more than 10% of the Company’s total revenue. The Company currently sources each such product from a single supplier. If demand decreases significantly, government regulation restricts their sale, the Company is unable to adequately source or deliver the products, or the Company ceases offering the products for any reason without suitable replacements, the Company’s business, financial condition and results of operations could be materially and adversely affected.
Fair Value of Financial Instruments Fair Value of Financial Instruments
 
The carrying amounts of the Company’s financial instruments, including cash and cash equivalents and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. The Company’s cash equivalents are valued based on level 1 inputs which consist of quoted prices in active markets.
 
Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.
Recently Issued and Adopted Accounting Pronouncements Recently Issued and Adopted Accounting Pronouncements

In November 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-18, Statement of Cash Flows - Restricted Cash, that requires amounts generally described as restricted cash or restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new standard will be effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, and early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting, that simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The new standard was effective for fiscal years beginning after December 15, 2016, including interim periods within those annual years, and early adoption was permitted. The Company adopted this guidance as of the quarter ended March 31, 2017. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases, that requires organizations that lease assets, referred to as “lessees”, to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases with lease terms of more than 12 months. ASU 2016-02 will also require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will include qualitative and quantitative requirements. The new standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those annual years, and early application is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.
 
In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. Under this guidance, entities are required to present deferred tax assets and deferred tax liabilities as noncurrent in a classified balance sheet. This guidance was effective for annual and interim periods beginning after December 15, 2016, with early adoption permitted. Entities were permitted to adopt this guidance either prospectively or retrospectively. The Company elected to early adopt this guidance prospectively as of the quarter ended December 31, 2016.

In July 2015, the FASB issued ASU No. 2015-11, Inventory: Simplifying the Measurement of Inventory. Under this guidance, inventory not measured using either the last in, first out (LIFO) or the retail inventory method are to be measured at the lower of cost and net realizable value.  Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable cost of completion, disposal, and transportation.  The new standard was effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, with early adoption permitted. The Company adopted this guidance as of the quarter ended March 31, 2017. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements.

In May 2014, the FASB issued ASU No. 2014-09, Revenue From Contracts With Customers, that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract.  Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard.  In July 2015, the FASB approved the deferral of the effective date for annual reporting periods that begin after December 15, 2017, including interim reporting periods. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements.

Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
Net Income Per Common Share (Tables)
12 Months Ended
Dec. 31, 2017
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
 
Year Ended December 31,
 
2017
 
2016
 
2015
 
Income
 
Shares
 
Per Share
 
Income
 
Shares
 
Per Share
 
Income
 
Shares
 
Per Share
Basic net income per common share:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders
$
23,578

 
11,251

 
$
2.10

 
$
55,086

 
11,382

 
$
4.84

 
$
47,241

 
12,302

 
$
3.84

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Warrants to purchase common stock

 

 
 
 

 

 
 
 

 
21

 
 
Non-vested restricted stock

 
16

 
 

 

 
25

 
 

 

 
49

 
 

Diluted net income per common share:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders plus assumed conversions
$
23,578

 
11,267

 
$
2.09

 
$
55,086

 
11,407

 
$
4.83

 
$
47,241

 
12,372

 
$
3.82

XML 34 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1
Balance Sheet Components (Tables)
12 Months Ended
Dec. 31, 2017
Balance Sheet Components [Abstract]  
Schedule of Additional Balance Sheet Components [Table Text Block]
 
December 31,
 
2017
 
2016
Cash and cash equivalents:
 
 
 
Cash
$
61,703

 
$
52,453

Cash equivalents
73,608

 
73,468

 
$
135,311

 
$
125,921

Inventories:
 
 
 
Finished goods
$
7,779

 
$
10,722

Raw materials
799

 
617

Inventory reserve for obsolescence
(180
)
 
(82
)
 
$
8,398

 
$
11,257

Property and equipment:
 
 
 
Office equipment
$
530

 
$
517

Office software
916

 
672

Machinery
30

 
28

Furniture and fixtures
276

 
241

Leasehold improvements
957

 
840

Construction in progress (including internal-use software development costs)
10

 
157

Property and equipment, at cost
2,719

 
2,455

Accumulated depreciation and amortization
(1,570
)
 
(1,067
)
 
$
1,149

 
$
1,388

Other accrued expenses:
 
 
 
Sales returns
$
614

 
$
1,632

Employee-related expense
5,568

 
10,541

Warehousing, inventory-related and other
1,423

 
2,816

 
$
7,605

 
$
14,989

Deferred revenue:
 

 
 

Unshipped product
$
2,411

 
$
2,191

Auto ship advances
1,665

 
2,327

Enrollment package revenue
379

 
430

 
$
4,455

 
$
4,948

XML 35 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements (Tables)
12 Months Ended
Dec. 31, 2017
Fair Value Disclosures [Abstract]  
Available-for-sale Securities [Table Text Block]
 
December 31, 2017
 
December 31, 2016
 
Adjusted Cost
 
Gross Unrealized Gains/Losses
 
Fair Value
 
Adjusted Cost
 
Gross Unrealized Gains/Losses
 
Fair Value
Municipal bonds and notes
$
13,320

 
$
(1
)
 
$
13,319

 
$
43,490

 
$

 
$
43,490

Corporate debt securities
49,432

 
(24
)
 
49,408

 
1,673

 
(2
)
 
1,671

Financial institution instruments
10,881

 

 
10,881

 
28,307

 

 
28,307

Total available-for-sale investments
$
73,633

 
$
(25
)
 
$
73,608

 
$
73,470

 
$
(2
)
 
$
73,468

XML 36 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies (Tables)
12 Months Ended
Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Future Minimum Rental Payments for Operating Leases
2018
$
1,586

2019
1,114

2020
895

2021
337

2022
245

Thereafter
513

Total minimum lease obligations
$
4,690

XML 37 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Equity (Tables)
12 Months Ended
Dec. 31, 2017
Stockholders' Equity Note [Abstract]  
Schedule of Dividends Payable
Declaration Date
 
Per Common Share
 
Amount
 
Payment Date
October 30, 2017 (special)
 
$
0.15

 
$
1,701

 
November 24, 2017
October 30, 2017
 
0.12

 
1,360

 
November 24, 2017
July 31, 2017 (special)
 
0.25

 
2,833

 
August 31, 2017
July 31, 2017
 
0.11

 
1,246

 
August 31, 2017
April 24, 2017 (special)
 
0.35

 
3,964

 
May 19, 2017
April 24, 2017
 
0.10

 
1,133

 
May 19, 2017
January 24, 2017 (special)
 
0.35

 
3,962

 
March 3, 2017
January 24, 2017
 
0.09

 
1,019

 
March 3, 2017
 
 
$
1.52

 
$
17,218

 
 
Declaration Date
 
Per Common Share
 
Amount
 
Payment Date
October 23, 2016 (special)
 
$
0.35

 
$
3,941

 
November 25, 2016
October 23, 2016
 
0.08

 
901

 
November 25, 2016
July 19, 2016
 
0.07

 
787

 
August 26, 2016
April 21, 2016
 
0.06

 
686

 
May 20, 2016
March 1, 2016
 
0.05

 
576

 
March 24, 2016
Total
 
$
0.61

 
$
6,891

 
 
Declaration Date
 
Per Common Share
 
Amount
 
Payment Date
October 21, 2015
 
$
0.05

 
$
598

 
November 20, 2015
July 28, 2015
 
0.04

 
489

 
August 28, 2015
May 4, 2015
 
0.03

 
372

 
May 29, 2015
February 27, 2015
 
0.02

 
250

 
March 27, 2015
Total
 
$
0.14

 
$
1,709

 
 
Nonvested Restricted Stock Shares Activity [Table Text Block] The following table summarizes the Company’s restricted stock activity under the 2016 Plan:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2015

 
$

Granted
51,015

 
34.13

Vested
(12,759
)
 
34.13

Nonvested at December 31, 2016
38,256

 
34.13

Granted
56,260

 
25.44

Vested
(35,336
)
 
29.58

Forfeited
(1,148
)
 
28.55

Nonvested at December 31, 2017
58,032

 
28.72

 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2014

 
$

Granted
67,076

 
12.15

Vested
(22,364
)
 
12.15

Nonvested at December 31, 2015
44,712

 
12.15

Vested
(22,364
)
 
12.15

Nonvested at December 31, 2016
22,348

 
12.15

Vested
(21,930
)
 
12.15

Forfeited
(418
)
 
12.28

Nonvested at December 31, 2017

 
12.15

XML 38 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2017
Income Tax Disclosure [Abstract]  
Schedule of Income before Income Tax, Domestic and Foreign
 
Year Ended December 31,
 
2017
 
2016
 
2015
Domestic
$
(2,965
)
 
$
(3,106
)
 
$
(7,820
)
Foreign
46,391

 
67,183

 
55,613

Income before income taxes
$
43,426

 
$
64,077

 
$
47,793

Schedule of Components of Income Tax Expense (Benefit)
 
Year Ended December 31,
 
2017
 
2016
 
2015
Current:
 
 
 
 
 
Federal
$
20,277

 
$
7,151

 
$
12

State
2

 
(81
)
 
100

Foreign
1,216

 
1,648

 
456

Total current taxes
21,495

 
8,718

 
568

Deferred taxes
(1,647
)
 
273

 
(16
)
Income tax provision
$
19,848

 
$
8,991

 
$
552

Schedule of Effective Income Tax Rate Reconciliation
 
Year Ended December 31,
 
2017
 
2016
 
2015
Income tax at federal statutory rate
$
15,200

 
$
22,427

 
$
16,250

Effect of permanent differences
459

 
12,496

 
370

Tax Cut & Jobs Act repatriation tax
20,792

 

 

Tax Cut & Jobs Act federal rate change
954

 

 

Change in valuation allowance
(43
)
 
(3,877
)
 
2,017

Foreign rate differential
(15,002
)
 
(21,713
)
 
(18,099
)
Foreign tax credits
(2,105
)
 
(261
)
 

Other reconciling items
(407
)
 
(81
)
 
14

Income tax provision
$
19,848

 
$
8,991

 
$
552

Income Tax Foreign Rate Differential [Table Text Block]
 
 
 
Year Ended December 31,
 
Statutory Tax Rate
 
2017
 
2016
 
2015
Cayman Islands
%
 
$
39,954

 
$
58,169

 
$
50,993

Hong Kong
16.5
%
 
3,315

 
3,992

 
2,645

China
25.0
%
 
2,584

 
3,855

 
1,493

Schedule of Deferred Tax Assets and Liabilities
 
December 31,
 
2017
 
2016
Deferred tax assets:
 
 
 
Net operating losses
$
192

 
$
235

Stock-based compensation
270

 
623

Accrued expenses
1,374

 
3,174

Tax credits

 

Other
6

 

Total deferred tax assets
1,842

 
4,032

Valuation allowance
(192
)
 
(235
)
Net deferred tax assets
1,650

 
3,797

Deferred tax liabilities:
 
 
 
Foreign earnings
(4
)
 
(3,650
)
Other
(267
)
 
(415
)
Total deferred tax liabilities
(271
)
 
(4,065
)
Net deferred tax asset (liability)
$
1,379

 
$
(268
)
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Information (Tables)
12 Months Ended
Dec. 31, 2017
Segment Reporting [Abstract]  
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area
 
Year Ended December 31,
 
2017
 
2016
 
2015
Net sales from external customers:
 
 
 
 
 
United States
$
3,348

 
$
4,100

 
$
3,246

Canada
1,938

 
1,809

 
2,746

Peru
508

 

 

Hong Kong1
174,926

 
263,482

 
245,737

China
7,282

 
9,086

 
4,425

Taiwan
5,591

 
6,213

 
5,965

South Korea
466

 
691

 
1,129

Russia, Kazakhstan and Ukraine2
913

 
858

 
1,139

Europe
2,278

 
1,234

 
382

Other foreign countries
313

 
255

 
91

Total net sales
$
197,563

 
$
287,728

 
$
264,860

Schedule of Segment Reporting Information, by Segment
 
Year Ended December 31,
 
2017
 
2016
 
2015
Net sales by product and service:
 
 
 
 
 
Product sales
$
187,591

 
$
269,731

 
$
253,041

Enrollment package revenue, freight and other
13,676

 
25,616

 
17,623

Less: sales returns
(3,704
)
 
(7,619
)
 
(5,804
)
Total net sales
$
197,563

 
$
287,728

 
$
264,860

Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country
 
December 31,
 
2017
 
2016
Long-lived assets:
 
 
 
United States
$
648

 
$
763

Hong Kong
78

 
140

China
112

 
199

Other foreign countries
311

 
286

Total long-lived assets
$
1,149

 
$
1,388

XML 40 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
Nature of Operations and Summary of Significant Accounting Policies - Narrative (Details)
¥ in Millions
3 Months Ended 12 Months Ended
Mar. 31, 2017
USD ($)
Dec. 31, 2017
USD ($)
installment
Dec. 31, 2016
USD ($)
installment
Dec. 31, 2015
USD ($)
Jun. 30, 2015
CNY (¥)
Property, Plant and Equipment [Line Items]          
Restricted cash | $   $ 3,100,000      
Loss on foreign exchange | $ $ (451,000)   $ (333,000) $ (204,000)  
Long-Term Incentive Plan, Payment Commencing in February of the Calendar Year Immediately Following the Conclusion of the Performance Period          
Property, Plant and Equipment [Line Items]          
Long-term incentive plan, percentage of award payable in cash   50.00%      
Long-term incentive plan, number of installments | installment   35      
Long-Term Incentive Plan, Payment Commencing in February 2021 and Ending in December 2023          
Property, Plant and Equipment [Line Items]          
Long-term incentive plan, percentage of award payable in cash     50.00%    
Long-term incentive plan, number of installments | installment     35    
Software and Software Development Costs [Member] | Minimum          
Property, Plant and Equipment [Line Items]          
Property, and equipment useful life   3 years      
Software and Software Development Costs [Member] | Maximum          
Property, Plant and Equipment [Line Items]          
Property, and equipment useful life 5 years        
Furniture and Fixtures | Minimum          
Property, Plant and Equipment [Line Items]          
Property, and equipment useful life   5 years      
Furniture and Fixtures | Maximum          
Property, Plant and Equipment [Line Items]          
Property, and equipment useful life   7 years      
China          
Property, Plant and Equipment [Line Items]          
Restricted cash | ¥         ¥ 20
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
Net Income Per Common Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Apr. 30, 2015
Earnings Per Share [Abstract]        
Net Income (Loss) Available to Common Stockholders, Basic $ 23,578 $ 55,086 $ 47,241  
Net income allocated to common stockholders (in dollars per share) $ 2.10 $ 4.84 $ 3.84  
Weighted Average Number of Shares Outstanding, Basic 11,251,000 11,382,000 12,302,000  
Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants     21,000  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights       88,097
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 2,232 345    
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 16,000 25,000 49,000  
Net Income (Loss) Available to Common Stockholders, Diluted $ 23,578 $ 55,086 $ 47,241  
Weighted Average Number of Shares Outstanding, Diluted 11,267,000 11,407,000 12,372,000  
Net income allocated to common stockholders plus assumed conversions (in dollars per share) $ 2.09 $ 4.83 $ 3.82  
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
Balance Sheet Components - Components of Balance Sheet Accounts (Details) - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Cash and Cash Equivalents [Abstract]        
Cash $ 61,703 $ 52,453    
Cash Equivalents, at Carrying Value 73,608 73,468    
Cash and Cash Equivalents, at Carrying Value 135,311 125,921 $ 104,914 $ 44,816
Inventory, Finished Goods, Gross 7,779 10,722    
Inventory, Raw Materials and Supplies, Gross 799 617    
Inventory Valuation Reserves (180) (82)    
Inventories, net 8,398 11,257    
Property and Equipment [Abstract]        
Office equipment 530 517    
Capitalized Computer Software, Gross 916 672    
Machinery and Equipment, Gross 30 28    
Furniture and Fixtures, Gross 276 241    
Leasehold Improvements, Gross 957 840    
Construction in Progress, Gross 10 157    
Property, Plant and Equipment, Gross 2,719 2,455    
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment 1,570 1,067    
Property, Plant and Equipment, Net 1,149 1,388    
Other accrued expenses:        
Accrued Sales Returns 614 1,632    
Accrued Employee Benefits, Current 5,568 10,541    
Accrued Warehousing And Inventory Related Expense 1,423 2,816    
Other Accrued Liabilities, Current 7,605 14,989    
Deferred Revenue [Abstract]        
Deferred Revenue, Current 4,455 4,948    
Unshipped Product [Member]        
Deferred Revenue [Abstract]        
Deferred Revenue 2,411 2,191    
Auto Ship Advances [Member]        
Deferred Revenue [Abstract]        
Deferred Revenue 1,665 2,327    
Enrollment Package Revenue [Member]        
Deferred Revenue [Abstract]        
Deferred Revenue 379 $ 430    
China        
Cash and Cash Equivalents [Abstract]        
Cash and Cash Equivalents, at Carrying Value $ 8,700      
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements (Details) - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities, Amortized Cost Basis $ 73,633 $ 73,470
Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax (25) (2)
Available-for-sale Securities 73,608 73,468
Municipal Bonds and Notes [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities, Amortized Cost Basis 13,320 43,490
Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax (1) 0
Available-for-sale Securities 13,319 43,490
Corporate Debt Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities, Amortized Cost Basis 49,432 1,673
Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax (24) (2)
Available-for-sale Securities 49,408 1,671
Financial Institution Instruments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities, Amortized Cost Basis 10,881 28,307
Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax 0 0
Available-for-sale Securities $ 10,881 $ 28,307
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies - Narrative (Details) - USD ($)
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Loss Contingencies [Line Items]      
Rent expense for operating leases $ 2,000,000.0 $ 1,800,000 $ 1,500,000
Minimum monthly purchase amount 40,000    
Minimum annual purchase amount $ 6,600,000    
Purchase commitment term 3 years    
Purchase commitment renewal term 3 years    
shareholder derivative claim [Member]      
Loss Contingencies [Line Items]      
Litigation Settlement, Amount $ 250,000    
Securities Class Action [Member]      
Loss Contingencies [Line Items]      
Litigation Settlement, Amount $ 1,750,000    
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies - Future Minimum Lease Obligations (Details)
$ in Thousands
Dec. 31, 2017
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
2016 $ 1,586
2017 1,114
2018 895
2019 337
2020 245
Thereafter 513
Total minimum lease obligations $ 4,690
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Equity - Narrative (Details)
3 Months Ended 9 Months Ended 12 Months Ended
Jan. 24, 2017
USD ($)
shares
Apr. 08, 2016
USD ($)
shares
Oct. 30, 2015
USD ($)
shares
Aug. 04, 2015
USD ($)
shares
Aug. 03, 2015
USD ($)
May 13, 2015
USD ($)
shares
May 04, 2015
USD ($)
Feb. 11, 2015
shares
Jan. 22, 2015
USD ($)
shares
Jan. 20, 2015
shares
Mar. 31, 2017
class
Mar. 31, 2016
USD ($)
Sep. 30, 2017
$ / shares
Dec. 31, 2017
USD ($)
$ / shares
shares
Dec. 31, 2016
USD ($)
$ / shares
shares
Dec. 31, 2015
USD ($)
$ / shares
shares
Apr. 07, 2016
shares
Jan. 12, 2016
USD ($)
Jul. 28, 2015
USD ($)
Dec. 31, 2014
$ / shares
shares
Aug. 13, 2012
shares
Class of Stock [Line Items]                                          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares                               0       23,984  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares                               23,984          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value | $ / shares                               $ 1.37          
Number of classes of stock | class                     2                    
Preferred stock, shares authorized                           5,000,000 5,000,000            
Preferred stock, par value (in dollars per share) | $ / shares                           $ 0.001 $ 0.001            
Common stock, shares authorized                           50,000,000 50,000,000            
Common stock, par value (in dollars per share) | $ / shares                           $ 0.001 $ 0.001            
Authorized amount of shares to be repurchased | $             $ 5,000,000.0                     $ 70,000,000.0 $ 15,000,000.0    
Treasury stock, purchase price | $     $ 3,600,000   $ 3,500,000   $ 3,500,000                            
Repurchase of common stock (in shares)     106,264 162,442   186,519                 903,031            
Repurchase of common stock | $     $ 5,000,000.0 $ 5,000,000.0   $ 5,000,000.0                 $ 23,704,000 $ 16,071,000          
Remaining authorized repurchase amount | $                           $ 32,000,000.0              
Number of shares authorized to be repurchased                                         100,000
Allocated Share-based Compensation Expense | $                           $ 35,000 $ 104,000 $ 86,000          
Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost | $                       $ 64,000                  
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant                           2,393,873              
Stock Issued During Period, Value, Restricted Stock Award, Gross | $ $ 1,400,000 $ 1,700,000                                      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value | $ / shares                               $ 0       $ 1.37  
George K. Broady                                          
Class of Stock [Line Items]                                          
Repurchase of common stock (in shares)                 91,817                        
Repurchase of common stock | $                 $ 1,100,000                        
Shares repurchased per trading day                 5,000                        
Restricted Stock [Member]                                          
Class of Stock [Line Items]                                          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number                           0 22,348 44,712       0  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value | $ / shares                           $ 12.15 $ 12.15 $ 0          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares                             $ 12.15            
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 56,260 51,015           6,116   60,960           67,076          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period                           (21,930) (22,364) (22,364)          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value | $ / shares                         $ 12.15 $ 12.15 $ 12.15            
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period                           (418)              
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value | $ / shares                           $ 12.28              
Equity Incentive 2016 Plan [Member] | Restricted Stock [Member]                                          
Class of Stock [Line Items]                                          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number                           58,032 38,256 0          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value | $ / shares                           $ 28.72 $ 34.13 $ 0          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares                           $ 25.44 $ 34.13            
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period                           56,260 51,015            
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period                           (35,336) (12,759)            
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value | $ / shares                           $ 29.58 $ 34.13            
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period                           (1,148)              
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value | $ / shares                           $ 28.55              
Common Stock | Equity Incentive 2016 Plan [Member]                                          
Class of Stock [Line Items]                                          
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized                                 2,500,000        
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Equity - Dividend Activity (Details) - USD ($)
12 Months Ended
Nov. 24, 2017
Aug. 31, 2017
May 19, 2017
Mar. 03, 2017
Nov. 25, 2016
Aug. 26, 2016
May 20, 2016
Mar. 24, 2016
Nov. 20, 2015
Aug. 28, 2015
May 29, 2015
Mar. 27, 2015
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Stockholders' Equity Note [Abstract]                              
Dividends Per Share, Common (in dollars per share) $ 0.12 $ 0.11 $ 0.10 $ 0.09 $ 0.08 $ 0.07 $ 0.06 $ 0.05 $ 0.05 $ 0.04 $ 0.03 $ 0.02 $ 1.52 $ 0.61 $ 0.14
CommonStockSpecialDividendsPerShareDeclared $ 0.15 $ 0.25 $ 0.35 $ 0.35 $ 0.35                    
Dividends, cash $ 1,360,000 $ 1,246,000 $ 1,133,000 $ 1,019,000 $ 901,000 $ 787,000 $ 686,000 $ 576,000 $ 598,000 $ 489,000 $ 372,000 $ 250,000 $ 17,218,000 $ 6,891,000 $ 1,709,000
Payment Date Nov. 24, 2017 Aug. 31, 2017 May 19, 2017 Mar. 03, 2017 Nov. 25, 2016 Aug. 26, 2016 May 20, 2016 Mar. 24, 2016 Nov. 20, 2015 Aug. 28, 2015 May 29, 2015 Mar. 27, 2015      
Dividends, Common Stock, Cash $ 1,701,000 $ 2,833,000 $ 3,964,000 $ 3,962,000 $ 3,941,000                    
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2017
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Operating Loss Carryforwards [Line Items]          
Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount $ 20,700        
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount 1,000   $ 954 $ 0 $ 0
Foreign Earnings Repatriated   $ 19,800      
Net operating loss carryforwards 0   0    
Foreign net operating loss carryforwards $ 1,250   $ 1,250    
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes - Components of Income Before Income Taxes (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Income Tax Disclosure [Abstract]      
Domestic $ (2,965) $ (3,106) $ (7,820)
Foreign 46,391 67,183 55,613
Income before income taxes $ 43,426 $ 64,077 $ 47,793
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes - Components of Benefit From Income Taxes (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Current:      
Federal $ 20,277 $ 7,151 $ 12
State 2 (81) 100
Foreign 1,216 1,648 456
Total current taxes 21,495 8,718 568
Deferred foreign taxes (1,647) 273 (16)
Income tax provision $ 19,848 $ 8,991 $ 552
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes - Income Tax Reconciliation (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2017
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Income Tax Disclosure [Abstract]        
Income tax at federal statutory rate   $ 15,200 $ 22,427 $ 16,250
Effect of permanent differences   459 12,496 370
TaxcutsandjobsactTransitionTax   20,792 0 0
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount $ 1,000 954 0 0
Change in valuation allowance   (43) (3,877) 2,017
Foreign rate differential   (15,002) (21,713) (18,099)
Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount   (2,105) (261) 0
Other reconciling items   (407) (81) 14
Income tax provision   $ 19,848 $ 8,991 $ 552
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes - Deferred Income Taxes (Details) - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Deferred tax assets:    
Net operating losses $ 192 $ 235
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost 270 623
Accrued expenses 1,374 3,174
Tax credits 0 0
Other 6 0
Total deferred tax assets 1,842 4,032
Valuation allowance (192) (235)
Deferred tax assets, net 1,650 3,797
Deferred tax liabilities:    
Foreign earnings (4) (3,650)
Other (267) (415)
Total deferred tax liabilities (271) (4,065)
Deferred Tax Assets, Net $ 1,379  
Total deferred tax liabilities   $ (268)
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes Income Taxes - Foreign Rate Differentials (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Income Tax Foreign Rate Differential [Line Items]      
Income (Loss) from Continuing Operations before Income Taxes, Foreign $ 46,391 $ 67,183 $ 55,613
CAYMAN ISLANDS      
Income Tax Foreign Rate Differential [Line Items]      
Income (Loss) from Continuing Operations before Income Taxes, Foreign $ 39,954 58,169 50,993
statutorytaxrate 0.00%    
Hong Kong      
Income Tax Foreign Rate Differential [Line Items]      
Income (Loss) from Continuing Operations before Income Taxes, Foreign $ 3,315 3,992 2,645
statutorytaxrate 16.50%    
China      
Income Tax Foreign Rate Differential [Line Items]      
Income (Loss) from Continuing Operations before Income Taxes, Foreign $ 2,584 $ 3,855 $ 1,493
statutorytaxrate 25.00%    
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.8.0.1
Related Party Transactions - Narrative (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Oct. 30, 2015
USD ($)
shares
Oct. 28, 2015
USD ($)
Aug. 04, 2015
USD ($)
shares
Jul. 31, 2015
USD ($)
May 13, 2015
USD ($)
shares
May 07, 2015
USD ($)
Apr. 29, 2015
Feb. 19, 2015
USD ($)
Jan. 22, 2015
shares
Feb. 28, 2013
Dec. 31, 2014
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
shares
Dec. 31, 2015
USD ($)
Related Party Transaction [Line Items]                            
Royalty rate                   2.50%        
Termination notice, number of days                       120 days    
Repurchase of common stock $ 5,000,000.0   $ 5,000,000.0   $ 5,000,000.0               $ 23,704,000 $ 16,071,000
Repurchase of common stock (in shares) | shares 106,264   162,442   186,519               903,031  
Director | George Broady                            
Related Party Transaction [Line Items]                            
Treasury stock acquired rate   0.4066   0.4085   0.4286                
Repurchase of common stock               $ 1,100,000            
Repurchase of common stock (in shares) | shares                 91,817          
Shares repurchased per trading day | shares                 5,000          
Director | George K. Broady                            
Related Party Transaction [Line Items]                            
Repurchase of common stock   $ 1,400,000   $ 1,500,000   $ 1,500,000                
Soothe | Broady Health Sciences                            
Related Party Transaction [Line Items]                            
Royalty rate             2.50%              
Royalty expense                     $ 11,700 $ 1,400 $ 3,400 7,000
Termination notice, number of days                       120 days    
ReStore [Member] | Broady Health Sciences                            
Related Party Transaction [Line Items]                            
Royalty expense                       $ 306,000 $ 475,000 $ 555,000
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.8.0.1
Employee Benefit Plans (Details Textual) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2017
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]        
Maximum compensation percentage   90.00%    
Age requirement for 401 K contributions   21 years    
Employer matching contribution, percent of employees' gross pay   4.50%    
Employers matching contribution, immediate vesting percentage 100.00%      
Defined contribution plan, cost recognized   $ 171,000 $ 134,000 $ 115,000
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Information - Net Sales by Market (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Segment Reporting Information [Line Items]      
Net sales $ 197,563 $ 287,728 $ 264,860
United States      
Segment Reporting Information [Line Items]      
Net sales 3,348 4,100 3,246
Canada      
Segment Reporting Information [Line Items]      
Net sales 1,938 1,809 2,746
PERU      
Segment Reporting Information [Line Items]      
Net sales 508 0 0
Hong Kong      
Segment Reporting Information [Line Items]      
Net sales 174,926 263,482 245,737
China      
Segment Reporting Information [Line Items]      
Net sales 7,282 9,086 4,425
Taiwan      
Segment Reporting Information [Line Items]      
Net sales 5,591 6,213 5,965
South Korea      
Segment Reporting Information [Line Items]      
Net sales 466 691 1,129
Commonwealth of Independent States (Russia, Kazakhstan and Ukraine)      
Segment Reporting Information [Line Items]      
Net sales 913 858 1,139
Europe [Member]      
Segment Reporting Information [Line Items]      
Net sales 2,278 1,234 382
Other foreign countries      
Segment Reporting Information [Line Items]      
Net sales $ 313 $ 255 $ 91
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Information - The Company's Net Sales by Product and Service (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Net sales by product and service:      
Product sales $ 187,591 $ 269,731 $ 253,041
Enrollment package revenue, freight and other 13,676 25,616 17,623
Less: sales returns (3,704) (7,619) (5,804)
Total net sales $ 197,563 $ 287,728 $ 264,860
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Information - Long Lived Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Segment Reporting Information [Line Items]    
Long-lived assets $ 1,149 $ 1,388
United States    
Segment Reporting Information [Line Items]    
Long-lived assets 648 763
Hong Kong    
Segment Reporting Information [Line Items]    
Long-lived assets 78 140
China    
Segment Reporting Information [Line Items]    
Long-lived assets 112 199
Other foreign countries    
Segment Reporting Information [Line Items]    
Long-lived assets $ 311 $ 286
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.8.0.1
Subsequent Events (Details) - Subsequent Event [Member] - USD ($)
Feb. 06, 2018
Feb. 01, 2018
Jan. 26, 2018
Subsequent Event [Line Items]      
Common Stock, Dividends, Per Share, Declared $ 0.13    
Restricted Stock [Member]      
Subsequent Event [Line Items]      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period   34,202  
Minimum [Member]      
Subsequent Event [Line Items]      
Long-term Purchase Commitment, Amount     $ 453,000
Maximum [Member]      
Subsequent Event [Line Items]      
Long-term Purchase Commitment, Amount     $ 3,600,000
EXCEL 60 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

&PO M=V]R:W-H965TTSQE;-DLP, M $T1 9 " :AV !X;"]W;W)K&UL4$L! A0#% @ &PO=V]R:W-H965TTS8,'>B6 ( /\& 9 M " >: !X;"]W;W)K&UL4$L! A0#% M @ &PO=V]R:W-H965TTQ=TG^,.EP .-E 0 4 " 4^( !X M;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0 ( '**>TR$\$WF7 ( +P+ M - " ;OD !X;"]S='EL97,N>&UL4$L! A0#% @ MTQG;1J6P $ +P; : " M 2#K !X;"]?TPW&7W(N $ -L; 3 " 1CM !;0V]N=&5N=%]4>7!E <&UL4$L%!@ V #8 K X 'O $! end XML 61 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 62 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 175 277 1 false 42 0 false 8 false false R1.htm 0001000 - Document - Document And Entity Information Sheet http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 1001000 - Statement - Consolidated Balance Sheets Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 1001501 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 1002000 - Statement - Consolidated Statements of Operations Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 1003000 - Statement - Consolidated Statements of Comprehensive Income Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome Consolidated Statements of Comprehensive Income Statements 5 false false R6.htm 1004000 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 6 false false R7.htm 1005000 - Statement - Consolidated Statements of Cash Flows Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 2102100 - Disclosure - Net Income Per Common Share (Notes) Notes http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNotes Net Income Per Common Share (Notes) Notes 8 false false R9.htm 2103100 - Disclosure - Balance Sheet Components Sheet http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponents Balance Sheet Components Notes 9 false false R10.htm 2104100 - Disclosure - Fair Value Measurements (Notes) Notes http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsNotes Fair Value Measurements (Notes) Notes 10 false false R11.htm 2105100 - Disclosure - Commitments and Contingencies Sheet http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 11 false false R12.htm 2107100 - Disclosure - Stockholders' Equity Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquity Stockholders' Equity Notes 12 false false R13.htm 2109100 - Disclosure - Income Taxes Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxes Income Taxes Notes 13 false false R14.htm 2110100 - Disclosure - Related Party Transactions Sheet http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions Related Party Transactions Notes 14 false false R15.htm 2111100 - Disclosure - Employee Benefit Plans Sheet http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlans Employee Benefit Plans Notes 15 false false R16.htm 2112100 - Disclosure - Segment Information Sheet http://www.naturalhealthtrendscorp.com/role/SegmentInformation Segment Information Notes 16 false false R17.htm 2113100 - Disclosure - Subsequent Events Sheet http://www.naturalhealthtrendscorp.com/role/SubsequentEvents Subsequent Events Notes 17 false false R18.htm 2201201 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies (Policies) Sheet http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies Nature of Operations and Summary of Significant Accounting Policies (Policies) Policies 18 false false R19.htm 2302301 - Disclosure - Net Income Per Common Share (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareTables Net Income Per Common Share (Tables) Tables http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNotes 19 false false R20.htm 2303301 - Disclosure - Balance Sheet Components (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsTables Balance Sheet Components (Tables) Tables http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponents 20 false false R21.htm 2304301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsNotes 21 false false R22.htm 2305301 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies 22 false false R23.htm 2307301 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.naturalhealthtrendscorp.com/role/StockholdersEquity 23 false false R24.htm 2309301 - Disclosure - Income Taxes (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.naturalhealthtrendscorp.com/role/IncomeTaxes 24 false false R25.htm 2312301 - Disclosure - Segment Information (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.naturalhealthtrendscorp.com/role/SegmentInformation 25 false false R26.htm 2401402 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Narrative (Details) Sheet http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails Nature of Operations and Summary of Significant Accounting Policies - Narrative (Details) Details http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies 26 false false R27.htm 2402402 - Disclosure - Net Income Per Common Share (Details) Sheet http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareDetails Net Income Per Common Share (Details) Details http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareTables 27 false false R28.htm 2403402 - Disclosure - Balance Sheet Components - Components of Balance Sheet Accounts (Details) Sheet http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails Balance Sheet Components - Components of Balance Sheet Accounts (Details) Details 28 false false R29.htm 2404402 - Disclosure - Fair Value Measurements (Details) Sheet http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables 29 false false R30.htm 2405402 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 30 false false R31.htm 2405403 - Disclosure - Commitments and Contingencies - Future Minimum Lease Obligations (Details) Sheet http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails Commitments and Contingencies - Future Minimum Lease Obligations (Details) Details 31 false false R32.htm 2407402 - Disclosure - Stockholders' Equity - Narrative (Details) Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails Stockholders' Equity - Narrative (Details) Details 32 false false R33.htm 2407403 - Disclosure - Stockholders' Equity - Dividend Activity (Details) Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendActivityDetails Stockholders' Equity - Dividend Activity (Details) Details 33 false false R34.htm 2409402 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 34 false false R35.htm 2409403 - Disclosure - Income Taxes - Components of Income Before Income Taxes (Details) Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails Income Taxes - Components of Income Before Income Taxes (Details) Details 35 false false R36.htm 2409404 - Disclosure - Income Taxes - Components of Benefit From Income Taxes (Details) Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails Income Taxes - Components of Benefit From Income Taxes (Details) Details 36 false false R37.htm 2409405 - Disclosure - Income Taxes - Income Tax Reconciliation (Details) Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails Income Taxes - Income Tax Reconciliation (Details) Details 37 false false R38.htm 2409406 - Disclosure - Income Taxes - Deferred Income Taxes (Details) Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails Income Taxes - Deferred Income Taxes (Details) Details 38 false false R39.htm 2409407 - Disclosure - Income Taxes Income Taxes - Foreign Rate Differentials (Details) Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxesForeignRateDifferentialsDetails Income Taxes Income Taxes - Foreign Rate Differentials (Details) Details 39 false false R40.htm 2410401 - Disclosure - Related Party Transactions - Narrative (Details) Sheet http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails Related Party Transactions - Narrative (Details) Details 40 false false R41.htm 2411401 - Disclosure - Employee Benefit Plans (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlansDetailsTextual Employee Benefit Plans (Details Textual) Details http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlans 41 false false R42.htm 2412402 - Disclosure - Segment Information - Net Sales by Market (Details) Sheet http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails Segment Information - Net Sales by Market (Details) Details 42 false false R43.htm 2412403 - Disclosure - Segment Information - The Company's Net Sales by Product and Service (Details) Sheet http://www.naturalhealthtrendscorp.com/role/SegmentInformationCompanysNetSalesByProductAndServiceDetails Segment Information - The Company's Net Sales by Product and Service (Details) Details 43 false false R44.htm 2412404 - Disclosure - Segment Information - Long Lived Assets (Details) Sheet http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLivedAssetsDetails Segment Information - Long Lived Assets (Details) Details 44 false false R45.htm 2413401 - Disclosure - Subsequent Events (Details) Sheet http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.naturalhealthtrendscorp.com/role/SubsequentEvents 45 false false All Reports Book All Reports nhtc20171231_10k.htm nhtc-20171231.xsd nhtc-20171231_cal.xml nhtc-20171231_def.xml nhtc-20171231_lab.xml nhtc-20171231_pre.xml q42017ex21-1.htm q42017ex23-1.htm q42017ex23-2.htm q42017ex31-1.htm q42017ex31-2.htm q42017ex32-1.htm http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2016-01-31 http://xbrl.sec.gov/country/2016-01-31 true true JSON 66 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nhtc20171231_10k.htm": { "axisCustom": 0, "axisStandard": 14, "contextCount": 175, "dts": { "calculationLink": { "local": [ "nhtc-20171231_cal.xml" ] }, "definitionLink": { "local": [ "nhtc-20171231_def.xml" ] }, "inline": { "local": [ "nhtc20171231_10k.htm" ] }, "labelLink": { "local": [ "nhtc-20171231_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-doc-2016-01-31.xml", "http://xbrl.sec.gov/dei/2014/dei-doc-2014-01-31.xml" ] }, "presentationLink": { "local": [ "nhtc-20171231_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-ref-2016-01-31.xml", "http://xbrl.sec.gov/dei/2014/dei-ref-2014-01-31.xml" ] }, "schema": { "local": [ "nhtc-20171231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2016/elts/us-parts-codification-2016-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2016/elts/us-roles-2016-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd", "http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd", "http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd", "http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd", "http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" ] } }, "elementCount": 419, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2016-01-31": 14, "http://www.naturalhealthtrendscorp.com/20171231": 7, "http://xbrl.sec.gov/dei/2014-01-31": 9, "total": 30 }, "keyCustom": 23, "keyStandard": 254, "memberCustom": 17, "memberStandard": 23, "nsprefix": "nhtc", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Document And Entity Information", "role": "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - Fair Value Measurements (Notes)", "role": "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsNotes", "shortName": "Fair Value Measurements (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - Commitments and Contingencies", "role": "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - Stockholders' Equity", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - Income Taxes", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - Related Party Transactions", "role": "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - Employee Benefit Plans", "role": "http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlans", "shortName": "Employee Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - Segment Information", "role": "http://www.naturalhealthtrendscorp.com/role/SegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - Subsequent Events", "role": "http://www.naturalhealthtrendscorp.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies (Policies)", "role": "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Nature of Operations and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2302301 - Disclosure - Net Income Per Common Share (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareTables", "shortName": "Net Income Per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Consolidated Balance Sheets", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-3", "lang": null, "name": "us-gaap:OtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "nhtc:ScheduleofAdditionalBalanceSheetComponentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Balance Sheet Components (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsTables", "shortName": "Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "nhtc:ScheduleofAdditionalBalanceSheetComponentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDividendsPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - Stockholders' Equity (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDividendsPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - Income Taxes (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312301 - Disclosure - Segment Information (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/SegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestrictedCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401402 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Narrative (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "shortName": "Nature of Operations and Summary of Significant Accounting Policies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestrictedCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402402 - Disclosure - Net Income Per Common Share (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareDetails", "shortName": "Net Income Per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "nhtc:ScheduleofAdditionalBalanceSheetComponentsTableTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - Balance Sheet Components - Components of Balance Sheet Accounts (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails", "shortName": "Balance Sheet Components - Components of Balance Sheet Accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "nhtc:ScheduleofAdditionalBalanceSheetComponentsTableTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:AvailableForSaleSecuritiesTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - Fair Value Measurements (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails", "shortName": "Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:AvailableForSaleSecuritiesTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001501 - Statement - Consolidated Balance Sheets (Parentheticals)", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LeaseAndRentalExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Commitments and Contingencies - Narrative (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails", "shortName": "Commitments and Contingencies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LeaseAndRentalExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405403 - Disclosure - Commitments and Contingencies - Future Minimum Lease Obligations (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails", "shortName": "Commitments and Contingencies - Future Minimum Lease Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2015Q4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Stockholders' Equity - Narrative (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "shortName": "Stockholders' Equity - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2015Q4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfDividendsPayableTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "D2017Q1nov24-nov24", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Stockholders' Equity - Dividend Activity (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendActivityDetails", "shortName": "Stockholders' Equity - Dividend Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfDividendsPayableTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "D2017Q1nov24-nov24", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - Income Taxes - Narrative (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - Income Taxes - Components of Income Before Income Taxes (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails", "shortName": "Income Taxes - Components of Income Before Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409404 - Disclosure - Income Taxes - Components of Benefit From Income Taxes (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails", "shortName": "Income Taxes - Components of Benefit From Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409405 - Disclosure - Income Taxes - Income Tax Reconciliation (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails", "shortName": "Income Taxes - Income Tax Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409406 - Disclosure - Income Taxes - Deferred Income Taxes (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails", "shortName": "Income Taxes - Deferred Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409407 - Disclosure - Income Taxes Income Taxes - Foreign Rate Differentials (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxesForeignRateDifferentialsDetails", "shortName": "Income Taxes Income Taxes - Foreign Rate Differentials (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "nhtc:IncomeTaxForeignRateDifferentialTableTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD_us-gaap_StatementGeographicalAxis_country_KY", "decimals": "-3", "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SalesRevenueGoodsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Consolidated Statements of Operations", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "D2013Q1Feb1-Feb28", "decimals": "INF", "first": true, "lang": null, "name": "nhtc:RoyaltyRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410401 - Disclosure - Related Party Transactions - Narrative (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails", "shortName": "Related Party Transactions - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "D2013Q1Feb1-Feb28", "decimals": "INF", "first": true, "lang": null, "name": "nhtc:RoyaltyRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411401 - Disclosure - Employee Benefit Plans (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlansDetailsTextual", "shortName": "Employee Benefit Plans (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SalesRevenueGoodsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412402 - Disclosure - Segment Information - Net Sales by Market (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails", "shortName": "Segment Information - Net Sales by Market (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD_us-gaap_StatementGeographicalAxis_country_US", "decimals": "-3", "lang": null, "name": "us-gaap:SalesRevenueGoodsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SalesRevenueGoodsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412403 - Disclosure - Segment Information - The Company's Net Sales by Product and Service (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/SegmentInformationCompanysNetSalesByProductAndServiceDetails", "shortName": "Segment Information - The Company's Net Sales by Product and Service (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SalesRevenueGoodsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412404 - Disclosure - Segment Information - Long Lived Assets (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLivedAssetsDetails", "shortName": "Segment Information - Long Lived Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "D2018Q1SD2-6_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413401 - Disclosure - Subsequent Events (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "D2018Q1SD2-6_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Consolidated Statements of Comprehensive Income", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome", "shortName": "Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TreasuryStockShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - Consolidated Statements of Stockholders' Equity", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity", "shortName": "Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TreasuryStockShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - Net Income Per Common Share (Notes)", "role": "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNotes", "shortName": "Net Income Per Common Share (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - Balance Sheet Components", "role": "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponents", "shortName": "Balance Sheet Components", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 42, "tag": { "country_CA": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CANADA", "terseLabel": "Canada" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/country/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails" ], "xbrltype": "domainItemType" }, "country_CN": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CHINA", "terseLabel": "China", "verboseLabel": "China" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxesForeignRateDifferentialsDetails", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLivedAssetsDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails" ], "xbrltype": "domainItemType" }, "country_HK": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "HONG KONG", "terseLabel": "Hong Kong" } } }, "localname": "HK", "nsuri": "http://xbrl.sec.gov/country/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxesForeignRateDifferentialsDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLivedAssetsDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails" ], "xbrltype": "domainItemType" }, "country_KR": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "KOREA, REPUBLIC OF", "terseLabel": "South Korea" } } }, "localname": "KR", "nsuri": "http://xbrl.sec.gov/country/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails" ], "xbrltype": "domainItemType" }, "country_KY": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CAYMAN ISLANDS", "terseLabel": "CAYMAN ISLANDS" } } }, "localname": "KY", "nsuri": "http://xbrl.sec.gov/country/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxesForeignRateDifferentialsDetails" ], "xbrltype": "domainItemType" }, "country_PE": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "PERU", "terseLabel": "PERU" } } }, "localname": "PE", "nsuri": "http://xbrl.sec.gov/country/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails" ], "xbrltype": "domainItemType" }, "country_TW": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "TAIWAN, PROVINCE OF CHINA", "terseLabel": "Taiwan" } } }, "localname": "TW", "nsuri": "http://xbrl.sec.gov/country/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLivedAssetsDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word \"Other\".", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r367" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate \"Yes\" or \"No\" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "domainItemType" }, "dei_EntityFilerCategory": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r367" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate \"Yes\" or \"No\" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate \"Yes\" or \"No\" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "stringItemType" }, "nhtc_AccruedSalesReturns": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": 1.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Sales Returns", "label": "Accrued Sales Returns", "terseLabel": "Accrued Sales Returns" } } }, "localname": "AccruedSalesReturns", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_AccruedWarehousingAndInventoryRelatedExpense": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": 3.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Warehousing And Inventory Related Expense", "label": "Accrued Warehousing And Inventory Related Expense", "terseLabel": "Accrued Warehousing And Inventory Related Expense" } } }, "localname": "AccruedWarehousingAndInventoryRelatedExpense", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_AgeRequirementFor401KContributions": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents age requirement for 401K contributions.", "label": "Age Requirement For 401K Contributions", "terseLabel": "Age requirement for 401 K contributions" } } }, "localname": "AgeRequirementFor401KContributions", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlansDetailsTextual" ], "xbrltype": "durationItemType" }, "nhtc_AmountsHeldnDistributorEWalletsPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the policy of amounts held in customer eWallets.", "label": "Amounts Held in Distributor eWallets [Policy Text Block]", "terseLabel": "Amounts Held in Distributor eWallets" } } }, "localname": "AmountsHeldnDistributorEWalletsPolicyTextBlock", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nhtc_AutoShipAdvancesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents Auto Ship advances.", "label": "Auto Ship Advances [Member]", "terseLabel": "Auto Ship Advances [Member]" } } }, "localname": "AutoShipAdvancesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "domainItemType" }, "nhtc_BalanceSheetComponentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Balance Sheet Components [Abstract]", "label": "Balance Sheet Components [Abstract]" } } }, "localname": "BalanceSheetComponentsAbstract", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "xbrltype": "stringItemType" }, "nhtc_BroadyHealthSciencesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents Broady Health Sciences.", "label": "Broady Health Sciences [Member]", "terseLabel": "Broady Health Sciences" } } }, "localname": "BroadyHealthSciencesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_CommonStockSpecialDividendsPerShareDeclared": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Special dividends declared during the period for each share of common stock outstanding.", "label": "CommonStockSpecialDividendsPerShareDeclared", "terseLabel": "CommonStockSpecialDividendsPerShareDeclared" } } }, "localname": "CommonStockSpecialDividendsPerShareDeclared", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendActivityDetails" ], "xbrltype": "perShareItemType" }, "nhtc_CumulativeTranslationAdjustmentRealizedInNetIncome": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents cumulative translation adjustment realized in net income.", "label": "Cumulative Translation Adjustment Realized In Net Income", "negatedLabel": "Cumulative translation adjustment realized in net income" } } }, "localname": "CumulativeTranslationAdjustmentRealizedInNetIncome", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nhtc_DeferredCompensationRewardPayableEqualConsecutiveMonthlyInstallments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the number of equal consecutive monthly installments of deferred compensation award payable.", "label": "nhtc_DeferredCompensationRewardPayableEqualConsecutiveMonthlyInstallments", "terseLabel": "Long-term incentive plan, number of installments" } } }, "localname": "DeferredCompensationRewardPayableEqualConsecutiveMonthlyInstallments", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "nhtc_DeferredCompensationRewardPaymentPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the percentage of deferred compensation award payable.", "label": "nhtc_DeferredCompensationRewardPaymentPercentage", "terseLabel": "Long-term incentive plan, percentage of award payable in cash" } } }, "localname": "DeferredCompensationRewardPaymentPercentage", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "nhtc_DocumentAndEntityInformation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Document And Entity Information" } } }, "localname": "DocumentAndEntityInformation", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "xbrltype": "stringItemType" }, "nhtc_EnrollmentPackageRevenueMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents enrollment package revenue.", "label": "Enrollment Package Revenue [Member]", "terseLabel": "Enrollment Package Revenue [Member]" } } }, "localname": "EnrollmentPackageRevenueMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "domainItemType" }, "nhtc_EquityIncentive2016PlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Incentive 2016 Plan", "label": "Equity Incentive 2016 Plan [Member]", "terseLabel": "Equity Incentive 2016 Plan [Member]", "verboseLabel": "Restricted Stock [Member]" } } }, "localname": "EquityIncentive2016PlanMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "nhtc_FinancialInstitutionInstrumentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to financial institution instruments.", "label": "Financial Institution Instruments [Member]", "verboseLabel": "Financial Institution Instruments [Member]" } } }, "localname": "FinancialInstitutionInstrumentsMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "nhtc_GeorgeBroadyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents George Broady.", "label": "George Broady Member", "terseLabel": "George Broady" } } }, "localname": "GeorgeBroadyMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_GeorgeKBroadyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "George K. Broady, a director of the Company.", "label": "George K. Broady [Member]", "terseLabel": "George K. Broady" } } }, "localname": "GeorgeKBroadyMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_IncomeTaxForeignRateDifferentialLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Income Tax Foreign Rate Differential components", "label": "Income Tax Foreign Rate Differential [Line Items]", "terseLabel": "Income Tax Foreign Rate Differential [Line Items]" } } }, "localname": "IncomeTaxForeignRateDifferentialLineItems", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxesForeignRateDifferentialsDetails" ], "xbrltype": "stringItemType" }, "nhtc_IncomeTaxForeignRateDifferentialTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Income Tax Foreign Rate Differential components", "label": "Income Tax Foreign Rate Differential [Table]", "terseLabel": "Income Tax Foreign Rate Differential [Table]" } } }, "localname": "IncomeTaxForeignRateDifferentialTable", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxesForeignRateDifferentialsDetails" ], "xbrltype": "stringItemType" }, "nhtc_IncomeTaxForeignRateDifferentialTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Table Text Block] for Income Tax Foreign Rate Differential components", "label": "Income Tax Foreign Rate Differential [Table Text Block]", "terseLabel": "Income Tax Foreign Rate Differential [Table Text Block]" } } }, "localname": "IncomeTaxForeignRateDifferentialTableTextBlock", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "nhtc_IncomeTaxReconciliationEffectOfPermanentDifferences": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Effect of permanent differences.", "label": "Effect of permanent differences", "terseLabel": "Effect of permanent differences" } } }, "localname": "IncomeTaxReconciliationEffectOfPermanentDifferences", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_LongTermIncentivePlanPaymentCommencingInFebruary2021AndEndingInDecember2023Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the Long-Term Incentive Plan (the \u201cLTI Plan\u201d), payments commencing in February 2021 and ending in December 2023.", "label": "Long-Term Incentive Plan, Payment Commencing in February 2021 and Ending in December 2023 [Member]", "terseLabel": "Long-Term Incentive Plan, Payment Commencing in February 2021 and Ending in December 2023" } } }, "localname": "LongTermIncentivePlanPaymentCommencingInFebruary2021AndEndingInDecember2023Member", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_LongTermIncentivePlanPaymentCommencingInFebruaryOfTheCalendarYearImmediatelyFollowingTheConclusionOfThePerformancePeriodMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the Long-Term Incentive Plan (the \u201cLTI Plan\u201d), payments commencing in February of the calendar year immediately following the conclusion of the performance period.", "label": "Long-Term Incentive Plan, Payment Commencing in February of the Calendar Year Immediately Following the Conclusion of the Performance Period [Member]", "terseLabel": "Long-Term Incentive Plan, Payment Commencing in February of the Calendar Year Immediately Following the Conclusion of the Performance Period" } } }, "localname": "LongTermIncentivePlanPaymentCommencingInFebruaryOfTheCalendarYearImmediatelyFollowingTheConclusionOfThePerformancePeriodMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_MunicipalBondsAndNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-term and short-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Bonds and Notes [Member]", "verboseLabel": "Municipal Bonds and Notes [Member]" } } }, "localname": "MunicipalBondsAndNotesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "nhtc_NumberOfClassesOfStock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number Of Classes Of Stock", "label": "Number Of Classes Of Stock", "terseLabel": "Number of classes of stock" } } }, "localname": "NumberOfClassesOfStock", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "integerItemType" }, "nhtc_NumberOfDaysTerminationNotice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents number of days termination notice.", "label": "Number Of Days Termination Notice", "terseLabel": "Termination notice, number of days" } } }, "localname": "NumberOfDaysTerminationNotice", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "nhtc_OfficeEquipment": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents other equipment.", "label": "Office equipment", "terseLabel": "Office equipment" } } }, "localname": "OfficeEquipment", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_OtherAccruedExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents other accrued expenses abstract.", "label": "Other accrued expenses:", "terseLabel": "Other accrued expenses:" } } }, "localname": "OtherAccruedExpensesAbstract", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "stringItemType" }, "nhtc_OtherForeignCountriesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents other foreign countries.", "label": "Other Foreign Countries [Member]", "terseLabel": "Other foreign countries" } } }, "localname": "OtherForeignCountriesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLivedAssetsDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails" ], "xbrltype": "domainItemType" }, "nhtc_PurchaseCommitmentMonthlyAmountMinimum": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the monthly purchase minimum the Company is required to purchase until the termination date.", "label": "nhtc_PurchaseCommitmentMonthlyAmountMinimum", "terseLabel": "Minimum monthly purchase amount" } } }, "localname": "PurchaseCommitmentMonthlyAmountMinimum", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_PurchaseCommitmentRenewalTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period of time that a purchase commitment agreement is automatically renewed for after the original term ends unless notice of termination is given by either party to the agreement.", "label": "nhtc_PurchaseCommitmentRenewalTerm", "terseLabel": "Purchase commitment renewal term" } } }, "localname": "PurchaseCommitmentRenewalTerm", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "nhtc_PurchaseCommitmentTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period of time that a purchase commitment agreement is in effect.", "label": "nhtc_PurchaseCommitmentTerm", "terseLabel": "Purchase commitment term" } } }, "localname": "PurchaseCommitmentTerm", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "nhtc_ReStoreMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents a product called ReStore\u2122.", "label": "ReStore [Member]", "terseLabel": "ReStore [Member]" } } }, "localname": "ReStoreMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_RoyaltyRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the royalty rate.", "label": "Royalty Rate", "terseLabel": "Royalty rate" } } }, "localname": "RoyaltyRate", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "percentItemType" }, "nhtc_RussiaAndKazakhstanAndUkraineMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Geographic locations of Russia and Kazakhstan and Ukraine.", "label": "Russia and Kazakhstan and Ukraine [Member]", "terseLabel": "Commonwealth of Independent States (Russia, Kazakhstan and Ukraine)" } } }, "localname": "RussiaAndKazakhstanAndUkraineMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails" ], "xbrltype": "domainItemType" }, "nhtc_ScheduleofAdditionalBalanceSheetComponentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Additional Balance Sheet Components [Table Text Block]", "label": "Schedule of Additional Balance Sheet Components [Table Text Block]", "terseLabel": "Schedule of Additional Balance Sheet Components [Table Text Block]" } } }, "localname": "ScheduleofAdditionalBalanceSheetComponentsTableTextBlock", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "nhtc_SecuritiesClassActionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Securities Class Action [Member]", "label": "Securities Class Action [Member]", "terseLabel": "Securities Class Action [Member]" } } }, "localname": "SecuritiesClassActionMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_ShareholderderivativeclaimMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "shareholder derivative claim [Member]", "label": "shareholder derivative claim [Member]", "terseLabel": "shareholder derivative claim [Member]" } } }, "localname": "ShareholderderivativeclaimMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_SootheMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents Soothe.", "label": "Soothe [Member]", "terseLabel": "Soothe" } } }, "localname": "SootheMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_Statutorytaxrate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Statutory tax rate of foreign subsidiary.", "label": "statutorytaxrate", "terseLabel": "statutorytaxrate" } } }, "localname": "Statutorytaxrate", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxesForeignRateDifferentialsDetails" ], "xbrltype": "percentItemType" }, "nhtc_StockRepurchaseProgramNumberOfSharesRepurchasedPerDay": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of shares acquired per day under a share repurchase program.", "label": "Stock Repurchase Program Number Of Shares Repurchased Per Day", "terseLabel": "Shares repurchased per trading day" } } }, "localname": "StockRepurchaseProgramNumberOfSharesRepurchasedPerDay", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "nhtc_TaxcutsandjobsactTransitionTax": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "One-time transition tax related to Tax Cuts and Jobs Act", "label": "TaxcutsandjobsactTransitionTax", "terseLabel": "TaxcutsandjobsactTransitionTax" } } }, "localname": "TaxcutsandjobsactTransitionTax", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_TreasuryStockAcquiredRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the treasury stock acquired rate times the number of shares purchased.", "label": "Treasury Stock Acquired Rate", "terseLabel": "Treasury stock acquired rate" } } }, "localname": "TreasuryStockAcquiredRate", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "pureItemType" }, "nhtc_TreasuryStockValueAcquiredCostMethodExcludingRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the cost of shares that were repurchased during the period, excluding those repurchased from a related party. Recorded using the cost method.", "label": "Treasury Stock Value Acquired Cost Method Excluding Related Party", "terseLabel": "Treasury stock, purchase price" } } }, "localname": "TreasuryStockValueAcquiredCostMethodExcludingRelatedParty", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_UnshippedProductMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents unshipped product.", "label": "Unshipped Product [Member]", "terseLabel": "Unshipped Product [Member]" } } }, "localname": "UnshippedProductMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20171231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r59" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r8", "r34", "r36", "r62" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": 2.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Employee Benefits, Current", "terseLabel": "Accrued Employee Benefits, Current" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r42", "r333", "r350" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "verboseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "auth_ref": [ "r43", "r333", "r350" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.", "label": "Accrued Income Taxes, Noncurrent", "terseLabel": "Accrued Income Taxes, Noncurrent" } } }, "localname": "AccruedIncomeTaxesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r62" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "verboseLabel": "Accrued commissions" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r57", "r183" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r78", "r79", "r80" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive (loss) income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r77", "r80", "r280" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive (Loss) Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r49" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).", "label": "Adjustments to Additional Paid in Capital, Other", "terseLabel": "Adjustments to Additional Paid in Capital, Other" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r228", "r230", "r245", "r246" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words \"stock-based compensation\".", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r230", "r242", "r244" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Allocated Share-based Compensation Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r0", "r7", "r13", "r135" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r332", "r349" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r30", "r31", "r73" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [ "r164", "r165", "r168" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "Available-for-sale Securities", "verboseLabel": "Available-for-sale Securities" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax", "verboseLabel": "Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAmortizedCost": { "auth_ref": [ "r61" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Available-for-sale Securities, Amortized Cost Basis", "terseLabel": "Available-for-sale Securities, Amortized Cost Basis" } } }, "localname": "AvailableForSaleSecuritiesAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesTextBlock": { "auth_ref": [ "r166", "r167", "r169", "r170", "r171", "r342", "r343" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Available-for-sale Securities [Table Text Block]", "verboseLabel": "Available-for-sale Securities [Table Text Block]" } } }, "localname": "AvailableForSaleSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r231", "r243" ], "lang": { "en-US": { "role": { "documentation": "Information by award type pertaining to equity-based compensation.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CapitalizedComputerSoftwareGross": { "auth_ref": [ "r366" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.", "label": "Capitalized Computer Software, Gross", "terseLabel": "Capitalized Computer Software, Gross" } } }, "localname": "CapitalizedComputerSoftwareGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r3", "r54" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash and Cash Equivalents [Abstract]", "terseLabel": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r4", "r28", "r54", "r105" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "CASH AND CASH EQUIVALENTS, end of period", "periodStartLabel": "CASH AND CASH EQUIVALENTS, beginning of period", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [ "r99", "r305" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r3", "r4", "r39", "r106", "r112", "r161" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r39", "r106", "r112", "r161", "r331" ], "lang": { "en-US": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r54" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash Equivalents, at Carrying Value" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r123" ], "lang": { "en-US": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommissionsPolicy": { "auth_ref": [ "r112", "r329", "r330" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for fees earned by the broker dealer, acting as an agent in the buying and selling of securities and administrative efforts on behalf of customers and may include the timing of commission revenue recognition and presentation in the financial statements. Commissions earned are usually related to the broker dealer's customers' trading volume and the dollar amounts of the trades.", "label": "Commissions, Policy [Policy Text Block]", "terseLabel": "Commissions" } } }, "localname": "CommissionsPolicy", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r64", "r186", "r337", "r355" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r64", "r185", "r189", "r195", "r301" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r207" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Common Stock, Dividends, Per Share, Cash Paid", "verboseLabel": "Dividends Per Share, Common (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r207" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Common Stock, Dividends, Per Share, Declared" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r48" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r48" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r48" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r48" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at December 31, 2017 and 2016" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Compensation and Retirement Disclosure [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r111", "r234" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Compensation Related Costs, Policy [Policy Text Block]", "terseLabel": "Long-Term Incentive" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r6", "r18", "r19", "r83" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss), net of tax:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r296", "r297", "r300", "r345", "r346", "r360" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Certain Risks and Concentrations" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CondensedBalanceSheetStatementTable": { "auth_ref": [ "r26", "r125", "r276", "r341", "r347" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.", "label": "Condensed Balance Sheet Statement [Table]", "terseLabel": "Condensed Balance Sheet Statement [Table]" } } }, "localname": "CondensedBalanceSheetStatementTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Condensed Balance Sheet Statements, Captions [Line Items]", "terseLabel": "Condensed Balance Sheet Statements, Captions [Line Items]" } } }, "localname": "CondensedBalanceSheetStatementsCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConsolidationItemsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r112", "r279", "r282", "r283" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r182" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": 6.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress, Gross", "terseLabel": "Construction in Progress, Gross" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "verboseLabel": "Corporate Debt Securities [Member]" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsSold": { "auth_ref": [ "r90" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs related to goods produced and sold during the reporting period.", "label": "Cost of Goods Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsSold", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CounterpartyNameAxis": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r9", "r118", "r270", "r274" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "verboseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r122", "r273" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "verboseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r9", "r118", "r270", "r274" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current taxes" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r9", "r118", "r270", "r274" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain": { "auth_ref": [ "r221", "r222" ], "lang": { "en-US": { "role": { "documentation": "Deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes equity-based compensation plans, defined benefit pension plans and defined benefit other postretirement benefit plans.", "label": "Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain]", "terseLabel": "Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain]" } } }, "localname": "DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commitment made to pay deferred cash remuneration expressed as a percentage of the individual's base salary.", "label": "Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage", "terseLabel": "Maximum compensation percentage" } } }, "localname": "DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlansDetailsTextual" ], "xbrltype": "percentItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis": { "auth_ref": [ "r221", "r222" ], "lang": { "en-US": { "role": { "documentation": "Information by type of deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes equity-based compensation plans, defined benefit pension plans and defined benefit other postretirement benefit plans.", "label": "Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]", "terseLabel": "Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for deferred compensation arrangements payable after one year (or the normal operating cycle, if longer). Represents currently earned compensation under cash arrangements (such as a profit-sharing plan, rabbi trust, and employee contract--excluding equity-based arrangements) that is not actually paid until a later date.", "label": "Deferred Compensation Cash-based Arrangements, Liability, Classified, Noncurrent", "verboseLabel": "Long-term incentive" } } }, "localname": "DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r11", "r118", "r272", "r274" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Deferred foreign taxes" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r11", "r103", "r118", "r272", "r274" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred Income Tax Expense (Benefit)" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r12", "r45", "r46", "r261", "r334", "r348" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r217", "r218" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.", "label": "Deferred Revenue", "terseLabel": "Deferred Revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Revenue [Abstract]", "terseLabel": "Deferred Revenue [Abstract]" } } }, "localname": "DeferredRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenueArrangementTypeAxis": { "auth_ref": [ "r35", "r213", "r214", "r215", "r216", "r217", "r218" ], "lang": { "en-US": { "role": { "documentation": "Information by type of deferred revenue arrangement.", "label": "Deferred Revenue Arrangement Type [Axis]", "terseLabel": "Deferred Revenue Arrangement Type [Axis]" } } }, "localname": "DeferredRevenueArrangementTypeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenueArrangementTypeDomain": { "auth_ref": [ "r35", "r212" ], "lang": { "en-US": { "role": { "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized.", "label": "Deferred Revenue [Domain]", "terseLabel": "Deferred Revenue [Domain]" } } }, "localname": "DeferredRevenueArrangementTypeDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r35", "r212", "r213", "r214", "r215", "r216", "r217" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred Revenue, Current", "verboseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r10", "r262" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Tax Assets, Gross [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r265" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "terseLabel": "Deferred Tax Assets, Net" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent": { "auth_ref": [ "r253", "r254", "r265" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.", "label": "Deferred Tax Assets, Net, Noncurrent", "terseLabel": "Deferred Tax Assets, Net, Noncurrent" } } }, "localname": "DeferredTaxAssetsLiabilitiesNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r263" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Deferred tax assets, net" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r247", "r268", "r269" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating losses" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration", "terseLabel": "Foreign net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r248", "r268", "r269" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r2", "r266", "r268", "r269" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Tax credits" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r247", "r268", "r269" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r247", "r268", "r269" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities", "verboseLabel": "Accrued expenses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r264" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r254", "r265" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Tax Liabilities, Gross [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesNoncurrent": { "auth_ref": [ "r253", "r254", "r255" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.", "label": "Deferred Tax Liabilities, Net, Noncurrent", "terseLabel": "Deferred Tax Liabilities, Net, Noncurrent" } } }, "localname": "DeferredTaxLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r248", "r268", "r269" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "negatedTerseLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": { "auth_ref": [ "r248", "r268", "r269" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiaries and other recognized entities not within the country of domicile of the entity.", "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings", "negatedLabel": "Foreign earnings" } } }, "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r226" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of the cost recognized during the period for defined contribution plans.", "label": "Defined Contribution Plan, Cost Recognized", "terseLabel": "Defined contribution plan, cost recognized" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlansDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "terseLabel": "Employer matching contribution, percent of employees' gross pay" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlansDetailsTextual" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.", "label": "Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage", "terseLabel": "Employers matching contribution, immediate vesting percentage" } } }, "localname": "DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlansDetailsTextual" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r103", "r181" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation and amortization" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r103" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DirectorMember": { "auth_ref": [ "r322" ], "lang": { "en-US": { "role": { "documentation": "Person serving on the board of directors (who collectively have responsibility for governing the entity).", "label": "Director [Member]", "terseLabel": "Director" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DividendPayableDateToBePaidDayMonthAndYear": { "auth_ref": [ "r108" ], "lang": { "en-US": { "role": { "documentation": "Date the declared dividend will be paid, in CCYY-MM-DD format.", "label": "Dividends Payable, Date to be Paid", "terseLabel": "Payment Date" } } }, "localname": "DividendPayableDateToBePaidDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendActivityDetails" ], "xbrltype": "dateItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r207", "r344" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends", "negatedLabel": "Dividends declared" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsCash": { "auth_ref": [ "r207", "r344" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.", "label": "Dividends, Cash", "terseLabel": "Dividends, cash" } } }, "localname": "DividendsCash", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r207" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "terseLabel": "Dividends, Common Stock, Cash" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Income per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r86", "r130", "r136", "r138", "r340", "r357" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net income allocated to common stockholders (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]", "terseLabel": "Weighted-average number of common shares outstanding:" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r86", "r130", "r340", "r357" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "verboseLabel": "Net income allocated to common stockholders plus assumed conversions (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r112", "r135", "r136", "r137" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Income Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r91", "r130", "r133", "r134", "r138" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share [Text Block]" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r305" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of exchange rates on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r200" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EuropeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Continent of Europe.", "label": "Europe [Member]", "terseLabel": "Europe [Member]" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r284", "r285", "r286", "r287", "r289", "r290" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r286" ], "lang": { "en-US": { "role": { "documentation": "Information by level within the fair value hierarchy.", "label": "Fair Value, Hierarchy [Axis]", "terseLabel": "Fair Value, Hierarchy [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r284" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r288", "r294", "r295", "r297", "r298", "r299" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Disclosures [Text Block]" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [ "r284", "r288" ], "lang": { "en-US": { "role": { "documentation": "Provides the general categories used to describe the frequency with which financial assets and liabilities (as defined) are measured at fair value (on a recurring or nonrecurring basis).", "label": "Fair Value, Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r112", "r292", "r293" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "auth_ref": [ "r104", "r302", "r303", "r304" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), Unrealized", "negatedLabel": "Loss on foreign exchange" } } }, "localname": "ForeignCurrencyTransactionGainLossUnrealized", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r112", "r304", "r311" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignEarningsRepatriated": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign earnings repatriated from subsidiaries outside the country of domicile.", "label": "Foreign Earnings Repatriated", "terseLabel": "Foreign Earnings Repatriated" } } }, "localname": "ForeignEarningsRepatriated", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesGross": { "auth_ref": [ "r182" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": 4.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures, Gross", "terseLabel": "Furniture and Fixtures, Gross" } } }, "localname": "FurnitureAndFixturesGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and Fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r177", "r178", "r179" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r112", "r180" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r89" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r121" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "Domestic" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r84", "r328", "r338", "r358" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r121" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Foreign", "verboseLabel": "Income (Loss) from Continuing Operations before Income Taxes, Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxesForeignRateDifferentialsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r122", "r258", "r265", "r267", "r273" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r15", "r122", "r271" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax provision", "totalLabel": "Income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r112", "r251", "r252", "r259", "r260", "r275", "r364" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r250", "r256", "r257" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r249", "r256", "r257" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount", "terseLabel": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount" } } }, "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r116", "r256", "r257" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "terseLabel": "Foreign rate differential" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r117", "r256", "r257" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "Income tax at federal statutory rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": { "auth_ref": [ "r256", "r257" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": 8.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount", "terseLabel": "Other reconciling items" } } }, "localname": "IncomeTaxReconciliationOtherReconcilingItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings": { "auth_ref": [ "r256", "r257" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.", "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount", "terseLabel": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount" } } }, "localname": "IncomeTaxReconciliationRepatriationOfForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsOther": { "auth_ref": [ "r256", "r257" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount", "negatedTerseLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount" } } }, "localname": "IncomeTaxReconciliationTaxCreditsOther", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r107" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Income taxes, net of refunds" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r102" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r102" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r102" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued commissions" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of (a) prepayments by customers for goods or services to be provided at a later date, (b) the amount of customer money held in customer accounts, including security deposits, collateral for a current or future transactions, initial payment of the cost of acquisition or for the right to enter into a contract or agreement, or (c) a combination of (a) and (b).", "label": "Increase (Decrease) in Customer Advances and Deposits", "terseLabel": "Amounts held in eWallets" } } }, "localname": "IncreaseDecreaseInCustomerAdvancesAndDeposits", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "auth_ref": [ "r102" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.", "label": "Increase (Decrease) in Deferred Compensation", "terseLabel": "Long-term incentive" } } }, "localname": "IncreaseDecreaseInDeferredCompensation", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r102" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r102" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories, net" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "auth_ref": [ "r102" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accrued Liabilities", "terseLabel": "Other accrued expenses" } } }, "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Increase (Decrease) in Other Current Liabilities", "terseLabel": "Other current liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedTerseLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInRestrictedCash": { "auth_ref": [ "r16", "r95", "r97" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.", "label": "Increase (Decrease) in Restricted Cash", "negatedLabel": "Increase in restricted cash" } } }, "localname": "IncreaseDecreaseInRestrictedCash", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "auth_ref": [ "r1", "r23", "r24", "r131", "r134" ], "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants", "verboseLabel": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants" } } }, "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r132", "r136" ], "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r68" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Inventory, Finished Goods, Gross" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r29", "r70", "r173" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories, net", "totalLabel": "Inventories, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r38", "r71", "r112", "r174", "r175" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsAndSupplies": { "auth_ref": [ "r69" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.", "label": "Inventory, Raw Materials and Supplies, Gross", "terseLabel": "Inventory, Raw Materials and Supplies, Gross" } } }, "localname": "InventoryRawMaterialsAndSupplies", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r70", "r126", "r173", "r176" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "negatedTerseLabel": "Inventory Valuation Reserves" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r291", "r361", "r362", "r363" ], "lang": { "en-US": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r291", "r361", "r362", "r363" ], "lang": { "en-US": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Operating Leases, Rent Expense", "terseLabel": "Rent expense for operating leases" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeasePolicyTextBlock": { "auth_ref": [ "r112", "r313", "r316", "r317", "r359" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangements (both lessor and lessee). This disclosure may address (1) lease classification (that is, operating versus capital), (2) how the term of a lease is determined (for example, the circumstances in which a renewal option is considered part of the lease term), (3) how rental revenue or expense is recognized for a lease that contains rent escalations, (4) an entity's accounting treatment for deferred rent, including that which arises from lease incentives, rent abatements, rent holidays, or tenant allowances (5) an entity's accounting treatment for contingent rental payments and (6) an entity's policy for reviewing, at least annually, the residual values of sales-type and direct-finance leases. The disclosure also may indicate how the entity accounts for its capital leases, leveraged leases or sale-leaseback transactions.", "label": "Lease, Policy [Policy Text Block]", "terseLabel": "Operating Leases" } } }, "localname": "LeasePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsGross": { "auth_ref": [ "r32", "r182" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": 5.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements, Gross", "terseLabel": "Leasehold Improvements, Gross" } } }, "localname": "LeaseholdImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r60" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r53", "r336", "r353" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r63" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.", "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.", "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationSettlementAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of judgment or settlement awarded to (against) the entity in respect of litigation.", "label": "Litigation Settlement, Amount", "terseLabel": "Litigation Settlement, Amount" } } }, "localname": "LitigationSettlementAmount", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.", "label": "Long-term Purchase Commitment, Amount", "terseLabel": "Long-term Purchase Commitment, Amount" } } }, "localname": "LongTermPurchaseCommitmentAmount", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r32", "r182" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment, Gross", "terseLabel": "Machinery and Equipment, Gross" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum", "verboseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum", "verboseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": { "auth_ref": [ "r99", "r101" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": { "auth_ref": [ "r99", "r101" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "auth_ref": [ "r99", "r100", "r104" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r18", "r19", "r85", "r104", "r136", "r339", "r356" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income", "totalLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r128" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net Income (Loss) Available to Common Stockholders, Basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r128", "r129" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net Income (Loss) Available to Common Stockholders, Diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued and Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r158" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets", "terseLabel": "Long-lived assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLivedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "auth_ref": [ "r236" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "terseLabel": "Nonvested Restricted Stock Shares Activity [Table Text Block]" } } }, "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r312", "r314" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "totalLabel": "Total minimum lease obligations" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r312", "r314" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "2016" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r312", "r314" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails": { "order": 5.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "2020" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r312", "r314" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails": { "order": 4.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "2019" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r312", "r314" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "2018" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r312", "r314" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "2017" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r312", "r314" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails": { "order": 6.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "terseLabel": "Thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r266" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r267" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r8", "r34", "r36", "r37", "r62" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "totalLabel": "Other Accrued Liabilities, Current", "verboseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r72" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r58" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r75", "r78", "r306", "r307", "r310", "r311" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r74", "r308" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "totalLabel": "Net change in foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax": { "auth_ref": [ "r78", "r81", "r82", "r309" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax", "negatedLabel": "Elimination of CTA upon dissolution", "negatedTerseLabel": "Release of cumulative translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r76", "r78" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax", "terseLabel": "Unrealized losses on available-for-sale securities", "verboseLabel": "Unrealized loss on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherDeferredCreditsCurrent": { "auth_ref": [ "r62" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unearned revenue or income classified as other, expected to be taken into income within one year or the normal operating cycle, if longer.", "label": "Other Deferred Credits, Current", "verboseLabel": "Amounts held in eWallets" } } }, "localname": "OtherDeferredCreditsCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r33", "r34", "r62" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "verboseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r94" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r14", "r98" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Repurchase of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r14", "r98" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r16", "r96" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r223", "r224", "r225", "r226", "r227" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for pension and other postretirement benefits.", "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]", "terseLabel": "Employee Benefit Plans" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r231", "r243" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name pertaining to equity-based compensation arrangements.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the equity-based compensation arrangement plan.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r47" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r47" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r47" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r47" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r47" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2017 and 2016" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from Warrant Exercises", "terseLabel": "Proceeds from exercise of warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductOrServiceAxis": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "Information by products and services or groups of similar products and services.", "label": "Products and Services [Axis]", "terseLabel": "Products and Services [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ProductsAndServicesDomain": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Products and Services [Domain]", "terseLabel": "Products and Services [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r57", "r184" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r56", "r182" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Property, Plant and Equipment, Gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r40", "r41", "r184", "r354" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property, Plant and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r55", "r112", "r184" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r40", "r182" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property, and equipment useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": { "auth_ref": [ "r44", "r335", "r351" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.", "label": "Purchase Commitment, Remaining Minimum Amount Committed", "terseLabel": "Minimum annual purchase amount" } } }, "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by range, including, but not limited to, upper and lower bounds.", "label": "Range [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extent of variation, for example, but not limited to, upper and lower bounds.", "label": "Range [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r17", "r21", "r22", "r318", "r319", "r320" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r321", "r323", "r324", "r325", "r326" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r119", "r321", "r323", "r324", "r325", "r326" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r54" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": { "auth_ref": [ "r4", "r54" ], "lang": { "en-US": { "role": { "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.", "label": "Restricted Cash and Cash Equivalents [Axis]", "terseLabel": "Restricted Cash and Cash Equivalents [Axis]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "auth_ref": [ "r54" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.", "label": "Restricted Cash and Cash Equivalents, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockAwardForfeitures": { "auth_ref": [ "r200", "r207" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The total value of forfeitures related to restricted stock awards forfeited during the period.", "label": "Restricted Stock Award, Forfeitures", "negatedTerseLabel": "Restricted Stock Award, Forfeitures" } } }, "localname": "RestrictedStockAwardForfeitures", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r135" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r50", "r207", "r352" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings (accumulated deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r111", "r112", "r113", "r219" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.", "label": "Revenue Recognition, Policy [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r92" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty Expense", "terseLabel": "Royalty expense" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesCommissionsAndFees": { "auth_ref": [ "r93" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).", "label": "Sales Commissions and Fees", "terseLabel": "Commissions expense" } } }, "localname": "SalesCommissionsAndFees", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesReturnsGoods": { "auth_ref": [ "r87" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/SegmentInformationCompanysNetSalesByProductAndServiceDetails": { "order": 1.0, "parentTag": "us-gaap_SalesRevenueGoodsNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate refunds recognized during an accounting period due to goods returned by customers (other than under warranty provisions). Returns are a deduction from gross revenue in arriving at net revenue.", "label": "Sales Returns, Goods", "negatedTerseLabel": "Less: sales returns" } } }, "localname": "SalesReturnsGoods", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationCompanysNetSalesByProductAndServiceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueGoodsGross": { "auth_ref": [ "r87" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/SegmentInformationCompanysNetSalesByProductAndServiceDetails": { "order": 3.0, "parentTag": "us-gaap_SalesRevenueGoodsNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue during the period from sale of goods in the normal course of business, before deducting returns, allowances and discounts.", "label": "Sales Revenue, Goods, Gross", "terseLabel": "Product sales" } } }, "localname": "SalesRevenueGoodsGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationCompanysNetSalesByProductAndServiceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueGoodsNet": { "auth_ref": [ "r87" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/role/SegmentInformationCompanysNetSalesByProductAndServiceDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.", "label": "Sales Revenue, Goods, Net", "terseLabel": "Net sales", "totalLabel": "Total net sales" } } }, "localname": "SalesRevenueGoodsNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationCompanysNetSalesByProductAndServiceDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueGoodsNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Sales Revenue, Goods, Net [Abstract]", "terseLabel": "Net sales by product and service:" } } }, "localname": "SalesRevenueGoodsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationCompanysNetSalesByProductAndServiceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r273" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r265" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDividendsPayableTextBlock": { "auth_ref": [ "r108" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of all or some of the information related to dividends declared, but not paid, as of the financial reporting date.", "label": "Schedule of Dividends Payable [Table Text Block]", "terseLabel": "Schedule of Dividends Payable" } } }, "localname": "ScheduleOfDividendsPayableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r136" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "verboseLabel": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r256" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock": { "auth_ref": [ "r158" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the names of foreign countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area.", "label": "Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]", "terseLabel": "Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country" } } }, "localname": "ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r315" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r121" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule of Income before Income Tax, Domestic and Foreign" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r57", "r184" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r119", "r321", "r323", "r324", "r325", "r326" ], "lang": { "en-US": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "auth_ref": [ "r88", "r157" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]", "terseLabel": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area" } } }, "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r145", "r146", "r147", "r150", "r180" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLivedAssetsDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r145", "r146", "r147", "r150", "r180" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Segment Reporting Information, by Segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r65", "r120", "r196", "r197", "r198", "r201", "r202", "r203", "r204", "r205", "r206", "r207" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentGeographicalDomain": { "auth_ref": [ "r27", "r159", "r365" ], "lang": { "en-US": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxesForeignRateDifferentialsDetails", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLivedAssetsDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r142", "r143", "r144", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r159", "r160" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLivedAssetsDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r93", "r172" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r102" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "verboseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Additional share-based compensation cost recognized as a result of an occurrence of an event that accelerates its recognition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r237" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r241" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r238" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r238" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r240" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r240" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r232" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r243" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r229", "r233" ], "lang": { "en-US": { "role": { "documentation": "Equity-based compensation award.", "label": "Equity Award [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r112", "r231", "r235" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.", "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShippingAndHandlingRevenue": { "auth_ref": [ "r87", "r220" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/SegmentInformationCompanysNetSalesByProductAndServiceDetails": { "order": 2.0, "parentTag": "us-gaap_SalesRevenueGoodsNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fees charged to customers for the delivery, generally by postal or freight service providers, of product or goods purchased.", "label": "Shipping and Handling Revenue", "terseLabel": "Enrollment package revenue, freight and other" } } }, "localname": "ShippingAndHandlingRevenue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationCompanysNetSalesByProductAndServiceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]", "terseLabel": "Software and Software Development Costs [Member]" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r67", "r200" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementGeographicalAxis": { "auth_ref": [ "r27", "r159", "r365" ], "lang": { "en-US": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxesForeignRateDifferentialsDetails", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLivedAssetsDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r108", "r109", "r110" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Stock Issued" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Shares, Other", "terseLabel": "Exercise of warrants (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "auth_ref": [ "r47", "r48", "r200", "r207" ], "lang": { "en-US": { "role": { "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited", "negatedTerseLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP). Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.", "label": "Stock Issued During Period, Shares, Share-based Compensation, Gross", "terseLabel": "Shares issued for stock-based compensation awards (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Value, Other", "terseLabel": "Exercise of warrants" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": { "auth_ref": [ "r47", "r48", "r200", "r207" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures", "negatedTerseLabel": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r47", "r48", "r200", "r207" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Stock Issued During Period, Value, Restricted Stock Award, Gross" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Gross value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP). Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.", "label": "Stock Issued During Period, Value, Share-based Compensation, Gross", "terseLabel": "Shares issued for stock-based compensation awards" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Authorized amount of shares to be repurchased" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.", "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased", "terseLabel": "Number of shares authorized to be repurchased" } } }, "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Remaining authorized repurchase amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r48", "r51", "r52", "r162" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r277", "r278", "r281" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "BALANCE", "periodStartLabel": "BALANCE" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r20", "r48", "r51", "r52", "r114", "r115", "r163", "r199", "r200", "r201", "r202", "r203", "r204", "r207", "r208", "r210" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r327" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r327" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r327" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Supplemental Balance Sheet Disclosures [Text Block]" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponents" ], "xbrltype": "textBlockItemType" }, "us-gaap_TitleOfIndividualAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Relationship to Entity [Domain]", "terseLabel": "Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r66", "r209" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r66", "r209" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "negatedTerseLabel": "Treasury stock, shares", "terseLabel": "Treasury stock, shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r48", "r200", "r207" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "negatedTerseLabel": "Repurchase of common stock (in shares)", "terseLabel": "Repurchase of common stock (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r66", "r209", "r211" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, at cost; 1,637,524 and 1,692,218 shares at December 31, 2017 and 2016, respectively" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r200", "r207", "r209" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedLabel": "Repurchase of common stock", "terseLabel": "Repurchase of common stock" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r139", "r140", "r141" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r129", "r134" ], "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r25", "r127", "r134" ], "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted Average Number of Shares Outstanding, Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Glossary": "Antidilution", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6505113" }, "r1": { "Glossary": "Call Option", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6506649" }, "r10": { "Glossary": "Deferred Tax Asset", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6510090" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3574-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3044-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586" }, "r11": { "Glossary": "Deferred Tax Expense (or Benefit)", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=63044130" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=68058157&loc=d3e18726-107790" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=68058157&loc=d3e18823-107790" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r12": { "Glossary": "Deferred Tax Liability", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6510232" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(d),(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(m)(1)(i)(B)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1448-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1377-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1505-109256" }, "r13": { "Glossary": "Diluted Earnings Per Share", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6510752" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1757-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1500-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1278-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=65016374&loc=d3e4984-109258" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=64851502&loc=d3e6061-108592" }, "r14": { "Glossary": "Financing Activities", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6513228" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=64851502&loc=d3e6132-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=64851502&loc=d3e6143-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8721-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8813-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599" }, "r15": { "Glossary": "Income Tax Expense (or Benefit)", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6515339" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "35", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599" }, "r16": { "Glossary": "Investing Activities", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6516133" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "305", "URI": "http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=65884222&loc=d3e22054-111558" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=66010992&loc=d3e26610-111562" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27161-111563" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27198-111563" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27232-111563" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27290-111563" }, "r17": { "Glossary": "Management", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6517382" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27337-111563" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27357-111563" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4492-108314" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4556-108314" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=64834752&loc=SL49117168-202975" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267" }, "r18": { "Glossary": "Net Income", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=51831255" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=73718637&loc=d3e25287-109308" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14615-108349" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14394-108349" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349" }, "r19": { "Glossary": "Other Comprehensive Income", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=51831270" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14453-108349" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14472-108349" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=6851643&loc=d3e12021-110248" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=6851643&loc=d3e12053-110248" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21553-112644" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644" }, "r2": { "Glossary": "Carryforwards", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6506874" }, "r20": { "Glossary": "Preferred Stock", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6521494" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r21": { "Glossary": "Principal Owners", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6521851" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 13.A.4(a).Q1)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(b))", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(b).Q1(c))", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(b).Q2)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(c).Q3)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.4(a).Q1)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.B.Q1)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r22": { "Glossary": "Related Parties", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=16382449" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "45", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=68075638&loc=d3e60635-111653" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65897934&loc=d3e2410-114920" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=66047640&loc=d3e39622-114963" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39675-114964" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=66904339&loc=d3e4534-113899" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901" }, "r23": { "Glossary": "Treasury Stock Method", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6527216" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r24": { "Glossary": "Warrant", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6528364" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=65896087&loc=d3e11149-113907" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=65896087&loc=d3e11178-113907" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=68052875&loc=d3e28680-109314" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=68052875&loc=d3e28680-109314" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e32059-109318" }, "r25": { "Glossary": "Weighted-Average Number of Common Shares Outstanding", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6528421" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e32123-109318" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e32247-109318" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e32280-109318" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e31917-109318" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e31931-109318" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e31958-109318" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32687-109319" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32698-109319" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32718-109319" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32809-109319" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-04(c)(Schedule I))", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=27047687&loc=d3e5864-122674" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32840-109319" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32559-109319" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32559-109319" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32621-109319" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32632-109319" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-04.(c) Schedule III)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=27047687&loc=d3e5864-122674" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=68079674&loc=d3e5283-111683" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=68079674&loc=SL4568447-111683" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=68079674&loc=SL4568740-111683" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=64809438&loc=d3e5614-111684" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=65897068&loc=SL4590271-111686" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355100-122828" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19190-110258" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=SL7498348-110258" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19279-110258" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=SL6742756-110258" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13279-108611" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13433-108611" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13504-108611" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13531-108611" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13537-108611" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612" }, "r3": { "Glossary": "Cash", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6506951" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=6875567&loc=d3e14489-108613" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64836518&loc=d3e30690-110894" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64836518&loc=d3e30700-110894" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32022-110900" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32157-110900" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=6453394&loc=d3e39740-112701" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "40", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=6456037&loc=d3e48589-112741" }, "r318": { "Glossary": "Affiliate", "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6504562" }, "r319": { "Glossary": "Control", "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6508935" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6812-107765" }, "r320": { "Glossary": "Immediate Family", "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6515043" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41256-110953" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41261-110953" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-06)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6882215&loc=d3e537971-122884" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=68064133&loc=d3e61044-112788" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=68064133&loc=d3e61082-112788" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.7-05(c)(Schedule II))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879921&loc=d3e569147-122900" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=65670824&loc=d3e14754-158437" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=28088331&loc=SL29635902-196195" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(2)(i))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C(1)(a))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28)", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r367": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12b", "Subsection": "1" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r4": { "Glossary": "Cash Equivalents", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6507016" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Glossary": "Common Stock", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6508022" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r6": { "Glossary": "Comprehensive Income", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=51831223" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4),(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r7": { "Glossary": "Contingent Stock Agreement", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6508534" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e681-108580" }, "r8": { "Glossary": "Current Liabilities", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6509677" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669686-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e689-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e709-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e557-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(a))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r9": { "Glossary": "Current Tax Expense (or Benefit)", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6509736" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.21)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3179-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585" } }, "version": "2.0" } ZIP 67 0000912061-18-000015-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000912061-18-000015-xbrl.zip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Ȥ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Ó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

];D#$5*@1,@ME"T0 LLMFC[K"1,8JQM MN9*2;/^^DJQX[9G+W9?84BY'=\;4'%):OM?-U_8EQF[V;;?=MS?SEZX[7"\6 M[<-+W%7MI_H0]_U_GNIF5W7]8?.\: ]-K!['0;OM@HSQBUVUV<]OE^.YS\WM MLG[MMIM]_-S,VM?=KFK^6\5M_7XSM_./$U\VSR_=<&)QNSQ4S_'/V/UU^-ST M1XM3E,?-+N[;3;V?-?'I9GYGKTL.PX!1\?@\],UAX'GWS^B_S(FWR=S7[5Q76__V3QV M+S?S?#Y[C$_5Z[;[4K__&J>$LOELRO[W^!:WO7QPTE_CH=ZVX]_9PVO;U;LI M2F]E5WT[?F[VX^?[%/]C&!Y TP Z#;#^AP-X&L#?![@?#G#3 "<&+(ZIC+4I MJZZZ73;U^ZPY_KR':IA%]MKUU7\83H[%'O_7EZ?MS[[=6G;+Q=L0:-*LCAHZ MUYP4BS[ZZ1*$+K$B-9PN+[#6"C:7DE)+@L!O JY5Q.C:,D M.T^&12IKK>%"Q"FUACQCKP%Z#4R9FD19;%K56"0#EAMP5T6P"WPLBJT!>QWHFZK;6*K,B[1)$2MZDU MN*$9,.V+1(A$3[0J9V;9$ZW.)G="M0:JJSRS(FFD\L$G?B8+N^R=)6U:-7+2 M%V(N"ND:R*S/E6TD,Y3ZN7!?MJQL.]E7)\UE?:PT#42R0Y=(1#XD'&,06$T" M^;NO)LUEH0N)/:0*5K8;H/*3W ?9S(&,#4O+6G1ED_!9 %(G&P):Z J9*@2B"QS8FEC,96LQI*35+( )IP' MB7P@HY!)C@*5=9PE)@=A-I'1KD7S74V:RWLGR!8-5%8N9DH@2G5GPB0D3<), M]CH"]&*2\ 2]D7,#R#*V0;9H(,O[I5AB M54B8A 2V**D%/V$TD4:3=213!]0AM4M!JD+6IT2J8%,W!883:3A9!5321#'2 M\4\E)9!#B328K*(I(3+I(@,5*#)0<>"4:\PE"F!VI6XLC D"&Q?% M-M+-7?U0/Y640,(FL8@G3 @"&Q?9;U:DN[IR"RA"'-2N$.FL[UF<>$J!"<&: M$%:QF"$BR,KIA70^+^0: H=+E9LQ*5B3PBHB,T %-(Z08K)"WADXGDO6' .# M$3 DEAD 0RU_@.C*>[G^02J;JG;B:9;>-=E,3F[6FYV"Y99H#51DC5&FM"37-*N6#/%4E:0*C;0&5>H_1/0N7[EFGIZB"'% %)RC;ABL(7B M?KV@G ,=R+!$NLL,+ZUC7C'@E5K$L6:,#T%N6($J#[J?:%4PB0TK8UHQ>)R7 M2<9.(G]1[D+NHI J..59J[R74V1Q]E!]%YOG\85%.WNH7_?=\&SZ[.SII<@= M#0_EQ?F5O2Z/KS:^ASF^:?FC:IXW^W9V7W==O1L?S#_5=1=[C^937]&76#V> M#K;QJ1N^AOY[H5T^S]02P,$% @ :IZ;P4&LZ6N$XI;O^?0)H^HVOZYG@0=>.#@^5IRVMX!/^G/5NTV,12 M"@7:":.)A2JC=^OC:1OB8\!? ;V;G4FHY&+,-VA7N0 M,A"AC'\C)YU2!N#\_,;^/=:.M5RX@WLCGT3IFXP>*"FAXIWT#Z;_ 6,].TK& MXG_!%22&!R68HS#2Q944G?-&C2PH1?&781=B0 M*"K_QCW/4VMZ8H?>MSP\\?J88&^*X(RMB'Y?$-WD/'Z;]-[>UT(Y7C?VOC/& 4E8W.$(- M?K#)D%#Y<+S%LQW&;#"\:<TRXJ)AKM@$ M -(# 8 >&PO=V]R:W-H965T&UL;5-A;]P@#/TKB!]0 MDMQ=UYV22+U6TR9MTJG3ML]EN/ES HEC05/ZZG@2;>>"@Y5YSUOX#NY'?S;>8@M++11H M*U 3 TU![]/C:1_B8\!/ :-=G4FHY(+X'(PO=4&3( @D5"XP<+]=X0&D#$1> MQN^9DRXI W!]?F7_%&OWM5RXA0>4OT3MNH+>45)#PP?IGG#\#',]!TKFXK_" M%:0/#TI\C@JEC2NI!NM0S2Q>BN(OTRYTW,?IYI#-L&U -@.R!7 7\[ I453^ MR!TOQZ>.#UFOC=5<,96Q#LOWGKOM4P/'W-V#41SS&F*R=8Q2P3S M[$N*;"O%*7L'S[;ANTV%NPC?K;/?)ML$^TV"?238_T>0OBEQ*^:M2K;JJ0+3 MQFFRI,)!QTE>>9>!O8^/R/Z%3]/^C9M6:$LNZ/S+QOXWB Z\E.3&CU#G/]AB M2&A<.'[P9S.-V60X[.TRV6W]:M@$ -(# M 9 >&PO=V]R:W-H965T1Y"2+-GM#DQQH6F91]_9 MEKD9O!0:SI:X02EN_YQ FK&@>_KF>!9MYX.#E7G/6_@._D=_MFBQA:46"K03 M1A,+34'O]\=3%N)CP$\!HUN=2:CD8LQ+,+[4!=T%02"A\H&!XW:%!Y R$*&, MWS,G75(&X/K\QOX8:\=:+MS!@Y&_1.V[@MY14D/#!^F?S?@$U[FUHS$3KWO>7CB_3'!WE3!&5L1[U"\0^^UW!_2G%T#T1QSFF*2=;D!!(*'U0X+C=X!&D#$*8QJ]) MD\XA W%Y?E=_CK5C+5?NX-'(GZ+R;4Z/E%10\U[Z%S-\@JF>/253\5_@!A+A M(1.,41KIXDK*WGFC)A5,1?&W<1.#FEV)LR.&,KXATF[]![*_;[C-V"S@0YCY!T 4EF!$/Q.4*Z M%N&,!4-GS'8=L-+SIIO_#YD]<_ %02P,$% @ &UL?5/;;IPP$/T5RQ\0L^PFFZX M*9NJ2J566J5J\NR% :SX0FRSI'_?L2$$M2@OMF=\SIF+Q]E@[(MK 3QY4U*[ MG+;>=P?&7-F"XN[*=*#QIC96<8^F;9CK+/ JDI1D:9+<,,6%ID46?2=;9*;W M4F@X6>)ZI;C]43,7_@ M(A(=, M,$9II(LK*7OGC9I4,!7%W\9=Z+@/X\UV/]'6">E$2&?";8S#QD Q\Z_<\R*S M9B!V['W'PQ-O#BGVI@S.V(IXA\D[]%Z*SEU MG.2%=Q[8NS2^R0=\G/:?W#9".W(V'E\V]K\VQ@.FDESA"+7XP69#0NW#<8]G M.X[9:'C333^(S=^X^ M02P,$% @ S 0 T@, !D !X M;"]W;W)K&UL?5-A;]P@#/TKB!]0[DC65J M]P?&7-F"%N[*]-#A36VL%AY-VS#76Q!5!&G%^&YWS;20'2VRZ#O9(C.#5[*# MDR5NT%K87T=09LSIGKX[GF73^N!@1=:+!KZ!_]Z?+%IL8:FDALY)TQ$+=4[O M]H=C&N)CP \)HUN=2:CD;,Q+,#Y7.=T%0:"@](%!X':!>U J$*&,UYF3+BD# M<'U^9W^,M6,M9^'@WJB?LO)M3F\IJ: 6@_+/9GR"N9Y/E,S%?X$+* P/2C!' M:92+*RD'YXV>65"*%F_3+KNXC]--DLRP;0"? 7P!W,8\;$H4E3\(+XK,FI'8 MJ?>]"$^\/W#L31F+*I,(GPY"^%R39!NDF01H+TPQ*W8M)_DK!53S78)DZ3(Z49NCC)*^\R ML'<\OLF?\&G:OPK;R,Z1L_'XLK'_M3$>4,KN"D>HQ0^V& IJ'XXW>+;3F$V& M-_W\@]CRC8O?4$L#!!0 ( '**>TR&A,LVM $ -(# 9 >&PO=V]R M:W-H965TO&IE7$Y;[[L38ZYL M00MWAQV8<%.CU<('TS;,=19$E4!:,;[9/# MI*%%EGP76V38>R4-7"QQO=;" M_CR#PB&G6_KF>)9-ZZ.#%5DG&O@"_FMWL<%B,TLE-1@GT1 +=4X?MZ?S/L:G M@&\2!K,P.7YC?U] MJCW4%%D%@=BQ]YW(C[Q M]L1#;\KH3*U(=T&\"]Y;L3W<9^P6B::8\QC#ES%S! OL$NP7=_*'Q8)]BO$NP3P?Z_):[%'/Y*PA8]U6";-$V.E-B;-,D+[SRPCSR] MR>_P<=H_"]M(X\@5?7C9U/\:T4.0LKD+(]2&#S8;"FH?CX=PMN.8C8;';OI! M;/[&Q2]02P,$% @ &UL?5/;;MLP#/T501]0.4ZZ9H%MH.DP=, *!!VV/2LV M;0O5Q97DN/W[4;+C>9NQ%TFD> X/*2H;C'UQ+8 G;TIJE]/6^^[ F"M;4-S= MF XTWM3&*N[1M USG05>19"2+$V2#TQQH6F11=_)%IGIO10:3I:X7BENWX\@ MS9#3#;TZGD73^N!@1=;Q!KZ!_]Z=+%IL9JF$ NV$T<1"G=/[S>&X"_$QX(> MP2W.)%1R-N8E&%^JG"9!$$@H?6#@N%W@ :0,1"CC=>*D<\H 7)ZO[)]C[5C+ MF3MX,/*GJ'R;TSTE%=2\E_[9#(\PU7-+R53\5[B Q/"@!'.41KJXDK)WWJB) M!:4H_C;N0L=]&&]NK[!U0#H!TAFPCP V)HK*/W'/B\R:@=BQ]QT/3[PYI-B; M,CAC*^(=BG?HO12;NWW&+H%HBCF.,>DR9HY@R#ZG2-=2'--_X.DZ?+NJEUG.2%=Q[8^S2^R>_P M<=J?N&V$=N1L/+YL[']MC >4DMS@"+7XP69#0NW#\0[/=ARST?"FFWX0F[]Q M\0M02P,$% @ &UL?5-A;]L@$/TKB!]08I)M661;:CI-F[1*4:>UGXE]ME'! M>(#C]M_OP*[KK>Z^ '?<>_?N.-+!V$?7 'CRI%7K,MIXWQT81M_)YJGIO9(MG"QQO=;"/A]!F2&C M"7UQW,FZ\<'!\K03-?P$_ZL[6;38S%)*#:V3IB46JHQ>)X?C+L3'@'L)@UN< M2:CD;,QC,+Z7&=T$0:"@\(%!X':!&U J$*&,WQ,GG5,&X/+\POXUUHZUG(6# M&Z,>9.F;C.XI*:$2O?)W9O@&4ST?*)F*_P$74!@>E&".PB@75U+TSAL]L: 4 M+9[&7;9Q'\8;_GF"K0/X!. S8!_SL#%15/Y%>)&GU@S$CKWO1'CBY,"Q-T5P MQE;$.Q3OT'O)DWV2LDL@FF*.8PQ?QLP1#-GG%'PMQ9&_@?-U^'95X3;"MW\I M?(=@MTJPBP2[_Y:X%K/])PE;]%2#K>,T.5*8OHV3O/#. WO-XYN\AH_3?BML M+5M'SL;CR\;^5\9X0"F;*QRA!C_8;"BH?#A^PK,=QVPTO.FF'\3F;YS_ 5!+ M P04 " !RBGM,2PP^V;0! #2 P &0 'AL+W=OU5K\ =]Q[]^XXT@'-DVT ''G1JK49;9SK#HS9H@$M[!5VT/J;"HT6 MSINF9K8S(,H(THKQS>:&:2%;FJ?1=S)YBKU3LH63(;;76I@_1U X9'1+7QV/ MLFY<<+ \[40-/\#][$[&6VQF*:6&UDILB8$JH[?;PS$)\3'@EX3!+LXD5')& M? K&US*CFR (%!0N, B_7> .E I$7L;SQ$GGE &X/+^R/\3:?2UG8>$.U6]9 MNB:C>TI*J$2OW",.7V"JYYJ2J?AO< 'EPX,2GZ- 9>-*BMXZU!.+EZ+%R[C+ M-N[#>,,_3[!U )\ ? ;L8QXV)HK*[X43>6IP(&;L?2?"$V\/W/>F",[8BGCG MQ5OOO>3;?9*R2R":8HYC#%_&S!',L\\I^%J*(W\'Y^OPW:K"783O_E-XO4Z0 MK!(DD2#YL,2UF)LW2=BBIQI,':?)D@+[-D[RPCL/["V/;_(O?)SV[\+4LK7D MC,Z_;.Q_A>C 2]E<^1%J_ >;#065"\=/_FS&,1L-A]WT@]C\C?._4$L#!!0 M ( '**>TR]ZR"1L@( !,+ 9 >&PO=V]R:W-H965T1J,36=!3<7L[B4515QV3S^#V0IJ-F%WA]_\'^ MV1W>'N:5:_$HJU_ESAQ7:9$F.['GI\H\R\L7,1QHEB;#Z;^)LZ@LO,O$:FQE MI=UOLCUI(^N!Q:92\_?^6C;N>NF?Y(LA# >P(8"- 873(;V0R_P3-WR]5/*2 MJ/[EM[S[QO2>V7>S[3;=JW#/;/+:[I[7M,B7Y-P1#9A-CV'7F!%!+/LHP9#$ MA@7A#(=/8(83%SZYR;# !%-(,'4$TQN"A7=$@%ED6&0&16: @'HB"!-Y%7,H M,@<$$T\$8:98)(2((,\SS*\V!**Q;W'0CRZX!ED*T^- M&P6O=L>)[\$-?.0?O!\7OW-U*!N=O$IC)R,WO^RE-,+FDMU9CQWMA#HN*K$W MW6UN[U4_IO4+(]MA!"7C'+S^"U!+ P04 " !RBGM,%#POS;MO8E_;J.#K 8[;MQ]@UW,[_P'NY9QS/[BD YIGVP X\J)5 M:S/:.-<=&;-% UK8&^R@]3<5&BV<-TW-;&= E)&D%>.;S8%I(5N:I]%W-GF* MO5.RA;,AMM=:F-<3*!PRNJ5OCD=9-RXX6)YVHH:?X'YU9^,M-JN44D-K);;$ M0)71N^WQE 1\!/R6,-C%F81*+HC/P?A>9G03$@(%A0L*PF]7N >E@I!/X\^D M2>>0@;@\OZE_C;7[6B["PCVJ)UFZ)J.WE)10B5ZY1QR^P53/GI*I^!]P!>7A M(1,?HT!EXTJ*WCK4DXI/18N7<9=MW(?QYO!YHJT3^$3@,^$VQF%CH)CY%^%$ MGAHTSR$_1HN $ -(# 9 M >&PO=V]R:W-H965TD21;9 MEII.TR9M4M1IVV]B7]NHX.L!CKNW'V#7\UK_ >[EG',_N*0#FF?; #CRHE5K M,]HXUYT8LT4#6M@[[*#U-Q4:+9PW3!7P$_)0PV,69A$JNB,_!^%)F- D)@8+"!07AMQL\@E)!R*?Q>]*D M<\A 7)Y?U3_%VGTM5V'A$=4O6;HFHT=*2JA$K]P3#I]AJN>>DJGXKW #Y>$A M$Q^C0&7C2HK>.M23BD]%BY=QEVW3.CU#C/]AL**A< M.![\V8QC-AH.N^D'L?D;YW\!4$L#!!0 ( '**>TR,VM%+M@$ -(# 9 M >&PO=V]R:W-H965T92YP$%4(&Y-+]^QF29EF7+X"-W_.S,?ED[+/K #QYT:IW M!>V\'XZ,N:H#+=R-&:#'F\98+3R:MF5NL"#J"-**\22Y95K(GI9Y])UMF9O1 M*]G#V1(W:BWL[Q,H,Q4TI:^.1]EV/CA8F0^BA>_@?PQGBQ9;66JIH7?2],1" M4]#[]'C*0GP,>)(PN<=)4OQ7^$*"L.# M$LQ1&>7B2JK1>:,7%I2BQN38FRHX8ROB'8IWZ+V6_)#D[!J(EIC3',,W,>D:P9!]3<'W M4ISX?W"^#S_L*CQ$^&&;_3;;)\AV";)(D/U38OJFQ+V8MRK9IJ<:;!NGR9'* MC'VSS;>=.JLSEM MG>N/C-FR!2WL#?;0^9L:C1;.FZ9AMC<@JDC2BO'=[L"TD!TMLN@[FR+#P2G9 MP=D0.V@MS.\3*!QSNJ?OCA?9M"XX6)'UHH%OX+[W9^,MMJA44D-G)7;$0)W3 MA_WQE 9\!/R0,-K5F81*+HBOP?A 2E@I!/X]>L29>0 M@;@^OZL_Q]I]+1=AX1'53UFY-J?WE%10BT&Y%QP_P5S/+25S\5_@"LK#0R8^ M1HG*QI64@W6H9Q6?BA9OTRZ[N(_3S2&=:=L$/A/X0KB/<=@4*&;^))PH,H,C M,5/O>Q&>>'_DOC=E<,96Q#N?O/7>:\&3)&/7(#1C3A.&KS#[!<&\^A*";X4X M\?_H?)N>;&:81'JRCGZXVQ9(-P72*)#^4V+ZH<0MS.V'(&S54PVFB=-D28E# M%R=YY5T&]H''-_D+GZ;]JS"-["RYH/,O&_M?(SKPJ>QN_ BU_H,MAH+:A>.= M/YMIS";#83__(+9\X^(/4$L#!!0 ( '**>TRG9?!'Q0$ #<$ 9 M>&PO=V]R:W-H965T6;ML8T"Q@&\3O^^@!W'W?)B9H8SY\P XW10^M4T !:]2]&:##?6 M=D="3-& 9.9.=="ZG4IIR:QS=4U,IX&5(4D*0I-D1R3C+<[3$#OK/%6]%;R% MLT:FEY+I/R<0:LCP"G\$GGC=6!\@>=JQ&GZ!_=V=M?/(S%)R":WAJD4:J@S? MKXZGK<<'P#.'P2QLY#NY*/7JG>]EAA-?$ @HK&=@;KG" PCAB5P9;Q,GGB5] MXM+^8/\6>G>]7)B!!R5>>&F;#!\P*J%BO;!/:GB$J9\M1E/S/^ *PL%])4ZC M4,*$+RIZ8Y6<6%PIDKV/*V_#.HP[.SJEQ1/HE$#GA$/0(:-0J/PKLRQ/M1J0 M'L^^8_Z*5T?JSJ;PP7 48<\5;USTFM/U+B573S1A3B.&+C"K&4$<^RQ!8Q(G M^E\ZC:>OHQ6N0_IZJ;Y/X@2;*,$F$&S^:7%_TV(,"GD$SZ.U$^F:]X:=%'6/9]PR952%EPI MR9VKI7%3/#L"*NO-O;/U^)9'QZIN&E,R_ROROU!+ P04 " !RBGM,UZ?Y M >T! !F!0 &0 'AL+W=O :F-F.Z'[][,-I8S>OF#?^=U[=S9W M6:_TBZD!;/0J16MR4EO;[2DU90V2FSO50>M.SDI+;IVI+]1T&G@5@J2@;+7: M4LF;EA19\!UUD:FK%4T+1QV9JY1<_SF 4'U.UN3-\=1<:NL=M,@Z?H$?8']V M1^TL.K%4C836-*J--)QS\K#>'U*/#X#G!GHSVT>^DI-2+][X6N5DY1," :7U M#-PM-W@$(3R12^/WR$DF21\XW[^Q?PZUNUI.W,"C$K^:RM8Y24E4P9E?A7U2 M_1<8ZTE(-!;_#6X@'-QGXC1*)4SX1N756"5'%I>*Y*_#VK1A[8>3Y'X,PP/8 M&,"F@#3HT$$H9/Z)6UYD6O61'NZ^X_Z)UWOF[J;TSG 5X*[!""="&"8>YQD10523\2 M)*N%"(99_GAT]I]+T)?0X28JU;4-TV7FG8;( PM]\@X?)M!WKB]-:Z*3LJ[; M0D^KW=";# %GZ[<[M]=#ZP^&5=TXU>@T6HN_4$L#!!0 ( M '**>TR_$'^%S@$ )P$ 9 >&PO=V]R:W-H965T<$7 XIWN);XKFI:N,2)$LZ M5L%/,+^ZL[(1F56*1D"K&]DB!66*'[;'4^SP'O"[@4$O]LAU[DP#8^2OS2%J5-\P*B MDO7B*0$8C7_D79EB6*#D@-9Y]Q]Q?O#U2>S:Y2_JC\-]L\=IFKQF-:$*N M3FC"G$8,76"V,X)8]=F"ABQ.]!\Z#=-WP0IWGKY;NA_^([ /"NR]P/Y3B[M5 MBR',/FP2!4VB@$"T,@EAXK!)'#2) P+W*Y,0YK R(8O;(4!5?BXTRF7?^IE< M9.?1>Z#^=GW Q[G]P535M!I=I+%WU-^D4DH#MI3-G6VXMD_%'' HC=O>V[T: M!V8,C.RFMX#,#U+V%U!+ P04 " !RBGM,^+I>]0X# !G#0 &0 'AL M+W=O$IW>Z$FG-FD3';LF8F?Y6,E1T[' MLDES5M0I+ZR*;:?V/1FO:*P,-.)7RDYU[]U2J;QP_JH&WS93VU41L8RMA:)( MY./(%BS+%).,XT]+:G<^E6'__9U]I9.7R;PD-5OP['>Z$?NI'=O6AFV30R:> M^.DK:Q,*;*O-_CL[LDS"5232QYIGM?YOK0^UX'G+(D/)D[?FF1;Z>6KYW\VP M 6T-:&= R8<&7FO@=08>_=# ;PW\:PV"UB"X-J2P-0@'!DY3+%W]92*2V:3B M)ZMJ-E"9J'U*QJ%8Q26& M= A'1M"%05$8.>8!X3QSS$KA EP0AZLJZ<)O#."$!/X MD,#7!/X9032H2(,)-:;0&(^XZ@\["J"C #B*!SL@N'#TQ0](WU%3?H#S/.\" M]P!PU/6-@8$D(=>7D\!3X)[0SPNZA"!#10D6)_$^K^FR!5U55"QA M C0<^08*+$X2W%!4+!,"=!(%P^,;@4Q^L)I(!"@B P76$XEOR!:KA2"Y#+*= M0U!L^%YAP5 D&,/I0[%@Z V"H5@P%&EAN+809,H6"X8"P<2&PYIB,5#_AFRQ M&"CX5%UF"T"QJ1?!BJ% ##$U4& QT!N^+12+@8(O1SSH958M:-0[I.AP79Q> M+YBS:J<[^=I:\T,A5(_3F^UN"_>Z6QW,+\CXH>DQ_],T5Y ?2;5+B]IZX4)V MJKJ?W'(NF S1O9,+LI>WGFZ0L:U0KY%\KYK6OQD(7K;7&J>[6\W^ 5!+ P04 M " !RBGM,54="J>T" #;"@ &0 'AL+W=O$-M\,_/[-)[%5ZW_V M0E:YTEUY")J3Y/FN-:K*@" 4!55>U/YJT8X]R=5"G%59U/Q)>LVYJG+Y;\U+ M<5WZV+\-/!>'HS(#P6IQR@_\)U>_3D]2]X+!RZZH>-T4HO8DWR_]!SQ_Q-08 MM,3O@E^;4=LS4WD1XM5TONV6/C**>,FWRKC(]>?"-[PLC2>MXV_OU!]B&L-Q M^^;]2SMY/9F7O.$;4?XI=NJX]!/?V_%]?B[5L[A^Y?V$F._UL__.+[S4N%&B M8VQ%V;2_WO;<*%'U7K24*G_KOD7=?J^]_YL9;$!Z S(8X.A# ]H;T'>#\$.# ML#<(/VO >@-F&03=W-O%S'*5KQ927#W9G8=3;HX=GC.]75LSV.Y.^Y]>ST:/ M7E8D"1?!Q3CJF77'D!&#!R+0WH<0! JQ)HXYF0;8N 1%4R1SD3B:(H] G(3! M0BFX%K1U0,?S9!'L( 0=A*V#<*+ 4KGNF*AEZHZA+$ZL%7$IQI#M*W.I,";A MGL6QC%P(I# M9(A<,H-(0N/[]Q##61Y35S^U]5,@YZ'4UNY2.NM16[=+Z;1'+,W!Z,&NN#RT MU5/C;<6Y5N91&XT.%=H#,0^^-;[&\ZRKL][==&7?CUP>BKKQ7H32Y43[Z.^% M4%R+1#.]K$==:0Z=DN^5:<:Z+;MRJ^LH<>I+R6"H9U?_ 5!+ P04 " !R MBGM,)*\.73T$ #*% &0 'AL+W=O+\=E]NUPT+WVUV_O[=M:]U'79 M_KOR57.\GF^3[<_+ZYG9O!D:_\8S^$*,//JU_[JAHB M!1\_IJ#SSO/Y;..?RI>J_]HN;^HI2K!2ES]/O[O]^'N-N^@FH]3DS(RFLFFNFW&J&:>8R9@9)[H!<@3 W"@R= 4R MV9T3%01C"[!LT$B9M3FD>FZIFENJY,9*N$IE";.L8)E)$9@,4?>2J5XRQ0OK M9I5)+URSEIHP2G4CN6HD%T;(L#F]RD4GOT#.1&M%E$=*4JA."NF$S;95(?K( MB;_"M11!&'B1HH#1<6D$8LA )$2$N*!45B 7A%G'D;K61+&7##HQ 14SO+J3 MZ+*? E)N1HK2+/*>0:H(106AP!&*RM8TY:!= M*ZHP1O,BXD>G*#IE_,52TMF'"ON LP\EU^PE2::4%%5A8S-*QQ\J^(-8"!U9 MF'^@*#IF4,,,IQY*@(15D'\9:"HH(K. =,R0D78PLL21CAF"]Q>%=#:0Q@9> M%%)F?9KRD:*HD#"R%%#DNU9! \;JJD]GLA\HBCX#2=G'R*+(+0J)#RU2OOHH M]I+UN4S*5U_LNX3T^4?9!\X;]/E'69XNLG%D<]PRO=GV3[O M]MWLH>G[IA[/>)Z:IO9\4_FG?KC,PG5[.ET[W?3-83HY3,[' ME\O_ %!+ P04 " !RBGM,IK@L7;<" !S"P &0 'AL+W=O\()$6,*@@J IBX^DK%10GH"@!M03)*X+$2Z/'I!;36$Q& M4TJ]5#!4DDUDDZ!B$D3,PA/38Q97UWSP,1L,@^M8H#H6B([4T[$8W:&+$N>> M$@R5I#DN)D7%I(B8#"?(4()L?H_D*$$^HT?R4:) *8F]$K&D D5$..??SRC1QS(JPH4O@F,86^4!2;\"!!!$XT&N)G .]P$ M<#N!.7[B0*_R+1(Z\L8Q#-)L2@_N*##'4@#SB\17,]]4 '<5F&,K,'8,79N1 MKR P71N8T(,;"V#.4DQ0X-8"[_ 6P,T%YK@+(/82Y[G_42,PDM-XPBT!-QB8 MXS#PEG\X,;,MAN 60^98C .E_ZD, L,J$UU-/V8<_/@?U&B=:-N-$P9Z__ 5!+ P04 " !R MBGM,AAX]"&T" !B" &0 'AL+W=O-X/$EO7+S*@E+EO%6LEBNW4*IY1DCF!:V(?.(-K?6;$Q<547HJSD@V M@I*C)54,^9X7HXJ4M9NE=FTOLI1?%"MKNA>.O%05$7\VE/';RL7N^\)+>2Z4 M64!9VI S_4[5CV8O] SU48YE16M9\MH1]+1RU_AYAT-#L(B?);W)P=@Q5@Z< MOYK)E^/*]4Q&E-%O[N@;J]IB,/Q>_1/UKPVB_A M0Q(;?T+W[P6V4\0XA]T4DL1P$@'H,[#\X,[GC(L0#!#: .%=@)&/38N)+:9N MG7KV,_([Q>$%@-L!N.@>=Y=X!"8> 8D'H\1;3#00"N=E8E F!F3"D4P\\1/' M#_PDH% ""$4CH2G&GSLN"U!D 8C$(Y$I9E9D"8HL 9$$#H ]N'J]?S_6>.8" MP$ 6B_$-@*&UL M=93;CILP$(9?!?D!UM@< A%!:K:J6JF5HJW:7CO))* UF-I.V+Y];4,0"]X; M?/KG_V:,[:(7\E55 #IX:WBK=JC2NMMBK$X5-$P]B0Y:LW(1LF':#.45JTX" M.[N@AF,:ABEN6-VBLG!S!UD6XJ9YW<)!!NK6-$S^VP,7_0X1])AXJ:^5MA.X M+#IVA9^@?W4':49XS?F K.0KQ:@?? MSCL4VH2 PTE;!V::.SP#Y];(I/%W]$03T@;.^P_W+ZYV4\N1*7@6_$]]UM4. M92@XPX7=N'X1_5<8ZTE0,!;_'>[ C=QF8A@GP97[!J>;TJ(974PJ#7L;VKIU M;3_Z/\+\ 70,H%, '6H90"[SSTRSLI"B#^2P]QVSOYALJ=F;DYUT6^'63/+* MS-[+* X+?+=&HV8_:.@[#9DTV/A/$.J%4&<0S0Q(NO$;1%Z#R!DDSJ!U!C0D MZ2+-093.1"3)4C\F]F)B'V:SP*Q%A)#8CTF\F,2'R1:8M2C+$S\E]5)2'R5? M4-:B*/K@SVR\E(V'0I<'R".*/Z@E\U(R9Q"_.X%T 0>2+2 MY*LS%J=YN*#@V>6S;]L/)J]UJX*CT.8>N]MV$4*#,0R?3,*5>4ZG 8>+MMV- MZXFG1[O\#U!+ P04 " !RBGM,EZ]5300& !>(@ &0 M 'AL+W=O%R'9N/2WG M;.^=F0[03KO/:4E;S@!AD[2=_?:;! >P+ 5W'H9+?[)DR?[+&(X_L_QW\9:F M9>_/NP6.=I,FN,EHNA M\+Q@N$SFJ_[HN'EODH^.L_=R,5^ED[Q7O"^72?[?:;K(/D_ZT&_?N)N_OI7U M&\/1\3IY3>_3\F$]R:M7P^THL_DR717S;-7+TY>3_M]P]*CBVJ A'N?I9['W MO%=/Y2G+?MM+_U61ON/V]' MOVPF7TWF*2G2LVSQSWQ6OIWTHWYOEKXD[XOR+ON\3O6$_'Y/S_Y'^I$N*KR. MI/+QG"V*YO_>\WM19DL]2A7*,OFS>9ROFL=//7YK1AL(;2"V!B+L-)#:0+H: M*&V@7 U\;>"[&@3:(-@90*=!J W"G4'0:1!I@VAGT)W66!O$K@;@M97S7*<- MVV*#LY>VW+"K-\3=)FW!0;JF%]J2PU[-5;=)6W3855T>F'Y;=@B<3=K"0^AL MTI8>G&L/;?$A=LV8:*LO/&>3MOIB5WUY8*]O-[M ?;9 MRS=2NTYJ18>CRJH:O'ZW4;[FCY56%=6['R.IU/'PHQY),Z<;1AB,;S)G%!.8 MS#G%A"9S03&1R5Q23&PR5P3C>R9S33%@,C<4(TSF&\5(D_E.,2C//R@&Y?F6 M8E">?U(,RO.88E">)Q2#\CPEF #E^8YB4)[O*0;E^1?%H#P_4 S*\R/%[/(\ MK#;,=M<(>M>(9@1IC!#0(TAZ!-F,H(P14(VF&\9OF%7#H,P^V(20<:3H2!0= MB2(B02MAJK[BQZ?]^(0?O)HV3+3G!P8RI-T$M)O =A.BM/T([.G0/D+:1VCY MP#,9AY8+WVO^H3UVF#,"BNB (F+2:(>--TRXOYH&GH>HR2'*B":FHXFM:$*T ME<([*;8U=N()7KN"$ M $4EU\HBIP0)@1<"7W:F#0'1A\( "X%OKS'1N4>8;@14.T)]_A'L?@1=OIBN M!'9;DF&$9Q;2NP<7QL: +(O-10$?.=.^@.I?:$O<:FC?5:!X5TQO KLYRD=&>/)NG1*;I"*+I1*B;G&K(2+4B-LL9!88=ZT0PC4<0C2="0C45 M=I? AT^-N)W6!'>2)II(Q*6947(AW8_C@E%*82NEU0V^"?L<'$,$W)09!1*4 M OG8E:U T"4*@A$@00A0I+ S6X!\WA,C/X*0GXC[6,4(@8B^4$EFAPMJAV.! M%_8.QQ)(($)8EQ%3 E,J!($W2Y=#\P,C(R:2$A/\L5Y#QIX4 T"K:^*&3:6M M.%S0C-9(2FOP/8,DA,2(QG3%*(FDE 3MX%,-&2N].LYAJ:4P\'!^;@@L $!K M[3M%>3'V.:6PT NY:P7N7H&X6(AQ?Y/VZ?(O ;'$6X#DA'6A,CW,F;$S&BR) MTVJ,VN5/#1U8NF,W;'(0,P-G%%T2BA[C#Y<:,I*D(&(\,7(N"3F/)?844),2 MG"M&SR6AYS%744;/Y1?T7#)Z+EWT7!+W!)$G!2ZWC55''WR!.B4P1O<4(];* M1:R5K<(B&N!;B0F!234 5/6IY?L9DS<#:Z#;HZ5K70B M'EAW_@3653=&$)6+("I"$ $4(U.*443EHHC*5L1JI_E<[1E%5)0BHAGM+D]GVQ2)]*>NG8?4\W_SB8?.BS-;ZUQS#[4]*1O\#4$L#!!0 ( M '**>TR!,%7@AP, *P0 9 >&PO=V]R:W-H965TXR>6RCM[GB6AD,/L M8.2GC(6[4I3$AF6:GI&$4:H/^^6U33;L\[.(HY1M,BT_)TF8_1FQF%\'.M&; M"Z_1X2B*"\:P?PH/[#L3/TZ;3(Z,FY5=E+ TCWBJ96P_T+^1APTM^!+X&;%K M?G>N%9Z\#!:[@6X6"V(QVXK"0B@/%S9F<5P8DLOX7=O4;U,6POOSQOJL M]%WZ\A;F;,SC7]%.' >ZKVL[M@_/L7CEUSFK_7%UK79^Q2XLEGBQ$CG'EL=Y M^:UMS[G@26U%+B4)/ZICE);':W7'([4,%UBUP+H)B/>EP*X%=E>!4PN<3X'[ MI<"M!6Y7@5<+O*Y+HK6 =A7XM<#ONJ2@%@1=9R!FDSFSL^26;-)9TJ2;6%T] M(4W"2>>,DR;EY"[GSM>2)NG$[2QITDX\(#&J)BF[;A**<-C/^%7+JGWC%!;; M$WF0*FF\N%KV<7E3=EXNKUZ&=D#[QJ6P5#.CBK%:C-]FQA@3M)F)RCBFV6:F M&$/:S QCK#;SB#%VFYECC--F%ACCMIDGC/':S!)C0)Q7& /BO,88$.=GE0'1 M>4&R!1*Q41'ZZ9,AB^I6619>659IP+XS0*B)6[!Q"W9IP;GWE8!ECBK&+YFT M9,P> >Z.40A4U02%0'5B# S_#(5 'A]1B)JM#YA]CFI H2U0"%9L%VB)0J _ M5B@$&FV-0B!)SRI$>BXL7,R2!^*T03/IX*7GX*7G(*4'IADYV#0@B&,,L@ T MP2 ;0-,NT.P_4,MU%W?=15P':1A5C'>?*]LK2A9XCW"6XRGGA)>DA)0GVF!'&@,UJC#&P%S$& M[+%3C $/\QG&P(< QH"GR1QA+%AY& -VJR>, 6V]Q!@0YQ7&@#BO,>8?FQ#% M,TX1"R +(XK5EEJ#8Y6S?&1SF:B<'7B.N@FAG-IS,XQSB%K[QMW+>O$[?AUF MARC-M3Z%B!T:50]V@EM6D=2@ZKMQG?[G+ M)%X!?M:H9Y.U(RO9$_(F-U\.*]>3AA!&)9<*4'PN:(,PED+"QF^MZ8XI)7&Z MOJKO5.VBECUD:$/PK_K JY6;N$9\U?2?T:ZGMAU=/%?T05A 9=.1(Z2 M8*9^G?+,.&FTBK#2P/?A6[?JVVO]*\U."#0A& DB]R-"J GAC1 ])$2:$-T( MR4-"K GQ_V9(-"$Q"&!HENK^%G*XSBGI'3KX3["9(Z(@,TQ\ MJ/)IC@B-2G9S2)K82PFM'0T5/[PSNK +1%:!2 E$4P'39#%@$H5IATJ]U//L M:6)KFMB2QC?2#)AXDL;W///HXYF711P9?9]CS+8_0MQ5DUBK22S5F%@P0J8/"4- MHB_T74$L#!!0 M ( '**>TR -XL@. ( $4& 9 >&PO=V]R:W-H965TU?7:($] 93&TGN?Y];4,X M8MQ[B>UE9G9V@Y?\QL6KK"A5P5O#6KD.*Z6Z%0"RK&A#Y!/O:*N?G+AHB-)' M<0:R$Y0<+:EA((DB#!I2MV&1V]A>%#F_*%:W="\">6D:(OYN*..W=1B']\!+ M?:Z4"8 B[\B9_J#J9[<7^@1&E6/=T%;6O T$/:W#YWBUPP9O ;]J>I.3?6 J M.7#^:@Y?C^LP,H8HHZ4R"D0O5[JEC!DA;>//H!F.*0UQNK^K?[:UZUH.1-(M M9[_KHZK6X2(,CO1$+DR]\-L7.M23AL%0_#=ZI4S#C1.=H^1,VM^@O$C%FT%% M6VG(6[_6K5UO@_Z=YB8GB%=+=+TW0-ML^T^V1.GHM$$QS<#5" V;38Y())AX10*N/*1)? MBDTRHR>/";9S!(P>(;LY),-^$]!;)[1\.*TA@WX!Y!5 5@ ]- H[C>HQV&): MB_F4++'3SJT'!>/(T=IY4-DBB?R64Z_EU&,YRWCF>7%PG&,9XU!$"5.^[9S%$91YE2_\VAEV=)U#":7J:'B M; >5#$I^:95Y)R?1<18^)^8R.O&-GI']2'N7Z0?L=R+.=2N# U?ZJML+>>)< M46TR>M(=K?1,'P^,GI399GHO^LG6'Q3OAJ$-QB]'\0]02P,$% @ &UL?5;; MCILP%/P5Q'L7,/>(("V)JE9JI6BKML\.<0):@ZGMA.W?US:$);:[+_&%F3ES M#L8GQ4CH*VL0XLY;AWNV=1O.AXWGL;I!'61/9$"]>'(FM(-<+.G%8P-%\*1( M'?: [R=>!]O>+0NU=Z!E0:X&DO#9<;7ED, M\()^(/YS.%"Q\A:54]NAGK6D=R@Z;]WG8+//)5X!?K5H9*NY(S,Y$O(J%U]/ M6]>7AA!&-9<*4 PWM$,82R%AX\^LZ2XA)7$]OZM_5KF+7(Z0H1W!O]L3;[9N MYCHG=(97S%_(^ 7-^<2N,R?_#=T0%G#I1,2H"6;JUZFOC)-N5A%6.O@VC6VO MQG'6O]/L!# 3P$((D@\)X4P(WPG1AX1H)D0:P9M24;790P[+@I+1H=/;': \ M1,$F$M6OY:8JMGHFRL/$[JV,PJSP;E)HQE03!JPPP8+PA/H2 MA"5,"@@\< M.Q,1^H^0O0E)$[N)T)IGJ/CA0YZY72"R"D1*(%H+1)K):L(D"M-/F?H@3;5L M350:Q(&6KPD*@-UN;+4;6^QJ,:H)$Z_M:E9-Q*=,=VIB M^W6TVL5A/3:JC5 MK$K,("!(-+<64!)IAWEO@J+X/RZN2W6YNM9L;=K-<Z2]Z M9Z*R/-U= M9NJOWR&]M#USCH2+FU[=QV=".!(6_2=1S$:T]&6!T9G+:2KF=&ILTX*38>[9 MWO+'H?P'4$L#!!0 ( '**>TR<4\:"\ ( /\* 9 >&PO=V]R:W-H M965TP%L_G?W.W/&-SFI]K7;2:F#M[IJNFFXTWI_'T7= M:B?KHKM3>]F8-QO5UH4VPW8;=?M6%FMG5%<1(R2-ZJ)LPMG$S3VULXDZZ*IL MY%,;=(>Z+MJ_C[)2IVE(P_>)YW*[TW8BFDWVQ5;^D/KG_JDUHVCTLBYKV72E M:H)6;J;A [U?4F8-G.)7*4_=V7-@4WE1ZM4.OJZG(;%$LI(K;5T4YG:48UO#\^=W[9Y>\2>:EZ.1<5;_+M=Y-PRP,UG)3'"K]K$Y?Y) 0 M#X,A^V_R*"LCMR0FQDI5G;L&JT.G53UX,2AU\=;?R\;=3_T;(08SW( -!FPT M,+%O&<2#0?QAD-XT2 :#Y,,@N6G !P,.#*(^=[>8BT(7LTFK3D';U\.^L&5' M[[GY7"L[Z;Z.>V?6LS.SQUF2))/H:!T-FL=>P\XT+"67FKFOH:,B,@0C!L,P M'ID? @3XKV+A*V) N?0E(L4Q8W2U8F$$9$#NO)5\%RNJ6X0!4HJO!18PKVGO _((&U,!<>1\[! M)E[X&IC-+<5%-AF:388L? 9 ,R_$IR0&H(@FS@0L;%_%"!4X;X[RY@@OJ-EY M[K-03@BL%$3&J* @LR7F+2-YCE-3@O^PB<_-O;\QP8@(^-,L4%D*2G")J*X4 M!KURQE $F4)DBM0&$9 8464>L"^BR15B]#AZH,PCSF!M#)J+K9EGL.07B"S+ M M=_8/4$L#!!0 ( '**>TQ8U]T9L@( %8* 9 >&PO=V]R:W-H965T MB?LZ1.'[Q$MYOB@S$6U6+3OSGUS]:I\[/8K&+,>RYHTL11-T_+0. M/Z&G':(FP"I^E_PN)_>!*64OQ*L9?#NNP]@0\8H?E$G!].7&=[RJ3";-\7=( M&HYKFL#I_7OV+[9X72;X3U9_RJ"[K, ^#(S^Q:Z5>Q/TK'PI*PV"H_CN_ M\4K+#8E>XR J:7^#PU4J40]9-$K-WOIKV=CK?]#UN]4R\U"@)Z*;>3"3MG?V/UVMU+.W39+B570SB0;- MMM?@B<91['P%B4=)I %&"@Q28!M/9A0$3D# !,0F2&8)$J>,7D.MIK$:5+B% M^!I,4A@D 4$2 "1U0'I-.ETDBQT07T/Q0D=2$"0%0*@#DGJ+()(Y;=OY(H(F MHAD*!5$H@)(Y*-1;Q>W(1XH91 9"9 !$[D!D?M,="%^Q )&#$#D 43@0N;\I M>>(^I[XHB0F&40H0I?!1J-/R;>&M\N"_,H!H\9U!,6Q",0"#7!>*_<;0U'U* M !7)BFP!9\$3D6]'=*&Y"#8TA(&*B%L1]EOGOGV0ADS+GM/ [H@@>W0?_D$T MWTB:N3R *D%+VPU[) ),DKINC7P'?, 9(Z'P?A:/*!-R>N'ZP[EXT,]D+ILX+]HI^$4%QGC!\U M^D4?\L9!Q4_*W&;ZONM/.OU B78XQ47C47+S'U!+ P04 " !RBGM,>$)G MW*L" "_"0 &0 'AL+W=OQ05UW>R$;7]LI>JXL9.U2'2C1)\YTE5 M&>$X3J**%W6X6OBU)[5:R),IBUH\J4"?JHJK/VM1RLLR1.'[PG-Q.!JW$*T6 M#3^([\+\:)Z4G46]RJZH1*T+60=*[)?A [K?H,01/.)G(2YZ, Z<*R]2OKK) ME]TRC)U%HA1;XR2X?9W%HRA+IV3M^-V)AOV>CC@P/6DCJT[%FE+Q MM_9=U/Y]Z?3?:3 !=P3<$]K@S!)(1R ?!/I/ NT(=$2(6E=\;#;<\-5"R4N@ MVO0VW/U%Z)[:Z&_=H@^V_V;#H^WJ>4639!&=G5"'6;<8/,"@'A%9]7X+#&VQ MQA,ZOM[@<8H@\35D,X6D"6P$ ?TDGD^N_$QA 0H*4"] KP2R4:!:3.(Q=83@)CD@@&$!%,-U&]^> M&S13^NB&['2@J_00Q$;9Z5#L.HFC,M\ *)Q0-F,T>)@\('Q#?D#0S%^ X/," MD8D$SN92!)\8B/Y'BN *1E )3U+$)BG"+!L7$( B&6/C%$U1B,X5$()/#93< MDB((1$?[1(-;K!+JX#L$'6SEJ3;N,ABL]EW( W:WX&A][;H3?SM^R+2MS3>N M#D6M@Q=I[!WK;\*]E$98&^,[&XRC[:;Z22GVQ@U3.U9M2]%.C&RZ=BGJ>[;5 M7U!+ P04 " !RBGM,\96S9+,# !-$0 &0 'AL+W=O_;+C M15J?B3TOY9VMJ(JTD:?5JU?O*YYN.J,B]R@AH5>D6>FN%MVUIVJU$&]-GI7\ MJ7+JMZ)(J_\N>"X.2Q?NN:2]XJ\4^?>5_\^;'_JF29][@99,5O*PS M43H5WR[=O^#\D?JM04?\S/BA'AT[[52>A?C5GMQNEBYI1\1S_M*T+E+Y\\[7 M/,];3W(<_RJG[A"S-1P?'[U?=9.7DWE.:[X6^3_9IMDMW=AU-GR;ON7-=W&X MX6I"@>NHV=_Q=YY+O!V)C/$B\KK[[[R\U8THE!ZPX)ANH+,'=DPXS,XX'%,.LW,.QZ2# MF76OK_BNA;ZD3;I:5.+@5+T*[--6;.!<6DGG[=6N*;N;LHUJ>?5]Q:)@X;VW MGA1ST3-TQ/@LTIGUE&%1J#-?,#^QSEQB?HQ85XB?@.C,->;'B'6#,8G.W"), M;,3ZBC&@,]\PANK,'<;X.G./K:$1ZP'SPW3F<?-R#WWE@F@>C9KYA3(1'87@4AG@P*N$>8Q(\2H!'"28>@!IU4 M'1.0[L_HDYG,A$:'75JXV-@%KG&.CCI6&WD+HAL.^;Q3;A6D52+HI:T' ML^UN\'DI?E605A80@T5EP"*'0)%0OAF*3D(%]DE99!,034PLV@T6400VOP;! M(GDP0_/6@&@*0T3J$@,#!+R> >K#MZ@48#)E6P*+%D#T!\MH40.(/]\&;U#( M5J$6T0!,-8Q =PK2.R\RDW"/86RR\2"4/Z$>%35NBLB:36J1%3J5E>DVCT*6 M?9Y:)(5BDF+)!+4].OW!LQ.UJ #%5" T)^Q/$T#"Z1,"PLG7@.D# L(% :)@ MWNC]H_W0<)]6KUE9.\^BD2\SW?O&5HB&2Y_D3"9^Q]/-<)+S;=,>1O*XZE_P M^Y-&[-7'"V_X@K+Z'U!+ P04 " !RBGM,L<]&XD " #P!@ &0 'AL M+W=OE%!C_D1;:.3.F;(:"[ED%\1;!OBD235!@>9RQ%SR"GY79U$N7$7KG.",[X2\4*[KV#RB5W')/\=;D D M7$4B?124BQZW>2R-#LA, 0@H$@?3\BA(80W@G) M0T)D"-&=\#BDV!#B"0'UN>MB[K# V9K1SF']=6BQNG7^*I;'52BC/AV])^O) MI?661TPPP@2)]QF3SS'^@$ R@B&,P!;&-IC1H^5RXF*."3XC M=G-$.(ES/X>DB3W0T%JO4//#<9[ITBX0604B+1"-!&)O6DP;YC_EC*U.8HO MI%BY#1/:G216)XE%()HXL6%BNY/4ZB2U""23^VG#I'8G"ZN3A45@\A/D/2;1 MF,8\R_5OP [-+U7#G2(5L,KH5G"D5(*/TGN0=*>7S,RP(G(6:IG+. M^B;<+P1MS?N"AD&ULE5AM;YLP$/XKB!]0\/D%J))(;:)I MDS:IZK3M,TV<>FME$[759U/*A"=I]5>7-OWM9JL,T).';Q&.QV>IN(II-=OE&_I3ZU^ZA M,:/HR+(J*EFWA:J#1JZGX1VY75#6&?2(WX4\M"?W01?*DU+/W>#;:AK&G4>R ME$O=4>3F\B+GLBP[)N/'WY$T/*[9&9[>O[%_Z8,WP3SEK9RK\D^QTMMIF(;! M2J[S?:D?U>&K' /B83!&_UV^R-+ .T_,&DM5MOUOL-RW6E4CBW&ERE^':U'W MU\/P)$E&,]P 1@,X&A#QH0$=#>B[ ?O0@(T&S#*(AE!Z;1:YSF>31AV"9OA[ M=WFWB\@M,^HON\E>[/Z9D:3Z*4C&C'W P9.,.2(B S[<0G EK@' MQQS.%YB["!J?0Q8N)!&X$Q2-D_;V]#1.$N,$#"5@/0$[=2"U=!H@HH?4@TY9 MP@6UHG5AD"8)6&P+!"98*CQ.<]1I[CC-B>>_$RB!N%RV!"5(/I=M@/"30"EE M%FCN@AB)[4V", 'S;),4=3=%! .<($,)LLL%(S&>D?'GDHT8?K;5J*T9ADKM M[%X@*$A\JA%/%2&(;M1#@5:).P)7*(?G.*$7*$>=:'GL".>"[*WV(>3<6;R> M$+>@L,2SU0B>W81?(1F>WT1<()EPMU'",A"V:BX.A,EDL*5#<(PG-/%XCA<6 MXE862'WZX!<67"IQQ>8, M,)SX*/"T M!W:%(Q7&7"K#">>$P;P=(?D"MWP M= ?W<'=U2]TLM+?2' &EW'Y]0T"$4)]N>'4!M[IPXBF3%$]V&E^N&\63G;J' MNZ/;B#FKZ6"CY@B* &66<@B*^BH[Q8L+=8L+)ZF'PM,P7-$Q4#S7Z04] W5? M\ZFSX1 0<&[+YH(R^UT_.FD+*]EL^I:[#99J7^NNNSJ9/;;U=]"UE=;\O6GW MA^;\G6;X5O C;S9%W09/2INFM6\MUTII:5R,;\Q_NI7YZC@HY5IWMXFY;X8> M?1AHM1N_/T3'CR"S_U!+ P04 " !RBGM,V#!WHE@" #_!@ &0 'AL M+W=OP\P8).((!U!52NU M4G15VV>'. $=8&H[X?KWM0WAB''O)=C+S.SLQJS3@;)77A$BG+>VZ?C.K83H MMY['RXJTF#_1GG3RS9FR%@NY91>/]XS@DR:UC0=\'WHMKCLW2W7LP+*47D53 M=^3 ''YM6\S^YJ2AP\X-W'O@I;Y40@6\+.WQA?P@XF=_8'+GS2JGNB4=KVGG M,'+>N<_!MD *KP&_:C+PQ=I1E1PI?56;KZ>=ZRM#I"&E4 I8/FYD3YI&"4D; M?R9-=TZIB,OU7?VSKEW6$R>LOB M8)-Z-R4T8?(1 Q:88$9X4GU. 6PIG&1B4HWABP_1H&X :%!JRPP.+0C_[3^]CJ M.K:X-KJ?CYAXZ3J$B^Z.IM& M90L*0?-T%Q94G"RT'BPCJV5DL6R8R='Z;&Q0#(W*]FL82! "B6': H-1 LT3 M[2W&0$O818]8[I3TV@GU-2VB\Q1_!FJ,&/%<3O=Q&+_+C%?#=\PN=<>=(Q5R M2.E11M-&\:2:C3-YW C:3]>--]]YV3]02P,$% M @ &ULE59MKYL@&/TKQA]P$7RI-M9DM\NR)5O2W&7;9]K2:BZ* UKO_OT N<8J M+NY+$3C/\9S3/M"\8_Q5E(1([ZVFC=CYI93M%@!Q*DF-Q1-K2:-V+HS76*HI MOP+1@$4>8NOY#N1/]H#5S,PL)RKFC2B8HW'R67G?X#;/8QU@4'\K$@G1L^> MMG)D[%5/OIQW?J 5$4I.4E-@-=S)GE"JF92.WY;4']ZI"\?/[^R?C'EEYH@% MV3/ZJSK+GOG=?^5W E5<*U$O>/$J#"?WNDF)*LM MBY)2X[=^K!HS=OW.)K9E[@)D"]!0 *-_%H2V()P4@%Z9L?H12USDG'4>[[^M M%NL?!=R&*LR37C39F3WE5JC5>Q&C. =W360QSST&C3#H$;&?(\)@@ E8%"! MG"J0J0_'*N "0>@D" U!]& CF=CH,8G!- 8#891-G#A 89JZI41.*=%<"H1N M@MA)$*\/(W$2)"O"Z#'QR&<2I9,LYIA-$KJ%;)Q"-C,AT0:Y"5(G0;H^BLQ) MD*V((IO;G"8QA\!H00<,W'T6S)2@="$+N-"J<'T:T-UG$*W(PX(>W,)9QSM M6;8@QMVST-&T<*'5H+O78/0?D;B[#<9K(HEGQT(X:FH;R1R$TF0B!HP.9GU3 M?L/\6C7".S*ISGAS$E\8DT01!D^*L%27\S"AY"+UH[I+/-[?4/U$LM;>OF#X M"U#\!5!+ P04 " !RBGM,FWM ]R(" #+!@ &0 'AL+W=O=;$.TS XPHE=N'X5[1?H#25AT+O_!E?@!FXS,3$.@BOW M#0X7I475JYA4*O;>M67MVK;7O]'\!-H3Z$ @\7\)44^(GB7$/2&^(Z#.BJO- MEFF69U*T@>R6MV%V%Y%5;*I_L).NV.Z?*8\RL]<\H8L,7:U0CWGI,'2"2:>8 MC0^SG&*V'DR$!PPR>0[)4F^RU E$$P'B%XB\ I$3B"<"],YMATD=IG88/".1 M/TKLC1)_B!*EB5\@\0HDS_N<>P7FG@SN5F/389*1SRBFF/K#++QA%IYR/JA4 MZA5(GS>Z] HL/1G$=]NNP\Q'1F.S[_"#G4>P_YQ@3Z0'BTH>'#7RO%OB/P"$ M/N&W!XT-1W.,/SI&HTO"7O/?F3R7M0KV0IO[QMT*)R$T&%$\,QNE,"_+,.!P MTK:[,'W97:_=0(NF?SK0\'[E_P!02P,$% @ G)U6R+"=*;$E7DI/7K^O6*X@$);1)@ V DM4U?_S[MK,!!Q1EN[N3GIFJ MZO/JVV^K M^5VZ3JI>L4ES>+(LRG52PS_+VV^K39DFB^HN3>OUZMNXWQ]_NTZR_ _?_['* MOO]C_?V;8KY=IWD='.6+X"2OL_HQ.,UYAJS(@\/@P]6;X.#%RS]^6W__QV_Q M)7XQBH/W15[?5?#6(ETT'[])Y[U@$(5!W(\FS8?OD[(7]&-Z.&T^_&F;PYM] M_YM/++6K-/FJ+.CZP^71^^"'T^.WEW_&%Q?GIR]N0J. MSR\O>AT3'L,2RF0%GUZDGX*?T\?FN.-M6>(RWV;5',;]*4U*/*?@35*W/G]X M&,6'@ZCC4V^S55H&Q_#>;5&VOG,TGZ?P')XN>&37@F4]E^FF*.LLOPVNZJ3> M5LWA?TI;/\D,OQ0K +^DE!6UAIT5'2_^FJY6AQ_SXB$/KM*D*G)8ZFE5;;O7 M6JS7 'E7=3'_& 97=TF95L'YMJ[J)%_@T@^R/*CHYQ94RA07VYM5-@_>KHJD M[@2AZ\=-ZRZB_N'/G2]"!9E2& 0O CCW MZ[MB6\$]M!=M(?RX"QV2JH(Y7[4>)]5= ),&<_PC_>LVNT]6,+[UD=/\'GXN MRBRMPB!/6W=[7M\!LLR=KS7'7!O9X(%Z/_E#42P> MLM6J^?ME"A0GF^.)XJ[:Q[5,806+X#KY%!S1(L+@+(5OG!6Y+,Z_NUV[\C]3 MI[_*DIMLE=5P>JTK $*"[*4*-LEC7LP2A2OJDTR3__S#R R5&EYG_[A^Z Y)1'ENV*U [P M[_][&D>3[P@_ZL<61%V4:N\54_(7_5Z_'P'PE &@]S;]+AB%_7X?_U_(>9!L MZSO [K^EB^^"O%"_9L@M%K2%PF(#21T T4G7-W#'2M*@05X*Q$RE>RG]76N) MXG VF87#:-A-0@I"&&)&4.>ZV" M \"9[7J[(A*]2)?9/*M;W._(&E,P[!=KN,T[P#( H.!@55352X2HHBT%78.@ M6&V!O\L9P=;F157#YL/Q8!*.XB%M#/XUB\,XFNISVG4$(:!PM4GG"+^KEO3" M$%QUPM23$$_?V?_]77SNX")!/+Q+ZPQX+IS2(3"\;V63;32 *8C'%DO@TCE, ME"&C+BJZX.#/1SA.R8))6W @<[WTBFPRX4T*>F.J7B')IEOJP2._SRK/-O >_115 MWMXP'29 1W!K78J9(0 YII@3\-:%?LFB;WNBX7-FW*RV%0J.H'*@Z 82=LGP ML=^G?DVSVSN8_C"!%Y/;-,BWQ H @.U-5S;K;IV FB0XDDG.]"1M_2\$TEUE M\R^[Q';PCR?-TM^3I77N7^&+1D^8KKX_>'9T= MGXAHJKGUT$.@2P+3 QA&?Z%P[+^Z/U\"*0P 'QZ2(:;WKFA M9T_6$AT4J07M9@X\ITV:3U89""$\!]+!ZZ-@NX&_%_#1 HBYAS-@QSJ,I:LJ*;+N!O@BC@KXA8YMWW6QE!9R%S8%XQ59$95 - \M MQ<./\%Y"!/%EFGE8XZY)?T$=XZ3C%EL5U%SM&%OYV53SL;^ \ M/KKZ,7C[[OS7J^#MY?G[X/SBY/+H^O3LA^#H^/KTE]/KTY.KMEG-O4@0C@M0 M%0'F_X+[)]DI2Y@.7>/%J2<8+ZL]]N=_P4=PTT!L#F\DY951NJC&4K M.&$A.CAX#9K TD/UCXE+D_K$ED>2^7>9&<_VW>A3IW]Z]LO)U5.G?R&4D*Y\ MX[7I=K($V%.YVX2K][*M^'0SD)VK9^[C[>D9P/)3^RB+>9H":20=*-V#=QAJ MNO'(J:V5+]F$L7/E)\ME.B=!,?TDXAGZG8BHSO3M&JV/6>;?76.X1\W^#K]%,=O ;E[V/;]'!R#0AT M?/[^) B%L ?[\_/@JL?CRY/@/Z!J@VB3O& )UHCIPRR%>B(-=\VL!MBA=M: M<^(;5,?H%A>L5-G4K:G]DFR D_")(_%89*R@HGA1&S,,@%FZJ8WJ&0 A3UZ^ MTLY4$D>;AD?DIL1ZU7F+8&(.YKF_D[*Y:T>O EO=5N)%E[K](H@'X6@R#:(H MC$<1_KL7]>$_HU'8GX[QY\$TAG\/>],A_F<2QL,(+="#/OX\P)\-+M*)(_4W M0LRKX%_*_<80^BD.D:^2.T031G0;.7+\QTG\.9TK+ M_GK'UVFM<,YU/*%S[<^<J1T/ .V;MM W6 M*: *O([N(7J>D%-,UF>D;;3A$\XMMRA,!>C9R> 56,)V51/OQK?O'C>%,G[# M,UN'D(TC.J8+M1J@0EL8:8P],@H.[B8->)N]G;!3HXZ+T\5A/(B)? R&(S4/ M'6M>$&"LM@O1*?#+CRD:I-(._._RO3C6?E).B]S'9[K&[2"^5UNX)A(MX4#< M]]]DU1P4#Q1B=Q)D)=%>_7@"I!GH\<7Y&;(GHL9SLPB\7(&F&_D0A?;(Y0,0 MP:DEE1#PRJ6H0#H[Z&6G__T5/WH1C*-PTD>T&<7A<#3@GZV!P600COM3_,]P M/(5QT6 4#B(D;U$\"F= 1RS?_2OTF62P\D5P6R />!%,PLD$L37JAY,X#BZ3 MAV -3*',DA5,/IO!"B9ZBL= /)0$%,4-2/EI-4_Q. ZB:3]X&1P ,J- /PT' M,UH.$MM)X/?KOPK.ETO$"?T+;G1 1!F^*@^K8ED_X/G.X,3&0#/>)_.[+$]A M-3 TG@9OM\"$"<=P]F7VB927()X 0P)*\PYE'B1C0;9&Z5>4D1DL:SKLHW,6 MX&L[)Z2%:X,AM_ ZW2%B &)*EL.)@!9X"'*;6<\BO4]7!:\;L;UZ":<81)W; MU:X]P+Q)- OP1D?!D>-?W&'&AR,&.DN''(5]H+1XSE$8#>GZ@'E- [^7_U5P MA1X-N#LX&*+8XVA([XP!_T_6FU7QF*:'9"43@"B *X&,$A H%.$9[) MA)LI<-#OD(N8/@[4/A[ UJ9P60A=X_X(/S4,9]-9T(PO>!5\R*N[;+.!G^#< M%W +R#_"(0%P'$:S*#C:UNB0SC:@6]TCYE6X\/$('@_B"<@C)> =]*[KA6[ZY@\N>'MT>AF '/[A)'A_;8"IW!2HR2% Y'B%1%X!ZA"D#B+&/_AW MA @X! (\PP=*"-,_'1?EID 9'M#[IK;D19#3PB%@X$$\A+GP'T#( ;8G _@) M?L$_(\O+#:NM@=R/05B]1 JF2"]B6)'G*3,EFJ.Q9%@:[/$%B-J*&@'Y>A'U MIOJ?N$+X8:1_$ E92!WAE0AMH\ -%^D!2R5^BK[G]78MIU3TSW#L!Z<4X#QYB2R MJMUD]:.[[0R% J#B)7NI];H3?<"PO1=##L]B4Q[M!57)-0:AP_IJT+?\2^CF ML_8:$(X)WD$.R4BRIK,E;F+6;<( >BU,3_CT'_>]'GTN#T6Y6CQD"_=+9(!$ M28D07,Z$3'3.J8Q[8XU:UM' VPCD(2O,2FDH+;$ZN-TFJ.RF:=4+3I?.82P* MP&S4OO15X%/U6?6-Q%P;G24 )@::I\%%\BB"9D6Q:CD.P"!9U T7VU2!BSH. M/DN*=BQX(>8(LXH.$+4^4KQ3ME/^E !DEH^,R10%=@> ZH-B.CZ\FSG(;(1+ M>C[ZHH V[!:E?/R^!4%9Y5BJTXR$RTT"0G5/1%9.1S"4N\4 S"B+OA-DJ&M9 M$V16"DK620[R([U1I\D:#@0%=B '-ZF-@68]!*0B/P>B)JLED"%A66Q+D(#2 MCSI CK?+!^]?H4.+-"XTUP;\@;:@\:+BY6K@8EL? P3M$.E[MLS2A59:A;.A MN$SVB\1R_^/\(%F[H(0,;^GN.G.($RZWV.*A@:;4>E-5 N!RQ#P1*+D%B6- @P>D7W72L,D%]0&C4QS,@[I$W-E@3<96UC@Y6U9:WN)RE71C\G]M9XEO> 1#/0K4)6@%.,K==:/!SE*L";A8#>/-G0MMX6Y2*X[P5G M"9 M^.*/(.$"V%R7Y(A ^;,74/1,&IP5O2!^%8T/Y_>'?1 \1H?7/_UX>/3V M_:<0K5X%RC(+.DP0JQ;!!9U6MER"*/,^NVPP0'0>\2^^SX-^3]>:[X.>B!'):?7P,WKV[P,N>%X?T,8L]:C;HY]YST]:)K1"R!AX1\N'B#F@/PW/'YZL MR<5RDP*!6Q)Z )T#SE>18'AGV.4"89NTWX>,[DDX*N*^8[*\26N@!>K:Q^RJ MIN/A7Z*1R&5\Q0?92X1_NN*H?W#S4A%I"RE.E$OHB $LF@TX7/AR"W)NU+\Y M'"&)6&]7MPJ4RI2G[P+[X[L2D/JZ1V9XO.#K; V[>PRN>G#]0)(KD2Y_2(L2 MOOQS+WA=%LGB,3BHB]L4O\"0C"0O[G]WFB_0*8962]3_\P4:>NE9]-U+!I^# MS-IJW#](]M^JM0GOAW9>/&8OW**8#A01W5A"U-&C$S(YK1M,Y0;OK]RRVPM0 M@&=8 ,_+\"\43;D^H#>R$83M($17?MI"YQ>0;,K[BG$!9#"RP:, PD; M0V/%P>5;52BB\@-QAAQ9&+RJ!&W>DBU^.S_ MK&P%+B/JNY,AA59L&B2<.MMLQ?^O4)R9;\DI)QLX&) &"&2 ABS@-E=X/1)% MGVA7PYPDOH)B1Q_L.?#'-+]-F#=7:5VSX1L/;[[EN&)KN<[>U10E6F5D]T;* M0PDB ]%NPZX?GEIY&K2XC3[\HE*4^)!D9FL5* ]'O8G1-?&F0!$&Q4L"8,VY MP=/S>5V01L#+5!*]J C\GDC[YC*L%2DA?[DEXK'-17"V M@%\D4%PW6EY* !A#)DG>RW)6$6[@R%,,;!$*B$Y,YH>HWBL9;PVDBA$?J4!. MUWR?W1:@YE:PA@7-;1/H-0J/B;WJC)4=.APRR8DL09LURP? 8&Z4LC<2UEUF M]RSJ'?/"3BW49Z*36/)#9;V[,.\:LH<@PK1!)+RK+9DO2P6TPHV0_KIR7$AB M"U/>=P7(I\"A5FAS_W_AD% H8RX:]-CX0/+>5UC?5Y! 7P4_K](L7Z:K16TM M]&!> "<32Y#-Q^U#UW*TXN.,P]XA:I]MZ0K7>4-D"5>V!-8]S_ "%UNFF]L< M[;= $V#Q=Z+8WFQ5@*7H)[=DU@4.8FE(S(V4V14.#UF8 *+2_8JE%SD*;C @$T?V: M$BR(.M]39@B+DY:WV*B/BN@9P02N=2V">5.[X>"QW9O#:?X) E(HB_P'"T>A M$667M7ZT_1$<6S)>257K#&?.9J:6PZSI0 M//L2Z8R4ZX<4#395< \\"&@UY^R171P]5HLLK1JBE&*G &[5%HLY()0[8@^# MAR/TX#\L@MBDJ+;XE#PJ;"2B*1V7Z8+0P='QOR:! MW$>Q/@IR8.8(WPM,%YX3>O+)I"S=$?4V5AWZLD5Z2>@K;/XU57+1N2W5]'U" M'7+K0@0//CRX:FMR931P#=S!^W0-M#%?L"WS ^J#ILJ#T/OWYQ\4=><06H!X M@$;ZG$P;HI#W%XR($ADI3V]!9M(!:DGP4*((Z(BL1O@TW!Y];,O!2DV5'8#:2:2:1:\#?S*=^@$^0N *:N4*W:PAK M M]2[A9'@&P$8ATMJF3)(B7KH"7Q%NC$^?I]+[%IB652LS88U1+6++4B?'A('6 M./<+RR+$:?F8,,LC&5O&)[:/3/U'=V4=$:;66)>(V]]N5%&338*&$<]U*27" M&+OB4!O(6]8<40K)[J[E_L?6674?CBM;6L!)4.O,2:$BCE N$#AG>7-_L5ML M\9IA&,GC%MXNSZOAO%2 M.'\7ZU73^8"OO5!T?!"1?KR*=?)H"T8)QZ=Z!5OM0%81B H%.+H #I*377HJD8SN M=UZIVS!P+?QQTO=/'J.HHQ)@)=R2<;&^$D=3 W;$\R)?= M8#P0P'%O<( W".LHW!6M=V&MTV#6]XUE ^7,#)P$D^E$744\5A%??+*1 M&3<.QM.QA&_(K^(U,6-&P6BB?I:#&TO$"&YBC%&%XW ZB[[TD"3-D&:E ,?1 M;&IMMB^/.=9C*O^"H<-@.)WIS:H'N*FA&30(!A3E^JB\5R-+-YB8<3&<:E_M M5OUN=BLQGI/^S-DM"2"R*131T2K.T3X+39&LX@'-J'L1*D3S1_-SF=:6;M:D M5*\+D7#>&%L*9^R8A-F*+-<"\%%LNPW:K]O4GC1A26K21F;W^RU3"<7W)FO@ M?&5EB0)%WK@M2OEZ$8VL""N4T"9]ZX>>LXFDY (=<[%YWZ3B.C8F\/1331[\ MAN5$KU:7'5)!J(=%?GA'4@_R!V8WZ@[(*N(Q0E,\!@9XS$FIMYSAJ^2!IR[3 M6Y'KJS P<<[::0AD1.[3]KKU4"%F(1,C.TCX-S=OW8MMF2(TIXH*DH@>M;[18>1;GWEOD5;9;<[G#J(59D4B_K+@JF], M=(8N"-'!.$K M_> :C0[>M&$P:$5\U9:!E\8[O<&HVZJ#;L&"+;JC'-0Z;^P M?\0ED;A!MI4\WX91V[; U#O6[IZW=3-D_RJ+C^S[VG!^H_%=>-)/.O#:H0JB M]V$95+'IZ0W@[Q3SXT\<:7@'C4L]X3P5_/RL/PC[@\A:4%8W%D"A1NC7ND73 M7VUM!/@(1Q>]B X*-4RNJF\6GC2O3FC-SMDNLNR;Y6P\W.W?P(YIZ25FL+-S6=0 M%=OR9R5H5(.%^([^APM\;2[P6Z/_ITX(.(7MX.;;L;/)XIX2(&G7S9 <=#,J MET4#+SAGYR'GY=*QPQ1Y,/I&4=BG$28,'LA@079#AN% VT"[D!:C5=E'0K"] M>F3+6BGQ\W BZ#=9)H#.%O+B0BD+2#DU-(=1TC11DR:#Q"I&MP6[AWZCK%+B M9)G=>?C6P(KA9UBU7RXMBD7,B) EK9FFR]F(0YWG0S93^UL6;113 MF><0"+;?EP8"V=QD7!\-7L^1U9K91^,X' [C+V7V(RPLI7DE6>S2% M-#77P/P"1O[S*'AP4*4IVX6G+TD KK;SN]\! AIZ[)&[4#JIE'A"A7M9DC)A MVZXP]<_ P >*NK8( YDK!PKJ639\%I).Q^$HFOW#D%1;1^/00[4;SN[N:!F^ ML292Z/@_'2;0 " ]4>-@ XX6.81W#OE^B"KY/::C,K(J7$J8ULIP0%6L$ZB*HLX,8MI\,=.0#2=AH0)WB)8Q'QTRD4 M83[LXC(!M7<SZ*5DAMENR'E3 M$G*G1X*26CXJ=,*D,#K:I^D&@@&&[JRH,N9"^2.[8*62.!8)0C7!-;,NK'L* M6:)>Y!@B&^7'O;P8,,Q@-FE_2']2)BD@./Z-*+%7 M!JF(5G;$HZ/\%0O.1<(?5?6N99J0:8',TN(;OZ5LI@6''&E5!M,O%J!S+?@) M*FG$+VE]97J8KH0M=BCFLG9,L@S6::H\@7;%&[Y.7N<\<51<6ECSJDRIP!?C MH7+B=]9B5)>@2 PH^FG*.96JQHIX>2(5W7[DW\KN77"K!IT.,_$8W5Q3N7I/ MBS@X:3T M-YZ-+M-18O7CRJJ H5SZO RY?%E,AY-"9=/!1U6T(:]*I]GIN,.0(U\3\P\$ MPT3EV9.L5Y1--M(+/I#L&8>CEJ/Z25)W8,716/4-6:#102]9.=^N$0GG:?52 MF3RD+*D3.,@G(7C=:?<,L;[';!!.)P.UU@Y[)'Z#Q"\C86E8<86%H2\E1!&8 M$:H9]KG850CMX_!\AHIFR4'HNW3SV%@@6VY+C@-99;>Y,-ZL-!*Q2+,R6D.< M1LI@P;SRI1Z F8Q;&B-LE&DO2S1 P\&SHB1C!+! M>D_;1+K$I9\(OK"2E0&'I2X6VDHFI7_(66BXLE-\D5))32P7+>2$3;ZJ UMT MI4S-ICX7@KY/])6/?I?W.=KG/B?_,O?IB7\QX2^5ESZUBIKI$!C/;;Y284._ MUDAO[F][P05)48FX]6'EIXJ(G!6Y%$[S]%<96=5=U%\_N/ V&/:B0? +3W$0 MQ>%D- M>RL\[)Q\'@VD8C\8R]@>7+L6CWG"HY\4B7X,QS!O/>J.I*1V,I:&B MX10?3'NCT>X/3H+1-.P/8AP[B1U*V?>H53M<^AKIQOUPMA<1]2*83KJ^2X'U M?5(16ML:4R2LT/N_#R(FFCUKKJN,^!X<'7;@: L9)=VC"QTQ9OI3W<)+TIKV M1LRL_&J4U2@FT1-&,'7GKO [#B. Y+T &\A3Q]6CRRNIPO/53?BRZMDG9I( MQ<^C'2RE=5*0KT@J+M@RC*?\<3Y^B++H8%[!?#EW%Z#9(QT3WDME?VN94 H5MF<\W=54I-@D&51ZF&](\OQ M98)B&R5_R ARS2<8-@UE]EG@C.OCUCLY16$9_KRIS4H[[^NC_ M.?%5?[5DW^PU,#1+/G&KK@1C%A?<.!F'4'_.?DW : M(V%6S8&&8U"1(^0ET72 ]9;'(#=V-]F2DH0Q%N9$$]5DPN68)[.!9^>XI\S3 MANNK[UNZI+X"T8-3OUZ@_!G3ZF!G(ZYE*[G7<7 PQ.C"UX6P$&N,$>!C6-=6E2/GY ;Z.)55CK+X8X8'[>I#A4F;A M=#BE$K>S641UKN/@2'>8R!Q3H38W>T]2$-/Z@;#>S@$A#X-3CGJAP$1ERAG+ M%\PNXX+2RS_7GZ] NDDW$?*T2"=#&,*3X=5)A1 MWRJ>C@E02<[U*^!'["^%Y3!!4P+)8#@#%6C2)Q0^WM92->BGXH:*/^&1)D Y M^9AQ+0 LDUG\;I:-BU6V.]L-&R]?JPK86&^AH1.X_$1LS\8#K .+YJG M"&A"/"D%CUSK4S968V[-081&=2R8B=+5)**7(RQO/K/0&3<#[&B!@@90@*@_ MHA?&".]J6>&;:OI;M4*YN"U>?$R5^D?= M?J$8<&X<#X*C1OEH3,69X'XB^-]K"T:;*,.P:3H2,!U>M%<),TZ'<3 DX\,O M/O3"Y2+L#Q %<$O^6<9 50: _1/W+.Q&.!J[3$??(:,NOOQ2%GT04SUMT'#P M@YZ%V[UO#^))1(/#_KA[?<&!>N>1"W4/J,XZ? F5*!)@B1Y:?0$=W*J?"AFF M&CMH[4#_%!60R4# FXNHB"3"E$!(->G%?PEI9/36E-'VUE!S]'EMJG2E.<]< MV!I +"N1F.I+R:C%R9"0C#QY3B-Y*%9$%C^,$G(<':]'(JE=:#2RGB M?5PL2&:.9M,Q:0I27D?YP*D *.TN]>M/N\[0BGH- Z!4I'E@BC#3+/1I8A$/ M.<1U\HG*<-(^39ZZ2O8UMX<\>S#ZAAPNT3?6/>L0:Y4#S3Y?#"/E@ H0OPXI M'K3%Y5#P$F5WFQ_JQZG5JAK-8 +L=A%B=KFKB(!HU,.5\8Q8F.H03U:_J"=3 M+=YU272@FM-O9)J< P((=U<+FEE=MNK.X>:UIGZL^_@B3UPN ME8?KBOX!I!.9(:[U]7:U0H\L55R,0.A4916NCE[COPUJ,1R+3EF1"8&(8,'F M!9F/2 +LB8&ILE&9PHAD6C-/$JQ-$7I5C)V.HKHC"9.T[$^4IGV3/A;HOU3U M63D^V<)>0G\N.*;HTYSP3&I0J& B]H^;5;/IX^CJ.)@,^V%@*VY<$:EI0)%M MA%3:44(%T&Y4ILN5RFRVJ*5S&J@/)Q2#T#P>6K )[.A:()7CDIU0!64BG5:, MOUZ4\;Z[-Z10M&N)9D59Q8/XV)#V9/2CZL&CZKN@H8H+H](3E541XG Y&3Q! M#*I1K 4A! [&5\X0=HR0)[=FD!TF[T M%;2+Z-@*DBH @1P9LQ@8M5.VB@N3R]98Q(:C642FI7O4(-Q$G5_OLI4;W&_= M _(MWP48'9F8KE'X%ENG#HWA#TTFKV3K!49:+1H4'VU[F2+^H3[35>-SAKL^ MBCRM<;>RUAI*\6=_':>YZ2;H8Z#D0R%U4FH7D*^DVJY5G(1E_=?$2QJF M+,AD%!8;Y%759)63PS([^IV401%O!1F+9C8:+9**W20Z> +='Q:-8%&;@B$2 MI?J[5^PZN?4ZG6TWY^.TM[[E*K9J@/LD#!\HPAQ:N%52@FH:QMT^7D16V*9\ M 7=Q:#,@>QI+AF_TK0P5$'KBH5J\7A7*HC5?VFN^-NB#QV=+MNZXY),.1T*< MUW)1F=YG7+,$KARX%0*F:=/CI'4!B"Q)8Y"V]+"JB#F M3H3>%Y*-'2T7^V!20CG&CJJ3:^&T0VZ]'$]D907W#FHV#\?J"-'&@5[P.J7Z MY&J?HHI(A3AVR3X$/ZR*&Y@:R!50QPQ7\JYX.+PF8! Y1EWY#Z?OKD]-7!L2 M> P"=Z](L3RNYCHHM7<@31J MIF9\L(Y(29XE6-A=(2&EJJH]G#X7OJ(+1(R&[TK:I[I@KLC&3"/YQ-TJ^514 M BA\E Z&B)\VQXH@JBC4 W8O@!>W1!AL1)6!U"^+>^X9E%*P3,XPA"M3T;XC MPJY!BA -%PT+L/5M_L9VW M*6HQS/$5LBF9J9='M&.?DC.W@BZ,TJ45&O[M\O6EE*D;5,#FYRSRF=A#BPEJRFN[!#&TBM(J M5]E'+J6:Y+1.OM^5JNV#*[CA1L]*J,Q*LT!AE)G&0-6_%=6-I"P?;Y+Y1]:K M]STQ;IJRZYP4QU*LZLGCRBK+XN2?VYKN+Z!;5XML;IHL40T[*F[:-+P5E7S* M-Z<2M$CL9F\BT0.RH21.1P^I8%:)GN6_&97([1-5S+>XQA=+CUK@U_)SYSIY MD>H:?1ZAYUQ@7KB&J+QE^"4((5LM PJDC3ZB!7FV#[OS77GLG';.ENI MPEK%Z4BOCWPI(/! M3>^MEGBMBH*)G:03\3/G?L9(LD/2,U>5''49#L-604!T% MQ!@@7T0SJ^^8,&"FLN:,GDQP""D'$7=GJK8+Q,&R:+HVQ."RCN9"=U82ZN(U MW#_:0CUL'4@X-T)%L\T39\AYFW@R.BBQ0LXM$=FQ;2W,.W27)BJ/5XG(FRZJ71H*P?-V0_8_[GJG M $>#$U<&I?+71/XPO _WGI2/?G.:45X[X+96$*L]QK1N!;V-M+]/;/L3N>(V M1P[K5Y"-X"0$WZJ405?;:;;9D;#0)'26LD*B4A=@LB?5MIW;,TDMC,*"'(R3 M).KHTTE;@@+F8FFM7UL3'!V?0,I[Z8KI"28RJ[8JA>G0JX7B@RJ_6^+%8(E> 19C7VR6&@<, X0#@3BQ.BV(*8$*>M&;.8 ML741OZZ6AKUFR-"ER,D7V(V,;0UBMMI_Y(Z(I,N3=T?7)V^"BZ/+ZS\%UY=' M9U='Q]>GYV=7V%>8&L!=%H]2!/2\T>AH=R8LO_=HNJ9Q;R90_T@7P\N53%;) M]+J:9Q2;$0;O>N]ZQSVTRU^GG^"HE)?,@/%/H1%4W7^E#J@E?IW4NME+&D<-6 M2G^"Y?:<9-[*E$>A9Q]T:H%.CVTDJ^//K#\EC_@.2AMRY/CQ'M=6J:0;,YL_ MW7:#9'B&QYBAT\* MF']J R\BK"#8I]19#70Z_IY5]*QNW46ZYU4H6RJ&%#*'@"^O#9&P,AYR> M.J _*#EU0J&ZSVEPVM!=K"H_C4Z8^:/>RM9W_]I$HU%*K-Y6.":R.BP91(5^ M\B"*I85GLR<@Q2)@#[&P,:75.,\6FN)^K]GX9&=?T[WP'R[],Y'U,KT"R5CC MJD(7I,*_=WP)W;Z1DO-YD^(9F5ZQ*GV!Y%^[_T#O*3J-GZ?]2^\@LOC*2> S M_X6AXY7=TG0,,IYNVB3/8^(JUO>NL<5>UZDB0CCV)&I9H.,6X,"!)O+?,+T; MQC#:$W$'_;'*+!].1B:S?#0:_2[1U\5>4+;#72FQ D%Y\478WJR<:O<_/3?U M?=SJ>AW$H'NN+RV+T2A5\]EE,DS@BBX0T>\-^^,QW87H+8V*:U:IB8Y:]U)# MAGN<_F6;6TVV<7AW*463F=(QL\=*4#3J'3Y5)*)Y5$[1")-'H:ZW4>*I65S# M+1KA5-EXH'@M;K=IT"RW07Z;)X^0;)8@OA\VZ]%\3CT+.T7Y2I43&9NB MD8/H7QFLIZ/_IF MJ6'C?TV@'G4#-59=FOP+@W0\_7U1:JOTVQ*D>1&RG85#S M[K3.)%AAGR3&X--Z]:K:)//T/_] B33E??J'[X.3]Q?OSO]T7MZ M'5R\.SJ[50.J^$*%/;JLJJ%4GJKTYZ]7;> MHP \C$MD)TJBH^@1Q_HJ\#LKG5P4IZ\<61HE]M!VW#P13]@+3DQA":"=,5=C MY":KY.]<91S70_'+*E=)1_[AON%KI@4<>_D6IEFAP51R:U$$C4['[9'1UW=, MS6^+"=WJI<&(4,_OI/VAO@T[XHRPD1(7K+,R+2@Q-:.L MFX3O5O"CD[YDQSQ&DT@7L1M81>RB:+2SBEVK*55Z2TAX:B)*NX9 M5R<_O#\YNPY.S]Z>7[X_0IN^LS$T0&GC4R7HPAI?GM8/12EYX>QS9(S#"K3) M>H6>D762YRH 6.@H&<68YTG#)\T^*6--ACW<40AU+2M@A*BV:RR-HDRTF'M^ MB*0W+>=T*S6>B;&@7&(;7NG,9[5OG#P:8#5FLL[D5944A'23X4*@1+Z-J&5V,+T&"0]@OR8S5 MO&ZU * ->#-IR6ZB>=6B249*"0RUW4.+5,YMY0-[9^XQ+Q$ MLDIL&0^H'S=2$QA4IX(N2D]#'\3NM!CP319;W65F8]*XR9?.;+H.L#D@B;[A28R;I1!)[2%[6#JD5:%ZZM,Y;A8\= M8OPBQJY2%=E'S%1)5WB+",^FCV_8T>8.B4BNTVB:X"^_[81@JN%#-28/DQ5^ MGOR+?&2Y!$XJX:72:; -5TEE\EP[ZAU[ +$->Y)$@6V8E%QBBMUB((1*/)?. M#WPC2^DQ(-*$%$^J_-(2AC:PA1@NZC9%O6H#%!UA*^&N%5^<3GZF/T$4"P,# MB(]KB'[5$"6P =F LI>'8409Y@-JXW8,H+9( BQ;,\74TOXLB,,)/+A(RVTP MZD];F:I61F\038;A+(8UC0?A5M-LH*11 "QS*4V0XFNG,814G819G>G"S8BE.Y-,Z70?142^XS*J/ MP5L.81>W<@^.SN:?=@<-#O64$[8:?5LQ-Q62[47#)]FA^3OXH*DS.8V81WUM MG/!_YI4. = 7#-#P#P*6_1H.P/XS@>R4LA_/_DOE'E(+EPE JY(1, M4[(N<,5 ;0$@#Z?$G9<];OFU&U*-R8Z-QG;U0>0&@S[0I@B M+/TUF^V@"E& ]C>^D?9F,",]&LXX,WTZ;8FJ@/OI7[<(.B=8:*[=![8YX-GJ MZ=6'UUYW5!1 >AC!454"A)E M&VF9.JT6"T!PT(9BHIK85B*)*TZ?; (ZNW(@E;BC(';;F"#M&*=![[?6>]$I M\6?W_E98I,4 M>%D@GJ+&0:$-*C4<3P0TB9PT3N7Z7CH'I0()I-^X",>DTE$8*%9Q9M"0?3:+ MU'$V@<>=?P-:,)H(7@R1PRFMWNJ(TZ129UJ1.3;99,38=Z[[E[67[">:.]X/FMSXP>IVH!."G MGA-N;4KFI@+LWD0?7Z,Y*Z/,+)'CE4EPG*/AP>2&NZP.T]FP;?P\45?N9&VH MS#63=MU(/Q:9TO0]UY9EE1.&A-:;;&HRL(U61#27-J-BF7WOU2W;O-.&OC-% MJFM]1HS.K;H[EJBJ7V(]LA62>JRJ=- ?6$7_'J2@-MOV0U;GVX%^0BPVM9Y( M:K.7[YAH< *817I36_T'0[+;E1DY%];;G&RD*Z0E^.RF0";(%6)4"#9.$**1 M-=4.@N56#:.PG 6<3Y4UDY*HP!+7]P6Z=I=1JZ)5!KM8.&LD,"[*[)9RP]=( M,S(5MN3D+0!-7)$)AM(6M3,E5'T;&X>$S-_9.G>D9R:15.U#3:B9J"%\-[I6 MA3B^/.B'R:"#F(IKF!T=\I>I= EW0[ *FG28'JR,$X[OWW6)8M#Q9?P8ZX2[ M6YTY=P@[.23=4+%DS/O)V"FUQ"J3]U1EDK:WS56^54"Y:8R,G&IA5==S8N%9 MGR$H2^&BB(%1?I'JR"'"FXK@XDX-/2F"6$FRNKM?C&*D7$FY"<#>LL[^IJDE M?&J= =/G?$!41+E80*'@Z5%B[)P7,XU(M E>.&<<8$N7CHT[.=BZQ#6_)CU% M5U6Q8V;2A(RB-)*GF$=;<# M]+5,BZ3NB[S;2(])%;I+\HR)'"GD5YS.I\L=G?X))M"O]X,/5 MFV!@]?/Q(M9+=D8JIY*(I-N;=59S;62IFZWCL+6\:*6/6T86TGEDI;;$!3(; M#L$*(EQDI3!^-ZH0PZX!//M:VNS@]EM,"0E2CEG:+?G#SX:L\:V+ND"36"G1 ML$C2-DB9]I2;?*\&SL^I_IDTA%K%?1(U(%'7IB]P:*;_"]$P"Z>1Z%N/I:00 M9;-L*VUZ0D/'[5U]B+6BQ3YO5!?3.GE;IFL M[9!=G$IAF\VI[C)!52SKAT3BN24AD7OLB3/U$,LCZ%$+$$]6!9\/]6"C]Y82 M#5RA\&)]=;DM\TQ'BR^S3_@WX-X[[#2-E)?,.AC*J'F>G%]JG0%P$665PW^N M\&72,I2UWG-(R]0]HUYP@K+4@E;#BR/=(\TYV3GG4B=9R:M Y\TM,U[E3.0R MTE228$OMUR1A"W/5*8ABAU1=ZVJ![;*AE56HR37'.2$?(#2C M[%<^.BOT9"GC?MB0C/HJ6A/PIIQJD-HQ7*HT>Z[U8N4!FP)(>]2HZ?E*5LKB MK/ $$A%U_B,[^BG_V_<),2@HE:"Q2ILK=DT)DP5[(=$^A>4NEGNET=MO:O-5!4(4]W$BKWVB[0;B M$H27"-RD?CUI#,YN@>GIT MUT$H\+63X!'(E'4Y*TI>B7.V%@+NJ)7&5\"E3\[UE=P53%,YFT0"VW<#<"O(068K5MGVZ M#O$2092LG$ "./7#JBJ"LKS>O7,J7")&U1\G =%3':M1LUNE"#NA@9QI:Z?Z MBI]31YJ9-/J.7%.6JDP.K$KK$3!S[1>$YC676[-SEY7NF7;E+K?$I2-!_A^E M\N8;M39,#_X54ZSV5.>;$ZF76RR)_!#7R%-UP[T]A@1O+>; E1IPY^G"M00/ M ]^[K;Z 6%W&:0O8X%):(+"MPI)XF-A=-NSG*/N0PG-;@";$(@9&%MPSG\!0 MF)0"!3T5*/%;:E%A V'$9L^:A]CQ9>]6N5/"ZPQ$RT,2D3BH$N$!&X_@+V1- MH*)! *WLH..H1F!SDC:M;?3*OH2ZSR)AZN*4.'3C13FVT2X)Y#LW;8I"<8C- M[XUMTIO_F!UJ\W.:+]I-1N*!9:XPY36M:9E'DK>&86>IN@FI4I(KVCQP9:RP MA)0&"UPHLJV%*Q/^HFM5&5*!/SM?)85)?4DKV$FC=G8+R54U:FYZ,'_<"Z&; M+WG46 Y]O#0L?Z^)/>\U',P*&RG>3M&Z1JC17;;9I )5&2;[;ZBN!-I0N"L!#DK(%SX, 9R+UE=H![9O!"2\#%N M 'XF Q Q-9_)4@(2'G7P,UFD2OZ4"MYO#Y.5ZS[=*CB9*+UB5@4"G9"[M[WS MWFOLLP)GQGX#8)L](7X.9^6(Z(QF(K-&I1$2!"7;=J*$+32$JJ/DOJIX;506 M2CB"-I!PT1-UMK&"J"4*$0SDOM W@'*D2AN9/$*LR* MI2A4@((KS#2<#(3+HBD@OM"I-;^DQ3 6[B@Q6;=LHK)HP,:+DL15I HE%53H M[8S-,"UK<55 K "6@+=*-%=]N-T$2VIGE5EWI,HC-ODFZ\RB%IM+W*MS3MT#.H2IY!HKT%N1UA9UBQCF5'MA92K;<4!"DIWI@$-V@!D5!5Y>'A MZ ^*"-YN0.PU-H;2TI7<8I,4?3>R&?$UE^;=8@ZL1Z\*X\GO MM>](J* >ZZQ,#)YB^--WR\>^@)-"63(AUJQ94XN+'.O:YGNZCPP/)MT(5 M22*C&^4(T'W JQ")BTZ(E2B32 -\B(/_V0 I):I4,I6Z7JRW110E71A^:3DP MK*GM/EZ8Q.Q^VAT!I]5:5\.F:J2N=HZRK6X!KYVRB0U4IM,I ;G.NZ8#+?M ##J(_.:CLU.8-J+='2]W&4UO0 \I=YT>\V.4936B\<< MK43OMXF>7#.&E_)I'Q=TD )E^U'")R8)CLBB(,&T3;VB2Z!*K:)O,+D)!#RH M5.)EU'_9\\?I^B;^N\?MGN;2G;[2'5N;:[!"<;76A*%!VHI'-5?\56LS%,/7 M*;>)TLXN.JUU 4NS5G(M,?YHES$M:70*6\-11@([4)JBO$UR\>-4RHA&167% ME1:VTQ+9S$;Q5B17A[H8+M&99%%LN$MNG1VNT9ZV0F^*)2*MTMNL6B5MVYI. M\W%3;QIKUSLWM^N(&Y6H^BR5.'>M%3"2X=SWU>%I&4J5N_'#I-;J&FG=31AI M0Q$E_'!.H4Y[F->*A'&9'C?0DLU,B:E\(@6$K!I^BRU;ZD]-'?10Q[TE>G-( M+YNQ9XTD++UP=MZY5X%-$;(57X$+1>IO:<'!J"U]BLD6:GDU %R^< DBZM?)\5*Z[![APSN8?5"84DK5+\,QPR MNP0"H(4TABK4WV;Q?HU UCD NT&2S9965<$/R/M"< MS IV,YNW?>0].+0'9.^A^ [F "@WY#[ 6+72],2H+2"Q7!SL'2&8-AR]'5?E M=N+@ KG.93#J4[X6#Q$3!L,P?03ODZ@2A8K26T5IOX0Z%87PU'XB:KN0;)R+,KC#1 MB58%6@W:-X"/;]&2RCY+7-"6VV,C>)LU^W8$^RW*VC1MDH][ODMG*]6P0'1: M,T'',A^;;($"-^A+]ZSQZOS ^4JZ$Z$=.B5+S T6*[7@ 86F]0W=.H.& N5= M('&X$R8DHIL[Z;50Q(<7H3Y5M7%4N%8K6*W@OM@!L#8<514H.94]62>W_J!' M;=M0;6QDOUA3.:?P_BUY+)F93=9 M;7HAZ&]SA7*%KM+II0ME+<$,C]XJ2RWDV]J3!'!Y]H7>%94OKK*&)-&&S \\ MG8^K*V_>;J+K)7)SNV.N>%7Q$^(V%7^>DKZQR$$52NLS%?-2;C<:8 P"J90' MI83[SDT2.%2$!M9)OV&560&$R(Y\.)\VN'J*]"<"5LP51%J=$&TT9KX<:EN> ME8Z@([;T%SASFPP%9A?:&R:53D)BXX4JM,VG9S5N163_NM309S:^X(!); 6> M!3]M,PG(..?/,6,LNUZ M[T#H/>;A(%&L4T_BH(GA]L*&GB$S,]CBR(X@QUSG2VN_6VC7P[G"6CF:E:.'V6VIR@2T M'6QS]M^?8'Q(CZ0^[Q)4(4Q=?^H3CX>KH%-Z\TKY!OD MD.?,+U6(^>W1U6NKSQ5]W/O:!R[OKMX[NOJ@7\,VEOCY0TQ>NE*!*A3+BC?R MEO(?#X-FQ&S(#$>G=BB$,0;,15K-R^R&S>)-^"/1SOW)OON;A@E\!SZ1C=7N MFTVN8=6']+!8'EK.<6 ,UB]LK58K!]1ZR!4SJ.R#H&\N\2 8="D32\Y61S^9 MHJH4*\EI;\VNJ,D2(W:T%QR#C1OM:IEK96M=6$"%/%,73'M:UBKA+[0-(;2I M%"TRA>CT5_VHD-Y"NI6?U%>U8]+$***%:5/7W4<%G\R-(3V=TRPM" >@U^&4:KLY0*I5J2$:KJ FNBK42G] MGCXCDZ? ?9$M[&Y2&L9W*XK[P;A=J?M),(]#L;RWB*C'3,GQT2HTW!][@''L M::J*)X1NGPQOL(P)I6Y%^3K%M_FQ:;I'N1V)="+GZU[Q5HA*FV!NNK%UH0KV M1+%V0N-9R#F(;01-/7($5L8>X?9=NMI(PE(AF;[2\K!]$VB3(D"N:ZJ.C:I= MKT860C8DJ/\I)3V;]MC-VW-OV)6,W MG25[4U$K*V7.045)'M-4JDVFY?I$NW2N>0^B37C9(,#639^HO7-E!/6 Z N9 M$ET:JE*^R\(4;6=9KK9_:O@\5UJ^L!;2F-F=LHOB-W.GQCU.W5H][@4R$2=3 M8B[2XZO@BB6!1P7.[]U6DGID!]ADZCDW1U3AV^Q.4!TW*82;^%#,+==Y"C@:R4,D:J+$24.*4U&I'4*OL_FM6F07V"I#QB2ITA W)RR=XZ0M7ZKU'"-,AI1H0[ NLK$H??]DN M;DUA!BL#S'T@;-Q.FV,XJVJ3&DBIE]O5DL14_6F+:Q*.$KG4R.S0_X2Z;;KL MD:SPB!$L#;C/R"Z'X6]*#'?IA$LH.YF?[G*)O^CJKC*#H:QD$[)$#),2J*@E M01K1V^>8+EKS_ 8L$:T",CM"B0ZN*;^]51;F"LOF;CF$YD3E!.D()A1'*ZP? M!M#U)EM1ZM&?:2;LK%8'KU?%_..>);3VK"HG&[CBVDEZ)<_^G1>>IZK6 (5F MJEI0..(5B1*J,;+NE,R^1ETQ2I7.>A'$@W"$5A&4=L2'0=(P_ M8]W#%\&P-QWB?R9A/(Q 20P'??QY@#^?Z([8"SQ,A%=3RN!5\"N%/$N,B H[ M<,I7-6M#=OTWCM!5<2@5C2VKI#L-G+E^8Z3_',[T77^UX]NLMA57PDFI9C?Z MLTGW=LYU/*%S[<^<(X6P> @FO:QQB*@PDN8;AH.9K0<1)I)1QF#5\%Y(_R 8X8\(4..0K[ MXPF=LU,>4%T#7NC_!3PW VG1D3ADA)6%&RF=[S L^% M #@.HUD4'&VQ>@,,PF 83F*'A8]'\'@03W9DJ 0# .PA0=.03AK_.QNVBDA: M[E1+:>ZF&4?M"D%6V:*O1R%:Y@&@4%+:!S,O@A]*S!7[8"H/_8 %>+Y]QU6' MK%U]YFOO==$K4^V*RE\1E8'#QY,]B!@,X=\1PN$0Z- ,'RB>HG\Z=@IEV95\ MAK-P"(!X$&-M5OQ''PL*CR<#^ E^P3\CRY6(3FI =\%7X_(&2)U.(\/B^)\Q M4")@(YK;\3^YWJBGUI-=3^H%$=V#@;(DV*J+,TUTUE&'D4#.:VUK('MXK89'1%K/.M[8^]%#O@/ M5>%KGTV_T65&+SBD8"\4LDN8OD$X:XG"G&"HW6DT2#4C'/0%[0Y(;TY6>*O] M7D34"WAP9-ESAS*T]2Z,CY$4C_N>T79S./LS_5Z,Q&P*@"8]QO0@]Q68'6MU M8S'QYD#IVCGT3#X8!8-P-AYROZ>9_X4^BK18UWO@#M/%-W?,'"N34-<[?93K M@&4!Y+DCX61[(Y3E0/.* 4B_[ ;C@9!)]P8'(RK!/AO:-RBVM?:[L-9I,.O[ MQM)ER,G0P$DPF4[454C-U+$ZV=0/95K%A&@=49M17NU6_F]V*=#(!L&EINH7JBF[%<+!C713!(PX ?'R: M$W^/>KR5C\:9JU1R564?T A9'(K:)BO M,(=\CIDR:F>>LFHCBY^JOWZ0$L@C1"U Q2%6D_Z%IS@ -6DRPJ+G_//.R!@#WJ#8=Z7M0N!F.8-Y[U1B!Z/G6@6NK!.786]=J' ,/1=(#6@S$ L;L#I\ 82Z3QF.K7 U1,V+@PF0UV'8EE!# '!$?"Q=M (#J0 MYFG-@_VRX^!B&J IOTT7%-[S FET3(N]8T>=0MP!DZ"G*X]AV1)T.R O8 M)R'$4OW#D>(IRJG )P(0. 0Y< KP/0U0Z6N4,#K UU'?C%$FC_ >3JW21;H= M-_91"*?4$V :SJC=PVC4,M(XAD=MOK5.]!+W!(27F!1N&8^K< U@YCDE: (@+?,L8\73/)*0 W!,(+]'K#??!3\5-\2CJ*8?L!)Q5\NFQ8K/8S8:MEX_YD=9 M'MRWZ\$!B1F@/6$03B=TOR&>E (=5M94_RI4O0ZH,QEJ/$BU)A&]' $MG\TL MA*1@,:K\42$.1_T1O3!&T%3+8DN%'>D()&\-X]'F]U+!\?!+X,R"*+4R@JPW M]HZ^MDW[2D.1AN0F1H-8EN3 TE;8?D,?R#D-X/ 5.C+B]D[+9<27!D0D(>6=B M0+[(R/FF'7#")F23PB:5DO%>8S(,CUBFDT#%N1U'&0-*8<^7HX:5"_6N"6XZ M@O^]MD"PB1$,>L8 SA31%Q83 9#%(-^BJ.*II@B@/V-<&""$XY;\LXR!: P MN2?N65A!-J\TB.KR; =#QDQ\^:4L^B FLQ\(!B/=QJ8S;N<@GD0T..R/N]<7 M'.C24FQ/') Y&+X$LL<>G0;WDB>4^YV\DB>JA99QO!_5NKY=7>BC.-9M8FX> M@Q],3YNC,DV^*D/XGQY?_]P>7[M I]VYT@*^$"%#1OR=(.*_08>KW:8XTW0B M;R)A%7+UQ'>4K"^L R2-4Y-QY\5E_L=^5>5^Q]VIOD9;E\/@#'W#)"(?O*'8 MN@JEJ&@\^@Z/^CV78F\9?0?!>VX&0;#>?/H>*[FH\\2J[@LOY9HJ(UQQSOK9QZK^IE$IDZM^IEOG;)) MQZWZF1=6_O__-_I\P1:R< M\I3_%>P D<\^3%VJ\\1?JK-%[^PZ\_H?;RSO+EQM1*6#S:ZR)6Y:WKLK_ ==I_E8YS3NWUCW>_]F)_[-$>)_&0D;T9X4Y M:>)X& @] ;K\K6K%!C" [ $XU@O\^UJU/VPY=S>EH3D[OG^ 9.%E<&2'OZCU M6&XO":/RJ*;L948IV-J%D835G&]4N) Q.AQC[:3SC6$G*GJH==88I8]OR ", MU;M$82,,SC0^6JYKG)B3870\DGJC?4Z CSJ4R9KCY),D.BXYTA9[2N@,!E^8 M&3LKONH!75DY;CIUSBK\^36N5>*D]@Y .FP8$-V!1RJ%V@_%NP#69J3#O1MN M[6@ Y^LPTWR=(EF.59XVA0OL_>D]WM7A1J&)5\*.%? N12_L&(_Q2^]U_!(+ M6U3UZLEW+0W_DH7/UMB.'BW=9]D,;VH?DFEJPKB"B"'4OF/!)OK)647':#_9 M[AAL(J7LM-2.P!G#LU27K;%V#=-JO.!&P] N;Z+O>L *R@B-8LX'C M2XG)$L>$?_EJFG=V9F[')[712IEQN@&^.;1S3A/WI11I)B3%AIJ%QPU\FG9WVB1?9T--IK'8UV M1M%H75=G LZHRZ =H]=UV4XI%15C9I=5Z?[6KD OOQ*O <>K<;HS[-9A\UH' M;5)P/"5#"9:G^@(\X3KRRFADM>Q1.C+^SP=3X2RJ'>9QSU](5/^,:3 M',_B%Y>'Y..ZTGNX/W]@K:\P)PRUR3Y#T=]"7+9.W+JV3UIXZM MR#_R'!.4E#JV>\[M+&1_UV2.<8\RM7>-&'>L^BK=Z).?&$5Z']@THY]^9_P9[XSV?(?!C,/+ MQCN.,XIWGL1/VU5/1[SM82P=/KDN!$"!KM@_1*ON'-JVB_S;VJY3<,92>5S0"*DB#&./+.$O_\* MNG' +)NPC2L/!+S0I4]H6(@%]&L7F.1_?\\9E:A?:=9+> MO*-5,ZC$+-6L2:W:\Z:Y)=F/-4%K:ZUS65$)1%3GNF!0Q8%Y/OW%<(OB=KJ2 M@M;.#"3 _ST^V<9&RRJ&4B;AB5=Z4)7CWG 3@@OI-B"Z3RMN5S['6L3?9RL^ M O<5$/^'M"CAQ9][P>NR2!9-A^;W]_'_>2B1D^C>XDM_9E9H@ M\]_ 6&^/V?\AS%A++WMJ\"JISB3( M[&&*.BONC4[OU6.4[N?5H&==STJM@;<>\B'TY4]._0_M5"?_)R?^AU:*H_&%"J3YY78_6-)E7W&^FYX3IJ09.56L#2%Z M8.@-[K 3Q[H XG_]V[_M HF.QP(4G4_1+-'U5,$%/^Z$C([' AN=3TMK5YWP MP8\[(:3CLXTK]V8IO6ZF<:6?%6@@B5D=*W_6PL3+R>78OG!= M*D.J;7:E!)DV=_10-4]25*<;(0L5G;A;4>N MT1-WIR_\2_'&D_[R-+78 8 F38?/0#\0"U2C[CBZIDQ40:QQHB]=PYSLZXZ8)0E8"SQ^)7G1E2_MOR!),X MP-6 P,ZLM<\!P_VRX7;P;C=";JD*:6;Y%F'6BG!O90VGK./YN,3QT9_>'YT% MIU?OCL[>7#6?:N(&A^TC;]X@9!WKWWR J7/MX9@QU_Y5Q=!<)!CN=6T5R-_/ M%TI^RR=\1N17>B($GMR+DYU#R,O5I8.P[W&V>QVV\]&O4=,TLIU6^+3C^]K# M/[;;X]MY\KMC((K'9%7[F6#LN_9KJT=1CEU[4CM(?9$\MA86Q7WO[SO\%ZC( M\2[1Z]+AV*1^8D4) \2<[+>85+M05I?ZPM,L4%)LRM2TT^\W;#)TC4XRAD)3:N\5B,)U&#L=A MWGY(X>UN#JK)F&@.GWEITM&M4T2?_"?#?A3\S&58,9[9%XL11_X@>MDR-MVL M,1CTUIE&)W10:W8YG>H_L'=Y14V:FM,-?0BBOE%U?213V2D!VN2E/FK'J41] M[[$ D\QRRN\U$TO"")7),_5L6[#G240]I*R]*Y6U]YZZ)'T&I]R9<;B3"CD) M:"U61[FA+5O+R>6'MEB%>9UM=--)G7Y3T /C">E]IJ6X9,,=[,[\;.&$9'YV M630[,N;VNR:K]OA_5.ZE75BIEE><:OD9-_AD]F;K%NQDSM91/"=[L_FR)V_3 M+UCJ7,W]SA"3HP(G[_+YQ]1*H6Q]>GO#'7_JX.2^%?;:?&I(=R>E)3FBS^;; M=AU&>ACY'[*0TO%F>R4[D-0UHUGV-:*,$N]51Q MF/:DWU95_?W_#U!+ P04 " !RBGM,A/!-YEP" "\"P #0 'AL+W-T M>6QE?[WS'/NEQ6*DUQ;<%Q@HTC/(J@H52Y1O/ MJY(",U2=BA)S[9>54J,TLH$,>I-?7_N,40XC$->LVNF*I"(FJL( MSGH3(PPH6TN5T&][MLMX\Q-V/UQ0 MDI50[VI=#K>ZZ3M\(W%&&JLW64] HZ.RI.NWE.2<85?,DPF#/1/&(>KR@$)( MX45T[-=F^G*<'R/FYSSG''$M$-TGKWO^? M3_D?,SX[_W/*]E]E3/@9.9KA>0 D9X= ^?"'XRSRNZ-02'*:SA%5KJI_06OHY-<89JJFY,B=89 MP4'^8(@'\W[7HH>(X"!_Q"FIV6N;<'BOQ]\!4$L#!!0 ( '**>TS0;FJ* ML0, ,<= / >&PO=V]R:V)O;VLN>&ULQ9E+3^,P$(#_BI7+L@>VS8.G M*-)"0:K$0D4K[B:9MA:)76RWP+]?)Z7+I&I'>QEZ:N*DSB?'GF_&N7@S]N79 MF!?Q7I7:]:*9]_/S3L?E,ZBD^V7FH,.5B;&5].'43CMN;D$6;@;@J[*3=+O' MG4HJ'5U>K/L:VL[E17WPI.#-?;77IT+F7BUA+)][43<*]W70C4VGZ]\5T;G] M'R8SF:@<^B9?5*#]"LI"*;TRVLW4W$5"RPIZT?H6\5L7XD9[Y3_$0*^Z"O=& MHGGTH.A%<3CVTH?_+)53SR5$PIZK<,$.BK@&YX.\#N>F5$5X>B&N9"EU#F+4 MC T"3 C 9&^ XF H$61*0*;?"#FJ(>H_.&$FXF$.%D%F!&2V-\AK4\T1Y!$! M>;0WR)$W.8(\)B"/]S>2TLT0Y D!><(+>1_Z'>C<5""&8.M77!D=5HZT( [N M#8(\)2!/>2%;"[J9AD;70XGHS@BZ,UZZ6ZFL>)+E L0?D&YA/]]S&#X/[B>. MX%TJA'>YIV-5*;]"D\$U87IZI:>@,K=2N3F?"79B0TDG,[).; M:EZ:#P!Q!1HFRHMA6,LM.LHC,;-(1C!MDJ\=&1=ECYA9'Z/%LX/714UWL]R( M=C%EC)A;&=*'&+?.6E;7FX@R6E25Q&E,3#DC9I8&:;8Q3@EC2AXQLSUVN:UF M;$B^TFO*'@FS/79*KJ%L50&4/Q+V0H60G#C F&2UPJR2;9I;#R5.&!+*+0FS M6[#OML)16DF8M;(E<&]EI.22,,N%#)3),<:D1),PBX8,E/U6!**TDS!K9V>@ M/-PL3!-*.PFS=G8&RCYXJ4J,26DG8=8.'2@/\88)I9UTGT5+&F-,2COI'LJ6 M,"_OI:V7_1)C4MI)]Z&=0]%72U6 +C FN4WVG>+Y&D7X7$,8DU)0RJR@#4P4 MD4+$'^ Z(J4LE#);B,2\PN$]I2R4,EMH _/K5#Q"WJK*4LI"*;.%-C#[, %K M0P'^V8XQ*0NES!9J86XPWQIOFC6/=X1IRR4,5MH^Q[&6NFX M^,DH"V7<%MJ2$X=A#$\;R7:-EE$6RK@MM!5S/(,F-K5>.F6AC-E"VS'OC)Z* MNR CC$E^KN$NA#:WB?Y-2UP'992!LL9 G?6WSB),<0W%?>C>A?9TQG;1J6 MP $ +P; : >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/%V3UNPD 0 MAN&K(!\@R\PL?U%(E88VR04L6# ";,N[4>#V<6AB)/"7 GTT6 @T\S9^9*U? MWL,^3]NJC,6VCH/C85_&>5:D5#\[%Y=%..3QJ:I#V?ZRKII#GMJOS<;5^7*7 M;X+3X7#LFNZ,[/6E.W.P6,VS9K&2;/"9-YN0YID[[MUWU>QB$4**[GR1IW9! M^Y=3'?ZSOEJOM\OP5BV_#J%,5RK^%F3N>I#V!RD]R/J#C![D^X,\/6C4'S2B M!XW[@\;TH$E_T(0>-.T/FM*#9OU!,WJ0#(&,0WX2PIJOM0"NA>^U +"%+[8 MLH5OM@"TA:^V +:%[[8 N(4OMP"ZA6^W +R%K[<"O96OMP*]]0'/VNAAFZ^W M KV5K[<"O96OMP*]E:^W KV5K[<"O96OMP*]E:^W KV5K[GN^ MWA[H[?EZ>Z"WY^OM@=[^ 6?=Z+";K[<'>GN^WKZC=RSR)JP^4K,M-_'>)1?# M;]9TX([IM _WSSA/O;F_HW1JMP1W_KS[+7Z>^AOA+E[6O?X 4$L#!!0 ( M '**>TPW&7W(N $ -L; 3 6T-O;G1E;G1?5'EP97-=+GAM;,W9WVZ" M,!0&\%G;KZ NF6&)BYI\-R*<_/(F$L+JI6+M:$F5')M:^7#J5TPH]*E6A 3H]&8 MI;KQU/BA;WM$L\DSY6I5^<'3[GK;>AHI8ZHR5;[4#5LWV5'3X;YA;*GJUKBB M-.XF+(@&+YO0Q85KTRA47<1.F'!\8WL>[GM;D[5E1O^*IO.\3"G3Z:H.M\3. M6%*9*XA\7<6N4):R=V_+9K'/.U?6OZHZ-&:;BOU:$%\OA]]6U!^@JUQRL@_; M@OI&=87=)S]KX&$WI-K2T-A0M;[L>;P0:1ZJCK4++_F(U&Z=C+*3AH?6U_MA MO[1==M_[7OA/T;'N<-Y;OUP. 9)#@N1(0'+<@N08@^2X \EQ#Y+C 20''Z$$ M01&5HY#*44SE**AR%%4Y"JL-:E&PO=&AE;64O=&AE M;64Q+GAM;%!+ 0(4 Q0 ( '**>TSLZ8@=G0( *$) 8 M " ?@( !X;"]W;W)K&PO=V]R:W-H965T M&UL4$L! A0#% @ TSSFE7DZ@, / 0 8 " :T2 !X;"]W;W)K MN9 " "," M& @ '-%@ >&PO=V]R:W-H965T&UL4$L! M A0#% @ ?LA8V!@ 0R( !@ ( !DQD 'AL M+W=OTQO,6'&*04 M $X: 8 " ?\? !X;"]W;W)K M)0 >&PO=V]R:W-H965T&UL4$L! A0#% @ TRV6W]:M@$ -(# 9 M " 3&UL4$L! A0#% @ MTS5K&='LP$ -(# 9 " ?TN !X;"]W M;W)K&UL4$L! A0#% @ &PO=V]R:W-H965TTPB MY%JAM $ -(# 9 " ;XT !X;"]W;W)K&UL4$L! A0#% @ L@D;(" 3"P &0 @ &4. >&PO=V]R:W-H M965TTP4/"_-MP$ -(# 9 M " 7T[ !X;"]W;W)K&UL4$L! M A0#% @ &PO=V]R:W-H965TTSSV@'AMP$ -(# 9 " M 4=! !X;"]W;W)K&UL4$L! A0#% @ T! !F!0 &0 M @ $Q10 >&PO=V]R:W-H965TTR_$'^%S@$ )P$ 9 " 55' !X;"]W;W)K M&UL4$L! A0#% @ &PO=V]R:W-H965TTPDKPY= M/00 ,H4 9 " <-/ !X;"]W;W)K&UL4$L! A0#% @ &PO=V]R:W-H965T MTP$4RPV_P$ , % 9 M " &UL4$L! A0# M% @ O54T$!@ 7B( !D ( !_UL 'AL+W=O M&PO=V]R:W-H965TTS#6-M%8@( +T' 9 " ?AE M !X;"]W;W)K&UL4$L! A0#% @ &PO=V]R:W-H965TTR<4\:"\ ( /\* 9 " ;9M !X;"]W;W)K&UL4$L! A0#% @ $)GW*L" "_"0 &0 @ '&